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I 
ABSTRACT 
This research has focused on the development of novel substrate mimics as potential DXR 
inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR), an essential enzyme 
in the mevalonate-independent pathway for the biosynthesis of isoprenoids in Plasmodium 
falciparum. DXR mediates the isomerisation and reduction of 1-deoxy-D-xylulose-5-
phosphate (DOXP) into 2C-methyl-D-erithrytol 4-phosphate (MEP) and has been validated as 
an attractive target for the development of novel anti-malarial chemotherapeutic agents. 
Reaction of various amines with specially prepared 4-phosphonated crotonic acid in the 
presence of the peptide coupling reagent, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC), has afforded a series of amido-phosphonate esters in moderate to good yields (48% - 
73%) which, using a RuCl3/CeCl3/NaIO4 catalyst system, have been dihydroxylated to furnish 
the dihydroxy-amido phosphonate ester pro-drugs; subsequent hydrolysis under microwave 
irradiation has afforded the corresponding phosphonic acids. A second series of potential 
inhibitors viz., 3-substituted aniline-derived phosphonate esters, their corresponding 
phosphonic acids and mono-sodium salts, have also been successfully synthesised. In these 
compounds, the essential functional groups are separated by one, two, three or four 
methylene groups, Deprotonation of the 3-substituted aniline substrates, followed by 
reaction with the appropriate ω-chloroalkanoyl chloride produced the ω-chloroamide 
intermediates, which were subjected to the Michaelis-Arbuzov reaction to afford the diethyl 
phosphonate esters in moderate to good yields (48% - 74%). Microwave-assisted TMSBr-
mediated cleavage of the phosphonate esters furnished the phosphonic acids, 
neutralisation of which afforded the mono-sodium salts.  
Furan-derived phosphate esters and phosphonic acids have been prepared as 
conformationally-restricted DOXP analogues. Functionalization at C-5 of the trityl-protected 
furan was achieved using the Vilsmeier-Haack formylation and Friedel-Crafts acylation 
reactions and, following de-tritylation, phosphorylation and oximation, using hydroxylamine 
hydrochloride, the novel oxime derivatives have been isolated as a third series of potential 
DXR inhibitors in very good yields (87% - 96%). Finally, in order to exploit an additional 
binding pocket in the PfDXR active site, a series of N-benzylated phosphoramidic derivatives 
were obtained in seven steps from the starting material, diethyl phosphoramidate. The 
 
 
II 
known inhibitors, fosmidomycin and its acetyl derivative FR900098, were also successfully 
synthesised as standards for STD-NMR binding and inhibition assays. In all, over 200 
compounds (136 novel) have been prepared and appropriately characterised using 1-and 2-
D NMR and IR spectroscopic analysis and, where necessary, HRMS or combustion analysis.  
Saturation Transfer Difference (STD) protein-NMR experiments, undertaken using selected 
compounds, have revealed binding of most of the ligands examined to EcDXR. Computer-
simulated docking studies have also been used to explore the preferred ligand-binding 
conformations and interactions between the ligands and essential DXR active-site residues, 
while DXR-enzyme inhibition assays of selected synthesised ligands have revealed certain 
patterns of inhibitory activity.      
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1. INTRODUCTION 
1.1. History of malaria  
The interaction and evolution of malaria and humans can be traced back to ancient human 
civilizations, more than 5000 years ago.1 The evidence of this affiliation or co-existence is 
authenticated within the manuscripts and writings of the Romans, Chinese, Indians, Greeks 
and Egyptians.1 This includes the identification of malarial antigen molecules from skin and 
lung samples extracted from Egyptian mummies dating from the periods 3200 and 1304 B.C. 
Enlarged spleens, a phenomenon associated with malaria, have also been detected in 
mummies aged more than 3000 years old.1  Documentation within the Chinese Classic of 
internal Medicine “Nei Ching”, written around 2700 B.C, alludes to the characteristic 
symptoms observed in patients afflicted with malaria; specifically recurring fevers, enlarged 
spleens, headaches and chills.1-2  
From the fifth century B.C. onwards, the identification and description of the disease along 
with its devastating effects are illustrated in the writings of several well-known philosophers 
and writers.1 They include Homer (ca. 8th Century B.C.) Sophocles (496-406 B.C.), 
Hippocrates (460-370 B.C.), Plato (428-347 B.C.), Aristotle (384-322 B.C.) and Shakespeare 
(1564-1616).1-3 During the Roman Empire and throughout the middle ages, malaria became 
more prevalent due to the growth in population worldwide and the increase of migration of 
people across nations. By the beginning of the 18th century, malarial infections were 
prominent and widespread across all continents.1 Furthermore, the intermittent illness had 
acquired various descriptive names, such as jungle fever, swamp fever and marsh fever, as a 
result of its association with tropical and low-lying water environments. In Western Europe, 
specifically Italy, the term mal’aria (meaning bad air) was used to express the cause and 
pathogenicity of the parasite in malaria victims.1,3  
Throughout the 19th century, particularly from the 1850’s onwards, scientists and 
pathologists made numerous unsuccessful attempts to isolate, identify and culture the 
pathogenic organism responsible for malaria.1 The discovery of the malaria-causing parasite 
in the blood of the human host was achieved through the work of a French surgeon, Charles 
Louis Alphonse Laveran, in 1880.1 This finding was facilitated by previous work done by 
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Heinrich Meckel in 1847, who observed the discolouration of organs in patients suffering 
from intermittent fevers. The discolouration was due to the presence of the reddish-brown 
malaria pigment, hemozoin, and Laveran initially proposed that it was the transparent, 
flake-like or granular form hemozoin molecules that was the cause of the disease.1,3 In 
addition to noticing the presence of hemozoin particles in the red blood cells of an infected 
person, Laveran also observed several forms of the mobile, flagellated male gametocytes as 
well as the spherical, motionless female gametocytes of the malaria parasite and 
subsequently proposed that the disease was caused by the single-celled protozoan organism 
Plasmodium, which he referred to as Oscillaria malariae.1-3 Over the following decade, 
Laveran’s observations were supported by detection of the parasite within human host red 
blood cells through experiments conducted by Marchiafava and Celli in 1884, Golgi in 1886, 
and MacCallum and Opie in 1897.1-3 Following the successful identification of Plasmodium 
as the causative agent of malaria, scientists began to investigate and postulate modes of 
transmission of the parasite. Both Laveran and Manson suggested that mosquitoes were 
vectors of the disease.1 Manson, who in 1878 had established the ability of mosquitoes to 
transmit the infectious microfilariae from the blood of patients suffering from elephantiasis, 
hypothesized that mosquitoes could be infected in a similar manner by the malaria 
pathogen as a result of its exflagellation morphology. Consequently, Manson influenced his 
apprentice and colleague, Ronald Ross, to perform experiments that would substantiate the 
mosquito transmission of malaria.1  
Ross, a physician in the British Indian Medical Service, commenced his investigation on 
mosquitoes as possible vectors of the malaria parasite in India in 1895. Initially, he 
successfully disproved the hypothesis (postulated by Manson) that the parasites were 
transferred from the mosquitoes to a new human host through the ingestion of water 
contaminated with the eggs of infected mosquitoes.1-2 Furthermore, he suggested that the 
transmission of the malaria plasmodia from mosquitoes to humans occurred through a bite 
or during feeding and concluded that the development of the human malaria parasite 
favoured a particular mosquito species, notably Anopheles.2 On 20 August 1897, Ross 
ultimately confirmed the Anopheles mosquitoes as vectors of human malaria when he 
observed the development of the oocyst and the presence of the black granular malaria 
pigment, hemozoin, within the stomach of mosquitoes which had fed on a malaria-infected 
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patient.1,3 A few years later, Ross demonstrated that malaria parasites infecting birds (i.e. 
sparrows and crows) developed into oocysts in the mosquito gut and subsequently migrated 
as sporozoites to the mosquito salivary glands from which they infected more birds during 
blood meals. He anticipated a similar transmission mechanism for human malaria, of which 
the experimental evidence was presented in 1898 by Grassi, Bignami and Bastianelli.1,3 The 
Italian scientists reported the transmission of the malaria parasite Plasmodium vivax (P. 
vivax), through the bite of the vector Anopheles Claviger, to a healthy volunteer. In addition, 
they also described the sporogonic cycle of Plasmodium falciparum (P. falciparum) and 
Plasmodium malariae (P. malariae) pathogens in anopheline mosquitoes.1 In 1900, Grassi 
suggested a host tissue development phase for the malaria parasite, due to the difference in 
the structure of the nucleus in parasites initially observed in the host erythrocytes 
(trophozoites) and the parasites within the salivary glands of the mosquito vector.1-3 The 
discovery of the Plasmodium malaria parasite in the tissues of both primate and human 
hosts was achieved in 1948 by H.E. Shortt and Garnham.1,3 Upon infecting (either through a 
mosquito bite or intravenous injection of sporozoites from the mosquito salivary glands) 
rhesus monkeys with Plasmodium cyanomolgi and human volunteers with P. vivax parasites, 
respectively, Shortt and Garnham detected the maturation of the malaria parasites in the 
livers of both simian and human hosts. In subsequent work, they established the tissue 
phases for the human malarial parasite P. falciparum (in 1949), P. ovale (1954) and P. 
malariae (1959).1,3 The latent tissue phase, referred to as hypnozoite, was observed and 
described by Krotoski and co-workers between 1980 and 1985.1,3 This stage of the parasite’s 
developmental cycle provided experimental evidence of the clinical relapse when humans 
afflicted with the disease lack the pathogen in their bloodstream and appear to be cured, 
but experience the disease’s symptoms years later.1,3 
Over the last half century, considerable efforts and advances have been made in the field of 
malarial research, particularly in understanding the biochemistry of the malaria vector and 
parasite, as well as in the discovery and design of drugs to prevent or cure malaria. These 
include:- the isolation of artemisinin from Artemisia annua in 1971 as a potential anti-
malarial compound; the successful culturing of the pathogenic P. falciparum parasite within 
red blood cells by Trager; the development of several effective diagnostic test kits for the 
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detection of malaria parasite antigens; and the completion of the genome sequencing of the 
vector Anopheles gambiae (A. gambiae) and the parasite P. falciparum in 2002.3-7  
1.2. Global impact of malaria  
1.2.1. Epidemiology of malaria  
Malaria is a vector-borne disease caused by protozoan parasites of the genus plasmodium 
and is regarded as the most deadly parasitic infection afflicting humans.1 Four plasmodia 
species are traditionally considered to account for all malarial infections in humans; 
Plasmodium ovale (P. ovale), Plasmodium vivax (P. vivax), Plasmodium malariae (P. 
malariae) and Plasmodium falciparum (P. falciparum).1 However, naturally acquired 
infections in humans have recently been reported for the parasite Plasmodium knowlesi (P. 
knowlesi), which has been traditionally associated with monkeys.8,9 P. vivax is geographically 
the most widespread of the parasites due to its ability to mature in mosquitoes at both low 
and high temperatures and under tropical climatic conditions.2,9 In West Africa, P. vivax is 
absent as the majority of the population do not possess the Duffy antigen receptor, which 
the parasite requires for entry into the human host’s red blood cells.10 P. falciparum is 
however, the most virulent human malaria parasite causing the majority of severe clinical 
cases. P. ovale and P. malariae are less common both in terms of geographic distribution 
and human infectivity.10 The female Anopheles mosquito is the vector responsible for the 
transmission of malaria.2,10 There are ca. 70 Anopheles species differing in behavioural 
characteristics which are considered vectors of malaria. Variations in mosquito behaviour 
include host feeding preference (zoophilic or anthropophilic), biting habit (endophagic or 
exophagic) and resting behaviour (endophilic or exophilic).2,10 A. gambiae and A. funestus 
are considered the most important malaria vector species in Africa and their behavioural 
patterns (anthropophilic, endophilic and endophagic), along with their high transmission 
efficiency and density, are factors which have been attributed to the enormous burden 
caused by malaria on the African continent. 6,11,12  
The distribution of malaria, however, is worldwide with the disease being endemic in 106 
countries across all the continents except Antarctica and Australia. Of the 106 malaria 
endemic countries, 43 are on the African continent.13 Recent estimates suggest that more 
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than 50 % of the world’s population (3.3 billion) are living in malarious areas and are 
exposed to the disease.14 Geographically, the disease is most prevalent within the tropical 
and sub-tropical regions (as depicted in figure 1).1,14 Sub-Saharan Africa bears the greatest 
burden, accounting for approximately 90 % of all reported clinical cases with, 85 % of all 
malaria associated deaths occurring amongst children under 5 years old and pregnant 
women.10,13-14 The severity of the disease in Africa is due to the fact that nearly all infections 
are caused by the most virulent malaria parasite, P. falciparum.10  
Figure 1. Estimated global malaria incidence per 1000 population.14 (Reproduced with 
permission from the World Health Organisation).  
 
The epidemiology of malaria is complex and the level of endemicity of the disease varies 
considerably within a given endemic region. Human activities at both a population and 
individual level have influenced the distribution pattern of malaria.15-16  The promotion of 
economic and agricultural development and the movement of populations (including 
urbanization and tourism), have contributed directly and indirectly to an increase in malarial 
transmission intensity.15-17 It is estimated that approximately 25 000 tourists and travellers 
from non-endemic countries are exposed to the disease annually upon visiting malaria 
endemic regions.17           
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The global impact and public health threat of malaria is staggering. According to the World 
Health Organization (WHO) world malaria report 2010, the disease was responsible for 225 
million clinical episodes in 2009, of which 781 000 resulted in death.13 Although efforts have 
been made to reduce the burden of malaria, the prevalence of the disease has remained 
high and in some cases increased.10,13-14 Reports from Burkina Faso indicate a 3-fold increase 
in the number of malaria cases, whereas in Ethiopia, there is evidence suggesting a shift in 
parasite infection cases from predominantly P. vivax to P. falciparum.18-19 Several factors are 
attributed to the increase in malaria prevalence worldwide. These include the emergence 
and spread of drug-resistant malaria parasites, particularly the virulent P. falciparum, 
towards chemotherapeutic drugs such as chloroquine.9,16 Chloroquine-resistant parasites 
were originally reported in South America (Venezuela and Colombia) and South East Asia 
(Thailand and Cambodia) in the late 1950’s, but are now widespread in all malaria endemic 
regions.16 Moreover, insecticide-resistant mosquitoes (e.g. A. gambiae and A. funestus) have 
emerged recently.20 Several studies on the interaction between malaria and HIV co-infection 
have suggested that the immune-suppression effect of HIV enhances malaria transmission 
by increasing susceptibility and plasmodium parasite density within the host, thus increasing 
the symptomatic malarial episodes, especially in pregnant women. 21-23 In addition, malaria 
adversely affects HIV-infected individuals by triggering CD4 cell activity and increasing viral 
loads, consequently accelerating the progression of HIV/AIDS.22-23 
Most parasitic diseases, including malaria, commonly occur in poor or developing countries 
and are rarely encountered in the developed countries.10 Consequently, the financial 
incentive (i.e. the generation of profits) for pharmaceutical companies in wealthy nations to 
discover and develop new anti-malarial drugs for the developing world populations is low 
and, as a result, progress in the discovery of new and effective anti-malarial drugs has been 
slow.10 Other factors considered to contribute to the increase in the incidence of malaria 
include:- climatic instability; social unrest; failure in implementing effective malaria-control 
programmes; and weak public health service systems.2,9,17 The past few years have 
witnessed increased efforts and commitment from international organizations towards 
controlling and ultimately eliminating malaria and its associated burdens. The Roll Back 
Malaria (RBM) partnership was established in 1998 to provide a coordinated global 
approach to fight malaria. RBM is an initiative whose vision is “a world free from the burden 
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of malaria“ and its goals include reducing the global malaria morbidity and mortality cases 
reported in the year 2000:- i) by 50% by the end of 2010; and ii) by 75% or more by the year 
2015.13-14 The Global Malaria Action plan was launched by the RBM partnership in 
September 2008, to re-define the goals and accelerate the efforts required to reach these 
targets.13 The fight against malaria is prioritised by the United Nations through the 
Millennium Development Goals (MDG’s) and by African countries through the Abuja 
Declaration of 2000.24-25 Other important organizations committed to overcoming malaria at 
a global level include:- the Malaria Vaccine Initiative; the Multilateral Initiative on Malaria 
(MIM); and the Global Fund to fight HIV/AIDS, Tuberculosis and Malaria.26-28 
The complex life cycle of the plasmodium parasite has presented several approaches to 
malaria control and prevention, which are currently being exploited.13,29 These control 
measures include:- i) the reduction of mosquito population densities through environmental 
management (by water treatment and the application of larvacides); ii) the use of chemo-
prophylactic and therapeutic drugs for prevention and treatment purposes [e.g. Artemisinin 
Combination Therapy (ACT)]; iii) the use of Indoor Residual Spraying (IRS) within households 
with WHO-approved insecticides (e.g. DDT and pytheroids) to reduce and interrupt malaria 
transmission and; iv) the use of Insecticide-Treated Nets (ITNs) and long-lasting ITNs (LLITNs) 
as barriers for reducing the transmission of malaria infections.29 With the high prevalence of 
malaria worldwide, the World Health Organisation (WHO) has endorsed the limited use of 
indoor residual spraying (IRS) with DDT as a method for malaria vector control until a less 
harmful alternative is obtained. IRS and ITNs vector-control methods are limited as they are 
heavily dependent on a single class of insecticides that require widespread usage, which 
increases the development of resistance by mosquito vectors.13,29 Brooke and colleagues 
documented the emergence of pyrethroid-resistant A. funestus vectors.30 Furthermore, the 
lifespans of ITNs and LLINTs are approximately 6 months and 3 years, respectively, thus 
requiring regular re-treatment and replacement, which is not financially viable in the long 
term.9,29  
New malaria vector control strategies are being investigated. One such approach involves 
the infection of the Anopheles vectors with entomopathogenic fungi such as Beauveria 
bassiana and Metarhizium anisopliae.31 Another vector control method being considered is 
the construction of transgenic mosquitoes, which are incapable of transmitting the 
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plasmodium parasite.32 Research on the development of malaria vaccines is ongoing, but 
requires continued funding from public and private organizations and it seems unlikely that 
an effective vaccine will become available for at least another decade.9,29,33   
1.3. Biology and life cycle of the malaria parasite 
The malaria parasites are host-specific and the life cycle is accomplished in two hosts, the 
human and the Anopheles mosquito (Figure 3).34 The parasite life cycle is complex with 
several asexual reproduction stages in the human host and sexual reproduction stages in 
the mosquito.  
Figure 2. The life cycle of Plasmodium parasites in the human and mosquito.34 (Reproduced 
with permission.) 
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Human malaria infections are initiated by the injection (through a bite during a blood-meal) 
of plasmodium sporozoites within the saliva of an infected mosquito into the host's 
bloodstream.34 The circulating sporozoites enter the hepatocytes in the liver shortly after 
inoculation and start to divide mitotically – the pre-erythrocytic stage. Invasion into the 
hepatocytes is mediated by specific binding of the parasite circumsporozoite protein (CSP) 
and thrombospondin-related adhesive protein (TRAP) to heparin sulphate proteoglycans on 
the hepatocytes.35 The intra-hepatocytic sporozoites divide asexually into pre-erythrocytic 
schizonts, each containing ca. 1 x 103 – 30 x 103 merozoites. Eventually, merozoites are 
released upon rupture of hepatocytes into the bloodstream and invade red blood cells 
(RBCs) to start the erythrocytic asexual phase. During invasion of RBCs, merozoites attach to 
RBC surface binding receptors (duffy glycoprotein for P. vivax and glycophorins for P. 
falciparum), undergo apical re-orientation, enter the erythrocytes through junctional 
movement and induce the formation of parasitophorous vacuoles.10,36  
Inside the erythrocytes, merozoites differentiate into ring trophozoites that ingest 
haemoglobin and nutrients within the vacuole and mature into multi-nucleate schizonts. 
The mature schizonts differentiate into thousands of merozoites causing the RBCs to swell 
and rupture, releasing the merozoites into the bloodstream which subsequently attach and 
re-infect new RBCs, such that the erythrocytic cycle is repeated. These repeated cycles lead 
to exponential growth of infected RBCs and it is during the bursting of erythrocytes that the 
clinical symptoms of malaria appear in the infected person.10,36 During the erythrocytic 
cycle, a proportion of merozoites follow a different developmental pathway and develop 
into male and female gametocytes, the sexual forms of the parasite.36 The stimulus that 
triggers gametocytogenesis is not fully understood, but is likely to be the response of the 
host immune system to the infection. Gametocytes are ingested by a female anopheles 
mosquito during a blood-meal and develop in the midgut of the mosquito into male and 
female gametes. Fertilization occurs to form a zygote that develops into an ookinete. The 
ookinete migrates through the midgut epithelium and matures into an oocyst under the 
basal membrane. The oocyst undergoes maturation to generate sporozoites which, upon 
rupture, migrate through the hemocoel to the salivary glands from where they are injected 
and infect humans during the next blood-meal taken by the mosquito.10,37 
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1.3.1. Biological differences amongst malaria parasite species  
There are species-specific biological differences within the plasmodium parasite generic life 
cycle. In P. vivax and P. ovale, a percentage of sporozoites invading the hepatic cells develop 
into hypnozoites (hypnozoite stage) which remain dormant in the liver.10 The presence of 
hypnozoites may cause relapse of clinical malaria symptoms months to years after the initial 
infection. Several differences in the biology of P. falciparum account for its higher 
pathogenicity and ability to cause the most severe manifestation of malaria.10 P. falciparum 
modifies the surfaces of infected RBCs causing them to adhere:- to the endothelium of 
capillaries (sequestration); to uninfected RBCs (rosetting); and to platelets (clumping). 
Adherence protects the parasite from the host’s immune response mechanisms and from 
being removed from circulation into the spleen.38 In addition, the P. falciparum genome 
contains the very large and diverse var gene family (ca. 60 genes) which encodes for the P. 
falciparum Erythrocyte Membrane Protein 1 (pfEMP1).10 pfEMP1 mediates parasite binding 
to the various host receptors and, through a phenomenon known as antigenic variation, 
allows the parasite to evade host immune responses.10,38 Several var genes encode for 
proteins that mediate adherence to Intercellular Adhesion Molecule 1 (ICAM-1) in the brain 
and adhesion to Chondroitin Sulphate A (CSA) in the placenta. Sequestration of parasites to 
these molecules is associated with cerebral malaria and the severe clinical manifestations 
observed in pregnant women.38  
1.3.2. Clinical symptoms and diagnosis of malaria  
The clinical symptoms of malaria occur during the erythrocytic life cycle phase of the 
parasite when RBCs rupture. Symptoms for uncomplicated malaria infections include fever, 
chills, headache, vomiting, diarrhoea, convulsions and muscular pains.10,17 Severe malaria is 
a complex disorder that affects several tissues and organs, and complications include renal 
failure, hypoglycaemia, hepatic dysfunction, severe anaemia, cerebral malaria, respiratory 
distress and metabolic acidosis.9-10 The standard method for diagnosing malaria involves 
light microscopy of thick and thin Giemsa-stained blood smears on glass microscope slides. 
Several advances have been made in the development of alternative diagnostic methods 
including:- fluorescence microscopy of parasite nuclei stained with acridine orange; rapid 
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dipstick immunoassays of various malaria antigens; and polymerase chain reaction (PCR) 
based assays.9,17 
1.4. Current anti-malarial drugs: mechanism of action and resistance 
Malaria is curable if it is diagnosed properly and treatment is provided promptly. The 
malaria chemotherapeutic drugs are generally classified into 3 groups, based on the 
plasmodium parasite life cycle phase they act on or interrupt, viz.,:- i) tissue schizonticides, 
which act against the development of liver stage parasites ii) blood schizonticides, which 
prevent parasite development at the intra-erythrocytic stage and iii) gametocides, which 
inhibit the maturation of sexual forms of the parasites.39 The intra-erythrocytic phase of the 
parasite’s life cycle is the most susceptible stage and is generally targeted by the available 
chemotherapeutic agents. Malaria chemotherapy currently relies on five classes of 
compounds, viz.,:- quinolines, artemisinins, anti-folates, hydroxynapthoquinones and 
antibiotics.39 
1.4.1. Quinolines  
Quinolines are heterocyclic aromatic compounds containing the quinoline nucleus 1, which 
comprises a pyridine ring fused to a benzene ring; they are also referred to as 1-
azanaphthalenes, benzopyridines or even, heterocyclic amines.40 The nitrogen atom is 
located next to the benzene ring and the chemistry of quinolines reflects a preference for 
electrophilic aromatic substitution on the benzene ring and nucleophilic aromatic 
substitution on the pyridine ring. The quinoline ring system is found in many natural 
products such as alkaloids, particularly in those with pronounced biological activities.41 
Many anti-malarial drugs (figure 3) are derivatives of quinine 2, an alkaloid first isolated 
from the bark of the cinchona tree in Peru and used, in Western medicine, to treat patients 
suffering from malaria since the 18th century.42-43 The structure of quinine 2 was elucidated 
by Paul Rabe in 1908, but its formal total synthesis was achieved by Woodward and Doering 
in 1944. The use of quinine for prophylaxis and treatment of uncomplicated malaria cases is 
limited due to its toxicity and adverse effects. However, it has excellent efficacy and is still 
used against highly drug-resistant parasites and to treat severe cases of malaria.42-43 Since 
the 1940’s, several quinoline anti-malarial analogues, based on quinine as a template, have 
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been synthesized. Some of these compounds exhibit better pharmacological profiles and 
include:- the 4-aminoquinolines (4-AQs) such as chloroquine 3 and amodiaquine 4; aryl-
amino alcohols such as mefloquine 5, halofantrine 6 and lumefantrine 7; and 8-
aminoquinolines such as primaquine 8 and tafenoquine 9.42,44-45 
 
Figure 3: Structures of quinoline, quinine and selected anti-malarial drugs.      
Chloroquine 3 [CQ; N'-(7-chloroquinolin-4-yl)-N,N-diethylpentane-1,4-diamine] has been 
used extensively for the treatment of malaria due to its low toxicity, low cost and excellent 
efficacy but, during the 1960’s, resistant-parasites emerged.45 In vivo, chloroquine 3 is 
metabolised by cytochrome P450 through a series of de-ethylation steps to yield the bis-
desethyl compound 10. Further oxidation produces the aldehyde 11 and then the carboxylic 
acid 12, which is finally dealkylated to 4-aminoquinoline (4-AQ) 13 (Scheme 1).44,46 CQ-
resistant strains are presently widespread in most malaria-endemic regions.  
Amodiaquine 4 is structurally related to CQ, containing a 4-hydroxy anilino group in the 
mannich side chain. Amodiaquine 4 is regarded suitable for prophylaxis use due to its long 
half-life. In vivo, amodiaquine 4 is rapidly dealkylated into its active derivative, N-
desethylamodiaquine (N-DEAQ).44,46 Although amodiaquine 4 is more active in parasite 
clearance than CQ and effective against CQ-resistant strains of P. falciparum, its clinical use 
has been limited by the development of hepatotoxicity and agranulocytosis in patients, 
along with the possibility of cross-resistance with CQ.17,45  
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Scheme 1. Metabolic degradation of chloroquine 3 in vivo by cytochrome P450. 
Mefloquine 5 and halofantrine 6 are therapeutic agents developed by the Walter Reed Army 
Institute and are active against CQ-resistant plasmodium parasites.17 As with amodiaquine 
4, mefloquine’s long half-life has made it useful as a prophylactic drug; however, when used 
for treatment of malaria, it is usually administered with artesunate (see p. 13).17,45 
Regrettably, its long half-life has led to the development of resistant plasmodium strains. In 
addition, the use of mefloquine 5 has been restricted due to frequently reported 
neuropsychiatric side effects, e.g. acute psychosis.17 The use of halofantrine 6, a substituted 
phenanthrene related to chloroquine 3, as a therapeutic agent has been restricted by its 
erratic absorption profile and its association with cardiotoxicity effects, such as cardiac 
arrhythmias.17 Lumefantrine 7, which is structurally related compound to halofantrine 6, 
was synthesized in China in the 1970’s and has been shown to act synergistically with 
artemether (see p. 15) for the treatment of uncomplicated P. falciparum malaria. This 
course of therapy is relatively safe, but there are concerns about the therapeutic potential 
of lumefantrine 7 due to the possibility of cross resistance with chloroquine 3 and 
mefloquine 5.17,45   
Primaquine 8, [(R,S)-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine], is an 8-
aminoquinoline synthesized to target the maturation of parasite gametocytes 
(gametocytocidal activity), but is also active in the pre-erythrocytic stages (hypnozoites) of 
P. falciparum, P. ovale and P. vivax.44-45 The drug is often referred to as an anti-relapse 
agent, as it interrupts the hypnozoite (dormant) stages, which leads to relapse in malaria 
infections. A disadvantage of primaquine 8 includes its short half-life as it is readily oxidised 
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to its carboxy derivative. Structural modifications of primaquine 8 directed the synthesis of 
the analogue tafenoquine 9, which has a much longer half-life and improved anti-parasitic 
activities. However, both primaquine 8 and tafenoquine 9 exhibit toxicity effects, including 
gastrointestinal effects and haemolysis in G6PD deficient patients.17,45 
1.4.1.1. Mechanism of action and resistance  
Quinoline anti-malarial drugs generally have the same mechanism of action, arising from 
their accumulation within the food vacuole (FV) of the plasmodium parasite during the 
erythrocytic stage of the life cycle (Figure 4).47-48 The catabolism of haemoglobin within the 
FV provides the parasite with a source of nutrients and amino acids which are essential for 
its biosynthetic pathways and growth. Toxic haem (ferriprotoporphyrin) moieties are 
generated as by-products during haemoglobin degradation, which are subsequently 
polymerized by the parasite to non-toxic haemozoin (malaria pigment) crystals. Quinoline-
antimalarial drugs typically interrupt the haem-detoxification process, through the 
formation of drug-haemozoin complexes and/or binding of the drug to the growing face of 
the haemozoin crystals, causing the termination of growth.45-47 The consequent 
accumulation of toxic haem molecules within the FV renders the parasites susceptible to 
oxidative stress, leading to death as shown in figure 4. Anti-parasitic functions may also 
include the inhibition of haemoglobin proteolysis, i.e. inhibition of aspartic and cysteine 
protease activity and the raising of the FV pH.45,47 
The mechanism of resistance against quinoline anti-malarial drugs is not fully understood 
and is still being investigated. The general current consensus is that plasmodium parasites, 
particularly P. falciparum, develop resistance to these drugs through:- i) specific point 
mutations in the pfcrt gene, which result in the reduced binding affinity of the drugs to 
haem molecules; and ii) mutations in the pfmdr 1 gene encoding for P-glycoprotein (Pgh-1), 
resulting in the amplification of the gene, leading to reduced drug accumulation in the FV 
and a decrease in drug concentrations via efflux from the FV.45-48 
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Figure 4: Proposed mode of action of CQ and related quinoline anti-malarials.48 (Reproduced 
with permission.)       
1.4.2. Artemisinin and its derivatives  
Artemisinin (quinghaosu) 14 is a sesquiterpene trioxane lactone, isolated from the Chinese 
medicinal herbal plant, Artemisia annua, and has exceptional anti-plasmodial activity 
against drug-resistant parasite strains.45 To improve the potency of artemisinin 14 and 
address drawbacks, such as poor solubility, short plasma half-life and limited bioavailability, 
simple chemical modifications of artemisinin 14 have resulted in the development of semi-
synthetic analogues.44-45 Reduction of artemisinin 14 afforded dihydroartemisinin (DHA) 15 
which is roughly seven times more potent than artemisinin 14 in vitro, while alteration of 
the lactone carbonyl group at C-10 led to the development of artemisinin derivatives, such 
as artemether 16, arteether 17 and sodium artesunate 18 (Figure 5).44-45 Artemether 16 and 
arteether 17 are oil-soluble drugs which are administered via intramuscular injection, whilst 
artesunate 18 is water-soluble and is suitable for both oral and intravenous 
administration.17,45 These analogues (16-18) are all rapidly hydrolysed in vivo to the 
hemiacetal  15, which is then metabolized through glucuronidation.  
Due to the short plasma half-lives of artemisinin drugs, high rates of recrudescent infections 
are frequently reported when they are administered as mono-therapeutic agents. To reduce 
recrudescence of infections and the development of resistant-parasites, the general 
recommendation is to combine artemisinin drugs is in combination with another effective, 
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long-acting, anti-malarial drug – an approach termed Artemisinin-based Combination 
Therapy (ACT).9,49 Several ACT formulations are currently available, including:- artemether-
lumefantrine; artesunate-amodiaquine and dihydroartemisinin-piperaquine. A major 
obstacle in the use of ACT’s as first-line therapeutics, especially in poor, malaria-endemic 
countries, is their cost. Treatment with ACTs is approximately ten times more expensive 
than with mono-therapy treatments.9   
 
 
 
 
 
Figure 5. Artemisinin and its synthetic derivatives as anti-malarial agents. 
1.4.2.1. Mechanism of action and resistance 
Artemisinin 14 and its analogues are believed to be active against all the erythrocytic stages 
of the malaria parasite’s life cycle. It has been suggested that the presence of the endo-
peroxide bridge is essential for the anti-parasitic effect of the drugs.43-45 The mechanism of 
action remains uncertain, but it has been suggested that it involves the reductive cleavage 
of the endo-peroxide moiety through interaction with intra-parasitic haem (iron-mediated) 
to generate free-radical species. These highly reactive radical species alkylate various 
parasite membranes including the endoplasmic reticulum, mitochondrial and plasma 
membranes, thus leading to their destruction (Figure 6).43-45 
 
 
 
Figure 6. Proposed mode of action of artemisinin 14.45  
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 More recently, the P. falciparum sacro-endoplasmic reticulum Ca2+-ATPase (pfATP6) has 
been identified as an important target for artemisinin and its analogues.45 There are 
currently no reported clinical cases of parasite resistance to artemisinin derivatives, 
although there are reports of reduced efficacy of the drugs both in vitro and in vivo at the 
Thailand-Cambodia border.9,45  
1.4.3. The Antifolates  
The antifolate anti-malarial drugs affect the pre-erythrocytic and erythrocytic stages of the 
parasite life cycle, in particular, the folate biosynthetic pathway.45 Several compounds that 
inhibit this pathway have been developed including pyrimethamine 19, sulphadoxine 20 and 
proguanil 21, shown in Figure 7. Proguanil 21 is converted in vivo to its active metabolite, 
the cyclic triazine cycloguanil 22, by cytochrome P450. Pyrimethamine 19 and sulphadoxine 
20 are generally used in combination therapy with each other, as they exhibit synergistic 
activity due to the fact that they both act on enzymes in the same biosynthetic pathway.45 
The long half-lives of these drugs have resulted in their use as prophylactic agents for 
intermittent preventive therapy in pregnancy (IPTp) and infants (IPTi).17  
 
 
 
Figure 7.  Current antifolate malaria chemotherapeutic drugs  
1.4.3.1. Mechanism of action and resistance  
The molecular targets of antifolates are well defined and, in contrast to other anti-malarial 
drugs, the mechanism of action has been comprehensively described.44 Pyrimethamine 19 
and proguanil 21 are competitive inhibitors of the enzyme, dihydrofolate reductase (DHFR), 
which catalyses the reduction of 7,8-dihydrofolate to tetrahydrofolate with concomitant 
oxidation of the NADPH co-factor.45,50 The sulfonamide 20 competitively inhibits another 
enzyme within the pathway, dihydropteroate synthase (DHPS), which catalyses the 
formation of 7,8-dihydropteroate from 2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydro-
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pteridine diphosphate and p-aminobenzoic acid (p-ABA). The inhibition of these two 
enzymes prevents formation of tetrahydrofolate co-factors, which are critical for the 
biosynthesis of pyrimidine and amino acids such as methionine and serine. The lack of 
pyrimidine inhibits DNA synthesis, whilst a deficiency in amino acids prevents parasite 
growth.45,50 Plasmodium resistance towards antifolates has developed rapidly and is 
widespread. Mutations in the dhfr and dhps gene encoding for the DHFR and DHPS enzymes 
have resulted in structural modified enzymes, particularly in the enzyme active-sites, thus 
preventing the drugs from binding competitively.45,50  
1.4.4. Hydroxynaphthoquinones  
Atovaquone 23 {2-[trans-4-(4ʹ-chlorophenyl)cyclohexyl]-3-hydroxy-1, 4-naphthaquinone} 
(Figure 8), was successfully developed by Glaxo Wellcome and is used in fixed-dose 
combination with proguanil 21 for chemo-prophylaxis and treatment of uncomplicated 
malaria infections.17,25 When used as a mono-therapy agent, a high rate of recrudescence 
occurs. However, a synergistic effect and improved activity is achieved when used in 
combination with proguanil 21.  
 
 
 
 
Figure 8. Ubiquinone 24 and its synthetic analogue atovaquone 23. 
1.4.4.1. Mechanism of action and resistance  
The anti-malarial activity of atovaquone involves the interruption of mitochondrial electron 
transport and subsequent collapse of the mitochondrial membrane potential in the 
parasites. Atovaquone is a structural analogue of ubiquinone 24 (Figure 8), which binds 
competitively and inhibits the cytochrome bc1 complex, thus interfering with electron 
transfer from ubiquinone to cytochrome C.45,51 The collapse of the mitochondrial membrane 
potential has been associated with apoptosis. The mechanism of resistance in Plasmodium 
parasites towards atovaquone is attributed to point mutations within the cytochrome b 
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gene, which result in amino acid alterations in the catalytic site of the enzyme, thus reducing 
binding affinity of the drug.51       
1.4.5. Antibiotics  
Antibiotics which are currently being used as anti-malarial agents include clindamycin, 
azithromycin, ciprofloxacin and doxycycline (Figure 9). The anti-malarial activities of these 
compounds involve the inhibition of DNA replication (DNA gyrase, RNA polymerase) and 
inhibition of protein synthesis by interacting with the 23S ribosomal RNA unit in plasmodium 
species.45   
 
 
 
Figure 9. Anti-malarial antibiotics 
1.5.  Synthetic approaches to current anti-malarial drugs  
1.5.1.  Synthesis of 4-aminoquinolines, quinoline aryl-amino alcohols and 8-
aminoquinolines. 
 
Woodward and Doering achieved the first formal synthesis of quinine 2 in 1944, with a lack 
of stereocontrol at the four asymmetric centres in the molecule and hence, experienced 
difficulty in separating the isomers (Figure 10).52-53  
 
 
 
 
Figure 10. Quinine 2 and selected stereoisomers. 
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Step 1. nucleophilic addition to aldehyde 
Step 3. intramolecular SN2
Step 2. reductive amination 
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O
CH3
N
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The first stereo-selective, total synthesis of quinine was reported by Stork and co-workers; 
the retrosynthetic strategy they adopted is summarised in Figure 11.53 
 
 
 
 
 
Figure 11. Stork’s retrosynthetic approach to quinine 2.53   
The desired stereoselective synthesis of quinine 2 was achieved through the construction of 
the azido aldehyde 34 (Scheme 2), trisubstituted piperidine 39 (Scheme 3) and deoxyquinine 
41 (Scheme 4) as key intermediates.53 The synthesis of compound 34 involved a 7-step 
process starting from (S)-4-vinylbutyrolactone 28. The vinyl lactone 28 was opened in the 
presence of diethylamine to give the primary alcohol in situ, which was protected as its tert-
butylsilyl (TBS) derivative 29. Alkylation of the TBS derivative 29 afforded the diethylamide 
30, which was deprotected with p-toluenesulfonic acid (PPTS) in EtOH to afford the trans-
3,4-disubstituted butyrolactone 31. Reduction of the lactone 31 using diisobutylaluminium 
hydride (DIBAL-H) led to the corresponding lactol, which was subjected to the Wittig 
reaction with methoxymethylene triphenylphosphorane to introduce an additional C-atom, 
thus furnishing the alcohol 32. The alcohol 32 was efficiently transformed to the azide 33, 
which was converted to the desired azido aldehyde 34 by hydrolysis in a two-phase 
system.53    
The synthesis of the trisubstituted piperidine 39 (Scheme 3) involved the lithiation of 6-
methoxy-4-methylquinoline 35 at C-6 and subsequent addition of the azide 34 via the 
carbonyl group to afford a mixture of the two epimers of secondary alcohol 36. The mixture 
was exposed to Swern oxidation to obtain the corresponding azidoketone 37, which was 
converted with triphenylphosphine in THF to the tetrahydropyridine 38. Reduction of 35 
with sodium borohydride in THF/MeOH mixture efficiently yielded the expected piperidine 
39.53 
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Scheme 2. Synthesis of the azido aldehyde 34. Reagents and conditions: i) Et2NH/AlMe3, 
TBSCl/imidazole/DMF ii) LDA, -78oC, ICH2CH2OTBDPS iii) PPTS, EtOH, 12h, xylenes, reflux 8-
10 h; iv) DIBAL-H, -78oC, Ph3P=CHOMe; v) Ph3P/DEAD, (PhO)2P(O)N3; vi) 5N-HCl, THF/DCM.      
 
 
 
 
Scheme 3. Synthesis of the trisubstituted piperidine 39. Reagents and conditions: i) LDA, 
THF, -78oC, 34 in THF, aq.NaHCO3; ii) DMSO, (ClCO)2, Et3N; iii) Ph3P, THF, reflux; iv) NaBH4, 
MeOH/THF. 
 
The completion of the synthesis of quinine 2 (Scheme 4) was achieved by deprotection of 
the silyl group of piperidine 39 to yield the alcohol 40. The quinuclidine ring of deoxyquinine 
41 was formed by mesylation of the alcohol 40 in the presence of pyridine and cyclization by 
refluxing in acetonitrile. Deoxyquinine 41 was then oxidised to yield quinine 2 .53  
 
 
 
 
 
Scheme 4.  Completion of the synthesis of quinine 2. Reagents and conditions: i) HF/CH3CN; 
ii) MsCl/Py, DCM; iii) CH3CN, reflux; iv) NaH/DMSO, then O2.  
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More recently, Jacobsen et al. 54 and Kobayashi et al. 55 have both published routes for the 
total, enantioselective synthesis of quinine 2 and its epimer quinidine 26. The retrosynthetic 
strategy adopted by Jacobsen and co-workers is summarised in Figure 12.   
                       
 
 
Figure 12. Jacobsen’s retrosynthetic strategy to quinine and quinidinine.54 
The cost-effective total synthesis of chloroquine 3 has been achieved by the Surrey and 
Hammer method (Scheme 5).56-57 This involves the condensation of m-chloroaniline 42 with 
ethyl ethoxalylacetate 43 to yield the aniline derivative 44, which undergoes pyrolytic 
cyclization to generate the carboxylate ester 45. Subsequent hydrolysis produces the 
corresponding acid derivative 46, thermal decarboxylation of which affords 4-
hydroquinoline 47. The chlorination of 47 is achieved with phosphorus oxychloride to yield 
4,7-dichloroquinoline 48, which is subjected to nucleophilic substitution with 4-
diethylamino-1-methylbutylamine 49 to give chloroquine 3.56-57 More recently, Margolis et 
al.58 have reported the synthesis of chloroquine 3 using a palladium catalyst system.  
 
 
 
 
 
 
Scheme 5. Surrey and Hammer’s total synthesis of chloroquine 3.56-57  
 The four reaction step synthesis of mefloquine 5 has been described by Lutz et al.59 
(Scheme 6). The initial step involves the condensation of ethyl 4,4,4-trifluoroacetoacetate 50 
and o-trifluoromethylaniline 51 with polyphosphoric acid (PPA) to obtain the 4-quinolone 
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52. Bromination using POBr3 produces 4-bromoquinoline 53, which is treated with BuLi, 
followed by CO2, to yield the 4-quinolinecarboxylic acid 54. The introduction of 2-
pyridyllithium 55 yields the pyridyl ketone 56, which is subjected to hydrogenation to afford 
mefloquine 5.  
 
 
 
 
 
 
Scheme 6. Lutz’s synthesis of mefloquine 5.59  
The large scale synthesis of primaquine 8 by Elderfield et al.,60 is illustrated below (Scheme 
7). This involves condensation of 1,4-dibromopentane 55 with potassium phthalimide 56 to 
obtain the phthalimido bromide 57. Substitution of bromine by 6-methoxy-8-
aminoquinoline 58 yields the phthalimido-quinoline intermediate 59, which is subsequently 
reacted with hydrazine to remove the phthalimido moiety and afford primaquine 8. 
 
 
 
 
Scheme 7. Synthesis of primaquine 8 by Elderfield.60  
1.5.2.  Synthesis of Artemisinin and its derivatives  
Over the last two decades, the total synthesis of the sesquiterpene endoperoxide lactone 
artemisinin 14 and its derivatives has been explored, since extraction from the herb A. 
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annua gives the compound in low yields.61 Schmidt and Hofheinz developed the first 
complete synthetic route for artemisinin 14 from (-)-isopulegol.62 Starting with (+)-
isolimonene 60, Ravindranathan et al. 63 completed the total stereoselective synthesis of 
artemisinin 14 via an intra-molecular Diels-Alder reaction, whilst Avery and co-workers 
detailed a 10-step stereoselective synthesis from (R)-(+)-pulegone.64 Recently, Yadav and co-
workers have described the complete synthesis of artemisinin 14 in fewer steps, with high 
stereoselectivity and high overall yield (Scheme 8).65 The synthetic route involves 
regioselective exocyclic hydroboration of (+)-isolimonene 60 with dicyclohexyl borane 61 to 
afford the alcohol 62 in 82% yield.  
 
 
 
 
 
 
 
 
 
 
Scheme 8. Yadav’s total stereoselective synthesis of artemisinin 14.65  
The alcohol 62 was oxidized using Jones reagent into its corresponding acid 63, which was 
then subjected to iodolactonization with KI and I2 in aq. NaHCO3 to obtain the 
diastereomeric iodolactones 64 and 65. Alkylation of iodolactone 64 was achieved via an 
intramolecular radical reaction using Chatgilialoglu’s reagent and methyl vinyl ketone 66, to 
form the alkylated lactone 67. Treatment of the keto moiety of 67 with ethanedithiol in the 
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presence of BF3.Et2O afforded the diastereomeric thioketal lactones 68 and 69 in overall 
quantitative yield. Subsequent hydrolysis and esterification of the thioketal lactone 69 in the 
presence of diazomethane yielded the ester 70, which was oxidized with PCC to afford the 
keto derivative 71.  Transformation of the keto ester 71 to the corresponding methyl vinyl 
ether 73 was achieved via the Wittig reaction with the triphenylphosphonium salt 72 and 
2M-KHMDS. In the presence of HgCl2.CaCO3, the thioketal 73 was deprotected to furnish the 
intermediate 73a. Subsequent photo-oxidation using O2 with Rose Bengal and acid 
hydrolysis afforded the artemisinin 14.65     
The transformation of artemisinin 14 into its derivative DHA 15 is conveniently achieved by 
reduction of the C-10 carbonyl group to the alcohol with sodium borohydride. In the 
presence of boron trifluoride-diethyl ether and the appropriate alcohol, DHA 15 is converted 
through an oxonium ion intermediate into the ester analogues 16, 17 and 18 and 
anhydroartemisinin 74 (Scheme 9).61,66 
 
 
Scheme 9. Synthesis of DHA and artemisinin analogues.   
1.6.  Strategies for the discovery of new anti-malarial drugs  
The need to develop new anti-malarial chemo-therapeutic and prophylactic agents has been 
increased by the emergence of plasmodium parasites which are resistant to the currently 
available drugs.67 Approaches which are currently being pursued include:- i) the 
development of analogues of existing anti-malarial drugs through chemical modifications; ii) 
the discovery of biologically active natural products; and iii) the rational design of  
compounds which are active against new biological targets.67-68   
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1.6.1. Development of analogues of existing anti-malarial drugs  
Chemical modification of existing anti-malarial therapeutics represents an effective and 
relatively inexpensive strategy.44,67 In the quest to synthesize new quinoline anti-malarials 
with greater potency and better pharmacological profiles, structure-activity relationship 
(SAR) studies of chloroquine 3 have been carried out to identify the structural features that 
are necessary for anti-plasmodial activity, and these are summarised in Figure 13.45-46  
 
 
 
 
 
 
 
Figure 13. Structural features of chloroquine and their effect on anti-plasmodial activity.  
Synthetic strategies in the design of new 4- and 8-AQs have focused on:- i) nucleophilic 
substitution of the quinoline nucleus; and ii) alteration of the length of the side chain and 
the nature of the terminal amino group on the side chain at C-4. 45-46,69 Solomon and co-
workers recently modified the side chain amino group of 4-AQs in order to study the effect 
of introducing heterocyclic moieties on the biological activity; their approach is summarised 
in Scheme 10. In the presence of N,N-dicyclohexylcarbodiimide (DCC) as a dehydrating agent 
or in refluxing toluene alone, the desired thiazolidin-4-ones 78-86, 5-methyl-thiazolidin-4-
ones 87-95, 1,3 thiazinan-4-ones 96-104 and 2,3-dihydrobenzo[e][1,3]thiazin-4-ones 105-
113 were produced from the appropriate 4-AQ’s 76a-c, the aldehydes 75a-c and the 
mercapto acids 77a-d.70 In another study, Wolf et al.71 described the synthesis and biological 
activity of 4-amino-7-chloroquinolyl amides, sulfonamides, ureas and thioureas with the 
variation of the side-chain length. The condensation of dasyl chloride 114 and ethanolamine 
afforded the sulphonamide derivative 115, which was treated with methanesulfonyl 
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chloride to obtain the mesylate 116. The desired sulfonamides 118a-f were formed by 
reacting the mesylate 116 with a series of quinoline-diamines 117 (Scheme 11). 
 
 
 
 
 
 
 
 
Scheme 10. Synthesis of heterocyclic derivatives as 4-AQ analogues. 
 The reaction of the diamine 119 with the appropriate isocyanate and isothiocyanate 120 
furnished the corresponding ureas and thioureas 126a-f. In addition, 119 was coupled with 
various acids 127 to afford the 7-chloro-4-aminoquinolyl-derived amides 128a-b.  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 11. Synthesis of novel 4-amino-7-chloroquinolyl amides, sulfonamides, ureas and 
thioureas. 
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In two related synthetic and anti-plasmodial activity studies, Chibale et al.72-73 synthesized a 
series of α-acylamino amides and lactams, based on the 4-AQ pharmacophore with variation 
in the side chain length, using Ugi isocyanide multi-component reaction chemistry. The 
reaction of 4,7-dichloroquinoline 129 with selected alkyl diamines afforded the quinoline 
derivatives 130, which were transformed into the Ugi adduct 134 in the presence of the 
aldehyde 131, an isocyanide 132 and a carboxylic acid 133. Using similar reaction conditions 
and resin-bound macroporous p-toluenesulfonic acid 137, the anticipated lactams 138 were 
isolated in reasonable yields (Scheme 12).73  
 
 
 
 
 
 
 
 
Scheme 12. Synthesis of α-acylamino amides and γ- and δ-lactams using Ugi isocyanide 
multi-component reaction chemistry. Reagents and conditions: i) 80oC, 1h ii) 135-140oC, 3h 
iii) MeOH, rt, 12-18h iv) 137, 1h v) filter, wash vi) 3% NH3/MeOH, filter, wash. 
   
Novel compounds based on the modification of the quinoline ring system have also been 
explored. Guy et al.74 reported the synthesis of 9-aminoacridine derivatives, which were 
screened for anti-malarial activity against chloroquine-resistant strains (Scheme 13). 
Treatment of the substituted salicylic acids 139 with methyl iodide and with 
trifluoromethanesulfonic anhydride furnished the triflates 140, which were coupled with 
substituted anilines 141 using the Buchwald protocol to yield the diaryl amines 142. The 9-
chloroacridines 143 were generated by hydrolysis of the methyl esters 142, followed by 
Friedel-Crafts cyclization with POCl3. In a parallel synthesis, 1,3-diaminopropane 144 was 
mono-protected with the nosyl group to obtain 145, which was treated with a series of 
carboxylic anhydrides 146. The resulting amides were reduced in situ with borane-
dimethylsulfide complex to afford the corresponding secondary amines 147. Subsequent 
reductive amination reactions with the aldehydes 148, followed by deprotection of the 
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nosyl group afforded the free amines 149, which were coupled with the acridines 143 to 
generate the products 150.74   
      
 
 
 
 
Scheme 13. Convergent synthesis of 9-aminoacridines from 9-chloroacridine and diaryl 
amines. Reagents and conditions: i) MeI, Cs2CO3, DMF ii) Tf2O, Et3N, DCM, -78 
oC to rt iii) 
141, Pd(OAc)2, BINAP, Cs2CO3, toluene iv) Ba(OH)2.8H2O, MeOH, 80 
oC, overnight v) POCl3, 
120 oC, 1h vi) 2-nitrobenzenesulfonyl chloride, DCM,0 oC to rt, overnight vii) 146, pyridine, 
THF viii) BH3-dimethyl sulfide complex, THF, 60 
oC, 30 min ix) 148, sodium 
triacetoxyborohydride, THF, sonicated, 35 oC, 1h x) Benzenethiol, Cs2CO3, degassed CH3CN, 
under argon xi) phenol, Cs2CO3, 3Å molecular sieves, DMSO, 100 
oC, 2h xii) DMSO, 100 oC, 
4h, methyl isocyanate polystyrene resin, overnight, rt. 
 
Synthetic approaches to new 8-AQ derivatives have been reported. Thus, Gomes et al.75 
recently described the synthesis of 8-AQ derivatives containing the imidazolidin-4-one ring 
and examined their rate of hydrolysis under physiological conditions (Scheme 14). The 
synthesis involved coupling of primaquine 8 with N-Boc protected amino acid to give the N-
Boc protected intermediate 152, which upon deprotection, afforded the amino acid 
derivative 153. Subsequent intramolecular cyclization of the intermediate 153 with an 
aldehyde or ketone furnished the desired product 154.        
 
Scheme 14. Synthesis of imidazolidin-4-ones of primaquine analogues. Reagents and 
conditions: i) N,N'-dicyclohexylcarbodiimide (DCCI), HOBt, Nα-Boc-protected amino acid 
(BocAAOH); ii) TFA, Na2CO3 iii) Me2CO or cyclic ketones or 3,4-(MeO)2–C6H3CHO in MeOH, 
Et3N, molecular sieves.  
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The discovery of ferrochloroquine (FQ) 155 as a potential anti-malarial drug has stimulated 
research into the design of metal-based aminoquinoline analogues.76 Several organo-
metallic compounds related to FQ have been successfully synthesized (Figure 14).76-79  
 
 
 
 
 
 
Figure 14. Metal-based 4-aminoquinoline anti-malarials. 
The synthetic strategy for accessing the quinoline metal-complex 155 involves an SNAr 
reaction between 4,7-dichloroquinoline 129 and the metallocene amine 160 in the presence 
of 1-methyl pyrrolidinone (NMP) and base.77-78 Alternatively, compound 129 may be reacted 
with the diamine 161 to afford the substituted quinoline amine 162, which upon treatment 
with the metallocenes 163 and 164 in the presence of sodium borohydride in methanol, 
gives the desired products 165 and 166 (Scheme 15).78      
 
 
 
 
 
 
 
Scheme 15. Synthesis of ferrochloroquine derivatives as potential anti-malarials. 
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Research on the development of new artemisinin derivatives with improved potency has 
focused on replacement of the C-10 hydroxyl group in DHA 15 by groups that are not readily 
susceptible to reduction or hydrolysis.44-45 Other structural modifications of the lactol ring 
system have involved derivatization at C-3, C-9, C-11 and C-13 respectively. In addition, 
compounds containing the peroxide moiety (1,2,4-trioxanes and tetraoxanes) have been 
used as synthetic scaffolds for the construction of potential novel inhibitors related to 
artemisinin 14.44,61 O’Neill et al.80 anticipated that accumulation of the C-10 ether linked 
diamino artemisinin analogues, would increase in the parasite food vacuole, thus increasing 
their anti-plasmodial activity. Their approach involved coupling DHA 15 with 1,4-
phenylenedimethanol 167 in the presence of boron trifluoride-diethyl ether (BF3.Et2O) to 
afford the alcohol 168, which was treated with mesyl chloride to obtain the corresponding 
mesylate 169. The desired diamino analogues 171 were isolated upon condensation of the 
mesylate 169 with the appropriate diamino nucleophiles 170 (Scheme 16).  
 
 
 
 
Scheme 16. Synthesis of C-10 ether linked diamino analogues of DHA 15.   
Chemical modification at the C-10 position was also investigated by Beué et al.81 through 
the synthesis of artemisinin analogues containing a fluorine substituent at the hemiacetyl 
carbon (C-10) and the α-methylene carbon (C-11) of DHA. The reaction of DHA 15 with the 
alcohol 172 in the presence of BF3.Et2O or TMSCl yielded the flurorinated artemisinin ether 
173. The fluorinated artemisinin alcohol 174 was produced by reacting artemisinin 14 with a 
molar equivalent of TMSCF3 and t-BAF.3H2O at room temperature for 25 hours, shown in 
scheme 17. The poor bio-availability and short plasma half-lives of the current artemisinin 
drugs are due to the susceptibility to hydrolysis of the acetyl group in vivo.45 Thus, the 
design of C-10 carba-analogues have been investigated by several research groups in the 
expectation that these compounds would be less prone to hydrolysis and exhibit long half-
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lives. Such an approach, reported by O’Neill et al.,82 involved the synthesis of fluorinated 
carba-analogues of artemisinin 14, with either an ether or ester linkage (Scheme 18).  
 
 
Scheme 17:  synthesis of fluorine-substituted artemisinin derivatives. 
DHA 15 was coupled with allyltrimethylsilane 175 to yield allyldeoxoartemisinin 176. 
Ozonolysis and subsequent reduction with sodium borohydride of the alkene afforded the 
alcohol 177, which was either deprotonated and reacted with appropriate substituted 
benzyl bromides 178 to obtain the ether products 179 or esterified with the corresponding 
substituted fluorinated acid chlorides 180 to yield the ester analogues 181. 
  
 
 
 
 
Scheme 18. Synthesis of C-10 carba-analogues of artemisinin 14.  
Yuthavong et al.83 have reported the synthesis of artemisitene 185, the oxidized form of 
DHA 15. The regiospecific transformation of artemisinin 14 to 185 was achieved through a 
one-pot synthesis involving lithiation to yield the enolate 182, formation of the 
phenylselenide bromide 183 and oxidation of which afforded the selenide species 184. 
Subsequent elimination of selenoxide gave the desired product 185 as a single isomer 
(Scheme 19). Michael addition of Grignard reagents to artemisitene 185 furnished the 
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Michael adducts 187 and 188, while, reaction of another molecule of artemisitene 185 with 
the enolate intermediate 186 afforded the dimer 189 (Scheme 20).83  
 
 
Scheme 19. Synthesis of artemisitene 185. 
 
Scheme 20. Michael addition of nucleophiles to artemisitene 185 using Grignard reagents.   
The design and synthesis of hybrid molecules as anti-malarial agents has recently been 
explored and offers a unique approach. These ‘dual inhibitors’ are envisaged to act against 
more than one target within the plasmodium parasite, thus making them potent against 
drug-resistant plasmodium strains.84 Quite recently, N’Da and co-workers described the 
synthesis and biological activity of artemisinin-quinoline hybrid dimers,85 and their synthetic 
strategy  is outlined in Scheme 21. Initially, DHA 15 was treated with BF3.Et2O and ethyl 
bromide 190 in DCM to obtain 2-(10β-dihydroartemisinoxy)ethyl bromide 191, which was 
subsequently reacted with various aminoquinolines 192-197 in DMF at between 70 oC and 
80 oC for 4 to 6 hours to yield the desired artemisinin-quinoline hybrids 198-203. 
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Scheme 21. Synthesis of artemisinin-quinoline hybrid molecules. 
1.6.2. Natural products  
Natural products derived from plants, bacteria and marine organisms are crucial sources for 
the discovery of lead compounds targeting various diseases and also offer novel scaffolds 
for the synthesis of analogues with improved potency and better pharmacokinetic 
profiles.41,86 Importantly, the two classes of current anti-malarial chemo-therapeutic agents 
i.e. quinolines and artemisinins, originate from plants. Natural products with anti-malarial 
activity that have been isolated from various plants and organisms include:- i) alkaloids such 
as naphthylisoquinolines, indoles and manzamines; ii) terpenes including diterpenes and 
sesquiterpenes; iii) flavonoids; iv) chalcones; and v) coumarins.86 Representative examples 
of compounds belonging to these classes are illustrated in Figure 15.  
The extraction and purification of natural products is often challenging and, consequently, 
poor yields are frequently obtained. New synthetic methodologies for the construction of 
novel compounds are continually being reported.86 The alkaloid febrifugine 210 and its 
stereoisomer, isofebrifugine 211, are present in traditional Chinese medicines used to treat 
fevers associated with malaria. These isomers have been isolated from the root of Dichroa 
febriguga and exhibit potent anti-plasmodial activity, but toxic side effects have limited 
their use.44,86 The synthesis of compounds 210 and 211 has been reported and chemical 
modifications have afforded potentially less toxic analogues. Scheme 22 outlines the 
asymmetric synthesis of the stereoisomers 210 and 211 reported by Takeuchi et al.87  
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Figure 15. Anti-malarial natural products. 
The approach involves reductive dynamic optical resolution of racemic-3-piperidones 204 
using baker’s yeast to obtain the chiral ketone 205 and alcohol 206. The alcohol 206 is 
converted via intramolecular bromoetherification with NBS to give the cyclic ether 207, 
dehydrobromination and bromoetherification of which affords a diastereomeric mixture of 
the methoxy intermediate 208. The quinazolinone 209 is produced by deacetalization of 
intermediate 208 and subsequent coupling with 4(3H)-quinazolinone. Hydrogenolysis of 209 
then affords isofebrifugine d-210, which is transformed upon heating to its isomer d-211.    
 
 
 
 
Scheme 22. Asymmetric synthesis of febrifugine and isofebrifugine.           
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In addition to isolating several novel naphthylisoquinoline alkaloids and exploring their anti-
plasmodial activity, Bringmann et al.88 synthesized a fluorescence-labelled analogue 219 of 
the natural product dioncophylline A 212. The attachment of a fluorescent moiety allows for 
the detection of dioncophylline A in malaria parasite-infected host erythrocytes. Their 
synthetic approach is outlined in Scheme 23. Bromination and O- and N-benzyl protection of 
dioncophylline A 212 afforded the N,O-dibenzylated -5-bromodioncophylline A 213, which 
was lithiated in situ and formylated with DMF to furnish the aldehyde 214; subsequent 
deprotection produced the phenol 215. Coupling of the sulfonyl amine 218 via reductive 
amination with compound 215 yielded the desired fluorescence-labelled analogue 219.   
 
   
 
 
 
 
 
 
 
 
Scheme 23. Synthesis of fluorescence-labelled dioncophylline A analogue.   
1.6.3. Rational drug design: inhibition of new biological targets  
Advances in molecular biology and the development of sophisticated computational 
methods have led to the rational approach to drug design.68 This innovative approach 
depends on the identification of pathogen enzymes as biological targets and the subsequent 
development of ligands that bind within the active-site and/or alter the biological function 
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of the target enzyme.68 Knowledge of the 3D-structure of the target enzyme, including a 
detailed understanding of the ligand-receptor binding site, may be obtained using x-ray 
crystallography, NMR spectroscopy and computer-aided molecular modelling techniques. 
Other approaches which are often integrated into the rational drug design process include;- 
virtual screening, synthetic combinatorial chemistry, high-throughput screening, docking, 
quantitative structure-activity relationships (QSAR) and quantitative structure-property 
relationships (QSPR).68 The rational design and optimization of potential inhibitors typically 
involves in silico binding affinity and in vitro biological activity studies  as well as studies of 
the pharmacokinetic properties of the ligand of interest.68 Biological pathways and enzymes 
in plasmodium species that have recently been targeted for the discovery of new anti-
malarial drugs are summarised in Table 1.67,89 One such target, which has been identified 
recently and which is the focus of this synthetic study, 1-deoxy-D-xylulose-5-phosphate 
reductoisomerase (DXR) – an enzyme which functions in the non-mevalonate pathway 
within the apicoplast organelle of plasmodium parasites.67,89 
Table 1. P. falciparum targets for novel drug design.89    
Target Enzyme/process Inhibitor 
   
Membrane biosynthesis Phospholipid synthesis (choline transporter) G-25 
Parasite proteases   Plasmepsins, falsipains  Leupeptin, pepstatin 
 
Shikimate pathway 5-enolpyruvyl shikimate-3-phosphate 
synthase 
Glyphosate 
 
Apicoplast DNA synthesis (DNA gyrase) 
Type II fatty acid biosynthesis (Fab H, Fab I)  
Quinolones 
Thiolactomycin, 
triclosan 
 
Mitochondrial system  Cytochrome C oxidoreductase  Atavoquone  
 
Redox system Thioredoxin reductase 
  
Gamma-GCS  
 
5,8-Dihydroxy-1,4-
naphthoquinone 
Buthionine sulfoximine 
 
Pyrimidine metabolism Thymidylate synthase 5-Fluoroorotate 
 
Isoprenoid biosynthesis 
 
 
Cyclin-dependent 
protein kinase 
1-deoxy-D-xylulose-5- phosphate 
reductoisomerase 
 
Pfmrk 
Fosmidomycin  
 
 
thiophene sulfonamide 
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1.7.  1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) as a target 
for anti-malarial drug design  
 
1.7.1. Isoprenoid biosynthesis via the mevalonate-independent pathway   
Isoprenoids are derived from the five-carbon isomeric isoprene units isopentenyl 
pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), and form a large and 
structurally diverse class of natural products.90 Currently, more than 30 000 isoprenoids 
have been discovered and these compounds are involved in carrying out various essential 
biological functions in all living organisms including:- i) electron transport processes 
(ubiquinone); ii) signal transduction (prenylated proteins); iii) growth regulation (steroid 
hormones and cytokinins) and; iv) membrane modulators (sterols).91 The precursors for 
isoprenoid biosynthesis, IPP and DMAPP, are constructed via two different biosynthetic 
routes. In mammals, plants, fungi and some bacteria, the precursors are synthesized by the 
mevalonate (MVA) pathway, discovered in the 1950’s and summarized in Figure 16.90 This 
biosynthetic route involves Claisen condensation of two molecules of acetyl-CoA 220 to 
form acetoacetyl-CoA 221, which further condenses with another molecule of acetyl-CoA 
producing 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) 222. Two successive nicotinamide 
adenine dinucleotide phosphate (NADPH)-dependent reductions of HMG-CoA 222 produce 
MVA 223, which is phosphorylated twice to yield mevalonic-5-diphosphate (MVA-PP) 225. 
Subsequent decarboxylation of MVA-PP gives IPP 226, which isomerizes via a 1,3-proton 
shift to give DMAPP 227.92  
 
 
 
 
 
Figure 16. The mevalonate (MVA) pathway for isoprenoid biosynthesis.92     
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The second pathway, termed the non-mevalonate or DOXP/MEP pathway, was discovered 
in 1993 and occurs in most eubacteria as well as plastids of algae and higher plants.91 Both 
pathways operate in higher plants, leading to cytosolic isoprenoids (sterols) via the MVA 
pathway and plastidic isoprenoids (carotenoids) are synthesized through the DOXP/MEP 
pathway. The DOXP/MEP pathway consists of the seven enzymatically catalysed steps 
summarized in Figure 17.91,93  
 
 
 
 
 
 
Figure 17. The reaction steps of the DOXP/MEP pathway.93    
The initial step, catalysed by the thiamine diphosphate-dependent DXP synthase (DXS) 
involves the condensation of pyruvate 228 and glyceraldehyde-3-phosphate 229 to form 1-
deoxy-D-xylulose 5-phosphate (DOXP) 230. In the next step, DOXP reductoisomerase (DXR) 
catalyses the conversion of DOXP 230 into 2-C-methyl-D-erythritol 4-phosphate (MEP) 231 
through an intramolecular rearrangement and NAPDH-dependent reduction step.91 
Subsequent cytidylylation of MEP 231 affords 4-diphosphocytidyl-2-C-methyl-D-erythritol 
(CDP-ME) 232, which is phosphorylated at the C-2 hydroxyl group by CDP-ME kinase to yield 
4-diphosphocytidyl-2-C-methyl-D-erythritol-2-phosphate (CDP-MEP) 233. In the next step, 
CDP-MEP 233 is transformed through cyclization into 2-C-methyl-D-erythritol 2,4-
cyclodiphosphate (MEcPP) 234 by MEcPP synthase.91 The reduction and dehydration of 
MEcPP 234 by 1-hydroxy-2-methyl-2-(E)-butenyl-4-diphosphate (HMBPP) synthase affords 
HMBPP 235 which, upon further reduction and dehydration catalysed by HMBPP reductase, 
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produces IPP 226, which is then isomerised by isopentenyl diphosphate (IPP) isomerise  to 
DMAPP 277.91,93            
A large number of human bacterial pathogens such as Escherichia coli, Mycobacterium 
tuberculosis, Helicobacter pylori and the malaria plasmodium species, utilize the DOXP/MEP 
pathway exclusively for the biosynthesis of isoprenoids.91,93 With regard to P. falciparum, 
enzymes within this pathway have thus been identified as targets for the rational design of 
novel anti-malarial drugs. Importantly, the absence of functionally equivalent enzymes in 
the human host has made the DOXP/MEP pathway an attractive target for therapeutic 
intervention.93,94 A key enzyme in the pathway, 1-deoxy-D-xylulose-5-phosphate 
reductoisomerase (DXR), has been validated as a suitable target for a new class of anti-
malarial drugs as its catalytic activity is specifically inhibited by the antibiotic fosmidomycin 
236 and its acetyl derivative FR900098 237 (Figure 18).93,95 
 
 
Figure 18. Inhibitors of the DXR enzyme.  
1.7.2. Catalytic mechanism of DOXP reductoisomerase (DXR)  
The catalytic mechanism for the conversion of 1-deoxy-D-xylulose-5-phosphate (DOXP) 230 
to 2-C-methyl-D-erythritol-4-phosphate (MEP) 231 by 1-deoxy-D-xylulose-5-phosphate 
reductoisomerase (DXR) has been extensively studied in recent years.91,96-97 This 
transformation is the committed step in the non-mevalonate pathway and involves the 
formation of the intermediate 2-C-methyl-D-erythrose-4-phosphate 238, apparently via an 
intramolecular rearrangement followed by an NADPH-dependent reduction step. The 
presence of one of the divalent metal cations Co2+, Mn2+ or Mg2+ is essential for enzyme 
function.93,97  Although conclusive evidence is yet to the provided, three different 
mechanisms for the intramolecular rearrangement step 230 - 231 (Figure 17) have been 
proposed. These are: - i) retro-aldol/aldol rearrangement; ii) α-ketol rearrangement; and iii) 
1,2-hydride/methyl shift type mechanism, as depicted in Figure 19.97 The retro-aldol/aldol 
mechanism (Figure 19a) involves the deprotonation of the C-4 hydroxy group of DOXP 230, 
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followed by C-3 and C-4 bond cleavage to give the enol/enolate of 3-hydroxyacetone 239 
and glycoaldehyde-3-phosphate 240. The recombination of these two moieties via an aldol 
addition reaction generates a new C-C bond between carbon atoms derived from C-2 and C-
4 of 230 to furnish intermediate 238.93,97 The α-ketol rearrangement mechanism (Figure 
19b) involves oxidation of the C-3 hydroxy group of DOXP 230 to the ketone, concomitant 
with migration of the 1-hydroxy-2-phosphoethyl moiety to the ketone C-2 to give the 
intermediate 238.97 Support for such a reaction mechanism is provided by acetohydroxy 
acid isomeroreductase catalysed reaction enzyme, involved in the biosynthetic pathway of 
the amino acids isoleucine, valine and leucine.91,98 The third mechanism (Figure 19c) 
proposed by Argyrou et al.97 involves a 1,2-hydride shift of the C-3 proton to the ketone C-2 
carbonyl group of DOXP 230, with a sequential 1,2-methyl shift to generate the 
intermediate 238. Subsequent reduction of the intermediate 238 with NADPH yields MEP 
231.  
 
 
 
 
 
 
 
 
Figure 19. Proposed mechanisms for the DXR-catalysed conversion of DOXP 230 to MEP 
231. 
 
The stereochemistry of the DXR catalysed rearrangement and NADPH-dependent reduction 
steps have been investigated using recombinant DXR enzymes from Synechocystis, E. coli 
and M. tuberculosis.97,99-100 These studies indicated that the NADPH co-factor and the 
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migrating C-4 moiety are located on opposite faces of the metal-DOXP complex. The 
migration of the C-4 moiety to C-2 on the re-face of the intermediate 238 is followed by 
attack of the C-4 pro-S hyride from NADPH, as depicted in Figure 20. In addition, it was 
established that the C-1 pro-S hydrogen of MEP 231 is generated from the C-3 hydrogen of 
DOXP 230, thus classifying DXR as a class B dehydrogenase enzyme.99-100 
 
 
 
 
Figure 20. Stereochemical features of DXR-catalysed conversion of DOXP to MEP. H* = 
NADPH pro-S hydrogen transferred to form MEP.99-100  
    
1.7.3. Molecular structure of DXR  
Various research groups have successfully solved and published X-ray crystallographic 
structures of the DXR enzyme from a variety of organisms, including:- E. coli, M. 
tuberculosis, Z. mobilis and, more recently, T. maritima and Y. pestis.91,101-109 However, a 
well-defined crystal structure of P. falciparum DXR (PfDXR) has yet to be published, although 
two homology models generated using comparative protein modelling, have been reported 
by Singh et al. and by Goble et al., respectively.110-111 The generation of these structures of 
the DXR enzyme has revealed important key features including:- i) the structure and 
conformational dynamics of DXR; ii) the ligand and metal binding residues of the catalytic 
site; and iii) kinetic parameters of DXR.     
1.7.3.1. Structure and conformational dynamics of DXR  
Analyses and evaluation of the architecture of EcDXR from the published crystal structures 
reveal that DXR exists as an 86 kDa homo-dimer, with each monomeric unit comprising of 
three distinct domains arranged in a pronounced cleft-like or V-shaped structure, as 
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N-terminal 
domain  
NADPH 
illustrated in Figure 21.101-105  The three domains are:- i) an N-terminal binding domain 
(residues 1-150) consisting of several parallel-stranded β-sheets and α-helices that binds the 
NADPH co-factor; ii) a central or connective domain (residues 150-285) consisting of the 
active site and the flexible or catalytic loop; and iii) the C-terminal, four-helix bundle domain 
(residues 312-398), connected to the catalytic domain and providing structural support for 
the active site.101,103,105 Structural analyses of the published apo-enzyme showed significant 
mobility of the catalytic and C-terminal domain of the three, protein conformers present in 
the asymmetric unit of the crystal.101 In addition, the apparent flexibility seen for the 
catalytic loop suggests that DXR is structurally flexible and undergoes conformational 
change upon substrate binding, with the catalytic loop folding over the active site as a ‘lid’,  
thus shielding the active site from the solvent environment.101,103-105 In the PfDXR homology 
model structure, Goble et al.111 established structural similarities between PfDXR and 
EcDXR. 
 
 
 
 
 
 
 
 
 
 
Figure 21. Ribbon representation of the EcDXR monomer showing the three domains, the 
NADPH co-factor, the N-terminal domain (blue); the connective domain (red); the catalytic 
loop (ochre); C-terminal four-helix bundle domain; and NADPH (yellow). Adapted from the 
structure published by Reuter et al.101  
Catalytic 
loop 
C-terminal 
domain  
Connective domain  
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1.7.3.2. DXR catalytic site: ligand-binding residues and binding of co-factors 
 X-ray crystal structures of DXR complexed with combinations of the substrate DOXP 230, 
the inhibitor fosmidomycin 236 and the co-factors, NADPH and the metal cations (Mn2+, 
Mg2+), have permitted identification of the active-site residues involved in their binding.102-
105 These structures reveal that the DXR active-site is comprised of three regions:- i) the 
phosphonate binding pocket; ii) the divalent-metal cation binding site; and iii) a relatively 
narrow hydrophobic region accommodating the carbon backbone of the substrate or 
inhibitor.103,105 A crystal structure of EcDXR determined by Mac Sweeney et al.105 reveals the 
phosphonate moiety of fosmidomycin 236 occupying the positively charged phosphonate 
binding pocket and interacting with active site residues Ser186, Gly187, Ser222, Met225, 
Asn227, Lys228 and Ile250 (Figure 22), with its carbon backbone of 236 aligned parallel to 
the Trp212 β-indole ring ca. 4 Å away; the hydroxamate moiety of the inhibitor adopts a 
planar configuration and interacts with the metal via a bidentate chelation.105  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. The EcDXR active site with fosmidomycin 236 interacting with binding residues. 
Fosmidomycin is shown in ball and stick format (coloured by element), NADPH in ball and 
stick format (coloured yellow) and amino acid residues shown in wireframe format 
(coloured by element).  Adapted from EcDXR PDB code 1Q0L105    
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 The structure of EcDXR complexed with DOXP 230 and NADPH reveal similar binding 
interactions, with the negatively-charged phosphonate moiety of DOXP interacting with 
residues Ser186, Ser222, Asn227 and Lys228.105 The carbon backbone of the molecule again  
aligns parallel to the β-indole ring of Trp212 whilst:- the C-2 carbonyl oxygen interacts with 
Glu152 and Ser151; the C-3 hydroxyl group interacts with Lys125 and Glu231; and the C-4 
hydroxyl group binds to Glu 152, Asn227 and Lys228, respectively. Also, NADPH is shown to 
interact with several residues in the N-terminal domain including Gly11, Ser12, Gly14, Ala35, 
Gly36 and Ala105.105 Yajima et al.103 observed that the binding of NADPH to EcDXR structure 
results in stabilization of the active site, with a more ordered flexible loop region.103 
Structural analyses of EcDXR complexed with fosmidomycin 230 and NADPH show the close 
binding proximity of the co-factor to the substrate 230, as shown is Figure 23.105  
 
 
 
 
 
 
 
 
 
 
 
Figure 23. The EcDXR active site with substrate DOXP 230 and NADPH interacting with 
specific binding residues. The close proximity of NADPH (shown in ball and stick format and 
coloured yellow) to DOXP (shown in ball and stick format and coloured by element) is 
essential for catalytic activity. Amino acid residue Trp212 is represented in stick format 
(coloured green). Adapted from EcDXR PDB code 1Q0Q.105   
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The position of NADPH relative to the DOXP 230 in the active site is significant for the 
catalytic activity of DXR, as the C-4 pro-S hydrogen of NADPH is transferred to C-2 to form 
MEP.99 NADPH is considered to interact with active-site residues before the substrate DOXP 
(or the inhibitor) binds and induces folding of the flexible loop over the active site. Several 
residues have been identified as essential for the correct positioning of DOXP 230 within the 
DXR catalytic site. These include residues His153, Gly185, Ser186, His209, Trp212, 
Met214,Glu231 and His257.102,104,112 The two residues Ser186 and His209, which form part 
of the flexible loop, have been implicated in tight DXR-NADPH-ligand binding complexes, 
whilst Gly185 and Met214 are described as ‘hinges’ for the folding-mechanism of the 
catalytic loop.105,113 The position of the divalent metal cation in MtDXR was established by 
Henriksson et al.107 and in EcDXR by Steinbacher et al.104 The metal cation is assumed to 
anchor the substrate in the desired conformation required for the rearrangement step and 
to stabilize the intermediate 238 through electrostatic interactions.97,107 The C-2 carbonyl 
oxygen and C-3 hydroxyl group of DOXP 230 has been shown to coordinate to the metal 
cation; a water molecule and the active-site residues Asp150, Glu152 and Glu231 have also 
been identified as metal-chelating groups, resulting in the distorted octahedral coordination 
complex shown in Figure 24.105,107 The interaction of fosmidomycin 236 with the metal 
cation is similar and involves a water molecule and the residues Asp151, Glu153 and Glu222 
in MtDXR, and residues Asp150, Glu152 and Glu231 in EcDXR to form an octahedral 
coordination sphere (Figure 24).103,105,107  
 
 
 
 
Figure 24. Chelation of the divalent metal cation by DOXP 230 and fosmidomycin 236.105,107  
1.7.3.3. Kinetic parameters of DXR  
The kinetic parameters for DXR enzymes isolated from several organisms have been studied 
and quantified, and are summarised in Table 2.114 The catalytic activity of DXR is optimal 
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within a pH range of 7 - 8.5 and temperature range of 50-60 oC. Studies have indicated DXR 
to have a preference for NADPH as oppose to NADH as co-factor and a higher affinity for 
Mg2+ over Mn2+ in vivo.97,114 The Michaelis constant (Km) describes the binding affinity of the 
substrate for the enzyme and quantifies the concentration of substrate at which the 
reaction occurs at half its maximum rate; whilst the catalytic constant (Kcat) measures the 
catalytic efficiency of the enzyme.92     
Table 2. Kinetic parametersa for DXR from several organisms. 114   
DXR enzyme Km (μM) Kcat (1/[S]) 
   
E. coli  3 – 250      29 – 38 
Z. mobilis        300      14 
S. coelicolor       190      19.2 
M. tuberculosis      4 – 240 2.1 – 5.3 
A. Thaliana      132       4.4 
T. maritima      40 000  0.29 
   
              
a
Parameters determined with substrate DOXP, NADPH and divalent metals Mg
2+
, Mn
2+
 or Co
2+
  
 
1.7.4. The design of DXR inhibitors: fosmidomycin and DOXP analogues   
1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) is an attractive target for the 
rational design of new anti-malarial chemotherapeutic drugs due to the fact that:-  i) the 
vital DOXP/MEP pathway for isoprenoid biosynthesis is present in P. falciparum, the most 
pathogenic species; and ii) neither DXR nor functionally homologous enzymes are present in 
humans, thus precluding undesirable side-effects during chemotherapy.91,93 Also significant 
was the discovery of fosmidomycin 236, an antibiotic isolated from Streptomyces 
lavendulae, as a specific and competitive inhibitor of DXR.95,115 Jomaa et al.116 established 
the anti-malarial activity of fosmidomycin 236 and its acetyl derivative FR900098 237, both 
of which inhibited the rodent malaria parasite P. vinckei in a dose-dependent manner. In 
vivo studies showed that fosmidomycin 236 was non-toxic and highly efficient in the 
treatment of patients with acute uncomplicated P. falciparum malaria, albeit with a high 
recrudescence rate. Unfortunately, the poor pharmacological properties exhibited by 
fosmidomycin 236 and FR900098 237, such as low bioavailability and short plasma half-life, 
due to its high hydrophilicity, have limited their use as therapeutic drugs.91,95  
 Introduction  
 ________________________________________________________________________________  
  
Page | 48  
 
However, the potent and specific DXR inhibitory activity of compounds 236 and 237 has 
encouraged structure-activity relationship studies and synthetic approaches towards the 
design of analogues as potential DXR inhibitors. The availability of DXR crystal structures 
(discussed above) with bound substrate 230 and fosmidomycin 236, have assisted in 
identifying the negatively charged hydroxamate functionality and phosphonate moiety as 
critical structural groups required for antimalarial activity.103,105 The C-2 carbonyl oxygen 
and C-3 hydroxyl group in DOXP 230 and the hydroxamate functional group in fosmidomycin 
are involved in divalent-metal cation chelation; whilst the phosphonate moiety occupies the 
phosphonate binding site. In addition, Mac Sweeney et al.105 observed that a defined 
distance (C-spacer) between these two polar functional groups is necessary for potent 
antimalarial activity. Synthetic strategies towards new DXR inhibitors have thus focused on:- 
i) the introduction of substituents in the C-backbone of DOXP 230 and fosmidomycin 236; ii) 
functionalization of the phosphonate moiety; and iii) modification of the hydroxamate 
group. 
 In recent years, various fosmidomycin analogues based on modification of the phosphonate 
group (Figure 25), have been synthesised and evaluated for their anti-malarial activities. 
With the aim of improving the bioavailability, prodrugs of fosmidomycin 236 and FR900098 
237, the phosphodiaryl 241, acyloxyalkyl ester 242 and alkyoxycarbonyloxyethyl 243 
analogues, showed a two-fold increase in anti-malarial efficacy in comparison to 
fosmidomycin 236 after oral administration in mice infected with P. vinckei, although the 
ester linkage is prone to hydrolysis in vivo.117-119  In other studies, Yajima et al.120 reported 
the synthesis of the  bi-phosphonates 244 and 245 which exhibited inhibitory activity 
against EcDXR with IC50 values of 4 and 7 μM respectively; and Woo et al.
121 designed 
fosmidomycin analogues by replacing the phosphonate group with a phosphate (246-247), 
carboxylate (248) and sulfamate (249) moiety. The biological activity of these novel 
compounds against recombinant Synechocystis sp. DXR showed that the phosphate 246 and 
its acetyl analogue 247 exhibited greater potency than fosmidomycin 236, but subsequent 
cleavage by phosphatases resulted in inactivation.121 Recently, a coordination-structure 
based approach was used by Song et al.122 to develop the lipophilic DXR inhibitors 250 and 
with moderate (IC50 of 4.5 and 1.4 μM) anti-inhibitory activity.
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Figure 25. Fosmidomycin analogues, based on modification of the phosphonate moiety, as 
DXR inhibitors.   
 
Analogues of fosmidomycin 236 and FR900098 237, in which the C-spacer between the 
phosphonate and hydroxamate moieties is functionalized, have been synthesised and their 
DXR activity evaluated (Figure 26). Van Calenbergh et al.123-126 have synthesised:- i) α,β-
unsaturated α-aryl-substituted analogues 252-254 of FR900098 237; ii) α-aryl-substituted 
fosmidomycin analogues 255-258; iii) conformationally-restricted cyclopropyl analogues 259 
and 260; and, recently, iv) the α-halogenated analogue 261.123-126 In vitro, the anti-malarial 
activity of the analogues 255-258 and 261 analogues was comparable with that of 
fosmidomycin 236; whilst analogues 252-254 and 259-260 exhibited low to zero anti-
malarial activity.  
 
Figure 26. Fosmidomycin analogues, based on the functionalization of the C-spacer, as DXR 
inhibitors.  
 
Structural studies of DXR have suggested that variation in the length of the C-spacer would 
decrease the binding affinity of potential inhibitors in the DXR active site, leading to reduced 
activity.105 Interestingly, other studies have indicated the presence of a hydrophobic binding 
pocket beyond the phosphonate-moiety binding site and also a hydrophobic pocket within 
the active-site, located between the C-backbone α-position and the phosphonate binding 
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region.127-129 These additional binding sites may be exploited and direct the synthesis of 
novel compounds with better DXR inhibitory activity. Structural modification of the metal-
binding hydroxamate moiety has also been explored. Mercklé et al.130 synthesised the cyclic 
analogue 262, which showed DXR inhibitory activity in the μM range. The design of 
fosmidomycin analogues in which the hydroxamate functionality has been inverted or its 
orientation reversed to a hydroxamic acid group has also been investigated (Figure 27). 
Kuntz et al.131 synthesised the hydroxamic analogues 263 and 264 which exhibited the same 
activity as fosmidomycin 236 against recombinant EcDXR; while Kurz et al.132-133 has 
reported the synthesis of carboxylic acid 265 and hydroxyurea 266 analogues of 
fosmidomycin 236. Recently, Kurz et al.134 reported the synthesis of α-phenyl substituted 
hydroxamic analogues and demonstrated the inhibitory activities of these analogues to be 
as potent as those of fosmidomycin 236 against recombinant PfDXR and the multidrug-
resistant K1 P. falciparum strain.134 
 
 
 
 
 
 
Figure 27. DXR inhibitors based on the modification of the hydroxamate moiety.   
 
Various research groups have reported the synthesis of structural analogues of the 
substrate DOXP 230 as potential inhibitors of DXR (Figure 28). Hoeffler et al. synthesised 
DOXP analogues 269 and 270 with one of the hydroxyl groups absent at either the C-3 or C-4 
position, and showed that these compounds acted as mixed-type inhibitors of EcDXR.135 
Kinetic analyses of EcDXR activity in the presence of these inhibitors indicated that the C-3 
and C-4 hydroxyl groups are essential for catalytic transformation of DOXP 230 to MEP 231, 
but not critical for inhibition activity. The analogues 271-273 inhibited EcDXR at mM 
concentration, showing that compounds with neutral or negatively charged donor atoms 
can coordinate with the metal cation in the active site, whilst the ethyl DOXP analogue 274 
and the trifluoromethyl analogue 275, exhibited steric interactions upon chelation at the 
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metal-binding site.136-137 The design of inhibitors which target the NADPH binding domain of 
DXR have also been explored. Link et al.138 reported the synthesis of the 3',N6-disubstituted 
adenosine NADPH analogue 276 (Figure 28), using a polymer-assisted solution-phase 
method. Biological evaluation of compound 276 revealed moderate anti-malarial activity 
(low mM) against P. falciparum strain Dd2 as well as EcDXR inhibitory activity.138 However, 
the study did not confirm the binding of the analogue 276 to the NADPH binding site and 
hence, the DXR inhibition observed could not be correlated with the anti-plasmodial activity.               
                             
 
 
 
 
 
Figure 28. Structural analogues of DOXP and NADPH as DXR inhibitors. 
 
1.8. Previous work in the group and aims of the present study 
In an effort to develop novel adenosine triphosphate (ATP) analogues as potential glutamine 
synthetase (GS) inhibitors for the treatment of tuberculosis various compounds were 
prepared, including the anilide 277 (Figure 29).139-141 Serendipitously, this compound was 
found to exhibit an explicit binding interaction with EcDXR in Saturation Transfer Difference 
(STD) protein-NMR experiments. Furthermore, EcDXR inhibition assay studies revealed that 
ligand 277 exhibited low-level inhibition of the enzyme, thus highlighting its potential as a 
lead compound in the design and synthesis of novel DXR inhibitors. In a cognate study in our 
group,129,142 the heterocyclic phosphonate esters 278a-e and 280a-e and their 
corresponding phosphonic acid salts 279a-e and 281a-e (Figure 29) were synthesised. In 
these compounds the benzene ring in compound 277 has been replaced by various 
heterocyclic systems. The potential of these analogues to act as DXR inhibitors was 
evaluated in silico and in vitro. EcDXR inhibition studies of these analogues, however, 
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revealed that they exhibited minimal to moderate inhibitory activity, whilst the presence of 
an additional binding pocket was observed during the in silico exploration of the DXR active 
site.129,142 The presence of this additional binding pocket led to the de novo design of a new 
class of potential inhibitors.  
      
 
 
 
 
 
Figure 29. DXR inhibitors synthesised in our research group.     
As indicated in the previous section, 1-deoxy-D-xylulose-5-phosphate reductoisomerase 
(DXR) is a key enzyme functioning in the biosynthesis of isoprenoid precursors in malaria-
pathogenic Plasmodium species and has been validated as a target for anti-malarial 
chemotherapy.93-95 Moreover, the antibiotic fosmidomycin 236 is a potent and selective DXR 
inhibitor of the virulent P. falciparum parasite.95,115 With detailed knowledge of the DXR 
active-site architecture, the aim of this research has been to design and prepare novel 
compounds as potential DXR inhibitors. More specifically, the project has involved the 
following parallel phases. 
1. The synthesis and characterization of:- 
i. dihydroxy-amido phosphonate esters and their corresponding phosphonic 
acids as DOXP and fosmidomycin analogues; 
ii. furan-derived phosphate esters and phosphonic acids as conformationally 
restricted DOXP analogues;  
iii.  several series of 3-substituted aniline-derived phosphonate esters and their 
corresponding phosphonic acids as potential DXR inhibitors;  
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iv. N-substituted benzylphosphoramidic acid derivatives as fosmidomycin 
analogues; and  
v. the known inhibitors fosmidomycin 236 and FR900098 237 for use as 
standards in DXR binding and inhibition studies.  
2. Biochemical and Microbiological studies, including:- 
i. the use of Saturation Transfer Difference (STD) protein-NMR experiments to 
detect the binding of selected synthesised compounds to EcDXR; and  
ii. DXR-enzyme inhibition assays of selected ligands to examine their ability to 
inhibit EcDXR and PfDXR activity.  
3. Molecular modelling, including simulated docking studies of selected ligands to 
establish preferred ligand-binding conformations, using the Cerius2 LigandFit 
module and Autodock version 4.0.    
2. Discussion 
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2. DISCUSSION 
With reference to the detailed aims and objectives, this discussion will focus on:- the 
synthesis of dihydroxy-amido phosphonate esters and phosphonic acid derivatives (Section 
2.1), 3-substituted aniline scaffolds (Section 2.2), furan-derived phosphates (Section 2.3) 
and N-benzyl substituted phosphoramidic acid derivatives (Section 2.4) as novel DXR 
inhibitors; the synthesis of fosmidomycin and FR900098 as standards for biological studies 
(Section 2.5); STD-NMR binding studies (Section 2.5), enzyme inhibition assays (Section 2.5); 
and docking studies (Section 2.6) of selected synthesised compounds.          
2.1. Synthesis of dihydroxy-amido phosphonate esters and phosphonic acid 
derivatives as novel DXR inhibitors 
 
Structure-activity relationship (SAR) studies of the DXR enzyme with the natural substrate 
DOXP 230 and of known inhibitors fosmidomycin 236 and FR900098 237 have led to the 
identification of structural groups which are considered critical for the inhibitory activity of 
DXR.103,105 These include the hydroxamate functionality and the phosphonic acid group, 
illustrated in Figure 30. A distance of three carbon atoms between these two functional 
moieties appears to be essential for inhibition of DXR. Our strategy for the synthesis of the 
first series of novel DXR inhibitors thus involved:-  i) mimicking the alkyl backbone of DOXP 
230 to retain enzyme-ligand binding specificity; and ii) modifying the phosphonate and 
hydroxamate moieties to obtain analogues with improved inhibitory activity.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Design strategy for the construction of novel DXR inhibitors, showing essential 
structural features.       
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In the design and synthesis of the dihydroxy-amido phosphonate esters 292 and their 
corresponding phosphonic acid derivatives 293, three synthetic routes were investigated, all 
of which commenced with ethyl (E)-crotonate; these are outlined in Scheme 24.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 24. Synthetic routes explored in the synthesis of the dihydroxy-amido phosphonate 
esters 292 and their corresponding acid derivatives 293.    
 
The initial step in Approach 1 (Scheme 24) involved bromination at the allylic position of 
commercially available ethyl (E)-crotonate 282, in the presence of a stoichiometric quantity 
of N-bromosuccinimide (NBS) as a source of bromine and a catalytic quantity of benzoyl 
peroxide, to obtain ethyl 4-bromocrotonate 283 in 56% yield (Scheme 25).143 This reaction is 
referred to as the Wohl-Ziegler bromination and involves a free-radical mechanistic 
Approach 1 
Approach 3 
Approach 2 
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CH3 OEt
O
OEt
O
Bri
282 283
pathway, initiated by the non-ionic fission of the weak N-Br bond.144 The use of NBS and 
carbon tetrachloride (CCl4) in this method provides several advantages. Firstly, the poor 
solubility of NBS in CCl4 ensures that the concentration of molecular bromine and hydrogen 
bromide (reagents generated in situ) are constantly kept low such that the bromination 
occurs exclusively at the allylic position and side reactions arising from addition across the 
double bond are prevented.145 Secondly, the resulting by-product, succinimide, is insoluble 
in cold CCl4 thus simplifying isolation of the product 283.  
     
 
 
Scheme 25. Synthesis of compound 283 via Wohl-Ziegler bromination.143  
Reagents and conditions: i) NBS, benzoyl peroxide, CCl4, 3 h, reflux.   
  
Figure 31 shows the 1H NMR spectrum of compound 283, indicating the two 4-methylene 
protons resonating as a doublet at 3.99 ppm. The 2- and 3-vinylic protons resonate as a 
doublet at 6.02 ppm and multiplet at 6.99 ppm, respectively whilst the 2'-methyl protons 
resonate as a triplet at 1.26 ppm and the 1'-methylene protons as a quartet at 4.18 ppm.  
   
 
 
 
 
 
 
 
 
Figure 31. 400 MHz 1H NMR spectrum of compound 283 in CDCl3.   
Br
O
O
4
3
2
1'
2'
3-CH 
2-CH 
1'-CH2 4-CH2 
2'-CH3 
 Discussion  
 ________________________________________________________________________________ 
 
Page | 57  
 
δ-  
δ+ 
P:
OEt
EtO OEt
+ Br
OEt
O
P
+
OEt
O
EtO
O
EtO
CH3
P
OEt
O
EtO
O
EtO
+
CH3
Br
Br
-
283 294
284295
Synthetic inhibitors of the DXR enzyme are typically characterised by the presence of a 
phosphonate moiety, which occupies the hydrophilic phosphate binding pocket in the DXR 
catalytic site.105,117-122 Several synthetic methods have been described, of which the 
Michaelis-Arbuzov reaction is one of the most versatile, for affording access to 
phosphonates, phosphinates and phosphine oxides.146-148 Thus, by subjecting compound 283 
to Michaelis-Arbuzov reaction conditions, the phosphonate ethyl ester 284 was obtained in 
reasonable yield (62%). The reaction involves the formation of an unstable 
trialkoxyphosphonium salt intermediate 294 by nucleophilic attack (SN2) of triethyl 
phosphite on the electrophilic alkyl halide 283.147-148 Subsequent halide ion mediated de-
alkylation of the intermediate 294 via another SN2 reaction affords the desired phosphonate 
ethyl ester 284 and an alkyl halide 295 (Scheme 26).  
 
 
 
 
 
Scheme 26. Synthesis of phosphonate ethyl ester 284 via the Michaelis-Arbuzov reaction.   
1H, 13C and 31P NMR spectroscopic analysis confirmed the formation of the product 284. The 
1H NMR spectrum (Figure 32) showed the presence of the 4-methylene proton signal as a 
double doublet at 2.70 ppm. The splitting of these methylene protons is due to the coupling 
to the adjacent 31P nucleus with a characteristic coupling constant of ca. 23 Hz and coupling 
to the adjacent vinylic proton (J = 7.6 Hz). The overlapping multiplets at 4.10 ppm and 1.27 
ppm are due to the 1' and 1''-methylene and 2' and 2''-methyl protons of the carboxylate 
and phosphonate ester ethyl groups, while the 2- and 3-vinylic protons resonate at 5.91 
ppm and 6.85 ppm, respectively. Analysis of the 13C NMR spectrum (Figure 33) clearly shows 
the characteristic splitting of the phosphonate methylene carbon (C-4) signal at ca. 29.9 
ppm with a large coupling constant of 138 Hz, due to the coupling to the 31P nucleus. The 
splitting of the signals corresponding to 1''- methylene and 2''-methyl carbons at 62.2 ppm 
and at 16.3 ppm, respectively, is also clearly evident, whilst the 2- and 3-vinylic carbon 
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signals appear at 125.8 ppm and 137.8 ppm, respectively; the C-1 carbonyl carbon signal is 
observed at 165.5 ppm. The 31P NMR spectrum showed a characteristic singlet at ca. 25 
ppm, confirming the presence of the phosphonate moiety.   
      
 
 
 
 
 
 
 
 
Figure 32. 400 MHz 1H NMR spectrum of compound 284 in CDCl3.     
 
 
 
 
 
 
 
 
 
Figure 33. 400 MHz 13C NMR spectrum of compound 284 in CDCl3.   
2'-CH3 and 
2 X 2''-CH3 
4-CH2  
1'-CH2 and 
2 X 1''-CH2 
2-CH 3-CH  
2 X C-2'' 
C-2' 
C-4 
C-1' 
2 X C-1'' 
C-2 
C-3 
C-1 
 Discussion  
 ________________________________________________________________________________ 
 
Page | 59  
 
P
OEt
O
EtO
O
OEt
P
NH
O
EtO
O
OEt R
284
285a-g
x
LiAlH
4
   +   5 eq. RNH
2
LiAl(NHR)
4 
16 h, 25 oC R
296 297a-g
298a-g
30 min, 25 oC
Et
2
O
x
3-5 days, r.t.
RNH
2
MWI / t -BuOK
RNH
2
150W, 100 oC, 3 min a     Me
b     Et
c     Pr
d     Pri
e     But
f     Ph
g     CH
2
Ph
x
In our design of novel DXR inhibitors, emphasis was placed on the construction of ligands in 
which the hydroxamate group, present in the known inhibitors fosmidomycin 236 and 
FR900098 237, is ‘rearranged’ into an amide moiety. The amide oxygen and nitrogen atoms 
are expected to chelate to the hard divalent metal cation, thus increasing the binding 
affinity of the molecules in the DXR active site. Although various research groups are 
involved in the design of novel DXR inhibitors, very few inhibitors bearing the amide 
functional group have been synthesised or their biological activity reported. Recently, Kurz 
et al. reported the synthesis of DXR inhibitors with a reversed orientation of the 
hydroxamate group, which exhibited similar anti-plasmodial activity against PfDXR as the 
known inhibitors fosmidomycin 236 and FR900098 237.149 Furthermore, in our strategy, it 
was reasoned that by varying the substituents on the nitrogen atom, the hydrophobicity of 
the molecules could be tuned and additional binding interactions with the active site 
residues could be explored.      
Various literature approaches were examined in an attempt to synthesize the phosphonated 
crotonamide derivatives 285a-g directly from the phosphonated ethyl ester 284 (Scheme 
27).150-152  
 
 
 
 
 
 
 
Scheme 27. Attempted synthesis of phosphono-crotonamide derivatives 285a-g via various 
literature methods.150-152  
 
Approach 1
 
 
  3
 
 
 
  
Approach 2 
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Usually, the aminolysis of esters requires drastic reaction conditions, such as high 
temperatures and long reaction times. In addition, strong alkali metal catalysts are often 
used to achieve this transformation.153-154 Driscoll et al., however, reported the direct 
conversion of esters to the corresponding amides under fairly mild conditions, isolating the 
products in good yields.150 We explored this method for the transformation of the 
phosphonated ethyl ester 284 to the phosphonated crotonamides 285a-g (Scheme 27, 
Approach 1), but, although the reaction mixtures were stirred for several days and 
monitored by TLC, no products were observed and only the starting materials were 
recovered.  
The next approach to be explored for the amidation of the phosphonated ethyl ester 284, 
involved the use of a metal complex as a convenient source of the nucleophilic amine to 
achieve the transformation. Weinreb et al. reported the reaction of trimethylaluminum with 
various amines to produce the dimethylaluminum amides in situ, which upon treatment 
with a variety of carboxylic esters furnished the corresponding carboxamides in satisfactory 
yields (69 - 100%).155 In a similar approach, Solladie-Cavallo reacted lithium aluminium 
hydride 296 with various amines 299a-d (Scheme 28) to generate the lithium aluminum-
amido complexes 300a-d in situ with liberation of hydrogen.151 Subsequent addition of the 
ester 301 to the metal-amido complexes 300a-d and, ester 302  to metal-amido complex 
300b, afforded the desired carboxamides 303a-d and 304b in good  yields, the former 
together with the diol 305.  
 
 
 
 
 
 
Scheme 28. Synthesis of amides from esters using lithium aluminium-amido complex 298.151   
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We therefore attempted the conversion of compound 284 to the corresponding 
phosphonated crotonamide derivatives 285a-g using Solladie-Cavallo’s methodology151 
(Scheme 27, Approach 2). The reaction was monitored by TLC but only trace amounts of the 
products appeared to be formed. The conjugation in compound 284 presumably deactivates 
the acyl carbon to nucleophilic attack by the metal-amido complex. The molar ratio of the 
lithiumaluminum-amido complexes 300a-d relative to compound 284 and the reaction time 
were then increased in an attempt to improve the yields, but this resulted in a mixture of 
products and Approach 2 was abandoned.  Interestingly, competing reactions in the metal-
amido complex catalysed conversion of esters to amides have also been described by 
Roskamp et al., who used a mixed tin-amide complex generated via a metathesis reaction of 
tin chloride and bis(trimethylsilyl)amido-lithium.156    
Hamelin et al. successfully synthesised a variety of carboxamides by reacting different esters 
and amines under solvent-free conditions in the presence of potassium tert-butoxide (t–
BuOK) and microwave irradiation.152 Based on this work, we subjected the phosphonated 
ethyl ester 284 and several amines to similar reaction conditions in the hope of isolating the 
desired phosphonated crotonamide derivatives 285a-g (Scheme 27, Approach 3). However, 
after filtration and evaporation of the solvent in vacuo, only the starting materials were 
recovered. Increasing the reaction time and temperature resulted in formation of a black 
solid, reflecting the decomposition of the substrate 284 at the elevated temperature.  
 In the synthesis of various carboxylic acid derivatives, including amides, acid chlorides are 
often used as activated acyl intermediates.157-158 Several reagents are commonly used for 
the conversion of carboxylic acids to their corresponding acid chlorides; these include 
phosphorous trichloride, thionyl chloride and oxalyl chloride.158-160 Given the difficulties 
experienced in the direct conversion of the phosphonated ethyl ester 284 to the  amide 
derivatives 285a-g, we explored the generation of the more reactive acid chloride, using 
ethyl (E)-crotonate 282 as the model substrate (Scheme 24, Approach 2). Initially, 
compound 282 was saponified using potassium hydroxide in ethyl alcohol to obtain, after 
acidification and recrystallisation, crotonic acid 286 as white crystals. Compound 286 was 
characterised by 1H NMR and IR spectroscopy, and converted to its corresponding acid 
chloride 287 using oxalyl chloride and a catalytic quantity of dimethylformamide (Scheme 
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29). The acid chloride 287 was purified by distillation and IR analysis showed the 
characteristic acyl chloride absorption band at 1757 cm-1.   
 
 
Scheme 29. Conversion of ethyl (E)-crotonate 282 to its corresponding acid 286 and acid 
chloride 287.  
Reagents and conditions: i) KOH in EtOH, r.t., 24 h then H3O
+ ii) (COCl)2, DMF, 4 h, N2.  
 
With the crotonyl chloride 287 successfully formed, the crotonamides 288c-g were 
synthesised in reasonable to good yields by treatment of the acid chloride 287 with a molar 
equivalent of each of the appropriate amines in the presence of triethylamine (Scheme 30). 
The synthesis of N-methylcrotonamide 288a and N-ethylcrotonamide 288b, however, 
required a different approach, as the amines used to obtain these amides were used as their 
hydrochloride salts. Proton sponge® [1,8-bis(dimethylamino)naphthalene],161 was used as a 
strong non-nucleophilic base (pKa = 12.34) to free the amines from their hydrochloride salt 
in situ, before treatment with the acid chloride 287 at 0 oC. Proton sponge has been 
successfully used in our group to promote nucleophilic substitution reactions of amine 
hydrochloride salts with coumarin substrates to furnish novel coumarin derivatives as 
potential HIV-1 protease inhibitors.162 The crotonamides 288a-g were all characterised by 1H 
and 13C NMR and IR spectroscopic analysis. Figure 34 shows the 1H NMR spectrum of N-
benzylcrotonamide 288g.  
 
 
 
 
 
Scheme 30. Synthesis of crotonamides 288a-g from crotonyl chloride 287.   
Reagents and conditions: i) RNH2, Et3N, 0 
oC to r.t., 24 h ii) RNH2.HCl, proton sponge, 
pyridine, 0 oC, 15 min, r.t., 24 h.  
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Figure 34. 400 MHZ 1H NMR spectrum of N-benzylcrotonamide 288g in CDCl3.  
The next step was expected to involve allylic bromination of the crotonamides 288a-g using 
the Wohl-Ziegler method 143 to obtain the brominated crotonamides 289a-g (Scheme 31). 
Attempted reaction of crotonamides 288a-g in the presence of NBS and a catalytic quantity 
of azobis(isobutyronitrile) (AIBN) in refluxing toluene was unsuccessful. Due to the 
sensitivity of this method to the solvent and temperature, different reaction conditions 
(Table 3) were investigated in an attempt to form compound 289f. Even under these varied 
conditions, the desired product could not be isolated. Competing reactions could include 
conjugate addition of hydrogen bromide, generated in situ, to the alkene group of the 
crotonamide 288f.  
 
 
 
 
Scheme 31. Attempted synthesis of brominated-crotonamides 289f using Wohl-Ziegler 
reaction. 
Reagents and conditions: i) NBS, benzoyl peroxide, CCl4, 3 hours, reflux.   
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Table 3. Attempted bromination of crotonamide 288f under various reaction conditions.  
Compound 
288f 
(equiv.) 
NBS 
(equiv.) 
  Solvent  Temperature 
(o C) 
      Catalyst  Time (h) 
 
1 
 
1.2 
 
toluene 
 
reflux  
 
AIBN 
 
3 
1 1 toluene r.t. AIBN 3 
1 0.5 toluene r.t. AIBN 12 
1 1 benzene reflux benzoyl peroxide 3 
1 1 CCl4 reflux  benzoyl 
peroxide 
6 
1 0.5 CCl4 r.t. benzoyl 
peroxide 
12 
1 1 C2H2Cl4 reflux AIBN 3 
      
      
 
A variety of coupling reagents have been developed for the formation of amide bonds 
directly from carboxylic acids and amines; these include N,N'-dicyclohexylcarbodiimide 
(DCC), N,N'-diisopropylcarbodiimide (DIC), 1,1'-carbonyldiimidazole (CDI) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC).163-166 With the success achieved in phosphonating 
compound 283 to afford the phosphonated ethyl ester 284, but the failure to obtain the 
brominated crotonamides 289a-g, the next strategy (Scheme 24, Approach 3), which 
involved direct coupling of γ-phosphonated crotonic acid 291 with amines, was explored.   
The previously synthesised substrates 283 and 284 were efficiently transformed,  using 
appropriate procedures, to furnish the γ-phosphonated carboxylic acid 291 (Scheme 32). 
Thus, hydrolysis of compound 283 afforded the brominated carboxylic acid 290 
quantitatively; subsequent phosphonation using the Michaelis-Arbuzov 146 reaction gave the 
desired carboxylic acid 291. Compound 291 was also obtained by hydrolysis of the 
phosphonated ethyl ester 284.   
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Scheme 32. Synthesis of the phosphonated carboxylic acid 291.  
Reagents and conditions: i) KOH in EtOH, r.t., 24 h then H3O
+ ii) triethyl phosphite, 9 h, 
reflux, N2.    
 
Comparison of the 1H NMR spectra of compound 284 (Figure 32) and compound 291 (Figure 
35), clearly reveals the disappearance of the 1'-methylene and 2'-methyl protons of the 
carboxylate ester moiety, as the overlapping multiplets at 4.15 ppm and 1.33 ppm integrate 
for the 1''-methylene and 2''-methyl protons of the phosphonate ester ethyl groups alone. 
The 4-methylene protons resonate at 2.81 ppm as a double doublet due to coupling to the 
31P nucleus, while the broad signal at ca. 5.10 ppm is assigned to the carboxylic acid proton.      
Figure 35. 400 MHZ 1H NMR spectrum of phosphonated carboxylic acid 291 in CDCl3.      
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Having synthesised compound 291 in reasonable yield, we decided to prepare the amido-
phosphonate esters 285a-g using EDC as the coupling reagent, in the presence of 
hydroxybenzotriazole (HOBt) and the appropriate primary amines (Scheme 33). The use of 
EDC-mediated coupling (as opposed to DIC- or DCC-mediated coupling) was motivated by 
the fact that EDC and its urea by-product are water soluble; hence, any excess reagent and 
by-product are easily separated from the desired products by aqueous extraction.166   
 
 
 
 
 
 
 
Scheme 33. Synthesis of amido-phosphonate esters 285a-g using EDC-mediated coupling. 
Reagents and conditions: i) EDC, HOBt, RNH2, DCM, 24 h, r.t., N2. 
The mechanism of the EDC-mediated coupling involves deprotonation of the carboxylic acid 
291 by EDC 306 to produce the carboxylate anion 307 and the activated carbodiimide 
species 308 and then, the highly electrophilic O-acylisourea intermediate 309. HOBt 310 is 
added to form the less reactive ester intermediate 311, which undergoes a nucleophilic acyl 
substitution by amines, to furnish, in our case, the desired amide derivatives 285a-g 
(Scheme 34). The HOBt suppresses competing reactions, including the formation of a stable 
N-acylurea by acyl migration and the formation of an acid anhydride in the presence of 
unreacted carboxylic acid.166       
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Scheme 34. Mechanism of the EDC-mediated coupling reaction of carboxylic acid 291 to 
form the amido-phosphonate esters 285a-g.  
 
The amido-phosphonate esters 285a-e and 285g are all new compounds, and were fully 
characterised by NMR spectroscopy and elemental analysis. The COSY spectrum of 
compound 285c is illustrated in Figure 36, while Figure 37 shows the HSQC spectrum of 
compound 285g. The couplings between the different protons present in compound 285c 
are clearly evident in the COSY spectrum (Figure 36). The 3''-methylene protons (J = 7.2 Hz) 
couple with the 2''-methylene protons, which couple in turn, to the 1''-methylene protons. 
The complex splitting pattern observed for the 1'-methylene protons is due to coupling to 
the 2'-methyl protons and the 31P nucleus. The 2-vinylic proton resonates as a double 
doublet (J = 13.6 and 1.6 Hz), indicative of coupling to the 3-vinylic proton and the allylic 4-
methylene protons.  In addition to coupling to the 2-vinylic proton, the 3-vinylic proton also 
exhibits coupling to the 4-methylene proton as well as long range coupling to the 31P 
nucleus.   
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Figure 36. COSY spectrum of compound 285c in CDCl3.  
The assignment of the carbon signals for compound 285g was achieved by analysis of the 
HSQC spectrum (Figure 37). The 1'- methylene and 2'-methyl carbon signals corresponding 
to the phosphonate ethyl ester groups resonate at 63.6 ppm and 16.1 ppm, respectively. 
Both of these signals are split into doublets, with coupling constants of 6.7 and 5.8 Hz, due 
to coupling with the 31P nucleus. The 4-methylene carbon signal at 35.4 ppm also appears as 
a doublet due to coupling with the adjacent 31P nucleus, but with a much larger coupling 
constant of 143.9 Hz, while the 1''-methylene carbon signal resonates as a singlet at 43.5 
ppm. The 2- and 3-vinylic carbon signals appear at 124.8 ppm and 138.3 ppm, respectively. 
The aromatic carbon signals are assigned as follows:- the signal at 127.5 ppm correlates to 
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C-5''; the signal at 127.8 ppm to C-3'' and C-7''; C-4'' and C-6'' correspond to the signal at 
128.7 ppm and the signal at 140.3 ppm to the C-2'' quaternary carbon.  
 
Figure 37. HSQC spectrum of compound 285g in CDCl3.  
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With the novel amido-phosphonate esters 285a-g successfully prepared, attention could be 
given to the final synthetic step required to furnish the targeted dihydroxy-amido 
phosphonate esters 292. This involved dihydroxylation of the alkene double bond. The 
hydroxyl groups were expected to hydrogen-bond with DXR active-site residues, such as Glu 
152, Asn 227, Lys 228 and Glu 231.105 Various methods can be used to accomplish 
dihydroxylation of alkenes. These include:- i) oxidation with KMnO4 in an alkaline solution, in 
the presence of a phase transfer catalyst ii) osmium tetraoxide-mediated asymmetric 
dihydroxylation using a stoichiometric quantity of oxidant such as tert-butylhydroperoxide, 
H2O2 or N-methylmorpholine-N-oxide; and iii) the Prevost-Woodward reaction using iodine 
in the presence of an equivalent of silver acetate or silver benzoate.167-169 Under anhydrous 
conditions (Prevost conditions), a vicinal diol with anti stereochemistry is formed, while in 
the presence of water (Woodward conditions), the syn-diol product is obtained.169  
However, over-oxidation of alkenes has been reported when using KMnO4, while the toxicity 
and high cost associated with OsO4 and, the cost of the expensive silver salts, limit the use 
of these reagents. In addition, these reactions depend on the nucleophilicity of the π-
electron-rich alkene double bond whereas in our analogues 285a-g, the double bond is 
deactivated towards electrophilic attack as a result of conjugation with the carbonyl group. 
Consequently, a different dihydroxylation approach was considered.         
Plietker et al. have recently developed a RuCl3/CeCl3/NaIO4 catalyst system for the 
dihydroxylation of deactivated alkenes, furnishing racemic syn-diol products in excellent 
yields.170-171 This ruthenium-based catalytic system has also been successfully used in our 
group to synthesise dihydroxy coumarin derivatives as intermediates in the construction of 
potential HIV protease inhibitors.162 Dihydroxylation of the phosphonated ester 284 (as a 
model substrate) using this catalytic system afforded the phosphonate diol 313 (Scheme 
35), the structure of which was confirmed by NMR spectroscopy and elemental analysis. The 
mechanism of the reaction involves [3 + 2]–cycloaddition of ruthenium tetraoxide 314 
(generated in situ from ruthenium trichloride) to the double bond in compound 284 to form 
the ruthenium(VI)-complex 315, which is oxidised to the ruthenate ester 316.171 Subsequent 
protonation of the cyclic ruthenate ester 316 under acidic conditions leads to the highly 
electrophilic ruthenate complex 317, which undergoes nucleophilic addition of water at the 
metal centre and cleavage of the ruthenium-oxygen bond, furnishing the desired syn-diol 
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313 and re-generation of the catalyst (Scheme 36). The acid-accelerated nucleophilic 
addition via protonation resembles the acid-catalysed hydrolysis of carboxylate esters.172  
 
 
 
Scheme 35. Dihydroxylation of phosphonate ester 284 using the ruthenium-based catalyst 
system.  
Reagents and conditions: i) RuCl3 (0.25 mol %), NaIO4 (1.5 eq.), CeCl3 (10 mol %), 
EtOAc/CH3CN/H2O (3:3:1), 0 
oC, 10 min.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 36. Mechanism for the dihydroxylation of compound 284 using the ruthenium-
based catalyst system. 
 
The 1H NMR spectrum (Figure 38) of compound 313 reveals the 1'-methylene and 2'-methyl 
proton signals of the phosphonate ethyl ester group overlapping with the signals for the 
ethoxy group at ca. 4.11 ppm and 1.28 ppm, respectively. The spectrum also confirmed the 
absence of the vinylic proton signals which had previously appeared between 6 and 7 ppm, 
supporting dihydroxylation of the double bond. The signals for the 2- and 3-methine protons 
appear at 4.35 and 4.33 ppm, respectively, while the pair of multiplets at 2.10 ppm and 2.3 
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ppm correspond to the diastereotopic methylene protons. The splitting pattern of these 
methylene protons reflects coupling to the adjacent 31P and 3-H nuclei, as well as to each 
other.  
While the overlap of signals in the 1H NMR spectrum may preclude unambiguous 
characterisation of the product, the well resolved 13C NMR spectrum (Figure 39) clearly 
supports identification of the product as the dihydroxy derivative 313. Thus, the 1'-
methylene and 2'-methyl carbon signals corresponding to the phosphonate ethyl ester 
group resonate as doublets, due to coupling with the 31P nucleus, at 62.0 and 16.3 ppm, 
respectively. The signals at 14.0 ppm and 61.8 ppm correspond to the 1''-methylene and 2''-
methyl carbons of the ethoxy group; the 4-methylene carbon resonates as a doublet (J = 
139.1 Hz) at 29.2 ppm, while the 3- and 2-methine carbon signals appear at 67.7 ppm and 
73.6 ppm, respectively. The C-1 carbonyl signal appears at 172.7 ppm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. 400 MHZ 1H NMR spectrum of compound 313 in CDCl3.    
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Figure 39. 100 MHz 13C NMR spectrum of compound 313 in CDCl3.  
Given the successful dihydroxylation of the phosphonated ester 284, using the ruthenium-
based catalyst, the amide analogues 285a-g were treated similarly to generate the 
dihydroxy-amido phosphonate esters 292a-g in reasonable yields (47% - 53%, Scheme 47). 
These compounds were fully characterised by NMR spectroscopy, elemental analysis and IR 
spectroscopy; the 1H and 13C NMR spectra are illustrated in Figures 40 and 41.   
 
 
 
 
 
 
 
 
Scheme 47. Synthesis of dihydroxy-amido phosphonate esters 292a-g using ruthenium-
based catalyst system.  
Reagents and conditions: i) RuCl3 (0.25 mol %), NaIO4 (1.5 eq.), CeCl3 (10 mol %), 
EtOAc/CH3CN/H2O (3/3/1), 0 
oC, 10 min.  
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The 1H NMR spectrum (Figure 40) of compound 292a shows the 2'-methyl and 1'-methylene 
proton signals corresponding to the phosphonate ethyl ester group resonating at 1.20 ppm 
and 4.03 ppm, respectively. The 1'-methylene signal is split into a multiplet due to coupling 
to 2'-methyl protons and the 31P nucleus. The signals corresponding to the diastereotopic 4-
methylene protons resonate as a pair of multiplets as a result of geminal coupling to each 
other, as well as vicinal coupling to the 3-methine proton and coupling to the 31P nucleus. 
The 3-methine proton signal is observed as a quartet (J = 7.2 Hz) at 3.46 ppm, while the 2-
methine proton resonates as a doublet (J = 7.6 Hz) at 4.21 ppm, respectively. The signal 
corresponding to the 1''-methyl group is observed as a singlet at 2.70 ppm, while the signals 
for the hydroxyl and amide protons appear at 2.30 ppm and 10.29 ppm, respectively. IR 
spectroscopic analysis showed the hydroxyl group absorption band at 3241 cm-1 and amide 
carbonyl group absorption band at 1675 cm-1.     
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. 400 MHz 1H NMR spectrum of compound 292a in CDCl3.  
In the 13C spectrum of compound 392a (Figure 41), the 1'-methylene and 2'-methyl signals 
corresponding to the phosphonate ethyl ester group resonate as doublets, due to coupling 
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to the adjacent 31P nucleus, at 61.4 ppm and 16.3 ppm, respectively. The 4-methylene signal 
appears as a doublet (J = 141.2 Hz) at 29.2 ppm, while the 3- and 2-methine signals resonate 
at 58.7 ppm (J = 10.9 Hz) and 80.0 (J = 13.2 Hz) ppm, respectively. The signal at 168.6 ppm 
corresponds to the carbonyl carbon.  
 
Figure 41. 100 MHz 13C NMR spectrum of compound 392a in CDCl3.  
The dihydroxy-amido phosphonate esters 292a-g were expected to be sufficiently lipophilic 
to facilitate absorption across phospholipid membranes, and thus serve as ester pro-drug 
analogues of DOXP 230 and fosmidomycin 236, being hydrolysed in vivo by plasma 
esterases.117-118,173 Consequently, we considered it necessary to prepare the corresponding 
phosphonic acid derivatives 293a-g as substrates for in vitro enzyme-binding and –inhibition 
assays. An established method for the cleavage of the ethoxy groups of phosphonate esters 
involves the use of trimethylsilyl bromide (TMSBr) at room temperature in 
dichloromethane, followed by hydrolysis.174 This methodology has been successfully used in 
our group and a thorough kinetic study of the reaction has been reported.129,142 Natarajan et 
al. have reported the microwave-assisted modification involving reaction of phosphonate 
esters in acetonitrile to obtain the corresponding phosphonic acids in excellent yields 
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(95%).175 This modification175 was therefore used and the phosphonate esters 292a-g were 
treated with two equivalents of TMSBr in acetonitrile for ten minutes under microwave 
irradiation, followed by hydrolysis (Scheme 38), to furnish the dihydroxy-amido phosphonic 
acids 293a-g in good yields (> 62%). The phosphonic acids 293a-g, which are all new 
compounds, were fully characterised by spectroscopic (NMR and IR) and elemental analysis.                
 
 
 
 
 
 
 
 
 
 
Scheme 38. Hydrolysis of dihydroxy-amido phosphonate esters 292a-g using TMSBr. 
Reagents and conditions:  i) TMSBr, CH3CN, 100 
oC, 10 min ii) MeOH-H2O(95:5 v/v), stir for 
30 min, r.t.   
The reaction involved the consecutive trans-esterification of each of the phosphonate ester 
groups of 292a-g leading to the formation of the bis(trimethylsilyl) esters 318a-g, which 
were hydrolysed readily to the phosphonic acids 293a-g upon treatment with aqueous 
methanol (Scheme 39).    
 
 
 
 
  
Scheme 39. Step-wise cleavage of phosphonate ethyl esters 292a-g with TMSBr. 
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methyl and 1'-methylene phosphonate ethyl ester groups at 1.31 ppm and 4.10 ppm, 
respectively, and the emergence of a broad signal at 10.14 ppm corresponding to the 
phosphonic acid protons. Assignment of the hydroxyl signals in compound 293d was 
assisted by analysis of the HMBC spectrum, which indicated correlation between the 
hydroxyl proton attached to C-2 and the C-1 carbonyl carbon signal. The IR spectrum reveals 
a broad hydroxyl group absorption band at ca. 3304 cm-1. The assignment of all the protons 
in compound 293d is illustrated in Figure 42 (bottom spectrum). In Figure 43, comparison of 
the 13C NMR spectra of compounds 292b and 293b also indicate the successful cleavage of 
the phosphonate ethyl ester moeity in 292b (top spectrum), as the signals corresponding to 
the ethyl groups, resonating at 16.1 ppm and 63.6 ppm, are absent in the spectrum of 
compound 293b (bottom spectrum).  
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Figure 42. 400 MHz 1H NMR spectra of phosphonate ester 292d (top) and corresponding 
phosphonic acid 293d (bottom) in CDCl3, showing the disappearance of the phosphonate 
ethyl ester signals (circled) upon hydrolysis.  
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Figure 43. 100 MHz 13C NMR spectra of phosphonate ester 292b (top) and corresponding 
phosphonic acid 293b (bottom) in CDCl3, showing the disappearance of the phosphonate 
ethyl ester signals (circled) upon hydrolysis.  
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Thus, following the set-backs encountered with Approaches 1 and 2 (Scheme 24), the 
desired DOXP and fosmidomycin analogues 293a-g were finally accessed via Approach 3 
(Scheme 24) as outlined in Scheme 40; with the yields for the selected steps summarised in 
Table 4. A selection of the prepared dihydroxy-amido phosphonate esters 292a-g and 
corresponding phosphonic acids 293a-g were subjected to STD-NMR enzyme binding studies 
(Section 2.5), using EcDXR.      
 
 
 
 
 
 
 
 
Scheme 40. Access to DOXP and fosmidomycin analogues 293a-g via Approach 3.  
Table 4. Yields (%) for selected steps in the preparation of the DOXP and fosmidomycin 
analogues 293a-g (Scheme 43).  
 
 R 
  
           
      a Me 285a      54 292a      67 293a      80 
      b Et 285b      48 292b      69 293b      77 
      c Pr 285c      71 292c      67 293c      72 
      d pri 285d      62 292d      71 293d      78  
      e But 285e      65 292e      66 293e      73 
      f Ph 285f      59 292f      62 293f      62 
      g      
 
CH2Ph 285g      73 292g      67 293g      74 
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2.2. Synthesis of 3-substituted aniline-derived phosphonate esters and 
phosphonic acids  
 
As mentioned previously (section 1.8, p. 51), the anilide 277 was serendipitously discovered 
to exhibit binding interactions with EcDXR in STD protein experiments, and shown to 
possess low-level inhibitory activity towards EcDXR. Consequently, we have sought to 
prepare several series of analogues of compound 277, with emphasis on the: - i) 
introduction of various meta-substituents on the benzene ring and; ii) alteration of the 
number of methylene groups between the amide functionality and the phosphonate group. 
The synthetic routes to the series of 3-substituted aniline-derived phosphonate esters 
(321a-g, 323a-g, 325a-g and 327a-g) are outlined in Scheme 41. With regard to DXR 
structure-activity studies, the amide moiety was expected to serve as a metal-chelating 
group in the DXR active site and the phosphonate moiety to occupy its appropriate binding 
pocket. Moreover, the benzene ring should provide a degree of hydrophobicity and the 
anilide system a measure of conformational rigidity. The distance between the essential 
amide and phosphonate groups was varied, to establish the effects on DXR active-site 
binding and in vitro inhibitory activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Scheme 41. Synthetic routes towards 3-substituted aniline-derived phosphonate esters.  
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2.2.1. Preparation of the chloroacetyl chloride-derived anilides 321a-g. 
2.2.1.1. Reaction of 3-substituted anilines with chloroacetyl chloride. 
The 3-substituted anilines 319a-g were deprotonated with sodium hydride in THF, and then 
treated with chloroacetyl chloride (Scheme 42) to furnish the chloroacetamides 320a-g in 
good yields (62% - 92%). The nucleophilicity of the primary amines 319a-g is enhanced by 
deprotonation, and attack at the more electrophilic carbonyl carbon in chloroacetyl chloride 
leads to preferential nucleophilic acyl substitution.      
 
 
 
 
 
 
Scheme 42. Formation of chloroacetamides 320a-g.  
The structures of all of the chloroacetamides 320a-g were confirmed by NMR and IR 
spectroscopic analysis. The 1H NMR spectra all exhibit the presence of the characteristic 
chloromethylene singlet at ca. 4.3 ppm, as shown in Figure 44 for compound 320f. Figures 
45 and 46 show the DEPT 135 and 13C NMR spectra of compound 320f, respectively. Analysis 
of the DEPT 135 spectrum (Figure 45) clearly showed the chloromethylene signal at 43.4 
ppm and allowed for the identification of the CH signals of the benzene ring and, 
identification of the carbonyl and quaternary carbon signals in the 13C spectrum (Figure 46). 
The assignment of the benzene ring proton signals was assisted by analysis of the COSY 
spectrum, shown in Figure 47. The aromatic proton signals were assigned following the 
identification of the 2'-H singlet at 8.60 ppm and 5'-H triplet (J = 7.2 Hz) at 7.62 ppm; the 4'- 
and 6'-H protons both resonate at 7.95 ppm and couple with the 5'-H proton. Analysis of the 
HSQC and HMBC spectra confirmed the assignment of the aromatic proton and carbon 
signals.      
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Figure 44. 400 MHZ 1H NMR spectrum of compound 320f in DMSO-d6.   
  
 
 
 
Figure 45. DEPT 135 NMR spectrum of compound 320f in DMSO-d6.    
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Figure 46. 100 MHz 13C NMR spectrum of compound 320f in DMSO-d6.   
Figure 47. COSY NMR spectrum of compound 320f in DMSO-d6. 
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In addition to isolating compound 320g, the N,O-bis-chloroacetylated product 320h was also 
obtained in 11 % yield when 3-aminobenzyl alcohol 319g was reacted with sodium hydride 
and chloroacetyl chloride.  In the 1H NMR spectrum of the bis-chloroacetylated product 
320h (Figure 48), the 2''- and 4'-chloromethylene protons resonate as a singlet at 4.19 ppm, 
while the 1'-methylene proton signal of the ester group appears at 4.32 ppm. The broad 
signal at 8.23 ppm corresponds to the amide proton. IR spectroscopic analysis revealed the 
presence of the amide carbonyl absorption band at 1673 cm-1 and the ester carbonyl 
absorption band at 1738 cm-1.         
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48. 400 MHZ 1H NMR spectrum of compound 320h in CDCl3.  
* mineral oil impurities from the storage of NaH.  
 
2.2.1.2. Phosphonation of chloroacetamides via Michaelis-Arbuzov reaction.  
Given the success in obtaining the chloroacetamides 320a-g, the next step involved the 
introduction of the phosphonate ester group via the Michaelis-Arbuzov reaction.146 Thus, 
the chloroacetamides 320a-g were treated with triethyl phosphite under reflux for ca. 9 
hours under inert atmosphere, to furnish the phosphonate esters 321a-g in reasonable 
yields (48% - 72%). Compounds 321b-g are all new and were fully characterised by NMR 
spectroscopy and high-resolution mass spectrometry. Figure 49 shows the 1H NMR 
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spectrum of compound 321b. The triplet at 1.34 ppm and the quintet at 4.17 ppm are 
characteristic of the phosphonate ethyl ester moiety, and hence, were observed for all of 
the phosphonate esters synthesised in the series. In addition, the disappearance of the 
chloromethylene singlet at 4.20 ppm and the emergence of the characteristic phosphonate 
2'-methylene proton signal at 2.97 ppm, resonating as a doublet with large coupling 
constant (J = 20.8 Hz) due to 31P nucleus coupling, clearly indicated the formation of the 
desired product. The singlet at 3.78 ppm corresponds to the methoxy methyl protons, while 
the amide proton resonates at 8.85 ppm.  
Figure 49. 400 MHZ 1H NMR spectrum of compound 321b in CDCl3. 
 In the 1H NMR spectrum for compound 321d (Figure 50), the characteristic triplet and 
quintet signals corresponding to the phosphonate ethyl ester moiety are clearly seen at 1.35 
ppm and 4.18 ppm; the 2'-methylene proton resonates at 2.99 ppm, with a large coupling 
constant of 20.8 Hz.  
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 Figure 50. 400MHz 1H NMR spectrum of compound 321d in CDCl3.   
The complex coupling observed in the aromatic region of the 1H NMR spectrum of the 3-
fluoro analogue 321d (Figure 50) between 6.60 ppm and 7.80 ppm is reproduced in Figure 
51 and is worthy of further discussion. The 4-H nucleus resonates at 6.74 ppm as a triplet of 
doublets due to coupling to the 19F nucleus (J = 2.0 Hz), in addition to coupling to both the 5-
H (J = 6.0 Hz) and 2-H (J = 2.4 Hz) nuclei. The doublet at 7.09 ppm corresponds to 6-H, which 
couples to 5-H (J = 6.4 Hz), while the 5-H nucleus resonates at 7.16 ppm as a triplet of 
doublets, as a result of coupling to the 4- and 6-H (J = 6.4 Hz) and the 19F nucleus (J = 1.6 Hz). 
Analysis of the COSY and HSQC data supported these assignments.                  
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Figure 51. Expanded region of the 400 MHz 1H NMR spectrum of compound 321d in CDCl3.  
2.2.1.3. Hydrolysis of methyl phosphonate esters using TMSBr.  
The next step involved the preparation of the phosphonic acid derivatives 328a-g and the 
corresponding sodium phosphonate salts 329a-g for the in vitro enzyme inhibition assays, 
since the phosphonate esters 321a-g are expected to be hydrolysed in vivo. The cleavage of 
the phosphonate ethyl ester group was accomplished, as described previously, using TMSBr 
in acetonitrile under microwave irradiation,175 followed by hydrolysis at room temperature 
(Scheme 43). The phosphonic acids 328a-g were isolated in reasonable yields (42% - 67%) 
and subsequently converted, quantitatively, to their corresponding sodium phosphonate 
salts 329a-g through treatment with 0.1M aqueous sodium hydroxide. All the products 
prepared in these reactions are new and were fully characterised by elemental and 
spectroscopic analysis.  
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Scheme 43. Synthesis of phosphonic acid derivatives 328a-g and corresponding mono-
sodium salts 329a-g. 
Reagents and conditions: i) TMSBr, CH3CN, microwave irradiation, 100 
oC, 10 min ii) MeOH-
H2O ( 95:5 v/v), 30 min, r.t. iii) 1.1 mol NaOH, EtOH, 30 min, r.t.    
Comparison of the 1H NMR spectra of the phosphonate ester 321f and the phosphonic acid 
328f (Figure 52) clearly shows the disappearance of the phosphonate ethyl ester signals 
following hydrolysis. As expected, the corresponding signals are also absent in the 13C 
spectrum of the phosphonic acid. A selection of the synthesised 3-substituted aniline 
phosphonate esters 321a-g, phosphonic acids 328a-g and corresponding monosodium salts 
329a-g were subjected to EcDXR-STD NMR binding studies and inhibition assays (Section 
2.5).       
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Figure 52. 400 MHz 1H NMR spectra of phosphonate ester 321f (top) and phosphonic acid 
328f (bottom) in DMSO-d6, showing the disappearance of phosphonate ethyl ester signals 
(circled) upon hydrolysis.    
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2.2.2. Preparation of the ω-chloropropionyl chloride-derived anilides 322-327a-g.  
An increase in inhibitory activity has been observed for several fosmidomycin analogues in 
which the distance between the phosphonate and hydroxamate moieties has been 
increased.117,131 Consequently, attention was given to introducing additional methylene 
groups between the two essential functional groups by reacting the various 3-substituted 
anilines 319a-g with 3-chloropropionyl chloride 330, 4-chlorobutanoyl chloride 330a and 5-
chloropentanoyl chloride 332, in place of chloroacetyl chloride which was successfully used 
to prepare compounds 321a-g (scheme 41). The ω-chloroamide derivatives 322a-g, 324a-g 
and 326a-g were isolated in good yields upon the deprotonation of the appropriate 3-
substituted aniline substrates 319a-g with sodium hydride, followed by reaction with the ω-
chloroalkanoyl chlorides 330-330b. The corresponding phosphonate esters 323a-g, 325a-g 
and 327a-g were obtained in reasonable yields ranging from 48% to 74% using Michaelis-
Arbuzov’s reaction.146 Microwave-assisted reaction of the phosphonate esters with TMSBr, 
175 followed by hydrolysis, furnished the corresponding phosphonic acid derivatives 331a-g, 
333a-g and 335a-g, which were subsequently treated with 0.1M aqueous sodium hydroxide 
to furnish the sodium phosphonic acid salts 332a-g, 334a-g and 336a-g (Scheme 44).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 44. Preparation of extended chain aniline-derived phosphonate esters and acids. 
Reagents and conditions: i) NaH, THF, 6 h, N2 ii) triethyl phosphite, 9 h, N2 iii)  TMSBr, CH3CN, 
100 oC, 10 min, MeOH-H2O ( 95:5 v/v), 30 min, r.t., iv) 1.1 mol NaOH, EtOH, 30 min, r.t.    
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All of the compounds prepared as outlined in Scheme 44 were fully characterised. Their 1H, 
13C and DEPT 135 NMR spectra all illustrate the effects of increasing the number of 
methylene groups. Comparison of the 1H NMR spectra of the ω-chloro-N-alkylanilides 322b, 
324b and 326b (Figure 53), for example, clearly show the presence of a pair of triplet (J = 6.4 
Hz) signals at 2.78 and 3.85 ppm integrating for two protons each, and thus, corresponding 
to the 3- and 2-methylene groups of compound 322b. The presence of a quintet at 2.17 
ppm and a pair of triplets at 2.53 ppm and 3.63 ppm in the 1H NMR spectrum of compound 
324b confirmed the presence of the propylene linking group. The 3-methylene group 
couples to both the 2- and 4-methylene groups and thus resonates as a quintet (J = 6.8 Hz) 
signal at 2.17 ppm, while the triplets (J = 6.8 and 6.4 Hz) at 2.53 ppm and 3.63 ppm 
correspond to the 2-and 4-methylene groups, respectively. Analysis of the 1H NMR spectrum 
of compound 326b show a series of methylene signals integrating for eight protons, 
confirming the butylene linkage group between the phosphonate and amide functional 
moieties. The 3- and 4-methylene protons correspond to the triplet (J = 3.6 Hz) signal at 1.78 
ppm, while the pair of triplets (J = 6.8 and 6.4 Hz) resonating at 2.29 ppm and 3.49 ppm 
represent the 2-and 5-methylene groups, respectively.  
The singlet at ca. 3.80 ppm in each of the 1H NMR spectra (Figure 53) of the products 322b, 
324b and 326b corresponds to the methoxy methyl protons. The signals resonating between 
6.60 ppm and 7.28 ppm integrate for four protons and correspond to the aromatic protons 
and, were assigned as follows; the 4'-H and 6'-H nuclei resonate at ca. 6.62 ppm and 6.96 
ppm as doublets (J = 8.4 and 8.0 Hz), while at the 5'-H nucleus resonates at ca. 7.16 ppm as 
a triplet (J = 8.4 Hz) as a result of coupling to the 4'-and 6'-H nuclei. In the 1H NMR spectra 
for compound 322b and 324b (Figure 53), the amide proton resonates at ca. 7.50 ppm, 
whereas the same proton signal is observed at 8.12 ppm for compound 326b.  
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Figure 53. Comparative 400 MHz 1H NMR spectra of compounds 322b, 324b and 326b in 
CDCl3, illustrating the increase in the number of methylene groups. *mineral oil impurities. 
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The 1H and 13C NMR signal assignments are supported by 2-D NMR data as illustrated for the 
set of spectra for the phosphonate ester 323b, shown in Figures 54-59. 1H NMR analysis 
(Figure 54) of the phosphonate ester 323b showed the characteristic triplet and multiplet 
signals corresponding to the phosphonate ethyl ester moiety resonating at 1.31 and 4.10 
ppm. The singlet at 3.78 ppm corresponds to the methoxy methyl protons while the amide 
proton resonates at 8.87 ppm. The complex splitting patterns seen for the 3- and 2-
methylene signals resonating at 2.17 and 2.70 ppm, respectively, is as a result of coupling to 
each other and to the 31P nucleus. Coupling between the 2- and 3-methylene protons and 
coupling of the phosphonate ethyl ester signals is clearly evident in the COSY spectrum 
(Figure 55). Comparison of the 1H-1H coupling constants and analysis of the COSY spectrum 
allowed for the assignment of the aromatic proton signals.  
The DEPT 135 spectrum (Figure 56) clearly showed the signals of the 2-and 3-methylene 
nuclei resonating at 20.7 and 29.9 ppm and allowed for the identification of the quaternary 
aromatic carbon signals in the 13C spectrum (Figure 57). The splitting (J= 142.5 Hz) of the 
signal at 20.7 ppm in the 13C spectrum permitted assignment of this signal to the 3-
methylene carbon adjacent to the 31P nucleus, while the doublet (J = 3.3 Hz) at 29.9 ppm 
corresponds to the 2-methylene carbon. The 1'-methylene and 2'-methyl signals 
corresponding to the phosphonate ethyl ester group resonate as doublets, due to coupling 
to the adjacent 31P nucleus, at 62.8 and 16.4 ppm, respectively. Analysis of the HSQC 
spectrum (Figure 58) confirmed the assignment of the aromatic carbon and protons signals 
and the methoxy carbon signal at 55.2 ppm. The HMBC spectrum (Figure 59) shows 
correlation of the C-2 carbon signal to the 3-methylene protons and, likewise, the C-3 
carbon signal to the 2-methylene protons. Analysis of the HMBC spectrum confirmed the 
assignment of the aromatic proton and carbon signals and allowed assignment of the 
carbonyl carbon signal due to correlation with the 2- and 3- methylene protons.  
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Figure 54. 400MHz 1H NMR spectrum of compound 323b in CDCl3.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55. COSY NMR spectrum of compound 323 in CDCl3.   
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Figure 56. DEPT 135 NMR spectrum of compound 323b in CDCl3.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 57. 100 MHz 13C NMR spectrum of compound 323b in CDCl3.  
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Figure 58. HSQC NMR spectrum of compound 323b in CDCl3.  
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Figure 59. HMBC NMR spectrum of compound 323b in CDCl3.  
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Tables 5 and 6 summarise the percentage yields of the desired 3-substituted aniline-derived 
phosphonate esters 321a-g, 323a-g, 325a-g and 327a-g, and the corresponding phosphonic 
acid derivatives 328a-g, 331a-g, 333a-g and 335a-g, respectively. A selection of the prepared 
aniline-derived phosphonate esters and corresponding phosphonic acids were subjected to 
STD NMR enzyme binding studies and inhibition assays (Section 2.5), using EcDXR.   
Table 5. Yields (%) of phosphonate esters obtained from Michaelis-Arbuzov’s reactions of ω-
chloro-N-alkylanilides (Scheme 44). 
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Table 6. Yields (%) of phosphonic acids obtained from hydrolysis of phosphonate esters 
(Scheme 44). 
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2.3. Synthesis of furan-derived phosphate analogues as conformationally 
restricted DOXP analogues  
Much of the synthetic work towards the design of structural analogues of the natural 
substrate DOXP 230 as potential inhibitors of DXR has focused on:- i) removal of one of the 
hydroxyl groups at either the C-3 or C-4 position; ii) alteration of the length of the carbon 
spacer and; ii) modification of the phosphate moiety.123-126 In addition, the construction of 
analogues of the antibiotic fosmidomycin 236 has involved modification of either the 
phosphonate or hydroxamate functional group, respectively.117-121,130-133 Interestingly, very 
few studies have reported DOXP 230 or fosmidomycin 236 analogues in which the three 
carbon spacer has been structurally modified. Van Calenbergh et al.125 have reported novel 
cyclopropyl analogues of fosmidomycin with restricted conformational mobility, by 
incorporating the C-1 and C-2 carbon atoms of the spacer in a three-membered ring. The 
inhibitory activity towards EcDXR and in vitro growth inhibitory activity for P. falciparum of 
one such analogue 259, was reported to be equally as potent as fosmidomycin 236.125 
Analogues of the natural substrate DOXP 230 in which conformational mobility is restricted 
are yet to be reported. Consequently, we envisioned the design of the furan derivatives 
337b-d which contain phosphate and oxime moieties as confomationally restricted isosteres 
of the natural substrate DOXP 230 (Figure 60). In an earlier study in our group,176 the 
capacity of the furan derivatives 337b-d to adopt similar stable conformations to DOXP 230 
was demonstrated, but synthetic access (Scheme 45) to these compounds could not be 
completed. The oxygen atom of the furan ring and oxime hydroxyl group of these novel 
analogues 337b-d was expected to chelate to the divalent metal cation, thus anchoring the 
molecules in the active site of DXR.    
 
 
 
 
Figure 60. Design of conformationally-restricted fosmidomycin analogue 259 and novel 
DOXP analogues 337b-d.     
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Scheme 45. Synthetic route towards conformationally-restricted DOXP analogues 337b-d.  
2.3.1. Protection of 3-furanmethanol via tritylation. 
Functionalization of the readily available 3-furanmethanol 338 required initial protection of 
the hydroxyl group. This was achieved by treatment with triphenyl methyl chloride 342 in 
the presence of excess triethylamine and a catalytic amount of 4-dimethylaminopyridine 
(DMAP),176 to obtain the trityl-protected furan 339 in 72 % yield (Scheme 46). Under the 
reaction conditions, the hydroxyl proton of 3-furanmethanol 338 is abstracted by the base 
to yield the deprotonated intermediate. Subsequent nucleophilic attack of the central 
carbon of the trityl halide 342 by the intermediate furnishes the desired trityl-protected 
furan 339, while the hydrogen chloride generated is neutralised by unreacted base. The 1H 
NMR spectrum (Figure 61) shows a singlet at 4.06 ppm corresponding to the 1'-methylene 
group, while the singlet at 6.42 ppm correlates to the 2-H nucleus. The multiplets between 
7.26 and 7.53 ppm integrate for seventeen protons corresponding to the fifteen trityl group 
protons and the 4- and 5-H protons on the furan ring.     
 
 
 
 
 
 
Scheme 46. Protection of 3-furanmethanol via tritylation. 
Reagents and conditions: i) Et3N, DMAP, THF, 80 
oC, 15 h, N2.   
 
O
OH
Cl
O
O i+
338
342 339
O
OH
O
O
338
339
O
O
O
R
O O
O
R
P
OH
OH
O
O O
N
R
P
OH
OH
O
OH
340b-d 
341b-d               337b-d            
R
b
c
d
H
Me
CH
2
C(CH
3
)
3
 Discussion 
 ________________________________________________________________________________  
Page | 102  
 
Figure 61. 400 MHz 1H NMR spectrum of 3-(trityloxymethyl) furan 339 in CDCl3.  
 
2.3.2. Functionalization of the 5-position of the furan ring.  
The next step involved the functionalization of the furan ring by means of electrophilic 
substitution at C-5. The reactivity of the furan ring has been extensively studied and 
electrophilic substitution is known to occur exclusively at the α-positions (C-2 and C-5).177-178 
We planned to introduce the formyl and acetyl groups at C-5 as the known inhibitor 
fosmidomycin 236 possesses a formyl group, whilst the natural substrate DOXP 230 and the 
more potent inhibitor FR900098 237 both contain an acetyl functional group. In addition, 
we hoped to exploit possible hydrophobic cavities beyond the metal-coordination site in the 
DXR-active site by introducing a tert-butylacetyl group. It is also possible that the carbonyl 
compounds 341b-d (precursors to the planned oximes 337b-d) might themselves act as DXR 
inhibitors.    
 Although the difference in reactivity between the 2- and 5-positions of the furan ring is 
expected to be small, we hoped that the presence of the bulky trityl group might provide 
steric hindrance to reaction at C-2 and thus direct substitution to C-5. Hence, 3-
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(trityloxymethyl)furan 339 was lithiated using butylithium at -30 oC for four hours; 
subsequent treatment with electrophile, DMF, and stirring for a further four hours afforded 
a mixture shown by NMR analysis to contain the isomeric aldehydes 340a and 340b. The 
isomers were separated successfully using semi-preparative HPLC to obtain compound 340b 
as the major product, in only 12 % yield (Scheme 47). In fact, this was the point at which the 
earlier synthetic attempt176 foundered. Due to the poor yield and lack of selectivity for the 
desired aldehyde 340b, a different method for the formylation of the 3-
(trityloxymethyl)furan 339 was explored.   
 
Scheme 47. Formylation of 3-(trityloxymethyl)furan 339 via lithiation.  
Reagents and conditions: i) butyllithium, THF, -30 oC, 4 h, N2 ii) DMF, -30 
oC, 2 h, r.t., 2 h.      
 
The Vilsmeier-Haack reaction179-180 is widely used for the introduction of the formyl group in 
aromatic and heteroaromatic ring systems and was, therefore, considered. The Vilsmeier 
reagent was prepared from the reaction of phosphoryl chloride with DMF, and the 
protected furan 339 was formylated successfully to furnish the desired aldehyde 340b in 
64% yield with the isomeric aldehyde 340a as the minor product (Scheme 48). The 
mechanism of the reaction is outlined in Scheme 49 and involves the reaction of POCl3 and 
DMF to form the chloromethyleneiminium species 344, which then reacts with the 
protected furan 339 in an electrophilic substitution process to produce the intermediate 
345. Aromatisation to form the iminium intermediate 346 followed by base-catalysed 
hydrolysis leads to the desired aldehyde 340b.       
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Scheme 48.  Synthesis of aldehydes 340a and 340b via Vilsmeier-Haack formylation.  
Reagents and Conditions: i) POCl3, DMF, 0 
oC for 2 h, 65 oC for 1 h ii) H2O/NaOH.     
 
 
Scheme 49. Vilsmeier-Haack mechanism for the formation of aldehyde 340b. 
    
The structures of the isomeric aldehydes 340a and 340b were confirmed by NMR 
spectroscopic analysis. Figure 62 shows the comparative 1H NMR spectra of aldehydes 340a 
and 340b, respectively. In the 1H NMR spectrum of compound 340b (top spectrum), the 5-H 
signal is clearly seen at 6.74 ppm; whereas in the 1H NMR spectrum of aldehyde 340a 
(bottom spectrum), the 5-H signal is not observed confirming successful formylation at this 
position. The signals resonating at 9.72 ppm (top spectrum) and 9.67 ppm (bottom 
spectrum) correspond to the aldehyde protons in compounds 340b and 340a, respectively. 
The 1'-methylene group signal resonates at 4.45 ppm for compound 340b, whereas this 
signal is seen at 4.14 ppm for aldehyde 340a. Figure 63 illustrates the comparative 13C NMR 
spectra of aldehydes 340a and 340b, with the signals assigned as indicated.    
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Figure 62. Comparative 400 MHz 1H NMR spectra of aldehydes 340b (top spectrum) and 
340a (bottom spectrum) in CDCl3.   
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Figure 63. Comparative 400 MHz 13C NMR spectra of aldehydes 340b (top spectrum) and 
340a (bottom spectrum) in CDCl3.   
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After the success of the Vilsmeier-Haack formylation, the introduction of the acetyl and tert-
butylacetyl groups at C-5 of compound 339 was investigated. Friedel-Crafts acylation and 
alkylation reactions are well established methods used for electrophilic substitution in 
aromatic and heteroaromatic ring systems.181-182 We exploited the broad scope of the 
Friedel-Crafts method in our effort to introduce the acetyl and tert-butylacetyl groups at C-5 
of the furan ring in compound 339. The reaction is usually carried out with aluminium 
trichloride (AlCl3) as the Lewis acid catalyst, but AlCl3 has been reported to induce the 
polymerisation of furan derivatives183 and we decided to conduct the reactions with 
anhydrous tin tetrachloride (SnCl4) and zinc chloride (ZnCl2) as catalysts.
184-185 Other 
catalysts that have been successfully used, but were not considered, include iodine,186 
ferrous trichloride,187 ortho-phosphoric acid188 and the metal triflates.189 For the acetylation 
of the furan derivative 339, acetic anhydride was preferred as the acylating agent as 
opposed to acetyl chloride since a weaker acid is liberated in the course of the reaction and 
it has been reported to give better reaction yields.190 The route to the furanyl ketones 340c 
and 340d is outlined in Scheme 50. Initially, acetic anhydride or tert-butylacetyl chloride was 
reacted with a catalytic quantity of SnCl4 in DCM and this mixture was treated with the 
protected furan 339. In another approach, a mixture of either acetic anhydride or tert-
butylacetyl chloride and ZnCl2 in DCM, was treated with the protected furan 339. 
Subsequent aqueous work-up with K2CO3 of the reaction mixtures obtained using the two 
approaches furnished the desired ketones 340c and 340d. Table 7 summarises the reaction 
conditions and yields obtained for the ketones 340c and 340d using the different Lewis acid 
catalysts.     
 
 
 
 
 
 
 
Scheme 50. Synthesis of furanyl ketones 340c and 340d using Friedel-Crafts methodology.  
Reagents and conditions: i) acetic anhydride or t-butylacetyl chloride, SnCl4, 0 
oC for 1 h, 40 
oC for 4 h, N2 ii) acetic anhydride or t-butylacetyl chloride, ZnCl2, 0 
oC for 1 h, 40 oC for 8 h, 
N2.    
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Table 7. Friedel-Crafts reaction of 3-(trityloxymethyl)furan 339 with acetic anhydride and 
tert-butylacetyl chloride in the presence of the Lewis acid catalysts, SnCl4 and ZnCl2.  
 
 
Product   Catalyst  Temperature 
(o C)a 
Time (h)a Yield (%)  
 
340c 
 
SnCl4 
 
0 ; 40 
 
1 ; 4  
 
64 
340d ZnCl2 0 ; 40  1 ; 8 37 
340c SnCl4 0 ; 40  1 ; 4 56 
340d ZnCl2 0 ; 40  1 ; 8  33 
                a 
For two periods. 
 
The furan system is more activated towards electrophilic attack at the α (2, 5)-positions than 
the phenyl rings of the trityl group and could be selectively acylated at lower temperatures. 
The Friedel-Crafts reactions were therefore carried out at 0 oC and then 40 oC, thus avoiding 
electrophilic substitution on the phenyl rings. Analysis of NMR spectra of the crude reaction 
mixtures indicated the formation of the ketones 340c and 340d as the major products; the 
unwanted isomers being limited to trace quantities due to the steric effect of the trityl 
group. The use of anhydrous SnCl4 as catalyst produced the furanyl ketones 340c and 340d 
in a shorter time and in better yields (Table 7), possibly due to the tin metal coordinating 
more strongly with the carbonyl oxygen of the acylating reagent. The ketones 340c and 
340d are new compounds and were fully characterised by NMR, IR and combustion analysis. 
Figure 64 shows the 1H NMR spectrum of the 3-(trityloxymethyl)furanyl ketone 340c. The 
singlet at 2.57 ppm corresponds to the acetyl methyl group, while the singlet at 4.42 ppm 
integrates for two protons and corresponds to the 1'-methylene protons. The overlapping 
signals between 7.14 and 7.33 ppm integrate for 17 protons and thus represent the fifteen 
protons of the trityl group and, the 3-H and 5-H nuclei of the furan ring. IR spectroscopic 
analysis revealed a carbonyl absorption band at 1675 cm-1. Figure 65 illustrates the 13C NMR 
spectrum of the 3-(trityloxymethyl)furanyl ketone 340d, with the signals assigned as 
indicated.  
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Figure 64. 400 MHz 1H NMR spectrum of compound 340c in CDCl3.    
    
Figure 65. 100 MHz 13C NMR spectrum of compound 340d in CDCl3.  
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2.3.3. De-tritylation and phosphorylation using mild acid hydrolysis.  
Following the successful synthesis of compounds 340b-d, the next step involved removal of 
the trityl protecting group and phosphorylation of the resulting alcohols. Various methods 
have been reported for the cleavage of the trityl moiety, including the use of boron 
trifluoride etherate in the presence of methanol,191 catalytic hydrogenation192 and 
treatment with diethylaluminium chloride.193 Although these reagents191-193 afford 
satisfactory yields, we decided to use mild acid hydrolysis conditions194 to remove the trityl 
group. Thus, compounds 340b-d were treated with formic acid in aqueous methanol for two 
hours at 50 oC. Removal of volatiles in vacuo gave the crude primary alcohols 347b-d, which 
were used without further purification. The alcohols 347b-d were phosphorylated to the 
corresponding phosphate esters 348b-d using diethyl chlorophosphate in pyridine (Scheme 
51). Compounds 340b-d were also sequentially de-tritylated and phosphorylated using a 
mixture of H3PO4 and THF (1:1 v/v),
176 providing access to the dihydrogen phosphates 341b-
d in reasonable yields ranging from 58% to 65% (Scheme 51).  Compounds 348b-d and 341c-
d are all new compounds and were fully characterised by NMR, IR and combustion analysis.  
 
 
 
 
 
 
 
 
 
 
 
Scheme 51. Synthesis of phosphate esters 348b-d and dihydrogen phosphate derivatives 
341b-d. 
Reagents and conditions: i) HCOOH/THF/H2O [(1:1:0.1 v/v/v)], 50 
oC, 2 h ii) diethyl 
chlorophosphate, pyridine, 0 oC, 1 h, r.t., overnight; iii) H3PO4 / THF [(1:1 v/v)], 2 days, r.t.    
 
 
Figures 66 and 67 illustrate the 1H and 13C NMR spectra of compound 348c, respectively. 
The success of the phosphorylation reaction is clearly indicated in the 1H NMR spectrum 
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(Figure 66) by the disappearance of the trityl group multiplet at ca. 7.20 ppm and the 
presence of the phosphate ethyl esters signals, the latter characterised by the methyl triplet 
at 1.30 ppm and the methylene signals as a multiplet at 4.06 ppm, due to coupling to the 
methyl protons and to the 31P nucleus. In addition, coupling of the 1'-methylene protons to 
the 31P nucleus is evident in the splitting of the signal at 5.05 ppm into a doublet (J = 1.6 Hz). 
The signal at 2.54 ppm corresponds to the acetyl methyl group, while the 3-H and 5-H nuclei 
of the furan ring resonate at 7.10 ppm and 7.12 ppm, respectively. Analysis of the 31P NMR 
spectrum showed the presence of a 31P signal at 0.8 ppm, while the IR spectrum showed the 
carbonyl and phosphate ester absorption bands at 1680 cm-1and 1223 cm-1, respectively.  
Figure 66. 400 MHz 1H NMR spectrum of phosphate ester 348c in CDCl3.  
 
In the 13C spectrum (Figure 67) of compound 348c, the phosphate ethyl ester signals at 16.3 
ppm and 61.5 ppm are split (J = 6.0 and 6.5 Hz), reflecting coupling to the 31P nucleus; the 1'-
methylene carbon also resonates at 61.5 ppm. These assignments are supported by the 
DEPT135 and HSQC data.               
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Figure 67. 100 MHz 13C NMR spectrum of compound 348c in CDCl3.   
 
Figures 68 and 69 illustrate the 1H and 13C NMR spectra of the dihydrogen phosphate 
derivatives 341b, respectively. In the 1H NMR spectrum (Figure 68) of compound 341b, the 
presence of the phosphate group is indicated by the splitting of the 1'-methylene signal at 
5.11 ppm by the nearby 31P nucleus. The proton signals for the phosphate hydroxyl groups 
are not seen due to proton exchange with the D2O solvent. Figure 69 illustrates the 
13C NMR 
spectrum of compound 341b, with the 1'-methylene carbon resonating at 61.9 ppm and is 
split (J = 6.5 Hz) due to 31P nucleus coupling; the remaining signals were assigned as 
indicated. Analysis of the 31P NMR spectrum showed the presence of the 31P signal at 0.8 
ppm, while the IR spectrum showed the carbonyl group and phosphate ester absorption 
bands at 1675 cm-1 and 1219 cm-1, respectively.      
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1'-CH2 
 
Figure 68. 400 MHz 1H NMR spectrum of compound 341b in D2O.  
 
Figure 69. 100 MHz 13C NMR spectrum of compound 341b in D2O.  
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2.3.4. Preparation of the phosphorylated furanyl oximes  
Several methods have been reported for the transformation of carbonyl compounds to their 
corresponding oximes, including:- using ionic liquids,195 grinding with hydroxylamine 
hydrochloride and sodium hydroxide pellets196 and microwave irradiation with 
hydroxylamine hydrochloride impregnated on wet, basic Al2O3.
197 However, we decided to 
access the novel DOXP analogues 337b-d using the classical method,198 which involved 
treating compounds 348b-d and 341b-d with an ethanolic solution of hydroxylamine 
hydrochloride in the presence of a catalytic quantity of sodium acetate (Scheme 52). The 
phosphate esters 349b-d were expected to act as pro-drugs of the diethyl dihydrogen 
derivatives 337b-d. The diethyl esters 349b-d were expected to exhibit better membrane 
permeability before being hydrolysed to active DXR inhibitors by esterases in vivo. The novel 
compounds 349b-d and 337b-d were isolated in good yields ranging from 87% to 96% and 
were fully characterised by spectroscopic methods (NMR and IR) and combustion analysis. A 
number of these compounds were subjected to EcDXR-STD NMR binding analysis (Section 
2.5).  
 
 
 
 
 
 
 
 
Scheme 52. Synthesis of phosphorylated oxime derivatives 349b-d and 337b-d.  
Reagents and conditions: i) NH2OH.HCl, NaOAc, EtOH, reflux for 1 h.    
 
Figure 70 illustrates the 13C NMR spectrum of compound 349c, showing the phosphate ethyl 
ester signals resonating at 16.2 ppm and 61.6 ppm and, significantly, the signal at 148.4 ppm 
corresponding to the oxime carbon. The remaining signals were assigned as indicated and 
analysis of the IR spectrum confirmed the presence of the C=N, hydroxyl and phosphate 
ester absorption bands at 1672, 3243 and 1225 cm-1, respectively.      
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Figure 70. 100 MHz 13C NMR spectrum of compound 349c in CDCl3.  
 
In the 13C NMR spectrum (Figure 71) of compound 337d, the signal at 151.3 ppm correlates 
to the oxime carbon, while the absence of the ethyl ester signals confirmed hydrolysis to the 
dihydrogen product. The IR spectrum confirmed the presence of the C=N, hydroxyl and 
phosphate absorption bands at 1678, 3260 and 1235 cm-1, respectively.     
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 Figure 71. 100 MHz 13C NMR spectrum of compound 337d in D2O. 
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2.4. Synthesis of N-benzyl substituted phosphoramidic acid derivatives 
based on a de novo design strategy.   
 
Studies of several EcDXR crystal structures with the known inhibitor fosmidomycin and 
natural substrate, DOXP, have identified the significant binding residues within the enzyme 
active and the essential structural features of the ligands which interact with the 
protein.103,105 In addition to structure-activity relationship data reported in literature, a 
thorough analysis of the 3-D topology of both the active sites of EcDXR and PfDXR has been 
conducted in a previous study in our group.129,142 This study revealed the presence of three 
additional pockets (I, II and III in Figure 72) adjacent to the phosphonate-binding region, 
which could be exploited in the design of novel inhibitors. The identification of these 
additional binding sites seems to provide an explanation for the increase in inhibitory 
activity observed for fosmidomycin analogues containing an aryl substituent on the carbon 
adjacent (α) to the phosphonate moiety – the α-aryl-substituent most likely occupies one of 
these pockets.129,142 Studies by Song et al.122 and Perruchon et al.128 have also suggested the 
presence of a hydrophobic binding pocket near the phosphonate-binding region. 
Furthermore, analysis of the pocket in the homology model of the PfDXR active site 
developed by Goble et al., revealed the presence of an additional cysteine-267 residue 
(Figure 72), as opposed to the serine-253 residue in EcDXR, and it was suggested that this 
difference could be exploited in the de novo design of specific PfDXR inhibitors.111,129  
Considering the information obtained from scrutinising the topology of the EcDXR and 
PfDXR active-sites and maintaining the essential phosphonate and hydroxamate functional 
groups present in fosmidomycin 236, the novel ligands 350a-d (Figure 73) were designed as 
specific inhibitors of PfDXR.129 A synthetic strategy was developed and initiated129 but, due 
to limited time, the preparation of compounds 350a-d could not be completed. 
Consequently, in the present study, attention was given to completing the synthesis of 
these novel fosmidomycin analogues. An α-benzyl group to occupy the additional binding 
pocket(s) (compounds 351a-d) or capable of forming thioether or disulfide linkages with the 
cysteine-197 and -267 residues (compounds 351b-d) was introduced, thus enhancing 
binding in the PfDXR active site.                    
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Figure 72. Active site of PfDXR, showing the three additional binding pockets (I, II and III) 
close to the phosphonate-binding site and the position of the cysteine-197 and -267 
residues. The surface zone at 8.0 Å from fosmidomycin 236 is shown with 30% transparency, 
coloured by hydrophobicity [polar (blue), non-polar (white), hydrophobic (orange)] and 
clipped in front. Protein residues less than 10 Å away from fosmidomycin 236 are shown in 
wireframe, coloured by atom type, and residues less than 8.0 Å away from fosmidomycin 
236 are labelled. Fosmidomycin 236 is shown in ball-and-stick format, coloured by atom 
type, NADPH as sticks coloured by atom type and the crystal structure water molecules as 
red spheres.129 (Reproduced with permission).  
 
 
 
 
 
 
 
Figure 73. Novel α- substituted analogues 350a-d and 351a-d.  
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The general synthetic strategy is outlined in Scheme 53 with the compounds prepared by 
Conibear129 indicated in red. In the present study, the entire sequence was completed using, 
as the primary substrate, the diethyl phosphoramidate 352.  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 53. Synthetic strategy towards the novel α-substituted analogues 351a-d.   
 
2.4.1. Synthesis of the diethyl phosphoramidate acetal 353 via silylation and alkylation. 
The initial steps towards the construction of the N-benzyl substituted phosphoramidic acid 
derivatives 351a-d is outlined in Scheme 54. Using a method reported by Zwierzak et al.199, 
diethyl phosphoramidate 352 was treated with hexamethyldisilazane in refluxing benzene 
to obtain the silylated derivative 358 in essentially quantitative yield (98 %). The protected 
amine 358 was then deprotonated with sodium hydride and treated with 
bromoacetaldehyde diethylacetal in the presence of a catalytic quantity of 
tetrabutylammonium bromide (TBAB) to furnish the protected acetal 359. Deprotection was 
effected by refluxing in ethanol for one hour, to afford the phosphoramidate acetal 353 in 
93% yield. 
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Scheme 54. Synthesis of phosphoramidate acetal 353.  
Reagents and conditions: i) hexamethyldisilazane (20% mol excess), benzene, 80 oC, 3 h ii) 
NaH, benzene, r.t., then bromoacetaldehyde diethylacetal, TBAB (10% mol), benzene, 80 oC, 
4 h iii) EtOH, reflux, 1 h.     
 
Figure 74 shows the 1H NMR spectrum of compound 353, with the triplet resonating at 1.15 
ppm corresponding to the methyl groups of the diethyl acetal moiety, while the 
corresponding methylene protons resonate as a pair of quartets at 3.49 ppm and 3.62 ppm, 
respectively. The chemical non-equivalence of the geminal protons in both the methylene 
groups results in the splitting pattern observed. The signals at 1.24 ppm and 4.00 ppm 
correspond to the methyl and methylene protons of the diethyl phosphoramidate group, 
respectively. The doublet at 3.28 ppm corresponds to the 1-methylene protons, while the 2-
methine proton resonates as a triplet at 4.58 ppm. 
  
 
 
 
 
 
 
 
 
 
 
Figure 74. 400 MHz 1H NMR spectrum of compound 353 in CDCl3.   
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2.4.2. Synthesis of the N-substituted benzyl phosphoramidate acetals 354a-d.  
The next step in the synthesis involved attachment of the various benzyl groups 360a-d to 
the phosphoramidate nitrogen in compound 353. Deprotonation of the NH group in 
compound 353 using sodium hydride, followed by treatment with the appropriate benzyl 
halides 360a-d yielded the N-substituted benzyl phosphoramidate acetals 354a-d in good 
yields ranging from 67 to 77% (Scheme 55). The benzyl substrates 360c-d used for the 
construction of compounds 354c-d were prepared as depicted in Scheme 56. The approach 
involved bromination of 3-aminobenzyl alcohol 361 using phosphorous tribromide to give 
the brominated derivative 360c. Diazotization of compound 360c followed by a reaction 
with sodium disulfide produced the disulfide compound 362, which was reduced in situ with 
sodium borohydride in anhydrous THF to furnish the thiophenol 360d.    
 
 
 
 
 
 
 
Scheme 55. Synthesis of N-substituted benzyl phosphonate acetals 354a-d.  
Reagents and conditions: i) NaH, THF, r.t., 24 h, N2.   
 
 
 
 
 
 
Scheme 56. Synthesis of benzyl substrates 360c and 360d.  
Reagents and conditions: i) PBr3, DCM, 0 
oC, 1 h then r.t., 24 h ii) H2O, HCl, NaNO2, Na2S2, 0 
oC, 1 h iii) NaBH4, THF, 0 
oC to r.t., 1 h.   
 
Spectroscopic analysis (NMR and IR) and combustion analysis confirmed the formation of 
compounds 354a-d. Figures 75 and 76 illustrate the 1H and 13C NMR spectra of compounds 
354a and 354d, respectively. In Figure 75, the aromatic protons of the benzyl group are 
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clearly seen resonating between 7.28 ppm and 7.37 ppm, while the signal corresponding to 
the benzylic proton appears at 3.84 ppm. In the 13C NMR spectrum of compound 354d 
(Figure 76), the aromatic carbons are all accounted for, resonating between 124.7 ppm and 
136.6 ppm, respectively. The benzylic carbon resonates at 68.9 ppm, while the signals 
corresponding to the phosphoramidate ethyl ester groups appear at 16.4 ppm and 62.7 ppm 
and are split due to coupling to the 31P nucleus. Analysis of the 31P NMR spectrum showed 
the presence of the 31P signal at 24.2 ppm, while the IR spectrum revealed the presence of 
the SH and P=O absorption bands at 2571 cm-1 and 1260 cm-1, respectively. 
Figure 75. 400 MHz 1H NMR spectrum of compound 354a in CDCl3.  
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Figure 76. 100 MHz 13C NMR spectrum of compound 354d in CDCl3.   
 
2.4.3. Synthesis of N-benzyl substituted phosphoramidic acid derivatives 351a-d. 
 
Since FR900098 237, the acetyl derivative of fosmidomycin 236, is approximately twice as 
active in vitro, we decided to incorporate the acetyl functionality in our target compounds 
351a-d, which were accessed by adapting methodology reported by Schlitzer et al,118-119 as 
outlined in Scheme 57. In addition to providing a point of attachment for the α-benzyl 
substituents, the presence of the nitrogen atom from the phosphoramidate group in 
compounds 351a-d facilitated synthesis by avoiding chirality problems arising from the 
asymmetry of the sp3 centre if the α-atom were carbon.  
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Scheme 57. Synthesis of N-benzyl-substituted phosphoramidic acid derivatives 351a-d.  
Reagents and conditions: i) 2M-HCl, r.t., 24 h ii) O-benzylhydroxylamine in MeOH, 40 oC, 3 h 
and then NaCNBH3, MeOH, HCl, r.t., 1 h iii) acetyl chloride, DCM, Et3N, r.t., 24 h, N2 iv) H2, 
Pd/C, MeOH v) TMSBr, DCM, 0 oC, 1 h and then H2O, r.t., overnight.     
 
Thus, acid-catalysed hydrolysis of the acetal moiety afforded the corresponding aldehydes 
355a-d in good yields ranging from 88% to 92%. NMR spectroscopic analysis confirmed the 
formation of the aldehydes 355a-d, as illustrated in the 1H NMR spectrum of compound 
355b in Figure 77. Successful cleavage of the acetal moiety is clearly evident with the 
disappearance of the diethyl acetal signals and the emergence of the aldehydic proton 
signal at 9.81 ppm. The methylene protons adjacent to the aldehyde carbonyl resonate at 
3.72 ppm, while the signal at 3.82 ppm corresponds to the methylene protons adjacent to 
both the nitrogen atom and benzene ring. The phosphonate ethyl ester signals resonate, 
characteristically, at 1.36 ppm and 4.13 ppm, while the signal at 4.82 ppm corresponds to 
the methylene protons adjacent to the hydroxyl group. The overlapping signals between 
7.58 ppm and 7.67 ppm integrate for the four aromatic protons. The IR spectrum showed 
the absorption bands for the hydroxyl and carbonyl groups at 3261 cm-1 and 1738 cm-1, 
respectively.   
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Figure 77. 400 MHz 1H NMR spectrum of compound 355b in CDCl3.        
The next step involved reductive amination of the aldehydes 355a-d using O-
benzylhydroxylamine, followed by sodium cyanoborohydride to furnish, via oxime 
intermediates, the O-benzyl-protected amines 356a-d in reasonable yields (63% to 68%). 
Acetylation of compounds 356a-d was achieved by using acetyl chloride in the presence of 
triethylamine, to obtain the O-benzyl-protected acetyl derivatives 357a-d. Compounds 
356a-d and 357a-d are all new and were fully characterised. Figures 78 and 79 illustrate the 
1H NMR spectra of compounds 356a and 357c, respectively. In Figure 79, the signals 
between 7.29 and 7.36 ppm integrate for the ten aromatic protons corresponding to the 
two benzyl groups and indicate the success of the reductive amination step. The vicinal 1-
and 2-methylene protons couple with each other and resonate as a complex multiplet at ca. 
2.90 ppm, while the two singlets at 3.82 and 4.73 ppm correspond to the 3- and 4-
methylene groups attached to the benzene rings. In the 1H NMR spectrum of compound 
357c (Figure 79), the success of the acetylation step was confirmed by the presence of the 
acetyl methyl singlet at 2.01 ppm. Significantly, introduction of the acetyl group deshields 
the 2-methylene protons, resulting in separation of the vicinal 1- and 2-methylene proton 
multiplets in the acetylated systems. Analysis of the COSY and HSQC spectra permitted 
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assignment of the aromatic protons signals in the anilino ring. The IR spectrum showed 
absorption bands for the NH2 and carbonyl groups at 3387 cm
-1 and 1692 cm-1. 
Figure 78. 400MHz 1H NMR spectrum of compound 356a in CDCl3.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 79. 400MHz 1H NMR spectrum of compound 357c in CDCl3.  
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The final two steps in the synthesis (Scheme 57) of the target compounds 351a-d involved 
the removal of the O-benzyl protecting group and hydrolysis of the diethyl ester groups of 
the phosphoramidate moiety. The O-benzyl protecting group was removed by catalytic 
hydrogenolysis using 10 % Pd/C in methanol to yield the hydroxamate derivatives 363a-d 
which, following treatment with TMSBr and hydrolysis, furnished the corresponding 
phosphoramidic acids 351a-d. The diethyl ester intermediates 363a-d could serve as ester 
prodrugs of the phosphoramidic acids 351a-d, exhibiting better lipophilicity prior to being 
hydrolysed by non-specific esterases in vivo. The novel products 363a-d and 351a-d were all 
fully characterised. Figure 80 illustrates comparative 13C NMR spectra of the 
phosphoramidate ester 363d and the phosphoramidic acid 351d; and clearly reveals the 
success of the hydrolysis reaction with the disappearance of the ethyl ester signals. Analysis 
of the IR spectrum for compound 351d showed the absorption band for the hydroxyl group 
at 3326 cm-1, while the absorption bands for the mercapto and carbonyl groups were 
observed at 2575 cm-1 and 1687 cm-1, respectively.    
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Figure 80. 100 MHz 13C NMR spectra of compound 363d (top, CDCl3) and compound 351d 
(bottom, D2O), showing the disappearance of the ethyl ester signals (circled) upon 
hydrolysis.  
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2.5. Enzyme-binding and -Inhibition studies.  
2.5.1. Synthesis of fosmidomycin and FR900098 as standards for biological studies. 
Fosmidomycin 236 and its acetyl derivative, FR900098 237, have been identified as potent 
inhibitors of DXR and clinical studies have proven that these molecules exhibit strong anti-
malarial activity in vitro.116,200 One of the aims of this project has been to determine the 
biological activity of a selection of the synthesised novel compounds (Sections 2.1, 2.2, 2.3 
and 2.4), against EcDXR and PfDXR in vitro. Consequently, we decided to synthesise 
fosmidomycin 236 and FR900098 237 for use as standards in the STD NMR binding and the 
enzyme-inhibition studies. Much interest has been generated in the design of 
fosmidomycin-like molecules as DXR inhibitors, and various research groups have reported 
different synthetic routes to fosmidomycin 236 and FR900098 237.118-119,201-202 We 
employed and adapted the method reported by Schlitzer et al.,118-119 outlined in Scheme 58.   
 
 
 
 
 
 
 
 
 
Scheme 58. Synthesis of known DXR inhibitors, fosmidomycin 236 and FR900098 237.118  
Reagents and conditions: i) 2M-HCl, r.t., overnight; ii) O-benzylhydroxylamine, MeOH, 40 oC, 
3 h and then NaCNBH3, MeOH, HCl, r.t., 1 h; iii) formic acid, sodium formate, 80 
oC, 2 h 203-204 
or acetyl chloride, DCM, Et3N, r.t., 24 h, N2; iv) H2, Pd/C, MeOH; v) TMSBr, DCM, 0 
oC, 1 h 
and then H2O, r.t., overnight.      
 
 
The first step in the synthesis of inhibitors 236 and 237 involved acidic hydrolysis of the 
commercially available acetal 364 to give the corresponding aldehyde 365 in reasonable 
yield (68%). The aldehyde 365 was subsequently treated with O-benzylhydroxylamine to 
give the oxime, which was reduced in situ in the presence of sodium cyanoborohydride and 
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hydrochloric acid to furnish the O-benzyl-protected hydroxylamine 366. Using a method 
adapted from Brahmachari et al.203 and Majee et al.204, compound 366 was successfully N-
formylated by refluxing with formic acid and a catalytic quantity of sodium formate to 
obtain the intermediate 367a. Also, compound 366 was acetylated with acetyl chloride in 
the presence of triethylamine to give the acetylated derivative 367b.  
Figures 81 and 82 illustrate the 1H and 13C NMR spectra of intermediates 367a and 367b, 
respectively. In the 1H NMR spectrum (Figure 81) of intermediate 367a, the success of the 
formylation reaction is indicated by the presence of the aldehyde signal at 8.13 ppm. The 
multiplets at 1.94 ppm and 1.74 ppm correspond to the 1- and 2-methylene groups, 
respectively, and are split due to coupling to each other and the adjacent 31P nucleus, while 
the signal for the 3-methylene protons resonates as a triplet at 3.72 ppm. The phosphonate 
ethyl ester signals resonate at 1.32 ppm and 4.08 ppm, while the singlet at 4.83 ppm 
corresponds to the benzylic methylene protons. The signal at 7.39 ppm integrates for five 
protons and thus corresponds to the benzene ring protons. In the 13C NMR spectrum (Figure 
82) of compound 367b, the methyl carbon of the acetyl group resonates at 19.7 ppm, while 
the carbonyl carbon signal appears at 162.9 ppm. The doublet at 23.5 ppm corresponds to 
the 1-methylene group, with a coupling constant of 141.2 Hz characteristic of coupling to an 
adjacent 31P nucleus. The C-2 and C-3 methylene carbons resonate at 20.7 ppm and 52.3 
ppm respectively, and are also split by coupling to 31P nucleus coupling, as are the signals at 
16.8 ppm and 61.9 ppm, which correspond to the phosphonate ethyl ester group; the acetyl 
carbonyl signal is evident at 163.0 ppm.  
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Figure 81. 400 MHz 1H NMR spectrum of intermediate 367a in CDCl3.     
 
Figure 82. 100 MHz 13C NMR spectrum of intermediate 367b in CDCl3.  
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The next step in the preparation of inhibitors 236 and 237 involved the removal of the 
benzyl protecting groups of intermediates 367a and 367b to yield the phosphonate ester 
derivatives 368a and 368b. Treatment of compounds 368a and 368b with TMSBr produced 
the silyl esters, in situ hydrolysis of which finally afforded fosmidomycin 236 and FR900098 
237, respectively. While requiring HPLC purification prior to use as bioassay standards, both 
compounds were fully characterised with the 1H and 13C spectroscopic data corresponding 
to the published data. Figures 83 and 84 show the 13C NMR spectra of fosmidomycin 236 
and FR900098 237 respectively, both of which reveal coupling of the 31P nucleus with all 
three methylene groups. The carbonyl carbon of the formyl group resonates at 155.7 ppm in 
the 13C spectrum of fosmidomycin 236, while the acetyl group in FR900098 237 is evidenced 
by the methyl signal at 20.0 ppm and the carbonyl signal at 162.8 ppm.    
Figure 83. 100 13C NMR Spectrum of fosmidomycin 236 in D2O.  
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Figure 84. 100 MHz 13C NMR spectrum of FR900098 237 in D2O.    
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2.5.2. Saturation transfer difference (STD) protein NMR binding studies.  
The saturation transfer difference NMR experiment is a screening assay which may be used 
to determine binding interactions between a set of ligands and a target protein.205-206 An 
STD spectrum is obtained by irradiating the protein at a frequency at which the ligands do 
not absorb. Intermolecular spin diffusion leads to the transfer of protein saturation to 
ligands which bind to the protein, and consequently, increase the signal intensities of these 
ligands; the non-binding ligands remain unaffected.205-206 A reference spectrum is also 
acquired by irradiating the ligand-protein mixture at a frequency at which none of the 
species resonate (off-resonance irradiation), resulting in equal saturation of all the species. 
Subtraction of the reference spectrum from the saturated spectrum produces a difference 
spectrum, showing only the signals of the ligands interacting with the protein.206 Sets of 
ligands can be studied simultaneously in a particular STD experiment, provided the 1H NMR 
spectra of the individual ligands are sufficiently different. 
STD experiments were conducted on a selection of the synthesised ligands (Section 2.1 - 2.4) 
to determine their binding to EcDXR. The EcDXR was expressed and purified, for the author, 
using standard protocols115,142 and a fraction, 20 μM in EcDXR, was used in each experiment. 
The EcDXR in sodium phosphate buffer (pH 7.0) was freeze-dried and re-suspended in an 
equal volume of D2O. The ligands were dissolved in the protein solution to give a 
protein:ligand molar ratio of 1:40. The STD experiments were carried out using parameters 
which had been optimized in a previous study in our group.129 The saturating on-resonance 
and off-resonance pulses were set at frequencies of 0.73 ppm and 20 ppm, respectively, 
while cycling between the on- and off-resonance phases was used to reduce the effects of 
changes in temperature or magnetic field homogeneity. 
The EcDXR-STD experiments were carried out on the phosphonic acid derivatives as the 
corresponding phosphonate esters were expected to act as pro-drugs and require in vivo 
hydrolysis before binding. The 1H NMR spectra of compounds 293a-d, 293f, 328a, 328e-f 
and 331a-b, and the corresponding STD difference spectra are illustrated as stacked plots in 
Figures 85 and 86. A spin-lock filter was not used in the experiments, resulting in the 
presence of the underlying protein spectrum in the difference spectrum. The results of the 
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EcDXR-STD binding experiments conducted on the selected novel compounds are 
summarized in Table 8.     
 
Figure 85. Stack-plot showing results from the EcDXR STD experiment conducted in D2O 
with compounds 293a-d and 293f. The correlations between individual ligand signals and 
signals in the difference spectrum are indicated by the coloured lines.   
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Figure 86. Stack-plot showing results from the EcDXR STD experiment conducted in D2O 
with compounds 328a, 328e,f and 331a,b. The correlations between individual ligand signals 
and signals in the difference spectrum are indicated by the coloured lines. 
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Table 8. Results of EcDXR STD binding experiments to screen selected ligands for binding to 
EcDXR, with observed binding interactions indicated by a positive (+) sign.        
 
a) Dihydroxy-amido phosphonic acids 293a-g.  
 
 
 
b) 3-Substituted aniline-derived phosphonic acids 328b,d-g; 331a-d; 333a,e,f; 335a,c.  
 
Compound R n STD result 
    
328b OMe 1 + 
328d F 1 - 
328e CN 1 - 
328f 
328g 
331a 
331b 
331c 
331d 
333a 
333e 
333f 
335a 
335c 
NO2 
CH2OH 
OH 
OMe 
Br 
F 
OH 
CN 
NO2 
OH 
Br 
1 
1 
2 
2 
2 
2 
3 
3 
3 
4 
4 
- 
+ 
+ 
+ 
+ 
- 
+ 
- 
- 
- 
- 
Compound R STD result 
   
293a Me + 
293b 
293c 
293d 
293e 
Et 
Pr 
Pri 
But 
+ 
- 
+ 
- 
293f Ph - 
293g CH2Ph - 
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Table 8 Contd.  
 
c) Furan-derived phosphates 337b and 337c.  
 
Compound R STD result 
   
337b H + 
337c Me + 
 
d) N-Benzyl-substituted phosphoramidic acids 351a and 351d.  
 
Compound  R STD result 
   
351a 
351d 
H 
SH 
+ 
+ 
 
                       
The STD experimental data (Table 8) for the dihydroxy-amido phosphonic acid derivatives 
indicate that compounds 293a,b and d bind to EcDXR, whilst compounds 293c and e-g do 
not. The binding interactions may be attributed to the fact that ligands 293a,b and d are 
similar in size to the known inhibitors fosmidomycin 236 and FR900098 237, and are thus 
able to occupy the enzyme’s active-site comfortably. Importantly, the presence of the 
hydroxyl groups at C-2 and C-3 are expected to provide additional hydrogen-bonding 
interactions with active-site residues. These conclusions are consistent with the molecular 
modelling results discussed in Section 2.6. Compounds 293c and e-g, on the other hand, 
contain propyl, butyl, phenyl or benzyl groups attached to the amide nitrogen, and the steric 
bulk of these groups are presumed to prevent these analogues from fitting into the 
sterically restricted DXR-active site. It seems that the binding site can accommodate the 
branched N-isopropyl group in ligand 293d but not the longer N-propyl group in 293c. 
Access to the metal-binding region, which the amide moiety in compounds 293a-g are 
expected to occupy, is constrained by the presence of the metal cation, the NADPH co-
factor and the channel through which the ligand enters the active-site.105,107 MacSweeney et 
al.105 have suggested that inhibitors greater in length than fosmidomycin 236 could displace 
NADPH or bind to an open conformation of DXR, although a decrease in inhibitory activity 
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has been reported for inhibitors with an acyl chain extended beyond the hydroxamate 
group.207   
STD experiments conducted with the 3-substituted aniline-derived phosphonic acids 328b,d-
g indicated binding of ligands 328b and 328g. From these results, it appears that the 
presence of a fluoro, nitro or cyano substituent on the phenyl ring has a negative effect on 
the binding affinity of compounds 328d-f, possibly due to unfavourable electrostatic 
interactions. Interestingly, the in silico docking of compounds 328e and 328f in the active 
site of a modelled structure of PfDXR in a collaborative study by Goble et al.,208  indicated 
that these compounds do not fully occupy the active site and that they bind in a reverse 
orientation compared to fosmidomycin 236. Further analysis of the STD results for the 3-
aniline derived phosphonic acids (Table 8) revealed that:- i) the compounds containing an 
OH, OMe or CH2OH substituent all showed positive binding to EcDXR, except for 335a (R = 
OH); ii) the extension of the carbon spacer to four methylene groups (n = 4) between the 
amide group and the phosphonic acid moiety appears to prevent compounds 335a and 335c 
from binding to EcDXR, whereas analogues with fewer methylene groups (331a,c; 333a) do 
appear to bind. These observations are consistent with those reported in literature, with the 
more active DXR inhibitors against DXR containing a hydroxyl group as part of the 
hydroxamate moiety and a three-carbon spacer between the phosphonate and metal 
binding groups being optimal. 105,122,125,131,134    
The positive binding data obtained for the furan analogues 337b,c is encouraging and 
supports the in silico docking observations (Section 2.6, p.143) which indicate binding of the 
phosphonate group and metal-chelating group to their respective sites in the EcDXR active-
site. The restricted flexibility provided by the furan ring in compounds 337b,c may well 
ensure that the inhibitors remain anchored in an ideal conformation within the active site. 
The N-benzyl substituted phosphoramidic acid analogues 351a and 351d were expected to 
show reasonable binding to EcDXR, as these novel analogues were designed following a 
detailed study in our group129 of the topology of the EcDXR and PfDXR catalytic sites. The N-
benzyl α-substituent was expected to occupy one of the reported hydrophobic binding 
pockets,122,128-129 thus increasing the compounds binding affinity to the enzyme. 
Furthermore, only α-phenyl substituted hydroxamic acid analogues of fosmidomycin 236 
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have previously been shown to exhibit inhibitory activities as potent as those of 
fosmidomycin 236 and FR900098 237.124-125,134  
The binding data obtained from the STD experiments have indicated that the technique is 
useful as an initial screen to identify potential DXR inhibitors, albeit with limitations. 
Although protein-ligand binding interactions were observed in the STD experiments, the 
possibility of the ligands binding non-specifically to regions other than the active-site cannot 
be excluded;209 in its standard form, the STD experiment only provides qualitative data. 
However, it may be possible to optimize the experiment for a particular ligand and conduct 
the experiment in the presence of the slow, tight- binding inhibitor fosmidomycin in order 
to accurately determine whether the observed protein-ligand binding is active-site specific 
or allosteric and to calculate binding affinities.129,209-210 Unfortunately, time constraints 
prevented further investigation.   
2.5.3. Enzyme inhibition assays.  
The mechanism for the catalytic conversion of DOXP 230 to MEP 231 by DXR involves an 
intramolecular rearrangement step followed by an NADPH-dependent reduction step.91 A 
DXR-inhibition bioassay has been developed based on the spectrophotometric 
measurement of the conversion of NADPH to NADP, to determine the capacity of novel 
compounds to inhibit both EcDXR and PfDXR.115,127 The compounds discussed in Section 2.2 
were tested for EcDXR inhibitory activity for the author211 and for PfDXR inhibitory activity in 
a collaborative study by Goble et al.208 The novel compounds synthesized and discussed in 
Sections 2.1, 2.3 and 2.4 were not subjected to the inhibition bioassay due to time 
constraints and the limited availability of the EcDXR and PfDXR enzymes precluded bioassay 
of the other novel ligands prepared in this study. It is expected, however, that these assays 
will be conducted in due course.   
To assess their inhibition potential, the selected ligands were tested at a concentration of 
250 μM, as this represented the initial concentration at which none of the ligands gave 
complete inhibition of the enzyme. Considering that fosmidomycin 236 is a slow-tight 
binding inhibitor of DXR,124 the synthesized ligands were pre-incubated with the enzyme 
and NADPH before the reaction was initiated with the addition of the substrate, DOXP 230. 
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For each ligand, the bioassays were carried out in triplicate and the specific activity of the 
enzyme was determined by analyzing the linear portion of the graph generated by plotting 
average absorbance (at 340nm) against time (over 10 minutes). The specific activity of the 
enzyme in the experiment lacking a ligand was considered to be 100% (i.e. 0% inhibition), 
which allowed the inhibitory activities to be expressed as relative percentages. 
Fosmidomycin 236 was used as a positive control for DXR inhibition and exhibited 99.3% 
inhibition at 0.3 μM.  
 
Table 9. Results for the inhibitiona of recombinant EcDXR at 250 μM for selected 
compounds.     
 
 
  
 
 
    R          n                
 
 
Inhibition (%)     
 
                      
Inhibition (%)  
 
 
Inhibition (%)  
                   
321a  
321c 
321e 
323a 
323b 
323g 
325a 
325c 
325f 
327a 
327b 
327d 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24.38 
21.35 
11.93 
33.51 
14.11 
17.92 
0.81 
-b 
-
b 
-b 
-
b 
-b 
  
328a 
328c 
328e 
331a 
331b 
331g 
333a 
333c 
333f 
335a 
335b 
335d 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
43.94 
26.46 
20.01 
49.23 
17.75 
26.81 
  0.66 
  -b 
   
-
b 
  -b 
   
-
b 
   -b 
 
329a 
329c 
329e 
332a 
332b 
332g 
334a 
334c 
334f 
336a 
336b 
336d 
 
 
 
 
 
 
 
 
 
 
 
 
41.58 
22.77 
22.47 
40.25 
12.13 
34.95 
0.96 
    -b 
    -
b
 
    -b 
    -
b 
      -b 
 
 
 
 
 
 
 
 
 
 
 
 
 
OH 1 
Br 1 
CN 1 
OH 2 
OMe 2 
CH2OH 2 
OH 3 
Br 3 
NO2 3 
OH 4 
OMe 4 
F 4 
a Activity in the absence of compound set at 100 %.  
b Negative % inhibition indicating activation of enzyme.  
 
The inhibition assay data summarised in Table 9 shows that the inhibitory potency of all the 
compounds tested is much lower than that of fosmidomycin 236 and other inhibitors 
reported in literature. Nonetheless, several structure-activity relationship patterns were 
observed. Compounds 328a, 329a, 331a and 332a exhibited inhibitory activity against 
EcDXR of more than 40% at 250 μM. Interestingly, all these compounds have the hydroxyl 
group attached at the meta-position of the benzene ring and the presence of this OH group 
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may well provide favourable electrostatic or hydrogen-bonding interactions within the 
enzyme’s active site. 
 All of the phosphonate ester inhibitors, except compounds 323b and 325a, exhibited a 
lower percentage inhibition compared to their corresponding phosphonic acid derivatives. 
The catalytic site of EcDXR is relatively polar in nature and is restricted by the phosphonate 
binding region on one side and the metal- and NADPH-binding site on the other.103,110,127 
Consequently, it is probable that the phosphonate ester ligands may be too hydrophobic 
and too bulky to be accommodated effectively in the active-site. Furthermore, Perruchon et 
al.128 have emphasized the importance of a double negative charge on the phosphonate 
moiety. However, the phosphonate ester inhibitors could exhibit higher inhibition activity 
than the corresponding phosphonic acids in vivo, as their lipophilic nature could allow them 
to penetrate the parasite’s membrane more readily, thus resulting in higher intra-parasitic 
drug concentrations.118, 119, 212 The difference in percentage inhibition values between the 
phosphonic acids and their corresponding mono-sodium salts is relatively small.  
It seems, from the data in Table 9, that the presence of two methylene groups between the 
amide group and the phosphonate moiety is advantageous but increasing the number to 
three or four decreases the inhibitory activity. This observation was expected, as analyses of 
the DXR active site have shown that the length of the cavity is restricted by the 
phosphonate-binding region at one end and the metal-and NADPH-binding site at the 
other.105,110,127,129 Furthermore, fosmidomycin 236 analogues in which the length has been 
varied have shown a decrease in inhibitory activity and it has been suggested that the 3-
carbon spacer between the hydroxamate- and phosphonate-binding groups in 
fosmidomycin 236 is ideal.149,207 Compounds with one or two methylene spacers showed 
low to moderate inhibitory activity, whilst minimal or zero inhibition was observed for the 
compounds with three or four methylene spacers. These results are consistent with the 
docking studies (Section 2.6) from which it was apparent that three or four methylene 
groups extend beyond the active site and do not bind as efficiently as the ligands with one 
or two methylene groups.  
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2.6. Molecular modelling and simulated docking studies  
Computer modelling studies were undertaken to explore the EcDXR receptor-binding 
potential of selected compounds synthesised in this study. The Accelrys Cerius2 module213 
was used to construct the selected compounds in silico as their mono-deprotonated species. 
Using Gaussian 03,214 the structure for each compound was optimised geometrically and 
energy-minimised at the density functional theory (DFT) B3LYP/6–31G(d) level. Docking 
studies of the geometry optimised and energy-minimised ligands was carried out using 
Autodock version 4.0,215 using the crystallographically-determined enzyme structure, EcDXR 
2EGH,103 as the protein-receptor model. The X-ray crystal structure EcDXR 2EGH, is 
complexed with fosmidomycin 236, the divalent metal cation Mg2+ and the NADPH co-
factor.103  
To validate the reliability of the docking procedure, fosmidomycin 236 was removed from 
the receptor cavity, energy-minimised and re-docked into the protein. Simulated docking of 
the energy minimised ligands involved the removal of fosmidomycin 236 and the solvating 
water molecules from the active site of the 2EGH crystal structure, whilst the NADPH co-
factor was retained. Using Autodock 4.0, Gasteiger charges were added and non-polar 
hydrogens were merged for the respective ligands and the protein model, while the active-
site residues Ser185, Ser221, Asn226, Lys227 and Glu 230 were assigned as flexible. The 
AutoGrid 4.0 algorithm was employed to represent the active site with a grid box of 
dimensions 60 x 60 x 60 units (grid-point spacing of 0.375 Å) along the x-, y- and z-
directions, and atom maps were calculated for all possible active-site residue-ligand 
interactions. In silico dockings were conducted using the Lamarckian algorithm with a 
population size of 150, allowing for a maximum of 27 000 generations and 2.5 x 106 energy 
evaluations. For each ligand docking experiment, ten possible docked-conformers were 
generated. The best docked-conformer for each of the ligands was selected upon analysis 
of:- i) the ligand binding affinity (Kcal.mol-1); ii) the ligand efficiency relative to fosmidomycin 
and; iii) the number of hydrogen-bonding interactions. The binding affinity measures the 
strength of the non-covalent interactions between the ligand and the protein.216-217 The 
ligand efficiency measures the binding free energy per atom of the ligand and provides an 
indication of the quality of fit of the ligand within the active site of the enzyme.218-219 A 
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ligand is classified as having a good binding affinity and good ligand efficiency by the 
magnitude of the negative values, as illustrated for fosmidomycin 236 (Table 10). The 
docked conformations were visualised using the Accelrys Discovery Studio Visualizer 2.0220 
software package. The binding affinity and ligand efficiency values computed for the lowest 
energy docked conformations of fosmidomycin 236 and of selected ligands are summarised 
in Table 10.  
 
Table 10. Binding affinity and ligand efficiency data of fosmidomycin and selected ligands 
docked into EcDXR.   
 
Compounda  Binding affinity 
(Kcal.mol-1) 
Ligand efficiency 
   
Fosmidomycin -15.22 -1.38 
293a -12.77 -0.98 
293b -10.19 -0.57 
293c -7.96 -0.53 
293d -8.30 -0.55 
293e -6.73 -0.42 
293f -7.54 -0.54 
293g -6.27 -0.48 
328a -9.64 -0.64 
328c 
328f 
-9.33 
-8.65 
-0.78 
-0.51 
331a -8.56 -0.54 
331e 
331g 
333a 
333b 
333g 
335a 
335d 
-9.93 
-8.46 
-5.70 
-6.19 
-4.15 
-4.46 
-4.67 
-0.58 
-0.47 
-0.34 
-0.34 
-0.23 
-0.26 
-0.27 
     a Modelled as mono-deprotonated species.   
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Table 10 contd.  
Compounda  Binding affinity 
(Kcal.mol-1) 
Ligand efficiency 
   
335e 
337b 
337c 
337d 
351a 
351b 
351c 
351d 
-5.98 
-10.84 
-10.20 
-5.89 
-9.39 
-8.80 
-9.84 
-9.36 
-0.46 
-0.77 
-0.68 
-0.31 
-0.49 
-0.42 
-0.56 
-0.47 
     a Modelled as mono-deprotonated species.  
The ligand structures used for the docking studies were the mono-deprotonated phosphonic 
acid derivatives. The importance of the phosphonate moiety being negatively charged and 
involved in hydrogen-bonding interactions has been highlighted.113,127-128 The corresponding 
phosphonate ester analogues were expected to act as pro-drugs, being hydrolysed in vivo 
before reaching the active-site. Furthermore, docking of N-heteroarylamino phosphonate 
ester derivatives in the EcDXR active site, in a cognate study in our group, revealed that the 
phosphonate ester analogues are too bulky to fit in the active site.129  
The active site of EcDXR is considered to be restricted in length by the presence of the 
phosphonate binding-site at one end and the divalent metal cation and NADPH binding-
region at the other.105,107  Analysis of the binding affinity and ligand efficiency values, as well 
as the binding conformations of the dihydroxy-amido phosphonic acids 293e-g and 3-
substituted aniline-derived phosphonic acids 333a,b,g and 335a,d,e, indicate that these 
ligands all exhibit some binding interaction with active site residues, but appear to be too 
large to fit, completely, in the EcDXR active site and thus extend beyond the catalytic cavity. 
Increasing the number of methylene groups (1 to 4) between the amide group and the 
phosphonate moiety resulted in decreases in the binding affinity and ligand efficiency 
values, reflecting the inability of the larger ligands (methylene group > 2) to occupy the 
EcDXR active site appropriately. These results are consistent with the EcDXR STD-NMR 
binding data (Table 8) and the enzyme-inhibition assay data (Table 9) discussed in previous 
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sections. Figures 87 and 88 illustrate the docked conformations of ligands 293f and 337e in 
the EcDXR active site, respectively. Interestingly, the benzene rings of both ligands 293f and 
335e occupy a region adjacent to the NADPH-binding site towards the top of the active site 
and project towards the channel region through which the ligand enters the active site. The 
occupation of the active-site by larger ligands such as 293f and 335e may result in these 
ligands binding to the open conformation of DXR, which has been suggested by 
MacSweeney et al.105 Moreover, Henriksson et al.107 identified a hydrated cavity lined by the 
residues Thr175, Ser245 and His248 (in MtDXR) and suggested that compounds larger than 
fosmidomycin 236 could extend into this cavity. The STD-NMR binding data (Table 8) and 
enzyme-inhibition data (Table 9), however, suggest that such arrangements prevent 
efficacious binding.       
 
 
 
 
Figure 87. Docked conformation of the dihydroxy-amido phosphonic acid ligand 293f in the 
EcDXR active-site (2EGH), illustrating hydrogen-bonding of the ligand with active-site 
residues and the ligand extending beyond the metal binding site. The crystal structure 
conformation of fosmidomycin 236 is shown in stick format coloured yellow and highlights 
the docking alignment of ligand 293f. Protein-active site residues are shown in wire-frame 
coloured by atom type, NADPH in stick coloured green, Mg2+ as a blue sphere and the ligand 
shown in stick format coloured by atom type. Hydrogen bonds are shown as green dashed 
lines.  
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Figure 88. Docked conformation of the 3-substituted aniline-derived phosphonic acid ligand 
335e in the EcDXR active-site (2EGH), illustrating hydrogen-bonding of the ligand with 
active-site residues and the ligand extending beyond the metal binding site. The crystal 
structure conformation of fosmidomycin 236 is shown in stick format coloured yellow and 
highlights the docking alignment of ligand 335e. Protein active-site residues are shown in 
wire-frame coloured by atom type, NADPH in stick format coloured green, Mg2+ as a blue 
sphere and the ligand in sticks coloured by atom type. Hydrogen bonds are shown as green 
dashed lines.  
 
The docking results (Table 10) show that ligands 293a,b and 337b,c exhibit the most 
favourable binding energy (relative to fosmidomycin), while ligands 293a, 328c and 337b 
demonstrate ligand efficiency values better than -0.70. Examination of the docked 
conformation of ligand 293a (Figure 89), suggests that the good binding affinity and ligand 
efficiency data observed for this ligand may be attributed to the close alignment with 
fosmidomycin. In addition, the carbonyl and NH groups of ligand 293a exhibit hydrogen-
bond with the active-site residues Lys 124, Glu151 and Asn226, while the phosphonic acid 
 Discussion 
 ________________________________________________________________________________  
Page | 148  
 
group occupies the appropriate binding-region and interacts with the active-site residues 
Ser185 and Ser253. The positive STD-NMR binding data (Table 8) and enzyme-inhibition 
data (Table 9) obtained for compound 293a, together with the favourable interactions 
observed in the in silico studies, presents ligand 293a as a feasible, new lead-compound, 
targeting DXR in the development of novel anti-malarial drugs.        
 
Figure 89. Docked conformation of the dihydroxy-amido phosphonic acid ligand 293a in the 
EcDXR active-site (2EGH), illustrating the close alignment of ligand 293a with fosmidomycin 
and hydrogen-bonding of the ligand with active-site residues. The crystal structure 
conformation of fosmidomycin 236 is shown in stick format coloured yellow. Protein active-
site residues are shown in wire-frame coloured by atom type, NADPH shown in stick format 
coloured green, Mg2+ as a blue sphere and the ligand in stick format coloured by atom type. 
Hydrogen bonds are shown as green dashed lines.    
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With regard to the conformationally-restricted furan-derived phosphate ligands 337b-d, 
ligand 337b exhibits the most favourable docked conformation within the active-site and 
exhibits hydrogen-bonding interactions with the residues, Lys 124, Glu151, Ser185, Ser221, 
Lys227 and Glu230 (Figure 90). Importantly, the presence of the furan-ring appears to 
restrict flexibility in the conformation of the linking group between the phosphonate-
binding and metal-binding sites, while permitting hydrogen-bonding interactions between :- 
i) the furan-ring oxygen atom with Lys 124; and ii) the hydroxyl group of the oxime moiety 
with Lys 124. Analysis of the docked conformation of the analogue 337d reveals that the 
ligand is too bulky to be accommodated in the active-site as the tert-butyl group extends 
well beyond the metal-binding site.  
Figure 90. Docked conformation of the furan-derived phosphate ligand 337b in the EcDXR 
active-site (2EGH), illustrating hydrogen-bonding of the ligand with active-site residues. The 
crystal structure conformation of fosmidomycin 236 is shown in stick format coloured 
yellow and highlights the docking alignment of ligand 337b. Protein active-site residues are 
shown in wire-frame coloured by atom type, NADPH in stick format coloured green, Mg2+ as 
a blue sphere and the ligand in stick format coloured by atom type. Hydrogen bonds are 
shown as green dashed lines.  
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Reasonable binding affinity data is observed for the 3-substituted aniline phosphonic acid 
dianionic ligands 328a, 328c, 328f and 331a, 331e, 331g. Interestingly, docking orientations 
opposite to that of fosmidomycin 236 were exhibited by most of these ligands in the active 
site, as shown for ligand 328f in Figure 91.  
 
Figure 91. Docked conformation of the 3-substituted aniline-derived phosphonic acid ligand 
328f in the EcDXR active-site (2EGH), illustrating ‘reverse’ binding of the ligand relative to 
fosmidomycin 236. The crystal structure conformation of fosmidomycin 236 is shown in 
stick format coloured by atom type. Protein active-site residues are shown in wire-frame 
coloured by atom type, NADPH in stick format coloured green, Mg2+ as a blue sphere and 
the ligand shown in stick format coloured by atom type. Hydrogen bonds are shown as 
green dashed lines.  
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The ‘reverse’-binding mode exhibited by these ligands has, in fact, also been reported for N-
heterocyclic phosphonic acid analogues evaluated in a cognate study in our group, and is 
attributed to the favourable electrostatic attraction between the divalent metal cation and 
the phosphonic acid anion group of the ligand.129,142 Furthermore, the authors have 
highlighted the fact that ligands exhibiting ‘reverse’ binding arrangements may still serve as 
DXR inhibitors as the binding interactions between the ligands and the enzyme are 
chemically feasible.129,141  Yajima et al.102 and Henriksson et al.107 have reported that the DXR 
enzyme undergoes conformational changes itself upon binding of a ligand and co-factor; 
changes which may permit several plausible orientations of the ligand in the active site.  
As previously discussed (Section 2.4, p. 141), the N-benzyl substituted phosphoramidic acid 
derivatives 351a-d were designed and synthesised as specific inhibitors of PfDXR. Thus, in 
silico docking of the ligands 351a-d was explored using both EcDXR (2EGH) and PfDXR (the 
homology model developed by Goble et al.)208 receptor cavities.ǂ Visual assessment of the 
dockings for the ligands 351a-d in EcDXR and PfDXR revealed, as expected, that the ligands 
adopt binding orientations similar to that of fosmidomycin 236, with the benzyl group 
adjacent to the phosphonate moiety occupying the hydrophobic pocket (pocket I in Figure 
72) adjacent to the phosphonate-binding site. On docking in the PfDXR receptor cavity, the 
phosphonate moiety of each of the ligands 351a-d exhibits hydrogen-bonding interactions 
with the active-site residues, Ser 199 and Gly 201, while the carbonyl group interacts with 
residue Ser 235. In addition, the following interactions were observed between ligands 
351a-d and amino acid residues in the PfDXR active-site:- i) Ser 161 acting as donor in 
hydrogen-bonding to the benzylic OH group in ligand 351b; ii) Ile 269 and His 270  
interacting with the 3-amino substituent in ligand 351c; and iii) Cys 197 hydrogen-bonding 
with the phosphonate moiety in ligand 351d. Figure 92 illustrates the binding conformation 
of ligand 351c in the PfDXR active-site with the benzyl ring occupying the pocket adjacent to 
the phosphonate-binding region.   
 
 
                                                          
ǂ
 Upon completion of this study, the PfDXR crystal structure has been published by Tanaka et al.
208b
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Figure 92. Docked conformation of the N-benzyl substituted phosphoramidic acid ligand 
351c in the PfDXR active-site showing the benzyl ring occupying the pocket adjacent to the 
phosphonate-binding region. The surface zone at 4.1 Å from ligand 351c is shown with 50% 
transparency, coloured by atom type and clipped in front. Protein active-site residues are 
shown in wire-frame coloured by atom type, NADPH in stick format coloured yellow, Mg2+ as 
a blue sphere and the ligand in stick format coloured by atom type. Hydrogen bonds are 
shown as green dashed lines.   
 
The in silico screening tools used in this study have provided information regarding the 
ability of the various synthesised ligands to be accommodated in the DXR active-site and a 
measure of their potential to interact through hydrogen-bonding with active-site residues. 
From an analysis of the simulated-docking data, we have established that:- i) ligands 293a,b, 
331a,g, 337b,c and 351a-d may be considered as feasible lead-compounds in the design and 
development of novel DXR inhibitors; and ii) the sterically restricted DXR active-site cannot 
adequately accommodate ligands possessing bulky substituents e.g. 293e-g, nor could it 
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accommodate ligands containing three or four methylene carbon linkers between the 
essential phosphonate- and amide-binding groups as in compounds 333a,b,g. In future, 
scrutiny of the topology and properties of the DXR active site, coupled with structural 
modifications of the synthesised compounds, may lead to the design of analogues with 
better binding and inhibition potential. 
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2.7. Conclusions 
The various aims identified at the outset of the study have largely been achieved. Attention 
has been focused on synthesizing novel compounds that can act as inhibitors of DXR. In the 
design of these novel compounds, consideration has been given, inter alia, to the 
replacement of the phosphate group in the natural substrate DXP, by a phosphonate 
moiety, and the hydroxamate functionality, present in the established inhibitor, 
fosmidomycin, by an amide moiety.   
Four general synthetic approaches (Scheme 24) have been explored in order to access the 
desired DXR inhibitors. In the first approach, the novel dihydroxy-amido phosphonate esters 
292a-g and their corresponding phosphonic acids 293a-g were successfully prepared. EDC-
mediated coupling of γ-phosphonated crotonic acid 291 with various amines afforded the 
amido-phosphonate esters 285a-g, which were dihydroxylated using a RuCl3/CeCl3/NaIO4 
catalyst system to furnish the dihydroxy-amido phosphonate esters 292a-g in good yields (> 
62%). Subsequent hydrolysis using TMSBr and aqueous methanol gave the targeted 
phosphonic acids 293a-g.     
In the second approach, several series of 3-substituted aniline-derived phosphonate esters 
(321a-g, 323a-g, 325a-g and 327a-g) and their corresponding phosphonic acids (328a-g, 
331a-g, 333a-g and 335a-g) and mono-sodium salts (329a-g, 332a-g, 334a-g and 336a-g) 
have been successfully synthesised as fosmidomycin 236 analogues. The series differed in 
the number of methylene groups (1-4) separating the phosphonate and amide moieties. 
These compounds were prepared by deprotonating the 3-substituted aniline substrates 
319a-g with sodium hydride, followed by reaction with chloroacetyl chloride and the ω-
chloroalkanoyl chlorides 330-330b to give the ω-chloroamide intermediates 320a-g, 322a-g, 
324a-g and 326a-g in generally good yields (> 59%). Subsequent phosphonation using the 
Michaelis-Arbuzov reaction afforded the diethyl phosphonate esters 321a-g, 323a-g, 325a-g 
and 327a-g in reasonable yields (48% - 74%). Microwave-assisted reaction of the 
phosphonate esters with TMSBr, followed by hydrolysis furnished the corresponding 
phosphonic acid derivatives 328a-g, 331a-g, 333a-g and 335a-g, and subsequent 
neutralisation with 0.1M aqueous sodium hydroxide furnished the mono-sodium 
phosphonic acid salts 329a-g, 332a-g, 334a-g and 336a-g.             
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Attention was then turned to developing the furan-derived phosphate analogues 349b-d 
and 337b-d as conformationally-restricted DOXP analogues. These novel analogues 337b-d 
were accessed via trityl-protected 3-furanmethanol 349, which was reacted with the 
specially prepared Vilsmeier reagent to furnish the desired formylated product 340b in 64% 
yield. Friedel-Crafts acylation of the protected furan 349, using SnCl4 as the Lewis acid 
catalyst, afforded the furanyl ketones 340c and 340d in 64% and 56% yields, respectively. 
Deprotection and phosphorylation of compounds 340b-d afforded the phosphate esters 
348b-d in 62-68% yields and, following hydrolysis, the dihydrogen phosphate derivatives 
341b-d were obtained in good yields (58% - 65%). Treatment of compounds 348b-d and 
341b-d with an ethanolic solution of hydroxylamine hydrochloride in the presence of a 
catalytic quantity of sodium acetate, furnished the targeted phosphorylated oxime 
derivatives 349b-d and 337b-d in very good yields (87% - 96%).   
Finally, based on a de novo design strategy, the N-benzyl substituted phosphoramidic 
derivatives 351a-d have been successfully prepared from the primary substrate, diethyl 
phosphoramidate 352. This approach involved silylation and alkylation of the substrate 352 
to afford the phosphoramidate acetal 353, which was reacted with appropriate benzyl 
substrates 360a-d to give the N-benzyl substituted phosphoramidate acetals 354a-d. 
Subsequent acid-catalysed hydrolysis of the acetal moiety gave the corresponding 
aldehydes 355a-d, which were reduced and O-benzylated to afford the O-benzyl-protected 
amines 356a-d. Acetylation and subsequent de-protection of the O-benzyl group gave the 
hydroxamate derivatives 363a-d and, following hydrolysis, the desired phosphoramidic acids 
351a-d were obtained in moderate yields (37% - 44%). In addition to establishing synthetic 
methodologies for accessing the novel DXR inhibitors discussed in Sections 2.1 – 2.4, the 
known DXR inhibitor fosmidomycin 236 and its acetyl derivative, FR900098 237, have also 
been prepared, for use as bio-assay standards, by adapting methods reported in 
literature.118-119,253 All of the prepared compounds have been fully characterised using 1- and 
2-dimensional NMR spectroscopic methods and, where appropriate, elemental (HRMS or 
combustion) analysis.  
Saturation Transfer Difference (STD) NMR experiments, conducted to explore the ability of 
synthesised ligands to bind to EcDXR, have revealed that certain ligands (293a,b,d, 328a,g, 
331a-c, 333a, 337a,c and 351a,d) bind to the enzyme, whilst other ligands (293c,e-g, 328d-f, 
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331d, 333e,f and 335a,c) do not.  The positive STD results have been attributed to several 
factors, viz :- 
i. ligands similar in size to fosmidomycin 236 being able to occupy the EcDXR active-
site comfortably; 
ii. the presence of the hydroxyl groups at C-2 and C-3 in ligands 293a,b and 293d 
providing additional hydrogen-bonding interactions with active-site residues; 
iii. the presence of a substituent containing an oxygen atom (i.e. OH, OMe and CH2OH) 
in ligands 328a,g, 331a-c and 333a providing favourable electrostatic interactions 
with active-site residues; 
iv. the restriction in conformational flexibility provided by the furan ring in ligands 
337a,c ensuring that the ligands maintain an ideal conformation within the active 
site; and 
v. the N-benzyl α-substituent in ligands 351a,d occupying the hydrophobic binding 
pocket adjacent to the phosphonate binding site, thus increasing the binding affinity 
of the ligands to the enzyme. 
 EcDXR inhibition assays were carried out, for the author,211 on selected 3-substituted 
aniline-derived analogues to assess their inhibition potential. Some of the ligands (328a, 
329a, 331a and 332a) exhibited > 40% inhibition at a concentration of 250 μM, whilst a 
decrease in inhibitory activity was observed when the number of methylene groups 
between the amide group and the phosphonate moiety, in the aniline-derived phosphonate 
analogues, was increased beyond two. Furthermore, the phosphonate esters generally 
exhibited less effective inhibition than their corresponding phosphonic acid derivatives, 
whereas the phosphonic acids and their corresponding mono-sodium salts exhibited similar 
inhibition levels – not surprisingly given that the assays were conducted in a buffered 
medium.   
Computer-simulated docking studies have been conducted, using EcDXR (crystal structure 
2EGH)103 to explore the ability of selected synthesised ligands to fit within the DXR active-
site and interact via hydrogen-bonding with active-site residues. Analysis of the docking 
results revealed that:- i) some of the ligands (293a,b, 328c, 337b,c and 351a-d) exhibited 
good binding affinity values with a high degree of conformational alignment with bound 
 Conclusion  
 ________________________________________________________________________________  
  
Page | 157  
 
fosmidomycin 236; ii) other ligands (293e-g, 333a,b,g, 335a,d,e and 337d) could not be 
accommodated within the active-site; iii) certain ligands (328a,c,f and 331a,e,g) exhibited 
docking orientations opposite (i.e. reverse binding)  to that of fosmidomycin 236.  
From the EcDXR-STD binding, enzyme inhibition and simulated docking data, it seems that 
compounds 293a, 293b, 331a and 331g could serve as lead compounds for the development 
of new anti-malarial drugs.  
 The results of this study have provided a number of opportunities for future research; these 
include:-  
i. optimisation of the STD NMR experiments to include fosmidomycin and FR900098 as 
highly competitive inhibitors and to access quantitative ligand binding affinity and 
ligand competition data;  
ii. EcDXR and PfDXR inhibition bio-assays of the dihydroxy-amido phosphonic acid 
derivatives, furan derived-phosphate analogues and N-benzyl substituted 
phosphoramidic acid derivatives at different ligand concentrations to determine the 
IC50 values and  inhibitory activity of the synthesised ligands; 
iii. P. falciparum growth inhibition assays of novel compounds, to assess the anti-
malarial activity and exploration of the toxicity of the inhibitors; and    
iv. synthetic elaboration of ligands identified as potential lead compounds.   
3. Experimental 
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3. EXPERIMENTAL 
 
3.1. General Procedures 
 
Unless stated otherwise, the reagents were supplied by Sigma Aldrich or Fluka and used 
without further purification. Solvents were purified by drying and re-distillation, as 
described by Perrin and Armarego.221 Reactions that required an inert atmosphere were 
conducted under nitrogen or argon gas. Thin layer chromatography was performed on 
Merck TLC silica gel 60 PF254 plates and viewed under UV light (254 nm) or developed with 
iodine vapour. Preparative layer chromatography was carried out using Merck silica gel 60 
PF254 as the stationary phase. Flash chromatography was conducted using Merck silica gel 60 
(particle size 0.040 – 0.063 mm) for normal-phase and Sep-Pak Vac 35cc C18 cartridges for 
reverse-phase. Normal-phase HPLC was carried out using a Whatman Partisil 10 semi-
preparative column and reverse-phase HPLC using a Phenomenex C-18 LUNA semi-
preparative column, with a Waters  R401 refractive index detector.   
 
Microwave-assisted reactions were conducted using a CEM-Discover microwave apparatus 
(model number 908010). NMR spectra were recorded on a Bruker AVANCE 400 MHz or 
Biospin 600 MHz spectrometers and were calibrated relative to the solvent signals (δH : 7.25 
ppm for CDCl3, 4.81 for D2O and 2.50 ppm for DMSO-d6; δC : 77.0 ppm for CDCl3 and 39.4 
ppm for DMSO-d6; δP : 0 ppm for 
31P in H3PO4 as a standard.   
 
Low-resolution mass spectra were acquired on a Finnigan MAT GCQ mass spectrometer at 
Rhodes University. High-resolution mass spectra were obtained at the University of 
Stellenbosch Central Analytical Facility using a Waters API Q-TOF Ultima spectrometer. 
Elemental analysis data were obtained using a Vario Elemental Microtube EL III analyzer. IR 
spectra were recorded on a Perkin-Elmer Spectrum 100 FT-IR spectrometer, as thin films or 
solid deposits between CsI discs, or as neat compounds on a diamond window.    
 
Percentage yields of chromatographed products are based on the mass of crude material 
separated chromatographically. Melting points were measured using a Reichert hot-stage 
apparatus, and are uncorrected. 
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3.2. Dihydroxy-amido phosphonate esters and their corresponding 
phosphonic acids  
 
Ethyl (E)-4-bromocrotonate 283 222  
 
 
 
 
A mixture of ethyl crotonate (6.2 mL, 50 mmol) and NBS (8.89 g, 50 mmol) in carbon 
tetrachloride (20 mL) was refluxed at 120 oC for 3 hours, whilst stirring. The resulting 
mixture was cooled to 0 oC and the succinimide was filtered off. The organic layer was 
washed with water (10 mL), separated, and dried with anhydr. Na2SO4. Filtration and 
evaporation of the solvent afforded the crude product, which was purified by flash 
chromatography [on silica gel; elution with hexane-EtOAc (49:1)] to obtain ethyl (E)-4-
bromocrotonate 283 as a yellow oil (5.39 g, 56 %); ʋmax (thin film/cm
-1) 1648 (C=O); δH/ppm 
(400 MHz; CDCl3) 1.26 (3H, t, J = 7.6 Hz, CH3), 3.98 (2H, d, J = 7.6 Hz, CH2Br), 4.18 (2H, q, J = 
7.2 Hz, CH2O), 6.02 (1H, d, J = 15.2 Hz, 2-H), 7.00 (1H, m, 3-H); δC/ppm (100 MHz; CDCl3) 14.1 
(C-2'), 29.1 (C-4), 60.7 (C-1'), 124.6 (C-2), 141.6 (C-3) and165.5 (C=O).  
 
(E)-4-(Diethoxyphosphoryl)crotonate 284 223  
 
 
 
 
 
Triethyl phosphite (1.82 g, 10.8 mmol) was added slowly to a stirred solution of ethyl 4-
bromocrotonate (1.03 g, 5.40 mmol) in toluene (10 mL) during a period of 1 hour, whilst the 
temperature of the mixture was maintained at 120 oC. After the addition, the mixture was 
stirred at the same temperature of a further 5 hours and then cooled to room temperature. 
The cooled mixture was then stirred with hexane (20 mL) for ca. 30 minutes followed by 
decantation of the hexane layer to remove the excess triethyl phosphite; this was repeated 
three times. The crude product was purified by flash chromatography [on silica gel; elution 
with hexane-EtOAc (3:1)], and subsequent evaporation of the solvent in vacuo afforded (E)-
4-(diethyoxyphosphoryl)crotonate 284 as a yellow oil (1.00 g, 75 %); ʋmax (thin film/cm
-1) 
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1748 (C=O) and 1231 (P=O); δH/ppm (400 MHz; CDCl3) 1.27 (9H, m, 3 x CH3), 2.70 (2H, dd, J = 
22.8 and 7.2 Hz, CH2P), 4.12 (6H, m, 3 x OCH2), 5.93 (1H, dd, J = 15.6 and 4.4 Hz, 2-H), 6.85 
(1H, q, J = 7.6 Hz, 3-H); δC/ppm (100 MHz; CDCl3) 14.1 (C-2'), 16.3 (2 x C-2''), 30.1 (C-4), 60.3 
(C-1'), 62.2 (2 x C-1'), 125.8 (d, JP−C = 11.0 Hz, C-2), 137.3 (d, JP−C = 13.6 Hz, C-3) and 165.5 
(C=O); δP/ppm  (162 MHz; CDCl3) 25.3 (P=O).    
  
(E)-4-(Diethoxyphosphoryl)-N-methylbut-2-enamide 285a 
 
 
 
 
 
 
 
To a solution of EDC (0.65 g, 3.4 mmol) and HOBt (0.52 g, 3.4 mmol) in DCM (15 mL) under 
N2, was added (E)-4-(diethoxyphosphoryl)but-2-enoic acid 291 (0.50 g, 2.3 mmol) and the 
mixture was stirred for 15 minutes. To the mixture, methylamine hydrochloride (0.46 g, 6.8 
mmol) in DMF (5 mL) and triethylamine (0.74 mL, 3.4 mmol) was added and the resulting 
solution was stirred for 24 hours at room temperature. The solvent was evaporated in vacuo 
and the residue was dissolved in EtOAc (25 mL). The organic solution was washed 
sequentially with water (2 x 50 mL), 10 % aq. NaHCO3 (2 × 50 mL) and brine (2 × 50 mL). The 
organic solution was dried with anhydr. MgSO4, the solvent removed in vacuo and the 
residue chromatographed [preparative layer chromatography; elution with hexane-EtOAc 
(4:1)] to yield (E)-4-(diethoxyphosphoryl)-N-methylbut-2-enamide 285a as a brown solid 
(0.36 g, 68 %), m.p. 104-106 °C (Found: C, 46.11; H, 7.67; N, 5.94 %. C9H18NO4P requires C, 
45.96; H 7.71; N 5.95 %); ʋ/cm-1 1701 (C=O) and 1218 (P=O);  δH/ppm (400 MHz; CDCl3) 1.27 
(6H, t, J = 6.8 Hz, 2 x CH3), 2.48 (2H, dd, J = 22.2 and 6.8 Hz, CH2P), 2.71 (3H,s, 1''-CH3), 4.17 
(4H, m, 2 x OCH2), 5.78 (1H, dd, J = 15.2 and 4.2 Hz, 2-H), 6.84 (1H, m, 3-H) and 7.62 (1H, s, 
NH); δC (100 MHz; CDCl3)  16.2 (d, JP–C = 5.9 Hz, 2 × CH3), 26.4 (C-1''), 30.2 (d, JP–C = 140.3 Hz, 
CH2P), 61.3 (d, JP–C = 6.5 Hz, 2 × OCH2), 126.5 (d, JP−C = 15.0 Hz, C-2), 137.5 (d, JP−C = 14.7 Hz, 
C-3) and 163.1 (C=O).     
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(E)-4-(Diethoxyphosphoryl)-N-ethylbut-2-enamide 285b 
 
 
 
 
 
 
The procedure described for the synthesis of (E)-4-(diethoxyphosphoryl)-N-methylbut-2-
enamide 285a was employed, using EDC (0.65 g, 3.4 mmol), HOBt (0.52 g, 3.4 mmol) and 
(E)-4-(diethoxyphosphoryl)but-2-enoic acid 291 (0.50 g, 2.25 mmol) in DCM (15 mL) and, 
ethylamine hydrochloride (0.56 g, 6.8 mmol) and triethylamine (0.74 mL, 3.4 mmol) in DMF 
(5 mL). The crude product was chromatographed [preparative layer chromatography; 
elution with hexane-EtOAc (4:1)] to yield (E)-4-(diethoxyphosphoryl)-N-ethylbut-2-enamide 
285b as a yellow solid (0.40 g, 71 %), m.p. 91-93 °C (Found: C, 47.91; H, 8.87; N, 5.61 %. 
C10H22NO4P requires C, 47.80; H, 8.83; N, 5.57 %); ʋ/cm
-1 1683 (C=O) and 1226 (P=O);  
δH/ppm (400 MHz; CDCl3) 1.14 (3H, t, J = 7.6 Hz, 2''-CH3), 1.23 (6H, t, J = 7.2 Hz, 2 x CH3), 2.50 
(2H, dd, J = 22.4 and 7.6 Hz, CH2P), 3.31 (2H,q, J = 7.2 Hz, 1''-CH2), 4.18 (4H, m, 2 x OCH2), 
5.95 (1H, dd, J = 15.4 and 4.1 Hz, 2-H), 6.79 (1H, m, 3-H) and 8.99 (1H, s, NH); δC (100 MHz; 
CDCl3) 14.2 (C-2''), 16.3 (d, JP–C = 6.0 Hz, 2 × CH3), 30.4 (d, JP–C = 145.0 Hz, CH2P), 36.8 (C-1''), 
61.7 (d, JP–C = 6.4 Hz, 2 × OCH2), 125.0 (d, JP−C = 13.5 Hz, C-2), 136.8 (d, JP−C = 15.4 Hz, C-3) 
and 166.3 (C=O).       
   
(E)-4-(Diethoxyphosphoryl)-N-propylbut-2-enamide 285c 
  
 
 
      
 
To a solution of EDC (0.65 g, 3.4 mmol) and HOBt (0.52 g, 3.4 mmol) in DCM (15 mL) under 
N2, was added (E)-4-(diethoxyphosphoryl)but-2-enoic acid 291 (0.50 g, 2.3 mmol) and the 
mixture was stirred for 15 minutes. To the mixture, propylamine (0.57 mL, 6.8 mmol) was 
added and the resulting solution was stirred for 24 hours at room temperature. The solvent 
was evaporated in vacuo and the residue was dissolved in EtOAc (25 mL). The organic 
extract was washed sequentially with water (2 x 50 mL), 10 % aq. NaHCO3 (2 × 50 mL) and 
P
NH
O
O
O
O
1
2
3
4
1'
2'
2'
1'
1''
2''
P
NH
O
O
O
O
1
2
3
4
1'
2'
2'
1'
1''
2''
3''
  Experimental  
 
Page | 162  
brine (2 × 50 mL). The organic solution was dried with anhydr. MgSO4, the solvent removed 
in vacuo and the residue chromatographed [preparative layer chromatography; elution with 
hexane-EtOAc (4:1)] to yield (E)-4-(diethoxyphosphoryl)-N-propylbut-2-enamide 285c as a 
yellow oil (0.39 g, 65 %) (Found: C, 49.75; H, 9.18; N, 5.31 %. C11H24NO4P requires C, 49.80; 
H, 9.12; N, 5.28 %); ʋ/cm-1 1654 (C=O) and 1227 (P=O);  δH/ppm (400 MHz; CDCl3) 0.90 (3H, 
t, J = 7.6 Hz, 3''-CH3), 1.32 (6H, t, J = 7.2 Hz, 2 x CH3), 1.51 (2H, m, 2''-CH2), 2.55 (2H, dd, J = 
22.6 and 7.6 Hz, CH2P), 3.25 (2H, t, J = 6.4 Hz, 1''-CH2), 4.10 (4H, m, 2 x OCH2), 5.58 (1H, s, 
NH), 5.76 (1H, dd, J = 15.2 and 2.6 Hz, 2-H) and 6.80 (1H, m, 3-H); δC (100 MHz; CDCl3) 11.7 
(C-3''), 16.4 (d, JP–C = 6.0 Hz, 2 × CH3), 23.2 (C-2''), 30.7 (d, JP–C = 141.2 Hz, CH2P), 42.6 (C-1''), 
61.4 (d, JP–C = 6.4 Hz, 2 × OCH2), 123.5 (d, JP−C = 13.0 Hz, C-2), 134.4 (d, JP−C = 15.2 Hz, C-3) 
and 166.3 (C=O).   
     
(E)-4-(Diethoxyphosphoryl)-N-isopropylbut-2-enamide 285d 
 
 
 
 
 
The procedure described for the synthesis of (E)-4-(diethoxyphosphoryl)-N-propylbut-2-
enamide 285c was employed, using EDC (0.65 g, 3.4 mmol), HOBt (0.52 g, 3.4 mmol), (E)-4-
(diethoxyphosphoryl)but-2-enoic acid 291 (0.50 g, 2.3 mmol) and isopropylamine (0.58 mL, 
6.8 mmol) in DCM (15 mL). The crude product was chromatographed [preparative layer 
chromatography; elution with hexane-EtOAc (4:1)] to yield (E)-4-(diethoxyphosphoryl)-N-
isopropylbut-2-enamide 285d as a yellow solid (0.44 g, 75 %), m.p. 82-84 °C (Found: C, 
49.87; H, 9.20; N, 5.31 %. C11H24NO4P requires C, 49.80; H, 9.12; N, 5.28 %); ʋ/cm
-1 1662 
(C=O) and 1229 (P=O);  δH/ppm (400 MHz; CDCl3) 1.15 (6H, d, J = 6.8 Hz, 2''- and 3''-CH3), 
1.31 (6H, t, J = 7.2 Hz, 2 x CH3), 2.59 (2H, dd, J = 22.8 and 7.2 Hz, CH2P), 3.99 (1H, m, 1''-H), 
4.12 (4H, m, 2 x OCH2), 5.22 (1H, s, NH), 5.77 (1H, dd, J = 15.2 and 4.2 Hz, 2-H) and 7.04 (1H, 
m, 3-H); δC (100 MHz; CDCl3) 16.4 (d, JP–C = 5.8 Hz, 2 × CH3), 22.8 (C-2'' and C-3''), 27.6 (d, JP–C 
= 144.0 Hz, CH2P), 41.1 (C-1''), 63.6 (d, JP–C = 5.8 Hz, 2 × OCH2), 125.0 (d, JP−C = 14.1 Hz, C-2), 
139.4 (d, JP−C = 14.3 Hz, C-3) and 165.9 (C=O).    
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(E)-4-(Diethoxyphosphoryl)-N-butylbut-2-enamide 285e 
 
 
 
 
 
The procedure described for the synthesis of (E)-4-(diethoxyphosphoryl)-N-propylbut-2-
enamide 285c was employed, using EDC (0.65 g, 3.4 mmol), HOBt (0.52 g, 3.4 mmol), (E)-4-
(diethoxyphosphoryl)but-2-enoic acid 291 (0.50 g, 2.3 mmol) and butylamine (0.65 mL, 6.8 
mmol) in DCM (15 mL). The crude product was chromatographed [preparative layer 
chromatography; elution with hexane-EtOAc (4:1)] to yield (E)-4-(diethoxyphosphoryl)-N-
butylbut-2-enamide 285e as a brownish oil (0.39 g, 63 %) (Found: C, 51.83; H, 9.42; N, 5.07 
%. C12H26NO4P requires C, 51.70; H, 9.38; N, 5.01 %); ʋ/cm
-1 1693 (C=O) and 1217 (P=O);  
δH/ppm (400 MHz; CDCl3) 0.92 (3H, t, J = 7.6 Hz, 4''-CH3), 1.20 (2H, m, 3''-CH2),  1.30 (6H, t, J 
= 7.6 Hz, 2 x CH3), 1.71 (2H, m, 2''-CH2), 2.68 (2H, dd, J = 22.8 and 7.8 Hz, CH2P), 3.20 (2H, m, 
1''-CH2), 4.11 (4H, m, 2 x OCH2), 5.82 (1H, dd, J = 15.4 and 4.2 Hz, 2-H), 7.02 (1H, m, 3-H) and 
5.58 (1H, s, NH); δC (100 MHz; CDCl3) 13.8 (C-4''), 16.3 (d, JP–C = 6.7 Hz, 2 × CH3), 20.3 (C-3''), 
27.9 (d, JP–C = 144.0 Hz, CH2P), 29.9 (C-2''), 41.4 (C-1''), 63.8 (d, JP–C = 5.8 Hz, 2 × OCH2), 125.3 
(d, JP−C = 14.1 Hz, C-2), 134.4 (d, JP−C = 14.3 Hz, C-3) and 166.1 (C=O). 
 
(E)-4-(Diethoxyphosphoryl)-N-phenylbut-2-enamide 285f 
 
 
   
  
 
The procedure described for the synthesis of (E)-4-(diethoxyphosphoryl)-N-propylbut-2-
enamide 285c was employed, using EDC (0.65 g, 3.4 mmol), HOBt (0.52 g, 3.4 mmol), (E)-4-
(diethoxyphosphoryl)but-2-enoic acid 291 (0.50 g, 2.3 mmol ) and aniline (0.63 mL, 6.8 
mmol) in DCM (15 mL). The crude product was chromatographed [preparative layer 
chromatography; elution with hexane-EtOAc (3:1)] to yield (E)-4-(diethoxyphosphoryl)-N-
phenylbut-2-enamide 285f as a brown solid (0.44 g, 66 %), m.p. 86-88 °C (Lit.224 88 °C); 
ʋ/cm-1 1682 (C=O) and 1232 (P=O); δH/ppm (400 MHz; CDCl3) 1.27 (6H, t, J = 7.6 Hz, 2 x CH3), 
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2.30 (2H, dd, J = 22.8 and 7.6 Hz, CH2P), 4.10 (4H, m, 2 x OCH2), 5.80 (1H, dd, J = 15.4 and 4.4 
Hz, 2-H), 6.99 (1H, m, 3-H), 7.02 (1H, t, J = 7.2 Hz, 4''-H), 7.39 (2H, t, J = 7.2 Hz, 3''-H and 5''-
H), 7.57 (2H, d, J = 7.6 Hz, 2''-H and 6''-H) and 8.70 (1H, s, NH); δC (100 MHz; CDCl3) 16.4 (d, 
JP–C = 5.8 Hz, 2 × CH3), 27.8 (d, JP–C = 144.0 Hz, CH2P), 63.6 (d, JP–C = 5.8 Hz, 2 × OCH2), 121.8 
(C-2'' and C-6''), 124.5 (C-4''), 125.0 (d, JP−C = 14.1 Hz, C-2), 129.2 (C-3'' and C-5''), 136.7 (C-
1''), 139.3 (d, JP−C = 14.3 Hz, C-3) and 165.9 (C=O).   
 
 (E)-4-(diethoxyphosphoryl)-N-benzylbut-2-enamide 285g 
 
 
 
 
 
The procedure described for the synthesis of (E)-4-(diethoxyphosphoryl)-N-propylbut-2-
enamide 285c was employed, using EDC (0.65 g, 3.4 mmol), HOBt (0.52 g, 3.4 mmol), (E)-4-
(diethoxyphosphoryl)but-2-enoic acid 291 (0.50 g, 2.3 mmol) and benzylamine (0.75 mL, 6.8 
mmol) in DCM (15 mL). The crude product was chromatographed [preparative layer 
chromatography; elution with hexane-EtOAc (3:1)] to yield (E)-4-(diethoxyphosphoryl)-N-
benzylbut-2-enamide 285g as a yellow solid (0.49 g, 71 %), m.p. 95-97 °C (Found: C, 57.57; H, 
7.69; N, 4.49 %. C15H24NO4P requires C, 57.50; H, 7.72; N, 4.47 %); ʋ/cm
-1 1692 (C=O) and 
1239 (P=O); δH/ppm (400 MHz; CDCl3) 1.27 (6H, m, 2 x CH3), 2.72 (2H, dd, J = 22.8 and 7.6 
Hz, CH2P), 4.11 (4H, m, 2 x OCH2), 4.48 (2H, s, 1''-CH2), 5.80 (1H, dd, J = 15.2 and 1.2 Hz, 2-H), 
6.89 (1H, m, 3-H), 7.31 (5H, m, 3''-H, 4''-H, 5''-H, 6''-H and 7''-H) and 8.19 (1H, s, NH); δC (100 
MHz; CDCl3) 16.4 (d, JP–C = 5.9 Hz, 2 × CH3), 27.6 (d, JP–C = 143.9 Hz, CH2P), 43.5 (1''-CH2), 63.6 
(d, JP–C = 5.8 Hz, 2 × OCH2), 124.8 (d, JP−C = 13.8 Hz, C-2), 127.5 (C-5''), 127.8 (C-3'' and C-7''), 
128.7 (C-4'' and C-6''), 138.3 (d, JP−C = 13.6 Hz, C-3), 140.3 (C-2'') and 165.8 (C=O).   
 
Crotonic acid 286 
 
 
 
Ethyl (E)-crotonate 282 (10 mL, 81 mmol) was added to a 2M solution of potassium 
hydroxide in ethanol (8 mL, 0.1 mol) and the mixture was stirred at room temperature for 
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24 hours. After completion of the reaction, the ethanol was evaporated at reduced pressure 
and the residue was dissolved in water (100 mL), extracted with diethyl ether (2 x 50 mL), 
and the organic phase discarded. The aqueous phase was acidified (pH 2.5) with 2M HCl and 
extracted with diethyl ether (3 x 50 mL). The combined organic phases were washed with 
water (2 x 50 mL) and brine (2 x 50 mL), and dried (anhydr. Na2SO4). Evaporation of the 
solvent in vacuo gave crude product, which was washed with cold hexane to afford crotonic 
acid 286 as white crystals (6.69 g, 96 %), m.p. 72-74 °C (Lit.225 71-73 °C); ʋ/cm-1 2891 (OH) 
and 1681 (C=O); δH/ppm (400 MHz; CDCl3) 1.94 (3H, d, J = 6.8 Hz, CH3), 5.88 (1H, d, J = 15.6 
Hz, 2-H), 7.11 (1H, m, 3-H) and 10.18 (1H, s, OH); δC (100 MHz; CDCl3) 18.8 (CH3), 121.6 (C-2), 
146.8 (C-3) and 169.3 (C=O).   
 
Crotonyl chloride 287 226  
 
  
 
Oxalyl chloride (3.69 g, 29.1 mmol) was added dropwise to a pre-cooled (-2 oC), stirred 
solution of crotonic acid (5.00 g, 58.1 mmol) in DMF (20 mL) under N2. The mixture was 
stirred for 1 hour, warmed to room temperature and stirred for an additional 3 hours. The 
reaction was quenched with water (5 mL) and extracted with DCM (3 x 50 mL). The 
combined organic phases were washed sequentially with water (100 mL), 10 % aq. NaHCO3 
(100 mL) and brine (100 mL), and dried (anhydr. MgSO4). The solvent was removed under 
reduced pressure to afford the crude product as a yellow liquid, which was purified by 
distillation to yield crotonyl chloride 287 as a clear liquid (2.71 g, 89 %);ǂ ʋ/cm-1 1757 (C=O); 
δH/ppm (400 MHz; CDCl3) 1.93 (3H, d, J = 6.0 Hz, CH3), 5.88 (1H, d, J = 15.6 Hz, 2-H) and 7.12 
(1H, m, 3-H); δC (100 MHz; CDCl3) 17.9 (CH3), 125.4 (C-2), 150.8 (C-3) and 165.7 (C=O).    
  
 (E)-N-methylbut-2-enamide 288a 
 
 
 
                                                 
ǂ
 Product was stored under N2 at 0 – 2 
o
C.  
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Methylamine hydrochloride (0.49 g, 7.2 mmol) and Proton Sponge® (2.05 g, 9.57 mmol) 
were dissolved in a mixture of pyridine (0.6 mL) and DCM (15 mL) at 0 oC under N2. 
Crotonoyl chloride 287 (0.50 g, 4.8 mmol) was then added through a septum and the 
resulting mixture was stirred for 15 min. the reaction mixture was warmed to room 
temperature and stirred for 24 hours. The solvent was removed in vacuo and the residue 
extracted with EtOAc (100 mL). The organic extract was washed sequentially with satd. aq. 
NaHCO3 (100 mL), water (100 mL) and brine (100 mL). The aqueous washings were 
extracted with EtOAc (2 x 100 mL) and the combined organic solutions were dried (anhydr. 
MgSO4). Subsequent evaporation of the solvent in vacuo gave the crude product, which was 
recrystallised from EtOH to yield (E)-N-methylbut-2-enamide 288a as white crystals (0.38 g, 
81 %), m.p. 69-71 °C (Lit.227-228 67-69 °C); ʋ/cm-1 1682 (C=O); δH/ppm (400 MHz; CDCl3) 1.89 
(3H, d, J = 6.0 Hz, 4-CH3), 2.73 (3H, s, 1'-CH3), 5.85 (1H, d, J = 15.6 Hz, 2-H), 7.12 (1H, m, 3-H) 
and 8.09 (1H, s, NH); δC (100 MHz; CDCl3) 18.1 (C-4), 26.2 (C-1'), 124.4 (C-2), 142.8 (C-3) and 
166.7 (C=O).      
 
(E)-N-ethylbut-2-enamide 288b 229 
 
 
The procedure described for the synthesis of (E)-N-methylbut-2-enamide 288a was 
employed, using ethylamine hydrochloride (0.59 g ,7.2 mmol),  Proton Sponge® (2.05 g, 9.57 
mmol) and crotonoyl chloride 287 (0.50 g, 4.8 mmol) in a mixture of DCM (15 mL) and 
pyridine (0.6 mL). Subsequent evaporation of the solvent in vacuo afforded (E)-N-ethylbut-2-
enamide 288b as a pale yellow oil (0.46 g, 85 %); ʋ/cm-1 1673 (C=O); δH/ppm (400 MHz; 
CDCl3) 1.12 (3H, t, J = 7.6 Hz, 2'-CH3), 1.89 (3H, d, J = 6.0 Hz, 4-CH3), 3.29 (2H, q, J = 7.6 Hz, 1'-
CH2), 5.88 (1H, d, J = 15.6 Hz, 2-H), 7.11 (1H, m, 3-H) and 8.24 (1H, s, NH); δC (100 MHz; 
CDCl3) 14.6 (C-2'), 18.2 (CH3), 36.3 (C-1'), 124.9 (C-2), 143.2 (C-3) and 166.5 (C=O).   
 
(E)-N-propylbut-2-enamide 288c 
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Crotonoyl chloride 287 (0.50 g, 4.78 mmol) was added dropwise to a pre-cooled (- 0 oC), 
stirred solution of propylamine (0.80 mL, 9.6 mmol) and triethylamine (0.79 mL, 5.7 mmol) 
in DCM (15 mL) under N2. The resulting mixture was stirred for 30 min, warmed to room 
temperature and stirred for an additional 24 hours. The solvent was removed in vacuo and 
the residue extracted with CHCl3 (50 mL). The organic extract was washed with water (2 x 
50mL) and brine (2 x 50 mL). The aqueous washings were extracted with CHCl3 (50 mL) and 
the combined organic solutions were dried (anhydr. MgSO4). Subsequent evaporation of the 
solvent in vacuo gave the crude product, which was recrystallised from MeOH to yield (E)-N-
propylbut-2-enamide 288c as a brown solid (0.47 g, 77 %) m.p. 84-86 °C (Lit. 82-83 °C 227,230); 
ʋ/cm-1 1673 (C=O); δH/ppm (400 MHz; CDCl3) 1.01 (3H, t, J = 7.2 Hz, 3'-CH3), 1.53 (2H, m, 2'-
CH2) 1.84 (3H, d, J = 6.0 Hz, 4-CH3), 3.24 (2H, m, 1'-CH2), 5.91 (1H, d, J = 15.6 Hz, 2-H), 7.05 
(1H, m, 3-H) and 8.41 (1H, s, NH); δC (100 MHz; CDCl3) 11.4 (C-3'), 18.1 (C-4), 22.9 (C-2'), 42.4 
(C-1'), 124.1 (C-2), 143.8 (C-3) and 166.3 (C=O).     
 
(E)-N-isopropylbut-2-enamide 288d 
 
 
 
The procedure described for the synthesis of (E)-N-propylbut-2-enamide 288c was 
employed, using isopropylamine (0.80 mL, 9.6 mmol), triethylamine (0.79 mL, 5.7 mmol) 
and crotonoyl chloride 287 (0.50 g, 4.8 mmol) in DCM (15 mL). Subsequent evaporation of 
the solvent in vacuo gave the crude product, which was recrystallised from MeOH to yield 
(E)-N-propylbut-2-enamide 288c as pale yellow crystals (0.49 g, 82 %), m.p. 88-90 °C (Lit.231 
89-90 °C); ʋ/cm-1 1683 (C=O); δH/ppm (400 MHz; CDCl3) 1.20 (6H, d, J = 7.0 Hz, 2'- and 3'-
CH3), 1.78 (3H, d, J = 6.0 Hz, 4-CH3), 3.86 (1H, q, J = 6.8 Hz, 1'-H), 5.82 (1H, d, J = 15.2 Hz, 2-
H), 7.02 (1H, m, 3-H) and 8.91 (1H, s, NH); δC (100 MHz; CDCl3) 18.3 (C-4), 23.1 (C-2' and C-
3'), 41.6 (C-1'), 124.2 (C-2), 143.1 (C-3) and 166.9 (C=O).   
 
(E)-N-butylbut-2-enamide 288e 232 
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The procedure described for the synthesis of (E)-N-propylbut-2-enamide 288c was 
employed, using butyllamine (0.91 mL , 9.6 mmol), triethylamine (0.79 mL, 5.8 mmol) and 
crotonoyl chloride 287 (0.50 g, 4.8 mmol) in DCM (15 mL). Subsequent evaporation of the 
solvent in vacuo afforded (E)-N-butylbut-2-enamide 288e as a yellow oil (0.47 g, 69 %); 
ʋ/cm-1 1658 (C=O); δH/ppm (400 MHz; CDCl3) 0.96 (3H, t, J = 7.6 Hz, 4'-CH3), 1.32 (2H, m, 3'-
CH2), 1.55 (2H, m, 2'-CH2), 1.82 (3H, d, J = 6.1 Hz, 4-CH3), 3.20 (2H, q, J = 7.2 Hz, 1'-CH2), 5.87 
(1H, d, J = 15.4 Hz, 2-H), 7.11 (1H, m, 3-H) and 8.22 (1H, s, NH); δC (100 MHz; CDCl3) 13.9 (C-
4'), 18.0 (C-4), 19.9 (C-3'), 31.8 (C-2'), 40.8 (C-1'), 124.6 (C-2), 144.1 (C-3) and 166.5 (C=O).  
 
(E)-N-phenylbut-2-enamide 288f 
 
 
 
 
The procedure described for the synthesis of (E)-N-propylbut-2-enamide 288c was 
employed, using aniline (0.89 mL , 9.6 mmol), triethylamine (0.79 mL, 5.7 mmol) and 
crotonoyl chloride 287 (0.50 g, 4.8 mmol) in DCM (15 mL). Subsequent evaporation of the 
solvent in vacuo gave the crude product, which was recrystallised from MeOH to yield (E)-N-
phenylbut-2-enamide 288f as light brown crystals (0.42 g, 65 %), m.p. 110-112 °C (Lit.233-234 
110-111 °C); ʋ/cm-1 1679 (C=O); δH/ppm (400 MHz; CDCl3) 1.79 (3H, d, J = 6.4 Hz, 4-CH3), 
5.85 (1H, d, J = 15.6 Hz, 2-H), 7.07 (1H, m, 3-H) 7.12 (1H, t, J = 7.2 Hz, 4'-H), 7.29 (2H, t, J = 
7.2 Hz, 3'-H and 5'-H), 7.60 (2H, d, J = 7.6 Hz, 2'-H and 6'-H) and 8.22 (1H, s, NH); δC (100 
MHz; CDCl3) 18.4 (C-4), 121.8 (C-2' and C-6'), 123.9 (C-2), 124.9 (C-4'), 128.9 (C-3' and C-5'), 
136.7 (C-1'), 143.9 (C-3) and 166.9 (C=O).      
 
(E)-N-benzylbut-2-enamide 288g 
 
 
 
 
The procedure described for the synthesis of (E)-N-propylbut-2-enamide 288c was 
employed, using benzylamine (1.05 mL , 9.6 mmol), triethylamine (0.79 mL, 5.7 mmol) and 
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crotonoyl chloride 287 (0.50 g, 4.8 mmol) in DCM (15 mL). Subsequent evaporation of the 
solvent in vacuo gave the crude product, which was recrystallised from MeOH to yield (E)-N-
benzylbut-2-enamide 288g as pale yellow crystals (0.41 g, 74 %), m.p. 110-112 °C (Lit.235 
112-114 °C); ʋ/cm-1 1684 (C=O); δH/ppm (400 MHz; CDCl3) 1.77 (3H, d, J = 6.4 Hz, 4-CH3), 
5.86 (1H, d, J = 15.6 Hz, 2-H), 7.10 (1H, m, 3-H), 7.29 (5H, m, 3'-H, 4'-H, 5'-H, 6'-H and 7'-H) 
and 8.21 (1H, s, NH); δC (100 MHz; CDCl3) 18.4 (C-4), 43.2 (1'-CH2), 124.0 (C-2), 127.4 (C-5'), 
128.0 (C-3' and C-7'), 128.8 (C-4' and C-6'), 140.3 (C-2'), 143.2 and 166.7 (C=O).   
 
(E)-4-bromobut-2-enoic acid 290 
 
 
 
(E)-Ethyl 4-bromocrotonate 283 (1.20 g, 6.22 mmol) was added to a 2M solution of 
potassium hydroxide in ethanol (1.1 mL, 19 mmol) and the mixture was stirred at room 
temperature for 24 hours. After completion of the reaction, the ethanol was evaporated at 
reduced pressure and the residue was dissolved in water (100 mL), extracted with diethyl 
ether (2 x 50 mL), and the organic phase discarded. The aqueous phase was acidified (pH 
2.5) with 2M-HCl and extracted with diethyl ether (3 x 50 mL). The combined organic phases 
were washed with water (2 x 50 mL) and brine (2 x 50 mL), and dried (Na2SO4). Evaporation 
of the solvent in vacuo gave crude product, which was washed with cold hexane to afford 
(E)-4-bromobut-2-enoic acid 290 as white crystals (1.01 g, 98 %), m.p. 72-74 °C (Lit.236 71-73 
°C); ʋ/cm-1 2891 (OH) and 1681 (C=O); δH/ppm (400 MHz; CDCl3) 3.98 (2H, d, J = 7.6 Hz, 
CH2Br), 6.00 (1H, d, J = 15.2 Hz, 2-H), 6.98 (1H, m, 3-H) and 8.83 (1H, s, OH); δC (100 MHz; 
CDCl3) 35.2 (CH2Br), 124.6 (C-2), 143.8 (C-3) and 169.7 (C=O).   
 
(E)-4-(diethyloxyphosphoryl)but-2-enoic acid 291 237 
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Method 1 
(E)-4-(Diethoxyphosphoryl)crotonate 284 (2.00 g, 7.99 mmol) was added to a 2M solution of 
potassium hydroxide in ethanol (1.41 mL, 23.9 mmol) and the mixture was stirred at room 
temperature for 24 hours. After completion of the reaction, the ethanol was evaporated at 
reduced pressure and the residue was dissolved in water (100 mL), extracted with diethyl 
ether (2 x 50 mL), and the organic phase discarded. The aqueous phase was acidified (pH 
2.5) with 2M-HCl and extracted with diethyl ether (3 x 50 mL). The combined organic phases 
were washed with water (2 x 50 mL) and brine (2 x 50 mL), and dried (anhydr. Na2SO4). The 
crude product was purified by flash chromatography [on silica gel; elution with hexane-
EtOAc (4:1)], and subsequent evaporation of the solvent in vacuo afforded (E)-4-
(diethyloxyphosphoryl)but-2-enoic acid 291 as a clear oil (1.72 g, 97 %); ʋ/cm-1 2893 (OH), 
1698 (C=O) and 1234 (P=O); δH/ppm (400 MHz; CDCl3) 1.33 (6H, m, 2 x CH3), 2.77 (2H, dd, J = 
26.4 and 3.2 Hz, CH2P), 4.16 (4H, m, 2 x OCH2), 5.10 (1H, s, OH), 5.86 (1H, dd, J = 15.6 and 4.4 
Hz, 2-H) and 7.07 (1H, m, 3-H); δC/ppm (100 MHz; CDCl3) 16.2 (2 x C-2'), 30.3 (CH2P), 62.3 (2 
x C-1'), 125.7 (d, JP−C = 11.0 Hz, C-2), 137.1 (d, JP−C = 13.6 Hz, C-3) and 165.8 (C=O). 
 
Method 2 
Triethyl phosphite (3.07 g, 18.2 mmol) was added slowly to a stirred solution of (E)-4-
bromobut-2-enoic acid 290 (1.50 g, 9.09 mmol) in toluene (15 mL) during a period of 1 hour, 
whilst the temperature of the mixture was maintained at 120 oC. After the addition, the 
mixture was stirred at the same temperature of a further 8 hours and then cooled to room 
temperature. The cooled mixture was stirred with hexane (20 mL) for ca. 30 minutes 
followed by decantation of the hexane layer to remove the excess triethyl phosphite; this 
was repeated three times. The crude product was purified by flash chromatography [on 
silica gel; elution with hexane-EtOAc (4:1)], and subsequent evaporation of the solvent in 
vacuo afforded (E)-4-(diethyloxyphosphoryl)but-2-enoic acid 291 as a clear oil (1.37 g, 68 %).  
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Diethyl [(2S, 3S)-2,3-dihydroxy-4-(methylamino)-4-oxobutyl]phosphonate 292a ǂ 
 
 
 
 
 
In a 100ml round-bottomed flask, a mixture of NaIO4 (642 mg, 3 mmol) and CeCl3.H2O (75 
mg, 0.2 mmol) in H2O (0.9 mL) was stirred and heated until a bright yellow suspension 
formed. The reaction mixture was then cooled to 0 °C, and EtOAc (3 mL), CH3CN (6 mL) and 
a 0.1M aq. solution of RuCl3 (50 µL, 0.01 mmol) were added successively. After stirring for 10 
minutes, a solution of (E)-4-(diethoxyphosphoryl)-N-methylbut-2-enamide 285a (240 mg, 
1.0 mmol) in EtOAc (3 mL) was added, and the resulting heterogeneous mixture was stirred 
until the full consumption (followed by TLC) of the starting material. After completion of the 
reaction, anhydr. Na2SO4 (1 g) was added followed by EtOAc (25 mL). The solid was removed 
and the organic layer was washed with satd. aq. Na2SO3 (50 mL) and water (50 mL), dried 
(anhydr. Na2SO4), and the solvents were removed in vacuo. The crude product was 
chromatographed [preparative layer chromatography; elution with hexane-EtOAc-MeOH 
(1:1:1)] to yield 292a as a yellow oil (65.9 mg, 49 %) (Found: C, 40.21; H, 7.53; N, 5.25 %. 
C9H20NO6P requires C, 40.15; H, 7.49; N, 5.20 %); ʋ/cm
-1 3241 (OH), 1675 (C=O) and 1231 
(P=O);  δH/ppm (400 MHz; CDCl3) 1.26 (6H, t, J = 7.2 Hz, 2 x CH3), 1.94 and 2.12 (2H, 2 x m, 4-
CH2P), 2.38 (2H, s, 2 x OH), 2.82 (3H, s, 1''-CH3), 3.45 (1H, q, J = 7.2 Hz, 3-H), 4.04 (4H, m, 2 x 
OCH2), 4.20 (1H, d, J = 7.6 Hz, 2-H) and  10.3 (1H, s, NH); δC (100 MHz; CDCl3) 16.4 (d, JP–C = 
6.0 Hz, 2 × CH3), 24.8 (1''-CH3), 29.5 (d, JP–C = 141.2 Hz, CH2P), 58.3 (d, JP–C = 10.9 Hz, C-3), 
61.4 (d, JP−C = 6.4 Hz, 2 x OCH2), 80.1 (d, JP−C = 13.2 Hz, C-2) and 168.6 (C=O).   
 
Diethyl [(2S, 3S)-2,3-dihydroxy-4-(ethylamino)-4-oxobutyl]phosphonate 292b ǂ  
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The procedure described for the synthesis of diethyl [(2S,3S)-2,3-dihydroxy-4-
(methylamino)-4-oxobutyl]phosphonate 292a was employed, using NaIO4 (642 mg, 3 mmol), 
CeCl3.H2O (75 mg, 0.2 mmol), RuCl3 (50 µL, 0.01 mmol) and (E)-4-(diethoxyphosphoryl)-N-
ethylbut-2-enamide 285b (283 mg, 1.0 mmol). The crude product was chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield 
diethyl [(2S,3S)-2,3-dihydroxy-4-(ethylamino)-4-oxobutyl]phosphonate 292b as a clear oil 
(66.7 mg, 47 %) (Found: C, 42.44; H, 7.89; N, 5.01 %. C10H22NO6P requires C, 42.40; H, 7.83; 
N, 4.94 %); ʋ/cm-1 3252 (OH), 1690 (C=O) and 1222 (P=O);  δH/ppm (400 MHz; CDCl3) 1.01 
(3H, t, J = 7.6 Hz, 2''-CH3), 1.32 (6H, t, J = 7.2 Hz, 2 x CH3), 1.78 and 2.10 (2H, 2 x m, 4-CH2P), 
3.24 (2H, q, J = 7.6 Hz, 1''-CH2), 4.10 (4H, m, 2 x OCH2), 4.46 (1H, d, J = 7.6 Hz, 2-H), 4.68 (1H, 
q, J = 7.2 Hz, 3-H), 5.08 (2H, s, 2 x OH) and  8.72 (1H, s, NH); δC (100 MHz; CDCl3) 14.2 (C-2''), 
16.1 (d, JP–C = 6.7 Hz, 2 × CH3), 27.6 (d, JP–C = 144.0 Hz, CH2P), 35.4 (C-1''), 60.7 (d, JP−C = 11.7 
Hz, C-3), 63.6 (d, JP–C = 5.8 Hz, 2 × OCH2), 79.7 (d, JP−C = 13.2 Hz, C-2) and 165.9 (C=O).   
 
Diethyl [(2S, 3S)-2,3-dihydroxy-4-(propylamino)-4-oxobutyl]phosphonate 292c ǂ 
 
 
 
 
The procedure described for the synthesis of diethyl [(2S,3S)-2,3-dihydroxy-4-
(methylamino)-4-oxobutyl]phosphonate 292a was employed, using NaIO4 (642 mg, 3 mmol), 
CeCl3.H2O (75 mg, 0.2 mmol), RuCl3 (50 µL, 0.01 mmol) and (E)-4-(diethoxyphosphoryl)-N-
propylbut-2-enamide 285c (263 mg, 1.0 mmol). The crude product was chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1.5:1)] to yield 
diethyl [(2S,3S)-2,3-dihydroxy-4-(propylamino)-4-oxobutyl]phosphonate 292c as a yellow oil 
(75.8 mg, 51 %) (Found: C, 44.53; H, 8.20; N, 4.76 %. C11H24NO6P requires C, 44.44; H, 8.14; 
N, 4.71 %); ʋ/cm-1 3130 (OH), 1692 (C=O) and 1239 (P=O); δH/ppm (400 MHz; CDCl3) 0.99 
(3H, t, J = 7.6 Hz, 3''-CH3), 1.31 (6H, t, J = 7.2 Hz, 2 x CH3), 1.54 (2H, m, 2''-CH2), 1.80 and 2.08 
(2H, 2 x m, 4-CH2P), 3.28 (2H, q, J = 6.8 Hz, 1''-CH2), 4.09 (4H, m, 2 x OCH2), 4.43 (1H, d, J = 
7.6 Hz, 2-H), 4.69 (1H, q, 7.6 Hz, 3-H), 7.75 (2H, s, 2 x OH) and  8.36 (1H, s, NH); δC (100 MHz; 
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CDCl3) 11.4 (C-3''), 16.5 (d, JP–C = 5.8 Hz, 2 × CH3), 23.0 (C-2''), 27.7 (d, JP–C = 143.9 Hz, CH2P), 
41.2 (C-1''), 61.7 (d, JP−C = 11.9 Hz, C-3), 63.7 (d, JP–C = 5.8 Hz, 2 × OCH2), 78.6 (d, JP−C = 13.6 
Hz, C-2) and 171.6 (C=O).   
 
Diethyl [(2S, 3S)-2,3-dihydroxy-4-(isopropylamino)-4-oxobutyl]phosphonate 292d ǂ 
 
 
 
 
 
The procedure described for the synthesis of diethyl [(2S,3S)-2,3-dihydroxy-4-
(methylamino)-4-oxobutyl]phosphonate 292a was employed, using NaIO4 (642 mg, 3 mmol), 
CeCl3.H2O (75 mg, 0.2 mmol), RuCl3 (50 µL, 0.01 mmol) and (E)-4-(diethoxyphosphoryl)-N-
isopropylbut-2-enamide 285d (263 mg, 1.0 mmol). The crude product was 
chromatographed [preparative layer chromatography; elution with hexane-EtOAc-MeOH 
(1:1:1)] to yield diethyl [(2S,3S)-2,3-dihydroxy-4-(isopropylamino)-4-oxobutyl]phosphonate 
292d as a clear oil (71.3 mg, 48 %) (Found: C, 44.48; H, 8.19; N, 4.75 %. C11H24NO6P requires 
C, 44.44; H, 8.14; N, 4.71 %); ʋ/cm-1 3253 (OH), 1691 (C=O) and 1235 (P=O); δH/ppm (400 
MHz; CDCl3) 0.98 (6H, d, J = 6.8 Hz, 2''- and 3''-CH3), 1.31 (6H, t, J = 7.2 Hz, 2 x CH3), 1.79 and 
2.12 (2H, 2 x m, 4-CH2P), 2.78 (2H, s, 2 x OH), 3.84 (1H, q, J = 7.0 Hz, 1''-H), 4.11 (4H, m, 2 x 
OCH2), 4.44 (1H, d, J = 7.6 Hz, 2-H), 4.85 (1H, q, J = 7.6 Hz, 3-H) and 8.71 (1H, s, NH); δC (100 
MHz; CDCl3) 16.1 (d, JP–C = 6.7 Hz, 2 × CH3), 22.9 (C-2'' and C-3''), 27.6 (d, JP–C = 143.9 Hz, 
CH2P), 41.1 (C-1''), 61.6 (d, JP−C = 11.9 Hz, C-3), 63.6 (d, JP–C = 5.8 Hz, 2 × OCH2), 78.5 (d, JP−C = 
13.6 Hz, C-2) and 171.7 (C=O).    
 
Diethyl [(2S, 3S)-2,3-dihydroxy-4-(butylamino)-4-oxobutyl]phosphonate 292e ǂ 
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The procedure described for the synthesis of diethyl [(2S,3S)-2,3-dihydroxy-4-
(methylamino)-4-oxobutyl]phosphonate 292a was employed, using NaIO4 (642 mg, 3 mmol), 
CeCl3.H2O (75 mg, 0.2 mmol), RuCl3 (50 µL, 0.01 mmol) and (E)-4-(diethoxyphosphoryl)-N-
butylbut-2-enamide 285e (277 mg, 1.0 mmol). The crude product was chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1.5:1)] to yield 
diethyl [(2S,3S)-2,3-dihydroxy-4-(butylamino)-4-oxobutyl]phosphonate 292e as a clear oil 
(73.2 mg, 47 %) (Found: C, 46.48; H, 8.51; N, 4.57 %. C12H26NO6P requires C, 46.30; H, 8.42; 
N, 4.50 %); ʋ/cm-1 3122 (OH), 1704 (C=O) and 1226 (P=O); δH/ppm (400 MHz; CDCl3) 1.12 
(3H, t, J = 7.6 Hz, 4''-CH3), 1.18 (6H, t, J = 7.6 Hz, 2 x CH3), 1.52 (4H, m, 2''-CH2 and 3''-CH2), 
1.81 and 2.11 (2H, 2 x m, 4-CH2P), 3.22 (2H, q, J = 6.8 Hz, 1''-CH2), 4.10 (4H, m, 2 x OCH2), 
4.50 (1H, d, J = 7.4 Hz, 2-H), 5.01 (1H, q, J = 7.2 Hz, 3-H), 7.67 (2H, s, 2 x OH) and 8.49 (1H, s, 
NH); δC (100 MHz; CDCl3) 14.0 (C-4''), 16.2 (d, JP–C = 5.9 Hz, 2 × CH3), 20.0 (C-3''), 29.5 (d, JP–C 
= 141.2 Hz, CH2P), 31.9 (C-2''), 40.4 (C-1''), 60.1 (d, JP−C = 11.2 Hz, C-3), 61.2 (d, JP–C = 6.4 Hz, 2 
× OCH2), 79.8 (d, JP−C = 13.2 Hz, C-2) and 169.9 (C=O).     
  
Diethyl [(2S, 3S)-2,3-dihydroxy-4-(phenylamino)-4-oxobutyl]phosphonate 292f ǂ 
 
 
 
 
The procedure described for the synthesis of diethyl [(2S,3S)-2,3-dihydroxy-4-
(methylamino)-4-oxobutyl]phosphonate 292a was employed, using NaIO4 (642 mg, 3 mmol), 
CeCl3.H2O (75 mg, 0.2 mmol), RuCl3 (50 µL, 0.01 mmol) and (E)-4-(diethoxyphosphoryl)-N-
phenylbut-2-enamide 285f (300 mg, 1.0 mmol). The crude product was chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield 
diethyl [(2S,3S)-2,3-dihydroxy-4-(phenylamino)-4-oxobutyl]phosphonate 292f as a brown oil 
(81.2 mg, 49 %) (Found: C, 50.78; H, 6.73; N, 4.29 %. C14H22NO6P requires C, 50.75; H, 6.69; 
N, 4.23 %); ʋ/cm-1 3356 (OH), 1657 (C=O) and 1232 (P=O); δH/ppm (400 MHz; CDCl3) 1.32 
(6H, t, J = 7.6 Hz, 2 x CH3), 1.78 and 2.03 (2H, 2 x m, 4-CH2P), 4.13 (4H, m, 2 x OCH2), 4.48 
(1H, d, J = 7.1 Hz, 2-H), 5.04 (1H, q, J = 7.2 Hz, 3-H), 7.28 (5H, m, Ar-H), 8.02 (2H, s, 2 x OH) 
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and  8.80 (1H, s, NH); δC (100 MHz; CDCl3) 16.3 (d, JP–C = 6.0 Hz, 2 × CH3), 29.3 (d, JP–C = 143.0 
Hz, CH2P), 60.0 (d, JP−C = 11.5 Hz, C-3), 62.1 (d, JP–C = 6.5 Hz, 2 × OCH2), 79.5 (d, JP−C = 13.6 Hz, 
C-2), 121.3 (C-2'' and C-6''), 124.1 (C-4''), 129.4 (C-3'' and C-5''), 137.6 (C-1'') and 169.6 
(C=O). 
 
Diethyl [(2S, 3S)-2,3-dihydroxy-4-(benzylamino)-4-oxobutyl]phosphonate 292g ǂ 
 
 
 
 
 
The procedure described for the synthesis of diethyl [(2S,3S)-2,3-dihydroxy-4-
(methylamino)-4-oxobutyl]phosphonate 292a was employed, using NaIO4 (642 mg, 3 mmol), 
CeCl3.H2O (75 mg, 0.2 mmol), RuCl3 (50 µL, 0.01 mmol) and (E)-4-(diethoxyphosphoryl)-N-
benzylbut-2-enamide 285g (345 mg, 1.0 mmol). The crude product was chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield  
diethyl [(2S,3S)-2,3-dihydroxy-4-(benzylamino)-4-oxobutyl]phosphonate 292g as a yellow oil 
(91.5 mg, 53 %) (Found: C, 52.27; H, 6.96; N, 4.12 %. C15H24NO6P requires C, 52.17; H, 7.01; 
N, 4.06 %); ʋ/cm-1 3180 (OH), 1688 (C=O) and 1228 (P=O); δH/ppm (400 MHz; CDCl3) 1.33 
(6H, t, J = 7.6 Hz, 2 x CH3), 2.01 and 2.19 (2H, 2 x m, 4-CH2P), 4.10 (4H, m, 2 x OCH2), 4.29 
(1H, d, J = 7.2 Hz, 2-H), 4.48 (2H, s, 1''-CH2), 4.98 (1H, q, J = 7.2 Hz, 3-H), 7.31 (5H, m, Ar-H), 
8.18 (2H, s, 2 x OH) and 8.82 (1H, s, NH); δC (100 MHz; CDCl3) 16.6 (d, JP–C = 6.8 Hz, 2 × CH3), 
28.1 (d, JP–C = 143.9 Hz, CH2P), 44.0 (1''-CH2), 61.1 (d, JP−C = 11.6 Hz, C-3), 62.2 (d, JP–C = 6.4 
Hz, 2 × OCH2), 80.2 (d, JP−C = 13.5 Hz, C-2), 127.9 (C-5''), 128.3 (C-3'' and C-7''), 129.1 (C-4'' 
and C-6''), 140.8 (C-2'') and 171.7 (C=O). 
 
[(2S, 3S)-2,3-Dihydroxy-4-(methylamino)-4-oxobutyl]phosphonic acid 293a ǂ  
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Trimethylsilyl bromide (0.13 mL, 0.88 mmol) was added to diethyl [(2S,3S)-2,3-dihydroxy-4-
(methylamino)-4-oxobutyl]phosphonate 292a (0.12 g, 0.44 mmol) in CH3CN (2 mL) and the 
mixture was heated in the microwave apparatus set to deliver 100 W of power, with a 
reaction temperature of 100 oC and reaction time of 10 min. After completion, the mixture 
was cooled to room temperature, treated with a 95:5 MeOH-H2O mixture (1.5 mL) and 
stirred for 30 min. The solvent was removed in vacuo and the residue chromatographed 
[reverse-phase chromatography on C18 cellulose; elution with MeOH] to yield [(2S, 3S)-2,3-
dihydroxy-4-(methylamino)-4-oxobutyl]phosphonic acid 293a as a clear oil (60.9 mg, 65 %) 
(Found: C, 28.33; H, 5.71; N, 6.62 %. C5H12NO6P requires C, 28.18; H, 5.68; N, 6.57 %); ʋ/cm
-1 
3184 (OH), 1683 (C=O) and 1244 (P=O); δH/ppm (400 MHz; D2O) 1.91 and 2.18 (2H, 2 x m, 4-
CH2P), 2.81 (3H, s, 1'-CH3), 4.38 (1H, d, J = 7.6 Hz, 2-H) and 4.71 (1H, q, J = 7.2 Hz, 3-H); δC 
(100 MHz; D2O) 26.5 (1'-CH3), 31.4 (d, JP–C = 143.9 Hz, CH2P), 59.8 (d, JP–C = 11.2 Hz, C-3), 79.9 
(d, JP−C = 12.7 Hz, C-2) and 171.8 (C=O).    
 
[(2S, 3S)-2,3-Dihydroxy-4-(ethylamino)-4-oxobutyl]phosphonic acid 293b ǂ  
 
 
 
 
 
 
The procedure described for the synthesis of [(2S, 3S)-2,3-dihydroxy-4-(methylamino)-4-
oxobutyl]phosphonic acid 293a was employed, using trimethylsilyl bromide (0.12 mL, 0.85 
mmol) and diethyl [(2S,3S)-2,3-dihydroxy-4-(ethylamino)-4-oxobutyl]phosphonate 292b 
(0.12 g, 0.43 mmol) in CH3CN (2 mL). The crude product was chromatographed [reverse-
phase chromatography on C18 cellulose; elution with MeOH] to yield [(2S, 3S)-2,3-dihydroxy-
4-(ethylamino)-4-oxobutyl]phosphonic acid 293b as a clear oil (66.4 mg, 68 %) (Found: C, 
31.57; H, 6.18; N, 6.11 %. C6H14NO6P requires C, 31.73; H, 6.21; N, 6.17 %); ʋ/cm
-1 3242 
(OH), 1667 (C=O) and 1244 (P=O); δH/ppm (400 MHz; D2O) 1.19 (3H, t, J = 7.6 Hz, 2'-CH3), 
1.77 and 2.02 (2H, 2 x m, 4-CH2P), 3.23 (2H, q, J = 7.6 Hz, 1'-CH2), 4.44 (1H, d, J = 7.6 Hz, 2-H) 
and 4.65 (1H, q, J = 7.2 Hz, 3-H); δC (100 MHz; D2O) 14.7 (C-2'), 27.8 (d, JP–C = 141.6 Hz, CH2P), 
35.4 (C-1'), 61.7 (d, JP−C = 11.7 Hz, C-3), 80.3 (d, JP−C = 13.3 Hz, C-2) and 171.5 (C=O).   
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[(2S, 3S)-2,3-Dihydroxy-4-(propylamino)-4-oxobutyl]phosphonic acid 293c ǂ 
 
 
 
 
The procedure described for the synthesis of [(2S, 3S)-2,3-dihydroxy-4-(methylamino)-4-
oxobutyl]phosphonic acid 293a was employed, using trimethylsilyl bromide (0.11 mL, 0.80 
mmol) and  diethyl [(2S,3S)-2,3-dihydroxy-4-(propylamino)-4-oxobutyl]phosphonate 292c 
(0.12 g, 0.40 mmol) in CH3CN (2 mL). The crude product was chromatographed [reverse-
phase chromatography on C18 cellulose; elution with MeOH] to yield [(2S, 3S)-2,3-dihydroxy-
4-(propylamino)-4-oxobutyl]phosphonic acid 293c as a yellow oil (64.6 mg, 67 %) (Found: C, 
34.94; H, 6.63; N, 5.88 %. C7H16NO6P requires C, 34.86; H, 6.69; N, 5.81 %); ʋ/cm
-1 3245 
(OH), 1652 (C=O) and 1262 (P=O); δH/ppm (400 MHz; D2O) 1.01 (3H, t, J = 7.6 Hz, 3'-CH3), 
1.56 (2H, q, J = 7.2 Hz 2'-CH2), 1.79 and 2.10 (2H, 2 x m, 4-CH2P), 3.22 (2H, q, J = 6.8 Hz, 1'-
CH2), 4.44 (1H, d, J = 7.3 Hz, 2-H) and 4.89 (1H, q, 7.2 Hz, 3-H); δC (100 MHz; D2O) 14.7 (C-3'), 
22.5 (C-2'), 27.8 (d, JP–C = 141.6 Hz, CH2P), 41.2 (C-1''), 61.7 (d, JP−C = 11.5 Hz, C-3), 80.1 (d, 
JP−C = 13.8 Hz, C-2) and 171.5 (C=O).   
 
[(2S, 3S)-2,3-Dihydroxy-4-(isopropylamino)-4-oxobutyl]phosphonic acid 293d ǂ 
 
 
 
 
The procedure described for the synthesis of  [(2S, 3S)-2,3-dihydroxy-4-(methylamino)-4-
oxobutyl]phosphonic acid 293a was employed, using trimethylsilyl bromide (0.11 mL, 0.80 
mmol) and diethyl [(2S,3S)-2,3-dihydroxy-4-(isopropylamino)-4-oxobutyl]phosphonate 292d 
(0.12 g, 0.40 mmol) in CH3CN (2 mL). The crude product was chromatographed [reverse-
phase chromatography on C18 cellulose; elution with MeOH] to yield [(2S, 3S)-2,3-dihydroxy-
4-(isopropylamino)-4-oxobutyl]phosphonic acid 293d as a yellow oil (61.7 mg, 64 %) (Found: 
C, 34.90; H, 6.72; N, 5.85 %. C7H16NO6P requires C, 34.86; H, 6.69; N, 5.81 %); ʋ/cm
-1 3090 
(OH), 1687 (C=O) and 1240 (P=O); δH/ppm (400 MHz; D2O) 1.12 (6H, d, J = 7.2 Hz, 2'- and 3'-
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CH3), 1.89 and 2.20 (2H, 2 x m, 4-CH2P), 3.88 (1H, q, J = 7.0 Hz, 1'-H), 4.23 (1H, d, J = 7.6 Hz, 
2-H) and 4.71 (1H, q, J = 7.6 Hz, 3-H); δC (100 MHz; D2O) 23.7 (C-2' and C-3'), 31.0 (d, JP–C = 
141.2 Hz, CH2P), 41.4 (C-1'), 60.6 (d, JP−C = 10.7 Hz, C-3), 81.8 (d, JP−C = 13.9 Hz, C-2) and 
169.4 (C=O).    
 
[(2S, 3S)-2,3-Dihydroxy-4-(butylamino)-4-oxobutyl]phosphonic acid 293e ǂ 
 
 
 
 
The procedure described for the synthesis of [(2S, 3S)-2,3-dihydroxy-4-(methylamino)-4-
oxobutyl]phosphonic acid 293a was employed, using trimethylsilyl bromide (0.11 mL, 0.77 
mmol) and diethyl [(2S,3S)-2,3-dihydroxy-4-(butylamino)-4-oxobutyl]phosphonate 292e 
(0.12 g, 0.38 mmol) in CH3CN (3 mL). The crude product was chromatographed [reverse-
phase chromatography on C18 cellulose; elution with MeOH:H2O (1:0.5)] to yield [(2S, 3S)-
2,3-dihydroxy-4-(butylamino)-4-oxobutyl]phosphonic acid 293e as a clear oil (60.1 mg, 62 %) 
(Found: C, 37.70; H, 7.15; N, 5.54 %. C8H18NO6P requires C, 37.65; H, 7.11; N, 5.49 %); ʋ/cm
-1 
3252 (OH), 1632 (C=O) and 1260 (P=O); δH/ppm (400 MHz; D2O) 1.16 (3H, t, J = 7.2 Hz, 4'-
CH3), 1.50 (4H, m, 2'-CH2 and 3'-CH2), 1.80 and 2.01 (2H, 2 x m, 4-CH2P), 3.23 (2H, q, J = 7.2 
Hz, 1'-CH2), 4.45 (1H, d, J = 7.2 Hz, 2-H) and 4.99 (1H, q, J = 6.9 Hz, 3-H); δC (100 MHz; D2O) 
14.1 (C-4'), 20.3 (C-3'), 30.6 (d, JP–C = 138.0 Hz, CH2P), 32.3 (C-2'), 40.6 (C-1'), 60.2 (d, JP−C = 
10.9 Hz, C-3), 79.0 (d, JP−C = 11.6 Hz, C-2) and 169.6 (C=O).      
 
[(2S, 3S)-2,3-Dihydroxy-4-(phenylamino)-4-oxobutyl]phosphonic acid 293f ǂ 
 
 
 
 
 
The procedure described for the synthesis of [(2S, 3S)-2,3-dihydroxy-4-(methylamino)-4-
oxobutyl]phosphonic acid 293a was employed, using trimethylsilyl bromide (0.10 mL, 0.72 
mmol) and diethyl [(2S,3S)-2,3-dihydroxy-4-(phenylamino)-4-oxobutyl]phosphonate 292f 
                                                 
ǂ
 Product isolated as racemic mixture.  
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(0.12 g, 0.36 mmol) in CH3CN (2 mL). The crude product was chromatographed [reverse-
phase chromatography on C18 cellulose; elution with MeOH:H2O (1:0.5)] to yield [(2S, 3S)-
2,3-dihydroxy-4-(phenylamino)-4-oxobutyl]phosphonic acid 293f as a yellow oil (61.4 mg, 62 
%) (Found: C, 43.69; H, 5.15; N, 5.05 %. C10H14NO6P requires C, 43.64; H, 5.13; N, 5.09 %); 
ʋ/cm-1 3070 (OH), 1685 (C=O) and 1264 (P=O); δH/ppm (400 MHz; D2O) 1.93 and 2.18 (2H, 2 
x m, 4-CH2P), 4.45 (1H, d, J = 7.6 Hz, 2-H), 5.03 (1H, q, J = 7.6 Hz, 3-H) and 7.27 (5H, m, 2'-H, 
3'-H, 4'-H, 5'-H and 6'-H); δC (100 MHz; D2O) 29.3 (d, JP–C = 141.2 Hz, CH2P), 60.8 (d, JP−C = 
11.5 Hz, C-3), 80.2 (d, JP−C = 13.9 Hz, C-2), 122.2 (C-2' and C-6'), 124.6 (C-4'), 129.3 (C-3' and 
C-5'), 138.2 (C-1') and 169.8 (C=O).  
 
[(2S, 3S)-2,3-Dihydroxy-4-(benzylamino)-4-oxobutyl]phosphonic acid 293g ǂ 
 
 
 
 
The procedure described for the synthesis of [(2S, 3S)-2,3-dihydroxy-4-(methylamino)-4-
oxobutyl]phosphonic acid 293a was employed, using trimethylsilyl bromide (0.10 mL, 0.70 
mmol) and diethyl [(2S,3S)-2,3-dihydroxy-4-(benzylamino)-4-oxobutyl]phosphonate 292g 
(0.12 g, 0.35 mmol) in CH3CN (2 mL). The crude product was chromatographed [reverse-
phase chromatography on C18 cellulose; elution with MeOH] to yield [(2S, 3S)-2,3-dihydroxy-
4-(benzylamino)-4-oxobutyl]phosphonic acid 293g as a yellow oil (62.1 mg, 62 %) (Found: C, 
45.75; H, 5.63; N, 4.87 %. C11H16NO6P requires C, 45.68; H, 5.58; N, 4.84 %); ʋ/cm
-1 3076 
(OH), 1666 (C=O) and 1252 (P=O); δH/ppm (400 MHz; D2O) 1.88 and 2.10 (2H, 2 x m, 4-CH2P), 
4.28 (1H, d, J = 7.4 Hz, 2-H), 4.83 (2H, s, 1'-CH2), 5.00 (1H, q, J = 7.2 Hz, 3-H) and 7.28 (5H, m, 
3'-H, 4'-H, 5'-H, 6'-H and 7'-H); δC (100 MHz; D2O) 27.6 (d, JP–C = 145.9 Hz, CH2P), 43.5 (1'-
CH2), 59.9 (d, JP−C = 10.9 Hz, C-3), 79.8 (d, JP−C = 14.6 Hz, C-2), 127.5 (C-5'), 127.8 (C-3' and C-
7'), 128.7 (C-4' and C-6'), 140.3 (C-2') and 168.9 (C=O).  
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Ethyl (2S, 3S)-4-(diethoxyphosphoryl)-2,3-dihydroxybutanoate 313 ǂ 
 
 
   
 
 
The procedure described for the synthesis of diethyl [(2S,3S)-2,3-dihydroxy-4-
(methylamino)-4-oxobutyl]phosphonate 292a was employed, using NaIO4 (642 mg, 3 mmol), 
CeCl3.H2O (75 mg, 0.2 mmol), RuCl3 (50 µL, 0.01 mmol) and (E)-4-(diethoxyphosphoryl)-
crotonate 284 (250 mg, 1.0 mmol). The crude product was chromatographed [preparative 
layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield ethyl (2S, 3S)-4-
(diethoxyphosphoryl)-2,3-dihydroxybutanoate 313 as a yellow oil ( 0.11 g, 53 %) (Found: C, 
42.29; H, 7.42 %. C10H21NO7P requires C, 42.25; H, 7.45 %); ʋ/cm
-1 3378 (OH), 1687 (C=O) 
and 1219 (P=O);  δH/ppm (400 MHz; CDCl3) 1.28 (9H, m, 3 x CH3), 2.00 (2H, s, OH), 2.04 and 
2.20 (2H, 2 x m, 4-CH2P), 4.10 (6H, m, 2 x OCH2 and 1''-CH2), 4.33 - 4.38 (2H, m, 2- and 3-H); 
δC (100 MHz; CDCl3) 14.0 (C-2''), 16.3 (d, JP–C = 6.1 Hz, 2 × CH3), 29.9 (d, JP–C = 139.1 Hz, CH2P), 
61.8 (C-1''), 62.0 (d, JP–C = 5.8 Hz, 2 × OCH2), 67.7 (d, JP−C = 11.6 Hz, C-3), 73.7 (d, JP−C = 13.2 
Hz, C-2) and 172.7 (C=O).    
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3.3. 3-Substituted aniline-derived phosphonate esters and their 
corresponding phosphonic acids  
 
3.3.1. Reaction of 3-substituted anilines with chloroacetyl chloride  
 
2-Chloro-N-(3-hydroxyphenyl)acetamide 320a 
 
 
 
 
 
To a stirred solution of 3-aminophenol  (3.01 g, 27.0 mmol) in THF (30 mL) under nitrogen 
was added NaH (60 % dispersion in mineral oil; 1.20 g, 48.0 mmol) in small portions to 
permit controlled evolution of hydrogen. Chloroacetyl chloride (2.20 mL, 28 mmol) was then 
added through a septum and the resulting solution was stirred for ca. 6 h. The solvent was 
evaporated in vacuo and the residue extracted with EtOAc (2 x 50 mL). The organic extract 
was washed sequentially with satd. aq. NaHCO3 (2 × 100 mL), water (2 x 100 mL) and brine 
(2 × 100 mL). The aqueous washings were extracted with EtOAc and the combined organic 
solutions were dried (anhydr. MgSO4). Evaporation of the solvent in vacuo afforded 2-
chloro-N-(3-hydroxyphenyl)acetamide 320a as a grey solid (4.78 g, 92 %), m.p. 132-134 °C 
(Lit.141 134.5-136 °C); ʋmax (solid deposit/cm
-1) 3367 (OH) and 1648 (C=O); δH/ppm (400 MHz; 
CDCl3) 4.22 (2H, s, 2-CH2), 6.47 (1H, dd, J = 6.0 and 2.0 Hz, 6'-H), 6.94 (1H, dd, J = 6.0 and 0.8 
Hz, 4'-H), 7.09 (1H, t, J = 8.0 Hz, 5'-H), 7.16 (1H, t, J = 2.0 Hz, 2'-H), 9.45 (1H, s, OH) and 10.16 
(1H, s, NH); δC/ppm (100 MHz; CDCl3) 43.6 (C-2), 106.3 (C-2'), 109.9 (C-6'), 110.9 (C-4'), 129.4 
(C-5'), 139.4 (C-1'), 157.6 (C-3') and 164.4 (C=O). 
 
2-Chloro-N-(3-methoxyphenyl)acetamide 320b   
 
 
 
 
 
OH
NH
Cl
O
1
2
1'
2'
3'
4'
5'
6'
NH
Cl
O
OMe
1
2
1'
2'
3'
4'
5'
6'
  Experimental  
 
Page | 182  
The procedure described for the synthesis of 2-chloro-N-(3-hydroxyphenyl)acetamide 320a 
was employed, using 3-methoxyaniline (0.91 mL, 8.1 mmol), NaH (60 % dispersion in 
mineral oil; 0.36 g, 15 mmol) and chloroacetyl chloride (0.65 mL, 8.1 mmol) in THF (15 mL), 
to yield 2-chloro-N-(3-methoxyphenyl)acetamide 320b as a light brown solid (1.35 g, 84 %), 
m.p 90-92 °C. (Lit.141 92-94 °C); ʋmax (solid deposit/cm
-1) 1680 (C=O); δH/ppm (400 MHz; 
CDCl3) 3.72 (3H, s, OCH3), 4.08 (2H, s, 2-CH2), 6.70 (1H, dd, J = 6.4 and 1.6 Hz, 6'-H), 6.83 (1H, 
dd, J = 6.8 and 0.8 Hz, 4'-H), 6.95 (1H, t, J = 8.0 Hz, 5'-H), 7.18 (1H, t, J = 1.8 Hz, 2'-H) and 8.20 
(1H, s, NH); δC/ppm (100 MHz; CDCl3) 42.8 (C-2), 55.3 (CH3), 105.8 (C-2'), 110.9 (C-6'), 112.1 
(C-4'), 129.7 (C-5'), 137.8 (C-1'), 160.1 (C-3') and 163.7 (C=O).   
 
N-(3-Bromophenyl)-2-chloroacetamide 320c  
 
 
 
 
 
 
 
The procedure described for the synthesis of 2-chloro-N-(3-hydroxyphenyl)acetamide 320a 
was employed, using 3-bromoaniline (0.63 mL, 5.8 mmol), NaH (60 % dispersion in mineral 
oil; 0.26 g, 11 mmol) and chloroacetyl chloride (0.41 mL, 5.8 mmol) in THF (15 mL), to yield 
N-(3-bromophenyl)-2-chloroacetamide 320c as a brown solid (1.25 g, 87 %), m.p 100-102 °C 
(Lit.141 98-100 °C); ʋmax (solid deposit/cm
-1) 1682 (C=O); δH/ppm (400 MHz; CDCl3) 4.11 (2H, 
s, 2-CH2), 7.12 (1H, t, J = 8.0 Hz, 5'-H), 7.21 (1H, d, J = 8.0 Hz, 4'-H), 7.40 (1H, d, J = 8.0 Hz, 6'-
H), 7.72 (1H, s, 2'-H), and 8.19 (1H, s, NH); δC/ppm (100 MHz; CDCl3) 42.7 (C-2), 118.5 (C-6'), 
122.6 (C-3'), 122.9 (C-2'), 128.2 (C-4'), 130.3 (C-5'), 137.8 (C-1') and 163.8 (C=O).   
 
2-Chloro-N-(3-fluorophenyl)acetamide 320d  
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The procedure described for the synthesis of 2-chloro-N-(3-hydroxyphenyl)acetamide 320a 
was employed, using 3-fluoroaniline (1.04 mL, 5.8 mmol), NaH (60 % dispersion in mineral 
oil; 0.26 g, 11 mmol) and chloroacetyl chloride (0.88 mL, 5.8 mmol) in THF (15 mL), to yield 
2-chloro-N-(3-fluorophenyl)acetamide 320d as a brown solid (1.52 g, 75 %), m.p 118-120 °C. 
(Lit.141 121-123 °C); ʋmax (solid deposit/cm
-1) 1682 (C=O); δH/ppm (400 MHz; CDCl3) 4.27 (2H, 
s, 2-CH2), 6.92 (1H, td, J =  5.2, 2.0 and 0.8 Hz , 4'-H), 7.35 (2H, m, 5' and 6'-H), 7.57 (1H, dt, J 
= 7.2 and 2.4 Hz, 2'-H) and 10.54 (1H, s, NH); δC/ppm (100 MHz; CDCl3) 43.4 (C-2), 105.9 (d, 
JF–C = 26 Hz, C-2'), 110.1 (d, JF–C = 21 Hz, C-4'), 115.0 (C-6'), 130.4 (C-5'), 140.0 (C-1'), 160.8 (d, 
JF–C = 240.2 Hz, C-3') and 164.9 (C=O).    
 
2-Chloro-N-(3-cyanophenyl)acetamide 320e 
 
 
 
 
 
 
 
The procedure described for the synthesis of 2-chloro-N-(3-hydroxyphenyl)acetamide 320a 
was employed, using 3-aminobenzonitrile (1.20 g, 10.1 mmol), NaH (60 % dispersion in 
mineral oil; 0.54 g, 23 mmol) and chloroacetyl chloride (1.04 mL, 10.1 mmol) in THF (15 mL), 
to yield 2-chloro-N-(3-cyanophenyl)acetamide 320e as a brown solid (1.57 g, 80 %), m.p 146-
148 °C; (Found: M+, 194.02408 C9H7ClN2O requires: M
+, 194.02432); ʋmax (solid deposit/cm
-1) 
2230 (C=N) and 1697 (C=O); δH/ppm (400 MHz; CDCl3) 4.29 (2H, s, 2-CH2), 7.55 (2H, d, J =  
5.2 Hz , 4'-H and 6'-H), 7.82 (1H, m, 5'-H), 8.07 (1H, s, 2'-H), and 10.67 (1H, s, NH); δC/ppm 
(100 MHz; CDCl3) 43.3 (C-2), 111.6 (C-3'), 118.5 (C=N), 121.9 (C-2'), 123.9 (C-5'), 127.3 (C-6'), 
130.3 (C-4'), 139.1 (C-1') and 165.2 (C=O).   
 
2-Chloro-N-(3-nitrophenyl)acetamide 320f  
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The procedure described for the synthesis of 2-chloro-N-(3-hydroxyphenyl)acetamide 320a 
was employed, using 3-nitroaniline (1.01 g, 7.27 mmol), NaH (60 % dispersion in mineral oil; 
0.33 g, 12.9 mmol) and chloroacetyl chloride (0.87 mL, 7.3 mmol) in THF (15 mL), to yield 2-
chloro-N-(3-nitrophenyl)acetamide 320f as a dark brown solid (1.37 g, 88 %), m.p 96-98 °C. 
(Lit.241 90-93 oC); ʋmax (solid deposit/cm
-1) 1683 (C=O); δH/ppm (400 MHz; CDCl3) 4.32 (2H, s, 
2-CH2), 7.62 (1H, t, J = 8.4 Hz, 5'-H), 7.93 (2H, m, 4'-H and 6'-H), 8.61 (1H, s, 2'-H), and 10.85 
(1H, s, NH); δC/ppm (100 MHz; CDCl3) 43.3 (C-2), 113.3 (C-2'), 118.2 (C-4'), 125.2 (C-6'), 130.2 
(C-5'), 139.5 (C-1'), 147.8 (C-3') and 165.3 (C=O).   
 
2-Chloro-N-[3-(hydroxymethyl)phenyl]acetamide 320g and 3-[(Chloroacetyl)amino]benzyl 
chloroacetate 320h 
   
 
     
 
 
 
 
 
The procedure described for the synthesis of 2-chloro-N-(3-hydroxyphenyl)acetamide 320a 
was employed, using 3-aminobenzyl alcohol (1.02 g, 8.12 mmol), NaH (60 % dispersion in 
mineral oil; 0.52 g, 21 mmol) and chloroacetyl chloride (0.67 mL,  8.1 mmol) in THF (15 mL). 
The solvent was evaporated in vacuo and flash chromatography gave two fractions. 
 
i) 2-Chloro-N-[3-(hydroxymethyl)phenyl]acetamide 320g as a  yellow solid (1.16 g, 62 
%), m.p 91-93 °C; (Found: M+, 201.03941 C9H10ClNO2  requires: M
+, 201.03706); ʋmax 
(solid deposit/cm-1) 3349 (OH) and 1680 (C=O); δH/ppm (400 MHz; CDCl3) 4.23 (2H, 
s,  2-CH2), 4.47 (2H, s, 1''-CH2), 5.21 (1H, s, OH), 7.01 (1H, d, J = 7.6 Hz, 4'-H),  7.26 
(1H, t, J = 7.6 Hz, 5'-H), 7.45 (1H, d, J = 8.0 Hz, 6'-H), 7.55 (1H, s, 2'-H) and 10.26 (1H, 
s, NH) ; δC/ppm (100 MHz; CDCl3) 43.5 (C-2), 62.6 (C-1''), 117.2 (C-2'), 117.5 (C-6'), 
121.7 (C-4'), 128.4 (C-5'), 138.2 (C-1'), 143.3 (C-3') and  164.4 (C=O).  
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ii) 3-[(Chloroacetyl)amino]benzyl chloroacetate 320h as a yellow solid (0.18 g, 11 %), 
m.p. 84-86°C; (Found: M+, 276.10711 C11H11Cl2NO3  requires: M
+, 276.11594); ʋmax 
(solid depsoit/cm-1) 1738 (O-C=O) and 1676 (C=O); δH/ppm (400 MHz; CDCl3) 4.20 
(2H, s, 4'-CH2), 4.29 (2H, s, 2''-CH2), 5.30 (2H, s, 1'-CH2), 7.28 (1H, d, J = 7.6 Hz, 6-H), 
7.47 (1H, t, J = 7.9 Hz, 5-H), 7.62 (1H, d, J = 8.14 Hz, 4-H), 7.71 (1H, s, 2-H) and 8.30 
(1H, s, NH); δC/ppm (100 MHz; CDCl3) 42.1 (C-4'), 44.1 (C-2''), 68.7 (C-1'), 121.2 (C-2), 
121.5 (C-4), 126.3 (C-6), 130.8 (C-5), 137.4 (C-3), 137.0 (C-1), 163.9 (C-1'') and 167.1 
(C-3').  
 
3.3.1.1. Synthesis of diethyl methylphosphonates using Michaelis-Arbuzov 
methodology   
 
Diethyl [N-(3-hydroxyphenyl)carbamoyl]methylphosphonate 321a 
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Triethyl phosphite (0.71 mL,  4.1 mmol) was added through a septum to 2-chloro-N-(3-
hydroxyphenyl)acetamide 320a (0.51 g, 2.8 mmol) under nitrogen in an oven-dried round-
bottomed flask equipped with a reflux condenser, and the resulting mixture was refluxed for 
ca. 9 h during which time the reaction was monitored by TLC. The cooled mixture was then 
stirred with hexane (20 mL) for ca. 30 minutes followed by decantation of the hexane layer 
to remove the excess triethyl phosphite; this was repeated three times. The crude product 
was purified by flash chromatography [on silica gel; elution with hexane-EtOAc (3:1)], and 
subsequent evaporation of the solvent in vacuo afforded diethyl [N(3-
hydroxyphenyl)carbamoyl)]methylphosphonate 321a as  a dark brown solid (0.52 g, 66 %), 
m.p. 116-118 °C (Lit.141 115-117 °C); ʋmax (solid deposit/cm
-1) 3263 (OH), 1667 (C=O), 1230 
(P=O) and 1024 (P−OEt);  δH/ppm (400 MHz; CDCl3) 1.32 (6H, t, J = 6.8 Hz, 2 × CH3), 3.03 (2H, 
d, JP–H = 21.1 Hz, CH2P), 4.17 (4H, q, J  = 7.2 Hz, 2 × OCH2),  6.60 (1H, dd, J = 6.0 and 1.4 Hz, 4-
H), 6.79 (1H, dd, J = 7.2 and 1.2 Hz, 6-H), 7.09 (1H, t, J = 8.0 Hz, 5-H), 7.46 (1H, t, J = 1.2 Hz, 2-
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H), 7.99 (1H, s, OH) and 8.96 (1H, s, NH); δC (100 MHz; CDCl3)  16.3 (d, JP–C = 6.0 Hz, 2 × CH3), 
36.4 (d, JP–C = 130.4 Hz, CH2P), 63.3 (d, JP–C = 6.6 Hz, 2 × OCH2), 107.3 (C-2), 111.1 (C-4), 112.1 
(C-6), 129.8 (C-5), 138.5 (C-1), 157.3 (C-3) and 162.7 (d, JP−C = 4.1 Hz, C=O);  δP/ppm  (162 
MHz; CDCl3) 24.2 (P=O).  
 
Diethyl [N-(3-methoxyphenyl)carbamoyl]methylphosphonate 321b   
 
 
 
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-
hydroxyphenyl)carbamoyl]methylphosphonate 321a was employed, using 2-chloro-N-(3-
methoxyphenyl)acetamide 320b (0.55 g, 2.8 mmol) and triethyl phosphite (0.95 mL, 5.5 
mmol). The crude product was purified by flash chromatography [on silica gel; elution with 
hexane-EtOAc (3:1)], and subsequent evaporation of the solvent in vacuo afforded diethyl 
[N-(3-methoxyphenyl)carbamoyl]methylphosphonate 321b as a yellowish-brown solid (0.35 
g, 65 %), m.p 88-90 °C. (Found: M+, 301.10976 C13H20NO5P requires: M
+, 301.10791; ʋmax 
(solid deposit/cm-1) 1684 (C=O), 1239 (P=O) and 1050 (P−OEt);  δH/ppm (400 MHz; CDCl3) 
1.34 (6H, t, J = 7.2 Hz, 2 × CH3), 3.02 (2H, d, JP–H = 20.8 Hz, CH2P), 3.77 (3H, s, OCH3) 4.17 (4H, 
q, J  =  7.2 Hz, 2 × OCH2),  6.63 (1H, dd, J = 6.0 and 2.0 Hz, 4-H), 7.01 (1H, dd, J = 6.4 and 1.2 
Hz, 6-H), 7.18 (1H, t, J = 8.0 Hz, 5-H), 7.23 (1H, t, J = 1.2 Hz, 2-H) and 8.84 (1H, s, NH); δC (100 
MHz; CDCl3)  16.3 (d, JP–C = 6.0 Hz, 2 × CH3), 35.5 (d, JP–C = 128.9 Hz, CH2P), 55.3 (OCH3) 63.0 
(d, JP–C = 6.6 Hz, 2 × CH2P), 105.4 (C-2), 110.4 (C-4), 113.3 (C-6), 129.6 (C-5), 138.9 (C-1), 
160.0 (C-3) and 162.0 (d, JP−C = 3.3 Hz, C=O); δP/ppm  (162 MHz; CDCl3) 23.8 (P=O). 
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Diethyl [N-(3-bromophenyl)carbamoyl]methylphosphonate 321c   
 
 
 
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-
hydroxyphenyl)carbamoyl]methylphosphonate 321a was employed, using 2-chloro-N-(3-
bromophenyl)acetamide 320c (0.67 g, 2.7 mmol) and triethyl phosphite (0.92 mL, 5.4 
mmol). The crude product was purified by flash chromatography [on silica gel; elution with 
hexane-EtOAc (3:1)], and subsequent evaporation of the solvent in vacuo afforded diethyl 
[N-(3-bromophenyl)carbamoyl]methylphosphonate 321c as a yellowish-brown solid (0.25 g, 
62 %), m.p 73-75 °C; (Found: M+, 351.04263 C12H17BrNO4P requires: M
+, 351.00581); ʋmax 
(solid deposit/cm-1) 1683 (C=O), 1238 (P=O) and 1050 (P−OEt);  δH/ppm (400 MHz; CDCl3) 
1.33 (6H, t, J = 6.8 Hz, 2 × CH3), 3.01 (2H, d, JP–H = 20.4 Hz, CH2P), 4.11 (4H, q, J  = 7.4 Hz, 2 × 
OCH2),  7.00 (1H, t, J = 8.0 Hz, 5-H), 7.08 (1H, d, J = 8.0 Hz, 4-H), 7.39 (1H, d, J = 8.0 Hz, 6-H), 
7.69 (1H, s, 2-H) and 7.75 (1H, s, NH); δC (100 MHz; CDCl3)  16.3 (d, JP–C = 5.7 Hz, 2 × CH3), 
35.6 (d, JP–C = 129.1 Hz, CH2P), 63.0 (d, JP–C = 6.6 Hz, 2 × OCH2), 112.4 (C-6), 117.8 (C-3), 122.3 
(C-2), 126.8 (C-4), 129.8 (C-5), 139.2 (C-1) and 162.2 (d, JP−C = 4.4 Hz, C=O); δP/ppm  (162 
MHz; CDCl3) 24.1 (P=O). 
 
Diethyl [N-(3-fluorophenyl)carbamoyl]methylphosphonate 321d  
 
 
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-
hydroxyphenyl)carbamoyl]methylphosphonate 321a was employed, using 2-chloro-N-(3-
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fluorophenyl)acetamide 320d (0.50 g, 2.6 mmol) and triethyl phosphite (0.92 mL, 5.3 mmol). 
The crude product was purified by flash chromatography [on silica gel; elution with hexane-
EtOAc (3:1)], and subsequent evaporation of the solvent in vacuo afforded diethyl [N-(3-
fluorophenyl)carbamoyl]methylphosphonate 321d as a brown solid (0.26 g, 56 %), m.p 83-85 
°C; (Found: M+, 289.08671  C12H17FNO4P requires: M
+, 289.08792); ʋmax (solid deposit/cm
-1) 
1680 (C=O), 1228 (P=O) and 1049 (P−OEt);  δH/ppm (400 MHz; CDCl3) 1.35 (6H, t, J = 7.2 Hz, 
2 × CH3), 3.04 (2H, d, JP–H = 20.8 Hz, CH2P), 4.17 (4H, q, J  = 6.8 Hz, 2 × OCH2),  6.74 (1H, ddd, J 
= 6.0, 2.4 and 2.0 Hz, 4-H), 7.09 (1H, d, J= 6.4, 6-H), 7.16 (1H, ddd, J = 2 x 6.4 Hz and 1.6 Hz, 
5-H) 7.45 (1H, dt, J = 6.4 and 2.0 Hz, 2-H) and 9.23 (1H, s, NH); δC (100 MHz; CDCl3) 16.3 (d, 
JP–C = 6.0 Hz, 2 × CH3), 35.5 (d, JP–C = 127 Hz, CH2P), 63.0 (d, JP–C = 6.5 Hz, 2 × OCH2), 107.0 (d, 
JF–C = 26.3 Hz, C-2), 111.0 (d, JF–C = 18.3 Hz, C-4),  114.9 (C-6), 129.8 (C-5), 139.8 (C-1), 162.1 
(d, JF−C = 243.2 Hz, C-3) and 164.0 (d, JP−C = 4.4 Hz, C=O); δP/ppm  (162 MHz; CDCl3) 23.5 
(P=O).  
 
Diethyl [N-(3-cyanophenyl)carbamoyl]methylphosphonate 321e  
 
 
 
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-hydroxyphenyl)carbamoyl]methyl 
phosphonate 321a was employed, using 2-chloro-N-(3-cyanophenyl)acetamide 320e (0.50 g, 
2.5 mmol) and triethyl phosphite (0.87 mL, 5.1 mmol). The crude product was purified by 
flash chromatography [on silica gel; elution with hexane-EtOAc (3:1)], and subsequent 
evaporation of the solvent in vacuo afforded diethyl [N-(3-cyanophenyl)carbamoyl]methyl 
phosphonate 321e as a yellowish-brown solid (0.21 g, 48 %), m.p 117-119 °C; (Found: M+, 
296.09070. C13H17N2O4P requires: M
+, 296.09259); ʋmax (solid deposit/cm
-1) 2230 (C≡N), 
1686 (C=O), 1217 (P=O) and 1050 (P−OEt);  δH/ppm (400 MHz; CDCl3) 1.37 (6H, t, J = 7.2 Hz, 
2 × CH3), 3.01 (2H, d, JP–H = 20.8 Hz, CH2P), 4.19 (4H, q, J  =7.6 Hz, 2 × OCH2), 7.44 (2H, m, 4-H 
and 6-H), 7.56 (1H, m, 5-H), 7.89 (1H, s, 2-H) and 9.88 (1H, s, NH); δC (100 MHz; CDCl3)  16.3 
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(d, JP–C = 6.0 Hz, 2 × CH3), 36.9 (d, JP–C = 129.3 Hz, CH2P), 63.3 (d, JP–C = 7.2 Hz, 2 × OCH2), 
112.6 (C-3), 118.4 (C≡N), 122.4 (C-2) 123.2 (C-5), 127.2 (C-6), 129.4 (C-4), 138.8 (C-1) and 
162.5 (d, JP−C = 4.4 Hz, C=O); δP/ppm  (162 MHz; CDCl3) 24.2 (P=O).  
  
Diethyl [N-(3-nitrophenyl)carbamoyl]methylphosphonate 321f  
 
 
 
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-hydroxyphenyl)carbamoyl]methyl 
phosphonate 321a was employed, using 2-chloro-N-(3-nitrophenyl)acetamide 320f (0.40 g, 
1.9 mmol) and triethyl phosphite (0.64 mL, 3.7 mmol). The crude product was purified by 
flash chromatography [on silica gel; elution with hexane-EtOAc (3:1)], and subsequent 
evaporation of the solvent in vacuo afforded diethyl [N-(3-nitrophenyl)carbamoyl]methyl 
phosphonate 321f as a dark brown liquid (0.42 g, 72 %) (Found: M+, 316.082395 
C12H17N2O6P requires: M
+, 316.08242); ʋmax (thin film/cm
-1) 1684 (C=O), 1262 (P=O) and 
1035 (P−OEt);  δH/ppm (400 MHz; CDCl3) 1.33 (6H, t, J = 7.2 Hz, 2 × CH3), 3.06 (2H, d, JP–H = 
21.2 Hz, CH2P), 4.17 (4H, q, J = 7.6 Hz, 2 × OCH2), 6.60 (1H, dd, J = 6.0 and 2.0 Hz, 4-H), 6.88 
(1H, dd, J = 6.4 and 2.0 Hz, 6-H),7.12 (1H, t, J = 8.4 Hz, 5-H), 8.29 (1H, t, J = 2.0 Hz, 2-H) and 
8.90 (1H, s, NH); δC (100 MHz; CDCl3) 16.3 (d, JP–C = 6.2 Hz, 2 × CH3), 35.6 (d, JP–C = 128.2 Hz, 
CH2P), 63.6 (d, JP–C = 6.8 Hz, 2 × OCH2), 114.1 (C-2), 118.5 (C-4), 124.8 (C-6), 124.9 (C-5), 
129.5 (C-1), 139.1 (C-3) and 162.6 (d, JP–H = 4.2 Hz, C=O); δP/ppm  (162 MHz; CDCl3) 24.6 
(P=O).    
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Diethyl {N-[3-(hydroxymethyl)phenyl]carbamoyl}methylphosphonate 321g  
 
 
 
 
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-hydroxy-
phenyl)carbamoyl]methylphosphonate 321a was employed, using 2-chloro-N-[3-
(hydroxymethyl)phenyl]acetamide 320g (0.30 g, 1.5 mmol) and triethyl phosphite (0.51 mL, 
3.0 mmol). The crude product was purified by flash chromatography [on silica gel; elution 
with hexane-EtOAc (3:1)], and subsequent evaporation of the solvent in vacuo afforded 
diethyl {N-[3-(hydroxymethyl)phenyl]carbamoyl}methylphosphonate 321g as a yellow oil  
(0.29 g, 65 %); (Found: M+, 301.108030. C13H20NO5P requires: M
+, 301.10791); ʋmax (thin 
film/cm-1) 3274 (OH), 1684 (C=O), 1376 (P=O) and 1050 (P−OEt);  δH/ppm (400 MHz; CDCl3) 
1.35 (6H, t, J = 6.8 Hz, 2 × CH3), 2.03 (1H, s, OH), 3.01 (2H, d, JP–H = 21.2 Hz, CH2P), 4.18 (4H, 
q, J = 7.2 Hz, 2 × OCH2), 4.59 (2H, s, CH2OH), 7.00 (1H, d, J = 7.6 Hz, 4-H), 7.20 (1H, t, J = 8.0 
Hz, 5-H), 7.42 (1H, s, 2-H), 7.45 (1H, d, 8.0 Hz,  6-H) and 9.20 (1H, s, NH); δC (100 MHz; 
CDCl3), 16.3 (d, JP–C = 5.8 Hz, 2 × CH3), 36.7 (d, JP–C = 128.4 Hz, CH2P), 63.0 (d, JP–C = 7.2 Hz, 
OCH2), 64.7 (CH2OH), 118.1 (C-2), 118.7 (C-6), 122.6 (C-4), 128.9 (C-5), 138.0 (C-1), 141.9 (C-
3) and 163.5 (d, JP–H = 3.8 Hz, C=O); δP/ppm  (162 MHz; CDCl3) 24.2 (P=O).       
 
3.3.1.2. Synthesis of methylphosphonic acids derivatives using TMSBr  
 
[N-(3-Hydroxyphenyl)carbamoyl]methylphosphonic acid 328a    
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Trimethylsilyl bromide (0.23 mL, 1.7 mmol) was added to diethyl [N-(3-hydroxyphenyl)-
carbamoyl]methylphosphonate 321a (0.25 g, 0.87 mmol) in CH3CN (3 mL) and the mixture 
was heated in the microwave apparatus set to deliver 100 W of power, with a reaction 
temperature of 60 oC and reaction time of 10 min. After completion, the mixture was cooled 
to room temperature, treated with a 95:5 MeOH-H2O mixture and stirred for 30 min. The 
solvent was removed in vacuo and the residue chromatographed [preparative layer 
chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [N-(3-
hydroxyphenyl)carbamoyl]methylphosphonic acid 328a as a yellow viscous liquid (0.22 g, 63 
%); (Found: M+, 231.02110 C8H10NO5P requires: M
+, 231.02966; ʋ/cm-1 3264 (OH), 1674 
(C=O) and 1241 (P=O); δH/ppm (400 MHz; DMSO-d6) 2.82 (2H, d, JP–H = 21.2 Hz, CH2P), 6.21 
(2H, s, 2 × OH) 6.42 (1H, dd, J = 6.0 and 2.0 Hz, 6-H), 6.91 (1H, dd, J = 8.0 and 2.0 Hz, 4-H), 
7.05 (1H, t, J = 8.0 Hz, 5-H), 7.12 (1H, t, J = 2.0 Hz, 2-H), 7.68 (1H, s, OH) and 9.06 (1H, s, NH); 
δC/ppm (100 MHz; DMSO-d6) 35.5 (d, JP–C = 130.4 Hz, CH2P), 108.1 (C-2), 114.7 (C-4), 117.6 
(C-6), 130.9 (C-5), 138.8 (C-1), 146.9 (C-3) and 163.5 (d, JP–C = 3.8 Hz, C=O); δP/ppm  (162 
MHz; CDCl3) 24.6 (P=O).    
 
[N-(3-Methoxyphenyl)carbamoyl]methylphosphonic acid 328b    
 
 
 
 
 
 
The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]methyl 
phosphonic acid 328a was employed, using diethyl [N-(3-methoxyphenyl)carbamoyl]methyl 
phosphonate 321b (0.25 g, 0.83 mmol) in CH3CN (3 mL) and trimethylsilyl bromide (0.23 mL, 
1.7 mmol). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [N-(3-
methoxyphenyl)carbamoyl]methylphosphonic acid 328b as a grey viscous liquid (0.21 g, 62 
%); (Found: M+, 245.03630 C9H12NO5P requires: M
+, 245.04531; ʋ/cm-1 3282 (OH), 1672 
(C=O) and 1232 (P=O); δH/ppm (400 MHz; DMSO-d6) 2.30 (1H, s, OH), 3.00 (2H, d, JP–H = 20.8 
Hz, CH2P), 3.82 (3H, s, OCH3), 5.95 (1H, s, OH), 6.04 (1H, d, J = 7.6 Hz, OH),  6.20 (1H, dd, J = 
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6.4 and 2.4 Hz, 4-H), 6.65 (1H, dd, J = 5.6 and 2.4 Hz, 6-H), 7.19 (1H, t, J = 8.0 Hz, 5-H), 7.35 
(1H, t, J = 2.0 Hz, 2-H) and 8.78 (1H, s, NH); δC/ppm (100 MHz; DMSO-d6) 35.5 (d, JP–C = 131.8 
Hz, CH2P), 55.3 (OCH3), 105.4 (C-2), 110.4 (C-4), 112.0 (C-6), 129.6 (C-5), 138.9 (C-3), 160.1 
(C-1) and 162.0 (d, JP–C = 3.0 Hz, C=O); δP/ppm  (162 MHz; CDCl3) 24.0 (P=O).    
 
[N-(3-Bromophenyl)carbamoyl]methylphosphonic acid 328c    
 
 
 
 
 
 
The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]methyl 
phosphonic acid 328a was employed, using diethyl [N-(3-bromophenyl)carbamoyl]methyl 
phosphonate 321c (0.11 g, 0.40 mmol) in CH3CN (3 mL) and trimethylsilyl bromide (0.11 mL, 
0.80 mmol). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:0.5)] to yield [N-
(3-bromophenyl)carbamoyl]methylphosphonic acid 328c as a  yellow viscous liquid (0.067 g, 
42 %); (Found: M+, 292.93953  C8H9BrNO4P requires: M
+, 292.94526; ʋ/cm-1 3289 (OH), 1668 
(C=O) and 1218 (P=O); δH/ppm (400 MHz; DMSO-d6) 2.79 (2H, d, JP–H = 21.2 Hz, CH2P), 3.71 
(2H, s, 2 × OH),  6.60 (1H, dd, J = 6.0 and 2.0 Hz, 4-H), 7.07 (1H, dd, J = 8.0 and 2.0 Hz, 6-H), 
7.19 (1H, t, J = 8.4 Hz, 5-H), 7.29 (1H, t, J = 2.0 Hz, 2-H) and 9.91 (1H, s, NH); δC/ppm (100 
MHz; DMSO-d6) 36.2 (d, JP–C = 131.2 Hz, CH2P), 112.6 (C-6), 118.0 (C-2), 122.5 (C-3), 127.0 (C-
4), 130.2 (C-5), 139.5 (C-1) and 163.2 (d, JP−C = 4.2 Hz, C=O); δP/ppm  (162 MHz; CDCl3) 24.1 
(P=O).  
 
 [N-(3-Fluorophenyl)carbamoyl]methylphosphonic acid 328d    
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The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]methyl 
phosphonic acid 328a was employed, using diethyl [N-(3-fluorophenyl)carbamoyl]methyl 
phosphonate 321d (0.20 g, 0.69 mmol) in CH3CN (3 mL) and trimethylsilyl bromide (0.19 mL, 
1.4 mmol). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [N-
(3-fluorophenyl)carbamoyl]methylphosphonic acid 328d as a yellow oil (0.13 g, 57 %); 
(Found: M+, 233.02363 C8H9FNO4P requires: M
+, 233.02532; ʋ/cm-1 3248 (OH), 1654 (C=O) 
and 1219 (P=O); δH/ppm (400 MHz; DMSO-d6) 3.01 (2H, d, JP–H = 21.3 Hz, CH2P) 3.43 (2H, s, 2 
x OH), 6.84 (1H, dd, J = 6.2 and 2.0 Hz, 4-H), 7.25 (2H, m, 5-H and 6-H), 7. 40 (1H, dt, J = 6.4 
and 2.0 Hz, 2-H) and 9.28 (1H, s, NH); δC/ppm (100 MHz; DMSO-d6) 35.4 (d, JP–C = 131.4 Hz, 
CH2P), 107.6 (d, JF–C = 26.2 Hz, C-2), 111.5 (d, JF–C = 18.1 Hz, C-4), 115.1 (C-6), 130.2 (C-5), 
140.6 (C-1), 162.4 (d, JF–C = 242.8 Hz, C-3) and 168.3 (d, JP−C = 3.8 Hz, C=O); δP/ppm  (162 
MHz; CDCl3) 24.8 (P=O). 
 
 [N-(3-Cyanophenyl)carbamoyl]methylphosphonic acid 328e  
 
 
 
 
 
 
The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]methyl 
phosphonic acid 328a was employed, using diethyl [N-(3-cyanophenyl)carbamoyl]methyl 
phosphonate 321e (0.15 g, 0.51 mmol) in CH3CN (3 mL) and trimethylsilyl bromide (0.13 mL, 
1.0 mmol). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:0.5)] to yield [N-
(3-cyanophenyl)carbamoyl]methylphosphonic acid 328e as a light yellow viscous liquid (0.10 
g, 59 %). (Found: M+, 240.02161 C9H9N2O4P requires: M
+, 240.02999; ʋ/cm-1 3284 (OH), 
2234 (C≡N), 1678 (C=O) and 1232 (P=O); δH/ppm (400 MHz; DMSO-d6) 2.82 (2H, d, JP–H = 
21.2 Hz, CH2P), 7.31 (2H, s, 2 × OH),  7.35 (1H, t, J = 8.0 Hz, 5-H), 7.51 (1H, dd, J = 7.2 and 2.0 
Hz, 4-H), 7.73 (1H, dd, J = 6.4 and 1.2 Hz, 6-H), 8.02 (1H, t, J = 2.0 Hz, 2-H) and 8.09 (1H, s, 
NH); δC/ppm (100 MHz; DMSO-d6) 36.8 (d, JP–C = 130.8 Hz, CH2P) 112.8 (C-3), 116.4 (C≡N), 
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125.5 (C-6) 126.8 (C-2), 128.2 (C-4), 129.6 (C-5), 138.9 (C-1) and 164.3 (d, JP–C = 4.4 Hz, C=O); 
δP/ppm  (162 MHz; CDCl3) 24.8 (P=O).    
 
 [N-(3-Nitrophenyl)carbamoyl]methylphosphonic acid 328f    
 
 
 
 
 
 
The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]methyl 
phosphonic acid 328a was employed, using diethyl [N-(3-nitrophenyl)carbamoyl]methyl 
phosphonate 321f (0.13 g, 0.40 mmol) in CH3CN (3 mL) and trimethylsilyl bromide (0.11 mL, 
0.80 mmol). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [N-
(3-nitrophenyl)carbamoyl]methylphosphonic acid 328f as a brown viscous liquid (0.089 g, 67 
%); (Found: M+, 260.01753 C8H9N2O6P requires: M
+, 260.01982; ʋ/cm-1 3275 (OH), 1682 
(C=O) and 1258 (P=O); δH/ppm (400 MHz; DMSO-d6) 2.84 (2H, d, JP–H = 21.2 Hz, CH2P), 6.62 
(1H, dd, J = 6.0 and 2.0 Hz, 4-H) 7.02 (2H, s, 2 x OH),  7.09 (1H, d, J = 8.0 Hz, 6-H), 7.21 (1H, t, 
J = 8.4, 5-H), 7.30 (1H, t, J = 2.0 Hz, 2-H) and 9.91 (1H, s, NH); δC/ppm (100 MHz; DMSO-d6) 
35.7 (d, JP–C = 131.2 Hz, CH2P), 114.6 (C-2), 118.9 (C-4), 125.2 (C-6), 125.8 (C-5), 129.6 (C-1), 
139.1 (C-3) and 162.6 (d, JP–C = 4.0 Hz, C=O); δP/ppm  (162 MHz; CDCl3) 24.2 (P=O).    
 
 N-[3-(Hydroxymethyl)phenylcarbamoyl]methylphosphonic acid 328g   
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The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]methyl 
phosphonic acid 328a was employed, using diethyl {N-[3-(hydroxymethyl)phenyl] 
carbamoyl}methyl phosphonate 321g (0.12 g, 0.40 mmol) in CH3CN (3 mL) and trimethylsilyl 
bromide (0.11 mL, 0.80 mmol). The solvent was removed in vacuo and the residue 
chromatographed [preparative layer chromatography; elution with hexane-EtOAc-MeOH 
(1:1:1)] to yield N-[(3-(Hydroxymethyl)phenylcarbamoyl]methyl phosphonic acid 328g as a 
yellow viscous liquid ( 0.043 g, 48 %); (Found: M+, 245.03614 C9H12NO5P requires: M
+, 
245.03531; ʋ/cm-1 3306 (OH), 1667 (C=O) and 1236 (P=O); δH/ppm (400 MHz; DMSO-d6) 
2.31 (1H, s, OH), 2.82 (2H, d, JP–H = 21.2 Hz, CH2P), 4.82 (2H, s, CH2OH), 6.95 (2H, s, 2 x OH), 
7.02 (1H, d, J = 7.4 Hz, 4-H), 7.25 (1H, t, J = 8.0 Hz, 5-H), 7.44 (2H, m, 2-H and 6-H) and 9.26 
(1H, s, NH); δC (100 MHz; DMSO-d6) 35.3 (d, JP–C = 129.7 Hz, CH2P), 64.9 (CH2OH), 118.3 (C-2), 
119.1 (C-6), 122.2 (C-4), 128.6 (C-5), 139.0 (C-1), 142.5 (C-3) and 166.3 (d, JP–C = 4.4 Hz, C=O); 
δP/ppm  (162 MHz; CDCl3) 23.9 (P=O).   
 
3.3.1.3. Synthesis of sodium hydrogen methylphosphonate derivatives 
 
Sodium hydrogen [N-(3-hydroxyphenyl)carbamoyl]methylphosphonate 329a 
 
 
  
 
 
 
[N-(3-Hydroxyphenyl)carbamoyl]methylphosphonic acid 328a (0.15 g, 0.65 mmol) was 
treated with a solution of NaOH (1.1 mol) in EtOH (0.6 mL) and the mixture was stirred for 
30 min. The solvent was removed in vacuo and the residue chromatographed [reverse-
phase column chromatography; elution with H2O-MeOH (1:1)] to yield sodium hydrogen [N-
(3-hydroxyphenyl)carbamoyl]methylphosphonate 329a as a light brown semi-solid (98 mg, 
98 %); ʋ/cm-1 3208 (OH), 1677 (C=O), 1228 (P=O); δH/ppm (400 MHz; D2O) 2.80 (2H, d, JP–H = 
22.4 Hz, CH2P), 6.39 (1H, dd, J = 6.0 and 2.0 Hz, 6-H), 6.90 (1H, dd, J = 8.0 and 2 Hz, 4-H), 7.08 
(1H, t, J = 8.0 Hz, 5-H) and 7.10 (1H, t, J = 1.2 Hz, 2-H); δC/ppm (100 MHz; D2O) 36.2 (d, JP–C = 
OH
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139.1 Hz, CH2P), 108.3 (C-2), 115.2 (C-4), 118.4 (C-6), 129.9 (C-5), 138.6 (C-1), 146.4 (C-3) 
and 164.1 (d, JP–C = 3.6 Hz, C=O).  
 
Sodium hydrogen [N-(3-methoxyphenyl)carbamoyl]methylphosphonate 329b  
   
      
 
 
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]methylphosphonate 329a was employed, using [N-(3-
methoxyphenyl)carbamoyl]methylphosphonic acid 328b (0.15 g, 0.61 mmol) and a solution 
of NaOH (1.1 mol) in EtOH (0.58 mL). The solvent was removed in vacuo and the residue 
chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen [N-(3-methoxyphenyl)carbamoyl]methylphosphonate 329b as a pale 
yellow semi-solid (0.11 g, 97 %); ʋ/cm-1 1687 (C=O), 1221 (P=O); δH/ppm (400 MHz; D2O) 
2.79 (2H, d, JP–H = 20.9 Hz, CH2P), 3.79 (3H, s, OCH3), 6.19 (1H, dd, J = 6.2 and 2.4 Hz, 4-H), 
6.66 (1H, dd, J = 6.2 and 2.4 Hz, 6-H), 7.20 (1H, t, J = 7.6 Hz, 5-H) and 7.31 (1H, t, J = 2.0 Hz, 
2-H); δC/ppm (100 MHz; D2O) 35.5 (d, JP–C = 143.8 Hz, CH2P), 55.2 (OCH3), 105.6 (C-2), 110.4 
(C-4), 112.6 (C-6), 129.5 (C-5), 139.0 (C-3), 159.9 (C-1) and 162.4 (d, JP–C = 3.0 Hz, C=O).  
 
Sodium hydrogen [N-(3-bromophenyl)carbamoyl]methylphosphonate 329c 
 
  
 
 
          
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]methylphosphonate 329a was employed, using [N-(3-
bromophenyl)carbamoyl]methylphosphonic acid 328c (0.15 g, 0.51 mmol) and a solution of 
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NaOH (1.1 mol) in EtOH (0.47 mL). The solvent was removed in vacuo and the residue 
chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen [N-(3-bromophenyl)carbamoyl]methylphosphonate 329c as a brown 
semi-solid (0.10 g, 94 %); ʋ/cm-1 (OH), 1681 (C=O), 1219 (P=O); δH/ppm (400 MHz; D2O) 2.80 
(2H, d, JP–H = 21.2 Hz, CH2P), 5.99 (1H, dd, J = 6.0 and 2.0 Hz, 4-H), 7.10 (1H, dd, J = 8.0 and 
2.0 Hz, 6-H), 7.20 (1H, t, J = 8.4 Hz, 5-H) and 7.28 (1H, t, J = 2.0 Hz, 2-H); δC/ppm (100 MHz; 
D2O) 36.1 (d, JP–C = 144.0 Hz, CH2P), 112.47 (C-6), 118.4 (C-2), 122.6 (C-3), 126.8 (C-4), 129.8 
(C-5), 139.3 (C-1) and 163.3 (d, JP−C = 4.1 Hz, C=O).  
 
Sodium hydrogen [N-(3-fluorophenyl)carbamoyl]methylphosphonate 329d 
 
 
 
 
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]methylphosphonate 329a was employed, using [N-(3-
fluorophenyl)carbamoyl]methylphosphonic acid 328d (0.15 g, 0.64 mmol) and a solution of 
NaOH (1.1 mol) in EtOH (0.59 mL). The solvent was removed in vacuo and the residue 
chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen [N-(3-fluorophenyl)carbamoyl]methylphosphonate 329d as a pale 
yellow semi-solid (96 mg, 97 %); ʋ/cm-1 1668 (C=O), 1231 (P=O); δH/ppm (400 MHz; D2O) 
2.98 (2H, d, JP–H = 21.4 Hz, CH2P), 6.82 (1H, dd, J = 6.2 and 2.0 Hz, 4-H), 7.27 (2H, m, 5-H and 
6-H) and 7. 38 (1H, dt, J = 6.4 and 2.0 Hz, 2-H); δC/ppm (100 MHz; D2O) 35.3 (d, JP–C = 138.4 
Hz, CH2P), 107.5 (d, JF–C = 25.8 Hz, C-2), 112.1 (d, JF–C = 18.5 Hz, C-4), 114.8 (C-6), 130.6 (C-5), 
140.3 (C-1), 162.1 (d, JF–C = 243.2 Hz, C-3) and 168.7 (d, JP−C = 3.8 Hz, C=O).  
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Sodium hydrogen [N-(3-cyanophenyl)carbamoyl]methylphosphonate 329e 
 
 
  
 
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]methylphosphonate 329a was employed, using [N-(3-
cyanophenyl)carbamoyl]methylphosphonic acid 328e (0.15 g, 0.64 mmol) and a solution of 
NaOH (1.1 mol) in EtOH (0.59 mL). The solvent was removed in vacuo and the residue 
chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen [N-(3-cyanophenyl)carbamoyl]methylphosphonate 329e as a pale 
yellow semi-solid (96 mg, 97 %); ʋ/cm-1 2228 (C≡N), 1679 (C=O), 1241 (P=O); δH/ppm (400 
MHz; D2O) 2.79 (2H, d, JP–H = 21.4 Hz, CH2P), 7.34 (1H, t, J = 8.0 Hz, 5-H), 7.52 (1H, dd, J = 7.2 
and 2.0 Hz, 4-H), 7.73 (1H, dd, J = 6.4 and 1.6 Hz, 6-H) and 8.01 (1H, t, J = 2.0 Hz, 2-H); 
δC/ppm (100 MHz; D2O) 36.6 (d, JP–C = 130.8 Hz, CH2P) 112.7 (C-3), 116.3 (C≡N), 125.7 (C-6), 
126.5 (C-2), 128.3 (C-4), 129.9 (C-5), 139.1 (C-1) and 164.5 (d, JP–C = 4.4 Hz, C=O).  
 
 Sodium hydrogen [N-(3-nitrophenyl)carbamoyl]methylphosphonate 329f 
 
 
 
 
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]methylphosphonate 329a was employed, using [N-(3-
nitrophenyl)carbamoyl]methylphosphonic acid 328f (0.15 g, 0.58 mmol) and a solution of 
NaOH (1.1 mol) in EtOH (0.50 mL). The solvent was removed in vacuo and the residue 
chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen [N-(3-nitrophenyl)carbamoyl]methylphosphonate 329f as a yellow 
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semi-solid (91 mg, 93 %); ʋ/cm-1 1679 (C=O), 1241 (P=O); δH/ppm (400 MHz; D2O) 2.83 (2H, 
d, JP–H = 21.2 Hz, CH2P), 6.60 (1H, dd, J = 6.0 and 2.0 Hz, 4-H), 7.10 (1H, dd, J = 7.6 and 2.0 Hz, 
6-H), 7.22 (1H, t, J = 7.9 Hz, 5-H) and 7.28 (1H, t, J = 2.0 Hz, 2-H); δC/ppm (100 MHz; D2O) 
35.7 (d, JP–C = 142.0 Hz, CH2P), 114.3 (C-2), 118.5 (C-4), 125.4 (C-6), 126.2 (C-5), 129.6 (C-1), 
139.3 (C-3) and 163.0 (d, JP–C = 3.8 Hz, C=O).  
 
Sodium hydrogen {N-[3-(hydroxymethyl)phenyl]carbamoyl}methylphosphonate 329g   
 
 
 
 
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]methylphosphonate 329a was employed, using [N-(3-
(hydroxymethyl)phenylcarbamoyl]methylphosphonic acid 328g (0.15 g, 0.61 mmol) and 1.1 
mol NaOH in EtOH (0.56 mL). The solvent was removed in vacuo and the residue 
chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen {N-[3-(hydroxymethyl)phenyl]carbamoyl}methylphosphonate 329g as 
a light yellow solid (86 mg, 94 %); ʋ/cm-1 1687 (C=O), 1232 (P=O); δH/ppm (400 MHz; D2O) 
2.80 (2H, d, JP–H = 21.2 Hz, CH2P), 4.83 (2H, s, CH2OH), 6.99 (1H, d, J = 7.6 Hz, 4-H), 7.28 (1H, 
t, J = 7.8 Hz, 5-H), 7.42 (2H, d, J = 7.6 Hz, 6-H) and 7.44 (1H, s, 2-H); δC (100 MHz; D2O) 34.8 
(d, JP–C = 142.8 Hz, CH2P), 64.6 (CH2OH), 118.7 (C-2), 119.3 (C-6), 122.4 (C-4), 128.7 (C-5), 
139.2 (C-1), 142.6 (C-3) and 166.5 (d, JP–C = 4.2 Hz, C=O). 
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3.3.2. Reaction of 3-substituted anilines with 3-chloropropanoyl chloride  
 
3-Chloro-N-(3-hydroxyphenyl)propanamide 322a   
 
 
 
 
 
 
To a stirred solution of 3-aminophenol  (1.50 g, 14.0 mmol) in THF (30 mL) under nitrogen 
was added NaH (60 % dispersion in mineral oil; 0.60 g, 24 mmol) in small portions to permit 
controlled evolution of hydrogen. 3-Chloropropionyl chloride (1.31 mL, 14.0 mmol) was then 
added through a septum and the resulting solution was stirred for ca. 6 h. The solvent was 
evaporated in vacuo and the residue dissolved in EtOAc (2 x 50 mL). The organic solution 
was washed sequentially with satd. aq. NaHCO3 (2 × 100 mL), water (2 x 100 mL) and brine 
(2 × 100 mL). The aqueous washings were extracted with EtOAc and the combined organic 
solutions were dried (anhydr. MgSO4). Evaporation of the solvent in vacuo afforded 3-
chloro-N-(3-hydroxyphenyl)propanamide as a brown solid (2.25 g, 80 %) m.p. 119-121 °C 
(Lit.238); ʋmax (solid deposit/cm
-1) 3362 (OH) and 1658 (C=O); δH/ppm (400 MHz; CDCl3) 2.74 
(2H, t, J  6.4 Hz, CH2CO), 3.82 (2H, t, J = 6.4 Hz, CH2Cl), 5.74 (1H, t, J = 9.2 Hz, 5-H), 5.99 (1H, 
dd, J = 9.2 and 1.2 Hz, 4-H), 6.57 (1H, dd, J = 6.0 and 1.2 Hz, 6-H), 7.13 (1H, t, J =  1.2 Hz, 2-H), 
7.50 (1H, s, OH) and 7.69 (1H, s, NH); δC/ppm (100 MHz; CDCl3) 42.6 (CH2CO), 44.1 (CH2Cl), 
106.3 (C-2'), 109.9 (C-4'), 110.9 (C-6'), 129.4 (C-5'), 139.4 (C-1'), 157.6 (C-3') and 164.4 (C=O).  
3-Chloro-N-(3-methoxyphenyl)propanamide 322b   
 
 
 
 
 
 
The procedure described for the synthesis of 3-chloro-N-(3-hydroxyphenyl)propanamide 
322a was employed, using 3-methoxyaniline (0.91 mL, 8.1 mmol), NaH (60 % dispersion in 
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mineral oil; 0.36 g, 15 mmol) and 3-chloropropionyl chloride (0.76 mL, 8.1 mmol) in THF (15 
mL), to yield 3-chloro-N-(3-methoxyphenyl)propanamide 322b as a yellow solid (1.49 g, 86 
%), m.p 92-94 °C (Lit.239 90-92 oC); ʋmax (solid deposit/cm
-1) 1681 (C=O); δH/ppm (400 MHz; 
CDCl3) 2.79 (2H, t, J = 6.4 Hz, CH2CO), 3.77 (3H, s, OCH3), 3.85 (2H, t, J = 6.4 Hz, CH2Cl), 6.66 
(1H, d, J = 8.0 Hz, 4'-H), 6.97 (1H, d, J = 8.0 Hz, 6'-H), 7.19 (1H, t, J = 8.0 Hz, 5'-H), 7.28 (1H, s, 
2'-H) and 7.56 (1H, s, NH); δC/ppm (100 MHz; CDCl3) 36.7 (CH2CO), 44.5 (CH2Cl), 55.3 (OCH3), 
105.5 (C-2'), 110.3 (C-6'), 111.9 (C-4'), 129.7 (C-5'), 135.3 (C-1'), 160.2 (C-3') and 171.1 (C=O).  
N-(3-Bromophenyl) 3-chloropropanamide 322c 
  
 
 
 
 
 
 
The procedure described for the synthesis of 3-chloro-N-(3-hydroxyphenyl)propanamide 
322a was employed, using 3-bromoaniline (0.63 mL, 5.8 mmol), NaH (60 % dispersion in 
mineral oil; 0.26 g, 10.8 mmol) and 3-chloropropionyl chloride (0.54 mL, 5.8 mmol) in THF 
(15 mL), to yield N-(3-bromophenyl)3-chloropropanamide 322c as a dark brown solid (1.23 
g, 81 %), m.p 106-108 °C (Lit.240); ʋmax (solid deposit/cm
-1) 1658 (C=O); δH/ppm (400 MHz; 
CDCl3) 2.80 (2H, t, J = 6.4 Hz, CH2CO), 3.86 (2H, t, J = 6.4 Hz, CH2Cl), 7.17 (1H, t, J = 8.0 Hz, 5'-
H), 7.24 (1H, d, J = 7.6 Hz, 4'-H), 7.41 (1H, d, J = 8.0 Hz, 6'-H), 7.45 (1H, s, 2'-H), and 7.77 (1H, 
s, NH); δC/ppm (100 MHz; CDCl3) 36.6 (CH2CO), 44.2 (CH2Cl), 118.7 (C-6'), 122.5 (C-3'), 123.1 
(C-2'), 128.0 (C-4'), 130.3 (C-5'), 137.9 (C-1') and 164.2 (C=O).   
3-Chloro-N-(3-fluorophenyl)propanamide 322d 
 
 
 
 
 
 
The procedure described for the synthesis of 3-chloro-N-(3-hydroxyphenyl)propanamide 
322a was employed, using 3-fluoroaniline (1.05 mL, 5.80 mmol), NaH (60 % dispersion in 
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mineral oil; 0.26 g, 11 mmol) and 3-chloropropionyl chloride (0.54 mL, 5.8 mmol) in THF (15 
mL), to yield 3-chloro-N-(3-fluorophenyl)propanamide 322c as a light yellow solid (1.04 g, 89 
%), m.p 87-89 °C (Lit.241); ʋmax (solid deposit/cm
-1) 1681 (C=O); δH/ppm (400 MHz; CDCl3) 
2.56 (2H, t, J = 6.4 Hz, CH2CO), 3.65 (2H, t, J = 6.4 Hz, CH2Cl), 6.80 (1H, td, J =  6.0, 2.0 and 0.8 
Hz, 4'-H), 7.12 (1H, d, J = 8.0 Hz, 6'-H), 7.24 (1H, dt, J = 7.2 and 1.6 Hz, 5'-H), 7.47 (1H, td, J = 
6.4, 2.4 and 0.8 Hz, 2'-H) and 7.49 (1H, s, NH); δC/ppm (100 MHz; CDCl3) 34.1 (CH2CO), 44.3 
(CH2Cl), 107.3 (d, JF–C = 26.4 Hz, C-2'), 111.0 (d, JF–C = 21.4 Hz, C-4'), 114.9 (C-6'), 130.1 (d, JF–C 
= 9.3 Hz, C-5'), 139.1 (d, JF–C = 11.0 Hz, C-1'), 163.0 (d, JF–C = 243.5 Hz, C-3') and 170.1 (C=O).    
 
3-Chloro-N-(3-cyanophenyl)propanamide 322e  
 
 
 
 
 
 
The procedure described for the synthesis of 3-chloro-N-(3-hydroxyphenyl)propanamide 
322a was employed, using 3-aminobenzonitrile (1.20 g, 10.1 mmol), NaH (60 % dispersion in 
mineral oil; 0.54 g, 23 mmol) and 3-chloropropionyl chloride (0.94 mL, 10 mmol) in THF (15 
mL), to yield 3-chloro-N-(3-cyanophenyl)propanamide 322e as a yellow solid (1.04 g, 89 %), 
m.p 108-110 °C (Lit.242 97-98 oC); ʋmax (solid deposit/cm
-1) 2232 (C≡N), 1658 (C=O); δH/ppm 
(400 MHz; CDCl3) 2.84 (2H, t, J = 6.0 Hz, CH2CO), 3.87 (2H, t, J = 6.0 Hz, CH2Cl), 7.42 (2H, m, 
4'-H and 6'-H), 7.75 (1H, dt, J = 7.6 and 2.0 Hz, 5'-H), 7.89 (1H, s, NH) and 7.95 (1H, t, J = 2.0 
Hz, 2'-H); δC/ppm (100 MHz; CDCl3) 34.3 (CH2CO), 44.2 (CH2Cl), 113.2 (C-3'), 118.9 (C=N), 
122.7 (C-2'), 124.3 (C-5'), 129.6 (C-6'), 131.2 (C-4'), 138.8 (C-1') and 168.7 (C=O).    
 
3-Chloro-N-(3-nitrophenyl)propanamide 322f  
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 The procedure described for the synthesis of 3-chloro-N-(3-hydroxyphenyl)propanamide 
322a was employed, using 3-nitroaniline (1.01 g, 7.27 mmol), NaH (60 % dispersion in 
mineral oil; 0.33 g, 13 mmol) and 3-chloropropionyl chloride (0.49 mL, 7.3 mmol) in THF (15 
mL), to yield 3-chloro-N-(3-nitrophenyl)propanamide 322f as a dark yellow solid (1.56 g, 94 
%), m.p 94-96 °C (Lit.239 95-97 oC); ʋmax (solid deposit/cm
-1) 1687 (C=O); δH/ppm (400 MHz; 
CDCl3) 2.88 (2H, t, J = 6.4 Hz, CH2CO), 3.89 (2H, t, J = 6.4 Hz, CH2Cl), 7.48 (1H, t, J = 8.0 Hz, 5'-
H), 7.94 (2H, dd, J = 7.6 and 1.2 Hz, 4'-H and 6'-H), 8.06 (1H, s, NH) and 8.40 (1H, t, J = 2.0 Hz, 
2'-H); δC/ppm (100 MHz; CDCl3) 39.5 (CH2CO), 40.4 (CH2Cl), 114.7 (C-2'), 119.2 (C-4'), 125.7 
(C-6'), 129.9 (C-5'), 138.5 (C-1'), 148.5 (C-3') and 168.3 (C=O).  
 
3-Chloro-N-[3-(hydroxymethyl)phenyl]propanamide 322g  
 
  
 
  
 
 
The procedure described for the synthesis of 3-chloro-N-(3-hydroxyphenyl)propanamide 
322a was employed, using 3-aminobenzyl alcohol (1.02 g, 8.12 mmol), NaH (60 % 
dispersion in mineral oil; 0.52 g, 21 mmol) and 3-chloropropionyl chloride (0.55 mL, 8.1 
mmol) in THF (15 mL), to yield 3-chloro-N-[3-(hydroxymethyl)phenyl]propanamide 322g as 
a grey solid (1.53 g, 88 %), m.p 101-103°C (Lit.239 97-99 oC); ʋmax (solid deposit/cm
-1) 1674 
(C=O); δH/ppm (400 MHz; CDCl3) 2.85 (2H, t, J = 6.4 Hz, CH2CO), 3.88 (2H, t, J = 6.4 Hz, 
CH2Cl), 4.63 (2H, s, 7'-CH2), 5.11 (1H, s, OH), 7.09 (1H, t, J = 6.4 Hz, 5'-H), 7.47 (1H, d, J = 6.8 
Hz, 4'-H), 7.54 (1H, d, J = 6.8 Hz, 6'-H), 7.62 (1H, s, 2'-H) and 7.72 (1H, s, NH); δC/ppm (100 
MHz; CDCl3) 38.9 (CH2CO), 40.4 (CH2Cl), 66.4 (CH2OH), 119.3 (C-2'), 119.9 (C-6'), 124.3 (C-4'), 
129.3 (C-5'), 137.7 (C-1'), 142.0 (C-3') and  167.9 (C=O).  
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3.3.2.1. Synthesis of diethyl ethylphosphonates using Michaelis-Arbuzov 
methodology   
 
Diethyl [N-(3-hydroxyphenyl)carbamoyl]ethylphosphonate 323a 
 
 
 
 
 
Triethyl phosphite (0.86 mL,  5.0 mmol) was added through a septum to 3-chloro-N-(3-
hydroxyphenyl)propanamide 322a (0.50 g, 2.5 mmol) under nitrogen in an oven-dried 
round-bottomed flask equipped with a reflux condenser, and the resulting mixture was 
refluxed for ca. 9 h during which time the reaction was monitored by TLC. The cooled 
mixture was then stirred with hexane (20 mL) for ca. 30 minutes followed by decantation of 
the hexane layer to remove the excess triethyl phosphite; this was repeated three times. 
The crude product was purified by flash chromatography [on silica gel; elution with hexane-
EtOAc (3:1)], and subsequent evaporation of the solvent in vacuo afforded diethyl [N(3-
hydroxyphenyl)carbamoyl)]ethylphosphonate 323a as  a dark brown oil (0.29 g, 58 %); 
(Found: M+, 301.11247 C13H20NO5P requires: M
+, 301.10791); ʋ/cm-1 3261 (OH), 1671 (C=O), 
1232 (P=O) and 1024 (P−OEt);  δH/ppm (400 MHz; CDCl3) 1.29 (6H, t, J = 6.8 Hz, 2 × CH3), 
2.13 (2H, m, CH2P), 2.68 (2H, m, CH2CO), 4.06 (4H, m, 2 × OCH2), 6.60 (1H, d, J = 8.4 Hz, 4-H), 
6.91 (1H, d, J = 7.6 Hz, 6-H), 7.08 (1H, t, J = 8.0 Hz, 5-H), 7.36 (1H, s, 2-H), 8.44 (1H, s, OH) 
and 8.92 (1H, s, NH); δC (100 MHz; CDCl3)  16.2 (d, JP–C = 6.0 Hz, 2 × CH3), 20.8 (d, JP–C = 142.5 
Hz, CH2P), 27.6 (d, JP–C = 3.7 Hz, CH2CO), 62.2 (d, JP–C = 6.6 Hz, 2 × OCH2), 107.2 (C-2), 111.1 
(C-4), 111.7 (C-6), 129.4 (C-5), 139.1 (C-1), 157.4 (C-3) and 169.5 (d, JP−C = 15.6 Hz, C=O);  
δP/ppm  (162 MHz; CDCl3) 24.1 (P=O).  
 
Diethyl [N-(3-methoxyphenyl)carbamoyl]ethylphosphonate 323b   
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The procedure described for the synthesis of diethyl [N-(3-
hydroxyphenyl)carbamoyl]ethylphosphonate 323a was employed, using 3-chloro-N-(3-
methoxyphenyl)propanamide 322b (0.50 g, 2.3 mmol) and triethyl phosphite (0.81 mL, 4.7 
mmol). The crude product was purified by flash chromatography [on silica gel; elution with 
hexane-EtOAc (3:1)], and subsequent evaporation of the solvent in vacuo afforded diethyl 
[N-(3-methoxyphenyl)carbamoyl]ethylphosphonate 323b as a yellow oil (0.32 g, 62 %); 
(Found: M+, 315.12861 C14H22NO5P requires: M
+, 315.12356); ʋ/cm-1 1679 (C=O), 1231 (P=O) 
and 1049 (P−OEt); δH/ppm (400 MHz; CDCl3) 1.31 (6H, t, J = 6.8 Hz, 2 × CH3), 2.15 (2H, m, 
CH2P), 2.71 (2H, m, CH2CO), 3.78 (3H, s, OCH3), 4.12 (4H, m, 2 × OCH2), 6.62 (1H, dd, J = 6.4 
and 2.0 Hz, 4-H), 7.05 (1H, d, J = 8.0 Hz, 6-H), 7.17 (1H, t, J = 8.4 Hz, 5-H), 7.35 (1H, t, J = 2.0 
Hz, 2-H) and 8.87 (1H, s, NH); δC (100 MHz; CDCl3)  16.3 (d, JP–C = 6.0 Hz, 2 × CH3), 20.7 (d, JP–C 
= 142.5 Hz, CH2P), 29.9 (d, JP–C = 3.4 Hz, CH2CO), 55.2 (OCH3), 62.1 (d, JP–C = 6.6 Hz, 2 × OCH2), 
105.2 (C-2), 109.7 (C-4), 111.7 (C-6), 129.4 (C-5), 139.8 (C-1), 160.0 (C-3) and 169.4 (d, JP−C = 
15.8 Hz, C=O); δP/ppm  (162 MHz; CDCl3) 23.8 (P=O). 
 
Diethyl [N-(3-bromophenyl)carbamoyl]ethylphosphonate 323c   
 
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-
hydroxyphenyl)carbamoyl]ethylphosphonate 323a was employed, using N-(3-
bromophenyl)3-chloropropanamide 322c (0.50 g, 1.9 mmol) and triethyl phosphite (0.65 
mL, 3.8 mmol). The crude product was purified by flash chromatography [on silica gel; 
elution with hexane-EtOAc (3:1)], and subsequent evaporation of the solvent in vacuo 
afforded diethyl [N-(3-bromophenyl)carbamoyl]ethylphosphonate 323c as a yellowish-brown 
oil (0.27 g, 53 %); (Found: M+, 363.02473 C13H19BrNO4P requires: M
+, 363.02351); ʋ/cm-1 
1680 (C=O), 1240 (P=O) and 1037 (P−OEt);  δH/ppm (400 MHz; CDCl3) 1.37 (6H, t, J = 6.8 Hz, 
2 × CH3), 2.21 (2H, m, CH2P), 2.73 (2H, m, CH2CO), 4.16 (4H, m, 2 × OCH2), 7.18 (1H, t, J = 7.6 
Hz, 5-H), 7.23 (1H, d, J = 8.4 Hz, 4-H), 7.61 (1H, d, J = 7.6 Hz, 6-H), 7.84 (1H, s, 2-H) and 9.30 
(1H, s, NH); δC (100 MHz; CDCl3)  16.4 (d, JP–C = 6.0 Hz, 2 × CH3), 20.6 (d, JP–C = 142.5 Hz, CH2P), 
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29.9 (d, JP–C = 3.3 Hz, CH2CO), 62.2 (d, JP–C = 6.6 Hz, 2 × OCH2), 115.3 (C-6), 117.9 (C-3), 122.3 
(C-2), 126.6 (C-4), 130.1 (C-5), 140.0 (C-1) and 169.5 (d, JP−C = 15.1 Hz, C=O); δP/ppm  (162 
MHz; CDCl3) 24.1 (P=O). 
 
Diethyl [N-(3-fluorophenyl)carbamoyl]ethylphosphonate 323d  
 
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-
hydroxyphenyl)carbamoyl]ethylphosphonate 323a was employed, using 3-chloro-N-(3-
fluorophenyl)propanamide 322d (0.50 g, 2.5 mmol) and triethyl phosphite (0.85 mL, 4.9 
mmol). The crude product was purified by flash chromatography [on silica gel; elution with 
hexane-EtOAc (3:1)], and subsequent evaporation of the solvent in vacuo afforded diethyl 
[N-(3-fluorophenyl)carbamoyl]ethylphosphonate 323d as a light yellow oil (0.24 g, 48 %); 
(Found: M+, 303.10843 C13H19FNO5P requires: M
+, 303.10357); ʋ/cm-1 1675 (C=O), 1234 
(P=O) and 1037 (P−OEt);  δH/ppm (400 MHz; CDCl3) 1.31 (6H, t, J = 7.2 Hz, 2 × CH3), 2.17 (2H, 
m, CH2P), 2.70 (2H, m, CH2CO), 4.11 (4H, m, 2 × OCH2), 6.81 (1H, td, J = 6.0, 2.0 and 1.6 Hz, 4-
H), 7.16 (1H, dd, J = 6.4 and 2.0 Hz, 6-H), 7.24 (1H, td, J = 6.4 and 1.6 Hz, 5-H) 7.49 (1H, dt, J = 
6.4, 2.0 and 1.6 Hz, 2-H) and 7.76 (1H, s, NH); δC (100 MHz; CDCl3) 16.3 (d, JP–C = 6.2 Hz, 2 × 
CH3), 20.7 (d, JP–C  = 142.3 Hz, CH2P), 30.1 (d, JP–C = 4.0 Hz, CH2CO), 62.2 (d, JP–C = 6.6 Hz, 2 × 
OCH2), 107.4 (d, JF–C = 26.2 Hz, C-2), 111.2 (d, JF–C = 21.2 Hz, C-4),  115.1 (d, JF–C = 2.9 Hz, C-6), 
130.1 (d, JF–C = 9.3 Hz, C-5), 139.0 (d, JF–C = 10.9 Hz, C-1), 162.9 (d, JF−C = 243.3 Hz, C-3) and 
167.9 (C=O); δP/ppm  (162 MHz; CDCl3) 23.4 (P=O).  
 
Diethyl [N-(3-cyanophenyl)carbamoyl]ethylphosphonate 323e  
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The procedure described for the synthesis of diethyl [N-(3-hydroxyphenyl)carbamoyl]ethyl 
phosphonate 323a was employed, using 3-chloro-N-(3-cyanophenyl)propanamide 322e 
(0.50 g, 2.4 mmol) and triethyl phosphite (0.82 mL, 4.8 mmol). The crude product was 
purified by flash chromatography [on silica gel; elution with hexane-EtOAc (3:1)], and 
subsequent evaporation of the solvent in vacuo afforded diethyl [N-(3-
cyanophenyl)carbamoyl]ethylphosphonate 323e as a yellow oil (0.30 g, 61 %); (Found: M+, 
311.11061 C14H19N2O4P requires: M
+, 311.11160); ʋ/cm-1 2232 (C≡N), 1657 (C=O), 1230 
(P=O) and 1042 (P−OEt); δH/ppm (400 MHz; CDCl3) 1.34 (6H, t, J = 7.2 Hz, 2 × CH3), 2.17 (2H, 
m, CH2P), 2.73 (2H, m, CH2CO), 4.13 (4H, m, 2 × OCH2), 7.34 (2H, m, 4-H and 6-H), 7.86 (1H, t, 
J = 8.0 Hz, 5-H), 7.96 (1H, t, J = 1.6 Hz, 2-H) and 9.62 (1H, s, NH); δC (100 MHz; CDCl3)  16.4 (d, 
JP–C = 6.1 Hz, 2 × CH3), 20.7 (d, JP–C = 142.3 Hz, CH2P), 29.9 (d, JP–C = 3.4 Hz, CH2CO), 62.4 (d, JP–
C = 6.6 Hz, 2 × OCH2), 112.7 (C-3), 118.7 (C≡N), 122.6 (C-2) 123.6 (C-5), 127.1 (C-6), 129.7 (C-
4), 139.5 (C-1) and 169.9 (C=O); δP/ppm  (162 MHz; CDCl3) 24.0 (P=O).   
 
Diethyl [N-(3-nitrophenyl)carbamoyl]ethylphosphonate 323f  
 
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-hydroxyphenyl)carbamoyl]ethyl 
phosphonate 323a was employed, using 3-chloro-N-(3-nitrophenyl)propanamide 322f (0.50 
g, 2.2 mmol) and triethyl phosphite (0.76 mL, 4.4 mmol). The crude product was purified by 
flash chromatography [on silica gel; elution with hexane-EtOAc (3:1)], and subsequent 
evaporation of the solvent in vacuo afforded diethyl[N-(3-nitrophenyl)carbamoyl]ethyl 
phosphonate 323f as a dark brown oil (0.33 g, 67 %); (Found: M+, 330.10042 C13H19N2O6P 
requires: M+, 330.09807); ʋ/cm-1 1679 (C=O), 1219 (P=O) and 1034 (P−OEt); δH/ppm (400 
MHz; CDCl3) 1.35 (6H, t, J = 7.2 Hz, 2 × CH3), 2.18 (2H, m, CH2P), 2.77 (2H, m, CH2CO), 4.15 
(4H, m, 2 × OCH2), 7.45 (1H, t, J = 8.4 Hz, 5-H), 7.90 (1H, dd, J = 8.0 and 1.6 Hz, 4-H), 8.13 (1H, 
dd, J = 8.4 and 1.6 Hz, 6-H), 8.40 (1H, t, J = 2.0 Hz, 2-H) and 9.92 (1H, s, NH); δC (100 MHz; 
CDCl3) 16.4 (d, JP–C = 6.1 Hz, 2 × CH3), 20.8 (d, JP–C = 142.9 Hz, CH2P), 29.7 (d, JP–C = 3.1 Hz, 
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CH2CO), 62.4 (d, JP–C = 6.6 Hz, 2 × OCH2), 114.1 (C-2), 118.1 (C-4), 125.1 (C-6), 129.7 (C-5), 
140.1 (C-1), 148.3 (C-3) and 169.9 (C=O); δP/ppm  (162 MHz; CDCl3) 24.4 (P=O).    
 
Diethyl {N-[3-(hydroxymethyl)phenyl]carbamoyl}ethylphosphonate 323g  
 
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-
hydroxyphenyl)carbamoyl]ethylphosphonate 323a was employed, using 3-chloro-N-[3-
(hydroxymethyl)phenyl]propanamide 322g (0.50 g, 2.3 mmol) and triethyl phosphite (0.80 
mL, 4.7 mmol). The crude product was purified by flash chromatography [on silica gel; 
elution with hexane-EtOAc (3:1)], and subsequent evaporation of the solvent in vacuo 
afforded diethyl {N-[3-(hydroxymethyl)phenyl]carbamoyl}ethylphosphonate 323g as a yellow 
oil (0.30 g, 61 %); (Found: M+, 315.12725 C14H22NO5P requires: M
+, 315.12356); ʋ/cm-1 3268 
(OH), 1667 (C=O), 1232 (P=O) and 1041 (P−OEt); δH/ppm (400 MHz; CDCl3) 1.33 (6H, t, J = 
6.8 Hz, 2 × CH3), 2.17 (2H, m, CH2P), 2.78 (2H, m, CH2CO), 4.12 (4H, m, 2 × OCH2), 4.46 (1H, s, 
OH), 5.00 (2H, s, CH2OH), 7.08 (1H, d, J = 7.6 Hz, 4-H), 7.28 (1H, t, J = 8.0 Hz, 5-H), 7.46 (1H, 
d, J = 8.0 Hz, 6-H), 7.58 (1H, s, 2-H) and 8.02 (1H, s, NH); δC (100 MHz; CDCl3) 16.3 (d, JP–C = 
6.0 Hz, 2 × CH3), 20.7 (d, JP–C = 142.5 Hz, CH2P), 29.9 (d, JP–C = 3.1 Hz, CH2CO), 62.1 (d, JP–C = 
6.6 Hz, OCH2), 63.4 (CH2OH), 118.2 (C-2), 119.1 (C-6), 122.4 (C-4), 129.4 (C-5), 139.1 (C-1), 
139.6 (C-3) and 169.6 (C=O); δP/ppm  (162 MHz; CDCl3) 24.0 (P=O). 
 
3.3.2.2. Synthesis of ethylphosphonic acid derivatives using TMSBr  
 
[N-(3-Hydroxyphenyl)carbamoyl]ethylphosphonic acid 331a    
 
 
 
 
Trimethylsilyl bromide (0.22 mL, 1.7 mmol) was added to diethyl [N-(3-hydroxyphenyl)-
carbamoyl]ethylphosphonate 323a (0.25 g, 0.83 mmol) in CH3CN (3 mL) and the mixture was 
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heated in the microwave apparatus set to deliver 100 W of power, with a reaction 
temperature of 60 oC and reaction time of 10 min. After completion, the mixture was cooled 
to room temperature, treated with a 95:5 MeOH-H2O mixture and stirred for 30 min. The 
solvent was removed in vacuo and the residue chromatographed [preparative layer 
chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [N-(3-
hydroxyphenyl)carbamoyl]ethylphosphonic acid 331a as a brown viscous liquid (0.12 g, 61 
%); (Found: C, 44.27; H, 4.98; N, 5.73 %. C9H12NO5P requires C, 44.09; H, 4.93; N, 5.71 %); 
ʋ/cm-1 3212 (OH), 1682 (C=O) and 1230 (P=O); δH/ppm (400 MHz; DMSO-d6) 2.12 (2H, m, 
CH2P), 2.70 (2H, m, CH2CO), 5.71 (2H, s, 2 x OH), 6.61 (1H, d, J = 8.2 Hz, 4-H), 6.89 (1H, d, J = 
7.6 Hz, 6-H), 7.11 (1H, t, J = 8.2 Hz, 5-H), 7.38 (1H, s, 2-H), 7.52 (1H, s, OH) and 8.82 (1H, s, 
NH); δC/ppm (100 MHz; DMSO-d6) 20.7 (d, JP–C = 142.5 Hz, CH2P), 27.7 (d, JP–C = 3.7 Hz, 
CH2CO), 107.1 (C-2), 111.0 (C-4), 111.8 (C-6), 129.8 (C-5), 139.5 (C-1), 158.1 (C-3) and 169.3 
(d, JP−C = 15.4 Hz, C=O). 
 
[N-(3-Methoxyphenyl)carbamoyl]ethylphosphonic acid 331b    
 
 
 
 
The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]ethyl 
phosphonic acid 331a was employed, using diethyl [N-(3-methoxyphenyl)carbamoyl]ethyl 
phosphonate 323b (0.25 g, 0.79 mmol) in CH3CN (3 mL) and trimethylsilyl bromide (0.21 mL, 
1.6 mmol). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [N-(3-
methoxyphenyl)carbamoyl]ethylphosphonic acid 331b as a yellow viscous liquid (0.14 g, 66 
%); (Found: C, 46.39; H, 5.49; N, 5.48 %. C10H14NO5P requires C, 46.34; H, 5.44; N, 5.40 %); 
ʋ/cm-1 3210 (OH), 1670 (C=O) and 1228 (P=O); δH/ppm (400 MHz; DMSO-d6) 2.14 (2H, m, 
CH2P), 2.73 (2H, m, CH2CO), 3.79 (3H, s, OCH3), 5.93 (2H, s, 2 x OH), 6.60 (1H, dd, J = 6.4 and 
2.0 Hz, 4-H), 7.08 (1H, d, J = 7.9 Hz, 6-H), 7.18 (1H, t, J = 8.2 Hz, 5-H), 7.37 (1H, t, J = 8.2 Hz, 2-
H) and 8.83 (1H, s, NH); δC/ppm (100 MHz; DMSO-d6) 20.7 (d, JP–C = 142.3 Hz, CH2P), 29.8 (d, 
JP–C = 3.1 Hz, CH2CO), 55.3 (OCH3), 105.4 (C-2), 109.7 (C-4), 111.8 (C-6), 129.7 (C-5), 139.5 (C-
1), 159.8 (C-3) and 169.2 (d, JP−C = 15.6 Hz, C=O).  
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[N-(3-Bromophenyl)carbamoyl]ethylphosphonic acid 331c    
 
 
 
 
The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]ethyl 
phosphonic acid 331a was employed, using diethyl [N-(3-bromophenyl)carbamoyl]ethyl 
phosphonate 323c (0.25 g, 0.69 mmol) in CH3CN (3 mL) and trimethylsilyl bromide (0.19 mL, 
1.4 mmol). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [N-
(3-bromophenyl)carbamoyl]ethylphosphonic acid 331c as a brown gum (0.18 g, 58 %); 
(Found: C, 35.15; H, 3.71; N, 4.51 %. C9H11BrNO4P requires C, 35.09; H, 3.60; N, 4.55 %); 
ʋ/cm-1 3189 (OH), 1672 (C=O) and 1219 (P=O); δH/ppm (400 MHz; DMSO-d6) 2.21 (2H, m, 
CH2P), 2.73 (2H, m, CH2CO), 5.21 (2H, s, 2 x OH), 7.20 (1H, t, J = 7.6 Hz, 5-H), 7.24 (1H, d, J = 
8.0 Hz, 4-H), 7.59 (1H, d, J = 7.6 Hz, 6-H), 7.82 (1H, s, 2-H) and 8.87 (1H, s, NH); δC/ppm (100 
MHz; DMSO-d6) 20.8 (d, JP–C = 142.5 Hz, CH2P), 29.8 (d, JP–C = 3.2 Hz, CH2CO), 115.1 (C-6), 
117.9 (C-3), 122.5 (C-2), 126.8 (C-4), 129.8 (C-5), 140.2 (C-1) and 169.7 (d, JP−C = 15.2 Hz, 
C=O). 
 
 [N-(3-Fluorophenyl)carbamoyl]ethylphosphonic acid 331d    
 
 
 
 
The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]ethyl 
phosphonic acid 331a was employed, using diethyl [N-(3-fluorophenyl)carbamoyl]ethyl 
phosphonate 323d (0.25 g, 0.82 mmol) in CH3CN (3 mL) and trimethylsilyl bromide (0.22 mL, 
1.6 mmol). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [N-
(3-fluorophenyl)carbamoyl]ethylphosphonic acid 331d as a yellow viscous liquid (0.17 g, 68 
%); (Found: C, 43.82; H, 4.56; N, 5.73 %. C9H11FNO4P requires C, 43.74; H, 4.49; N, 5.67 %); 
ʋ/cm-1 3228 (OH), 1689 (C=O) and 1236 (P=O); δH/ppm (400 MHz; DMSO-d6) 2.13 (2H, m, 
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CH2P), 2.73 (2H, m, CH2CO), 4.95 (2H, s, 2 x OH), 6.79 (1H, td, J = 6.0, 2.0 and 1.6 Hz, 4-H), 
7.17 (1H, d, J= 6.2 Hz, 6-H), 7.27 (1H, ddd, J = 6.4, 6.0 and 1.6 Hz, 5-H) 7.46 (1H, dt, J = 6.4 
and 1.6 Hz, 2-H) and 8.21 (1H, s, NH); δC/ppm (100 MHz; DMSO-d6) 20.7 (d, JP–C = 142.5 Hz, 
CH2P), 29.9 (d, JP–C = 3.8 Hz, CH2CO), 107.7 (d, JF–C = 26.2 Hz, C-2), 111.3 (d, JF–C = 21.2 Hz, C-
4), 115.3 (d, JF–C = 2.8 Hz, C-6), 130.5 (d, JF–C = 9.2 Hz, C-5), 139.3 (d, JF–C = 11 Hz, C-1), 163.4 
(d, JF−C = 243.1 Hz, C-3) and 168.1 (C=O).  
  
 [N-(3-Cyanophenyl)carbamoyl]ethylphosphonic acid 331e  
 
 
 
 
The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]ethyl 
phosphonic acid 331a was employed, using diethyl [N-(3-cyanophenyl)carbamoyl]ethyl 
phosphonate 323e (0.25 g, 0.81 mmol) in CH3CN (3 mL) and trimethylsilyl bromide (0.22 mL, 
1.6 mmol). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [N-
(3-cyanophenyl)carbamoyl]ethylphosphonic acid 331e as a light yellow viscous liquid (0.12 g, 
60 %); (Found: C, 47.19; H, 4.32; N, 11.12 %. C10H11N2O4P requires C, 47.25; H, 4.36; N, 11.02 
%); (0.10 g, 59 %); ʋ/cm-1 3284 (OH), 2238 (C≡N), 1678 (C=O) and 1232 (P=O); δH/ppm (400 
MHz; DMSO-d6) 1.56 (2H, s, 2 x OH), 2.15 (2H, m, CH2P), 2.72 (2H, m, CH2CO), 7.33 (2H, m, 4-
H and 6-H), 7.83 (1H, t, J = 8.0 Hz, 5-H), 7.96 (1H, t, J = 1.6 Hz, 2-H), and 9.03 (1H, s, NH); 
δC/ppm (100 MHz; DMSO-d6) 20.7 (d, JP–C = 142.5 Hz, CH2P), 30.3 (d, JP–C = 3.2 Hz, CH2CO), 
113.0 (C-3), 118.9 (C≡N), 122.9 (C-2) 124.1 (C-5), 127.3 (C-6), 129.8 (C-4), 139.8 (C-1) and 
170.0 (C=O).  
  
 [N-(3-Nitrophenyl)carbamoyl]ethylphosphonic acid 331f    
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The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]ethyl 
phosphonic acid 331a was employed, using diethyl [N-(3-nitrophenyl)carbamoyl]ethyl 
phosphonate 323f (0.25 g, 0.76 mmol) in CH3CN (3 mL) and trimethylsilyl bromide (0.14 mL, 
1.5 mmol). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:0.5)] to yield [N-
(3-nitrophenyl)carbamoyl]ethylphosphonic acid 331f as a dark yellow gum (0.19 g, 71 %); 
(Found: C, 39.52; H, 4.10; N, 10.29 %. C9H11N2O6P requires C, 39.43; H, 4.04; N, 10.22 %); 
ʋ/cm-1 3229 (OH), 1664 (C=O) and 1239 (P=O); δH/ppm (400 MHz; DMSO-d6) 2.12 (2H, m, 
CH2P), 2.70 (2H, m, CH2CO), 4.45 (2H, s, 2 x OH), 7.34 (1H, t, J = 8.2 Hz, 5-H), 7.78 (1H, dd, J = 
8.0 and 1.6 Hz, 4-H), 8.10 (1H, dd, J = 8.0 and 1.6 Hz, 6-H), 8.30 (1H, t, J = 2.0 Hz, 2-H) and 
9.62 (1H, s, NH); δC/ppm (100 MHz; DMSO-d6) 20.8 (d, JP–C = 142.9 Hz, CH2P), 30.2 (d, JP–C = 
3.3 Hz, CH2CO), 114.5 (C-2), 118.3 (C-4), 125.4 (C-6), 129.8 (C-5), 140.2 (C-1), 148.6 (C-3) and 
170.2 (C=O).   
 
 N-[3-(Hydroxymethyl)phenylcarbamoyl]ethylphosphonic acid 331g   
 
 
 
 
 
The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]ethyl 
phosphonic acid 331a was employed, using diethyl {N-[3-(hydroxymethyl) 
phenyl]carbamoyl}ethylphosphonate 323g (0.25 g, 0.79 mmol) in CH3CN (3 mL) and 
trimethylsilyl bromide (0.21 mL, 1.6 mmol). The solvent was removed in vacuo and the 
residue chromatographed [preparative layer chromatography; elution with hexane-EtOAc-
MeOH (1:1:1)] to yield N-[3-(hydroxymethyl)phenylcarbamoyl]ethyl phosphonic acid 331g as 
a yellow  viscous oil ( 0.14 g, 67 %); (Found: C, 46.41; H, 5.51; N, 5.38 %. C10H14NO5P requires 
C, 46.34; H, 5.44; N, 5.40 %); ʋ/cm-1 3267 (OH), 1687 (C=O) and 1232 (P=O); δH/ppm (400 
MHz; DMSO-d6) 2.15 (2H, m, CH2P), 2.77 (2H, m, CH2CO), 4.51 (1H, s, OH), 5.14 (2H, s, 
CH2OH), 7.12 (1H, d, J = 7.6 Hz, 4-H), 7.31 (1H, t, J = 8.0 Hz, 5-H), 7.51 (1H, d, 8.0 Hz, 6-H), 
7.62 (1H, s, 2-H), 7.80 (2H, s, 2 x OH) and 8.06 (1H, s, NH); δC/ppm (100 MHz; DMSO-d6) 20.8 
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(d, JP–C = 142.5 Hz, CH2P), 29.9 (d, JP–C = 3.2 Hz, CH2CO), 63.7 (CH2OH), 118.6 (C-2), 119.4 (C-
6), 122.5 (C-4), 129.8 (C-5), 139.0 (C-1), 139.8 (C-3) and 170.1 (C=O).  
3.3.2.3. Synthesis of sodium hydrogen ethylphosphonate derivatives 
 
Sodium hydrogen [N-(3-hydroxyphenyl)carbamoyl]ethylphosphonate 332a 
 
 
  
 
[N-(3-Hydroxyphenyl)carbamoyl]ethylphosphonic acid 331a (0.15 g, 0.61 mmol) was treated 
with a solution of NaOH (1.1 mol) in EtOH (0.58 mL) and the mixture was stirred for 30 min. 
The solvent was removed in vacuo and the residue chromatographed [reverse-phase 
column chromatography; elution with H2O-MeOH (1:1)] to yield sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]ethylphosphonate 332a as a grey semi-solid (0.12 g, 89 %); ʋ/cm-1 
3267 (OH), 1671 (C=O) and 1231 (P=O); δH/ppm (400 MHz; D2O) 2.13 (2H, m, CH2P), 2.73 
(2H, m, CH2CO), 6.59 (1H, d, J = 8.2 Hz, 4-H), 6.90 (1H, d, J = 7.6 Hz, 6-H), 7.12 (1H, t, J = 8.2 
Hz, 5-H) and 7.35 (1H, s, 2-H); δC/ppm (100 MHz; D2O) 20.6 (d, JP–C = 142.6 Hz, CH2P), 28.0 (d, 
JP–C = 3.6 Hz, CH2CO), 107.2 (C-2), 110.8 (C-4), 111.7 (C-6), 129.5 (C-5), 139.8 (C-1), 158.2 (C-
3) and 169.5 (d, JP−C = 15.2 Hz, C=O). 
 
Sodium hydrogen [N-(3-methoxyphenyl)carbamoyl]ethylphosphonate 332b  
   
      
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]ethylphosphonate 332a was employed, using [N-(3-
methoxyphenyl)carbamoyl]ethylphosphonic acid 331b (0.15 g, 0.58 mmol) and a solution of 
NaOH (1.1 mol) in EtOH (0.55 mL). The solvent was removed in vacuo and the residue 
chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen [N-(3-methoxyphenyl)carbamoyl]ethylphosphonate 332b as a pale 
yellow semi-solid (0.12 g, 91 %); ʋ/cm-1 3184 (OH), 1677 (C=O) and 1232 (P=O); δH/ppm (400 
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MHz; D2O) 2.13 (2H, m, CH2P), 2.75 (2H, m, CH2CO), 3.78 (3H, s, OCH3), 6.62 (1H, dd, J = 6.3 
and 2.0 Hz, 4-H), 7.11 (1H, d, J = 8.0 Hz, 6-H), 7.19 (1H, t, J = 8.0 Hz, 5-H) and 7.32 (1H, t, J = 
2.0 H, 2-H); δC/ppm (100 MHz; D2O) 20.8 (d, JP–C = 142.2 Hz, CH2P), 29.9 (d, JP–C  = 3.2 Hz, 
CH2CO), 55.1 (OCH3), 105.7 (C-2), 110.1 (C-4), 111.6 (C-6), 129.8 (C-5), 139.4 (C-1), 159.6 (C-
3) and 169.5 (d, JP−C = 15.6 Hz, C=O).   
 
Sodium hydrogen [N-(3-bromophenyl)carbamoyl]ethylphosphonate 332c 
 
  
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]ethylphosphonate 332a was employed, using [N-(3-
bromophenyl)carbamoyl]ethylphosphonic acid 331c (0.15 g, 0.49 mmol) and a solution of 
NaOH (1.1 mol) in EtOH (0.46 mL). The solvent was removed in vacuo and the residue 
chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen [N-(3-bromophenyl)carbamoyl]ethylphosphonate 332c as a brown 
semi-solid (0.11 g,  87 %); ʋ/cm-1 3079 (OH), 1692 (C=O) and 1215 (P=O); δH/ppm (400 MHz; 
D2O) 2.19 (2H, m, CH2P), 2.71 (2H, m, CH2CO), 7.22 (1H, t, J = 7.6 Hz, 5-H), 7.25 (1H, d, J = 8.0 
Hz, 4-H), 7.56 (1H, d, J = 7.6 Hz, 6-H) and 7.81 (1H, s, 2-H); δC/ppm (100 MHz; D2O) 20.8 (d, 
JP–C = 142.5 Hz, CH2P), 29.8 (d, JP–C = 3.1 Hz, CH2CO), 115.2 (C-6), 117.5 (C-3), 123.2 (C-2), 
126.5 (C-4), 130.2 (C-5), 139.8 (C-1) and 170.0 (d, JP−C = 15.2 Hz, C=O). 
 
Sodium hydrogen [N-(3-fluorophenyl)carbamoyl]ethylphosphonate 332d 
 
 
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]ethylphosphonate 332a was employed, using [N-(3-
fluorophenyl)carbamoyl]ethylphosphonic acid 331d (0.15 g, 0.61 mmol) and a solution of 
NaOH (1.1 mol) in EtOH (0.58 mL). The solvent was removed in vacuo and the residue 
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chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen [N-(3-fluorophenyl)carbamoyl]ethylphosphonate 332d as a pale 
yellow semi-solid (0.14 g, 94 %); ʋ/cm-1 3150 (OH), 1682 (C=O) and 1233 (P=O); δH/ppm (400 
MHz; D2O) 2.15 (2H, m, CH2P), 2.65 (2H, m, CH2CO), 6.80 (1H, td, J = 6.0, 2.0 and 1.6 Hz, 4-
H), 7.15 (1H, dd, J= 6.2 and 2.0 Hz, 6-H), 7.25 (1H, ddd, J = 6.4, 2.0 and 1.6 Hz, 5-H) and 7.42 
(1H, dt, J = 6.4 and 2.0 Hz, 2-H); δC/ppm (100 MHz; D2O) 20.8 (d, JP–C = 142.1 Hz, CH2P), 30.0 
(d, JP–C = 3.6 Hz, CH2CO), 107.8 (d, JF–C = 26.2 Hz, C-2), 111.7 (d, JF–C = 21.2 Hz, C-4), 115.1 (d, 
JF–C = 2.6 Hz, C-6), 130.2 (d, JF–C = 9.2 Hz, C-5), 139.8 (d, JF–C = 10.8 Hz, C-1), 163.7 (d, JF−C = 
242.8 Hz, C-3) and 167.7 (C=O).  
 
 Sodium hydrogen [N-(3-cyanophenyl)carbamoyl]ethylphosphonate 332e 
 
 
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]ethylphosphonate 332a was employed, using [N-(3-
cyanophenyl)carbamoyl]ethylphosphonic acid 331e (0.15 g, 0.59 mmol) and a solution of 
NaOH (1.1 mol) in EtOH (0.56 mL). The solvent was removed in vacuo and the residue 
chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen [N-(3-cyanophenyl)carbamoyl]ethylphosphonate 332e as a pale 
yellow semi-solid (0.13 g, 96 %); ʋ/cm-1 2236 (C≡N), 1655 (C=O) and 1214 (P=O); δH/ppm 
(400 MHz; D2O) 2.12 (2H, m, CH2P), 2.80 (2H, m, CH2CO), 7.27 (2H, m, 4-H and 6-H), 7.79 
(1H, t, J = 8.0 Hz, 5-H) and 7.93 (1H, t, J = 1.6 Hz, 2-H); δC/ppm (100 MHz; D2O) 20.8 (d, JP–C = 
142.4 Hz, CH2P), 29.9 (d, JP–C = 3.2 Hz, CH2CO), 112.6 (C-3), 118.2 (C≡N), 122.4 (C-2) 124.3 (C-
5), 127.8 (C-6), 129.8 (C-4), 139.6 (C-1) and 169.9 (C=O).  
 
Sodium hydrogen [N-(3-nitrophenyl)carbamoyl]ethylphosphonate 332f 
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The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]ethylphosphonate 332a was employed, using [N-(3-
nitrophenyl)carbamoyl]ethylphosphonic acid 331f (0.15 g, 0.55 mmol) and a solution of 
NaOH (1.1 mol) in EtOH (0.52 mL). The solvent was removed in vacuo and the residue 
chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen [N-(3-nitrophenyl)carbamoyl]ethylphosphonate 332f as a yellow 
semi-solid (0.12 g, 91 %); ʋ/cm-1 3143 (OH), 1670 (C=O) and 1218 (P=O); δH/ppm (400 MHz; 
D2O) 2.17 (2H, m, CH2P), 2.79 (2H, m, CH2CO), 7.41 (1H, t, J = 8.4 Hz, 5-H), 7.85 (1H, dd, J = 
8.2 and 1.6 Hz, 4-H), 8.12 (1H, dd, J = 8.0 and 1.6 Hz, 6-H) and 8.40 (1H, t, J = 2.0 Hz, 2-H); 
δC/ppm (100 MHz; D2O) 20.9 (d, JP–C = 142.8 Hz, CH2P), 30.1 (d, JP–C = 3.2 Hz, CH2CO), 114.2 
(C-2), 117.8 (C-4), 125.5 (C-6), 129.9 (C-5), 140.1 (C-1), 148.0 (C-3) and 170.2 (C=O).   
Sodium hydrogen {N-[3-(hydroxymethyl)phenyl]carbamoyl}ethylphosphonate 332g   
 
 
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]ethylphosphonate 332a was employed, using [N-(3-
(hydroxymethyl)phenylcarbamoyl]ethylphosphonic acid 331g (0.15 g, 0.58 mmol) and a 
solution of NaOH (1.1 mol) in EtOH (0.55 mL). The solvent was removed in vacuo and the 
residue chromatographed [reverse-phase column chromatography; elution with H2O-MeOH 
(1:1)] to yield sodium hydrogen {N-[3-(hydroxymethyl)phenyl]carbamoyl}ethylphosphonate 
332g as a light yellow semi-solid (0.12 g, 89 %); ʋ/cm-1 3198 (OH), 1653 (C=O) and 1230 
(P=O); δH/ppm (400 MHz; D2O) 2.18 (2H, m, CH2P), 2.80 (2H, m, CH2CO), 4.86 (2H, s, CH2OH), 
7.08 (1H, d, J = 7.6 Hz, 4-H), 7.28 (1H, t, J = 8.0 Hz, 5-H), 7.44 (1H, d, 8.0 Hz, 6-H) and 7.58 
(1H, s, 2-H); δC/ppm (100 MHz; D2O) 20.7 (d, JP–C = 142.3 Hz, CH2P), 29.8 (d, JP–C = 3.2 Hz, 
CH2CO), 63.5 (CH2OH), 118.2 (C-2), 119.7 (C-6), 123.4 (C-4), 130.4 (C-5), 139.6 (C-1), 139.5 
(C-3) and 169.5 (C=O).   
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3.3.3. Reaction of 3-substituted anilines with 4-chlorobutanoyl chloride  
 
4-Chloro-N-(3-hydroxyphenyl)butanamide 324a   
 
 
 
 
To a stirred solution of 3-aminophenol  (1.50 g, 14.0 mmol) in THF (30 mL) under nitrogen 
was added NaH (60 % dispersion in mineral oil; 0.60 g, 24 mmol) in small portions to permit 
controlled evolution of hydrogen. 4-Chlorobutanoyl chloride (1.18 mL, 14.0 mmol) was then 
added through a septum and the resulting solution was stirred for ca. 6 h. The solvent was 
evaporated in vacuo and the residue dissolved in EtOAc (2 x 50 mL). The organic solution 
was washed sequentially with satd. aq. NaHCO3 (2 × 100 mL), water (2 x 100 mL) and brine 
(2 × 100 mL). The aqueous washings were extracted with EtOAc and the combined organic 
solutions were dried (anhydr. MgSO4). Evaporation of the solvent in vacuo afforded 4-
chloro-N-(3-hydroxyphenyl)butanamide 324a as a brown solid (2.15 g, 71 %) m.p. 88-90 °C; 
(Found: M+, 213.05711 C10H12ClNO2 requires: M
+, 213.05566); ʋ/cm-1 3176 (OH) and 1662 
(C=O); δH/ppm (400 MHz; CDCl3) 2.17 (2H, m, 3'-CH2), 2.73 (2H, t, J = 6.8 Hz, CH2CO), 3.59 
(2H, t, J = 6.4 Hz, CH2Cl), 6.45 (1H, dd, J = 6.0 and 2.0 Hz, 4-H), 6.51 (1H, dd, J = 6.0 and 2.4 
Hz, 6-H), 6.97 (1H, t, J = 8.0 Hz, 5-H), 7.48 (1H, t, J =  1.2 Hz, 2-H), 7.65 (1H, s, OH) and 7.69 
(1H, s, NH); δC/ppm (100 MHz; CDCl3) 26.8 (C-3), 33.1 (CH2CO), 44.2 (CH2Cl), 106.4 (C-2), 
109.4 (C-4), 111.2 (C-6), 129.7 (C-5), 139.8 (C-1), 158.2 (C-3) and 166.7 (C=O).  
 
4-Chloro-N-(3-methoxyphenyl)butanamide 324b   
 
 
 
 
The procedure described for the synthesis of 4-chloro-N-(3-hydroxyphenyl)butanamide 
324a was employed, using 3-methoxyaniline (0.91 mL, 8.1 mmol), NaH (60 % dispersion in 
mineral oil; 0.36 g, 15 mmol) and 4-chlorobutanoyl chloride (0.68 mL, 8.1 mmol) in THF (15 
mL), to yield 4-chloro-N-(3-methoxyphenyl)butanamide 324b as a yellow solid (1.38 g, 75 %) 
m.p 56-58°C (Lit.243 50-54 oC); ʋ/cm-1 1687 (C=O); δH/ppm (400 MHz; CDCl3) 2.17 (2H, m, 3'-
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CH2), 2.54 (2H, t, J = 6.8 Hz, CH2CO), 3.65 (2H, t, J = 6.0 Hz, CH2Cl), 3.79 (3H, s, OCH3), 6.65 
(1H, dd, J = 6.4 and 1.6 Hz, 4-H), 6.95 (1H, d, J = 7.6 Hz, 6-H), 7.19 (1H, t, J = 8.0 Hz, 5-H), 7.29 
(1H, s, NH) and 7.32 (1H, t, J = 2.0 Hz, 2-H); δC/ppm (100 MHz; CDCl3) 26.7 (C-3'), 36.7 
(CH2CO), 44.4 (CH2Cl), 55.2 (OCH3), 105.2 (C-2), 110.7 (C-6), 111.8 (C-4), 129.8 (C-5), 135.2 
(C-1), 160.2 (C-3) and 171.2 (C=O).   
 
N-(3-Bromophenyl) 4-chlorobutanamide 324c 
  
 
 
 
The procedure described for the synthesis of 4-chloro-N-(3-hydroxyphenyl)butanamide 
324a was employed, using 3-bromoaniline (0.63 mL, 5.8 mmol), NaH (60 % dispersion in 
mineral oil; 0.26 g, 11 mmol) and 4-chlorobutanoyl chloride (0.48 mL, 5.8 mmol) in THF (15 
mL), to yield N-(3-bromophenyl)4-chlorobutanamide 324c as a brown solid (1.15 g, 72 %), 
m.p 85-87 °C; (Found: M+, 275.00328 C10H11BrClNO requires: M
+, 274.97125); ʋ/cm-1 1691 
(C=O); δH/ppm (400 MHz; CDCl3) 2.18 (2H, m, 3'-CH2), 2.55 (2H, t, J = 6.8 Hz, CH2CO), 3.64 
(2H, t, J = 6.4 Hz, CH2Cl), 7.16 (1H, t, J = 8.0 Hz, 5-H), 7.22 (1H, d, J = 8.0 Hz, 4-H), 7.37 (1H, d, 
J = 8.0 Hz, 6-H), 7.40 (1H, s, 2-H), and 7.77 (1H, s, NH); δC/ppm (100 MHz; CDCl3) 26.8 (C-3'), 
33.4 (CH2CO), 44.6 (CH2Cl), 118.5 (C-6), 122.2 (C-3), 123.6 (C-2), 127.8 (C-4), 129.9 (C-5), 
137.8 (C-1) and 164.1 (C=O).   
 
4-Chloro-N-(3-fluorophenyl)butanamide 324d 
 
 
 
 
The procedure described for the synthesis of 4-chloro-N-(3-hydroxyphenyl)butanamide 
324a was employed, using 3-fluoroaniline (1.05 mL, 5.8 mmol), NaH (60 % dispersion in 
mineral oil; 0.26 g, 11 mmol) and 4-chlorobutanoyl chloride (0.48 mL, 5.8 mmol) in THF (15 
mL), to yield 4-chloro-N-(3-fluorophenyl)butanamide 324d as a yellow solid (0.84 g, 68 %), 
m.p 62.64 °C (Lit.244 55-56 oC); ʋ/cm-1 1681 (C=O); δH/ppm (400 MHz; CDCl3) 2.18 (2H, m, 3'-
CH2), 2.55 (2H, t, J = 7.2 Hz, CH2CO), 3.64 (2H, t, J = 6.0 Hz, CH2Cl), 6.78 (1H, ddd, J =  6.4, 2.4 
and 1.2 Hz, 4-H), 7.12 (1H, dd, J = 8.4 and 2.0 Hz, 6-H), 7.25 (1H, dt, J = 6.8 and 1.6 Hz, 5-H), 
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7.48 (1H, td, J = 6.4, 2.0 and 1.2 Hz, 2-H) and 9.41 (1H, s, NH); δC/ppm (100 MHz; CDCl3) 26.8 
(C-3'), 33.6 (CH2CO), 44.2 (CH2Cl), 107.4 (d, JF–C = 26.2 Hz, C-2), 111.2 (d, JF–C = 21.2 Hz, C-4), 
114.8 (C-6), 130.0 (d, JF–C = 9.5 Hz, C-5), 139.3 (d, JF–C = 10.8 Hz, C-1), 162.9 (d, JF–C = 242.8 Hz, 
C-3) and 169.9 (C=O).   
  
4-Chloro-N-(3-cyanophenyl)butanamide 324e  
 
 
 
The procedure described for the synthesis of 4-chloro-N-(3-hydroxyphenyl)butanamide 
324a was employed, using 3-aminobenzonitrile (1.20 g, 10.1 mmol), NaH (60 % dispersion in 
mineral oil; 0.54 g, 23 mmol) and 4-chlorobutanoyl chloride (0.84 mL, 10 mmol) in THF (15 
mL), to yield 4-chloro-N-(3-cyanophenyl)butanamide 324e as a yellow solid (2.00 g, 89 %), 
m.p 84-86 °C (Lit.244 87-88 oC); ʋ/cm-1 2230 (C≡N), 1663 (C=O); δH/ppm (400 MHz; CDCl3) 
2.18 (2H, m, 3'-CH2), 2.59 (2H, t, J = 7.2 Hz, CH2CO), 3.65 (2H, t, J = 6.4 Hz, CH2Cl), 7.39 (2H, 
m, 4-H and 6-H), 7.62 (1H, s, NH), 7.70 (1H, t, J = 7.6 Hz, 5-H) and 7.94 (1H, t, J = 2.0 Hz, 2-H); 
δC/ppm (100 MHz; CDCl3) 27.6 (C-3'), 34.0 (CH2CO), 44.3 (CH2Cl), 112.9 (C-3), 118.5 (C=N), 
122.6 (C-2), 123.8 (C-5), 127.7 (C-6), 129.9 (C-4), 138.6 (C-1) and 170.4 (C=O).  
 
4-Chloro-N-(3-nitrophenyl)butanamide 324f  
 
 
 
 
The procedure described for the synthesis of 4-chloro-N-(3-hydroxyphenyl)butanamide 
324a was employed, using 3-nitroaniline (1.01 g, 7.27 mmol), NaH (60 % dispersion in 
mineral oil; 0.33 g, 13 mmol) and 4-chlorobutanoyl chloride (0.61 mL, 7.3 mmol) in THF (15 
mL), to yield 4-chloro-N-(3-nitrophenyl)butanamide 324f as a dark yellow solid (1.55 g, 88 
%), m.p 78-80 °C (Lit.245 82 oC); (Found: M+, 242.04819 C10H11ClN2O3 requires: M
+, 
242.04582); ʋ/cm-1 1675 (C=O); δH/ppm (400 MHz; CDCl3) 2.21 (2H, m, 3'-CH2), 2.66 (2H, t, J 
= 8.0 Hz, CH2CO), 3.92 (2H, t, J = 6.8 Hz, CH2Cl), 7.52 (1H, t, J = 8.4 Hz, 5-H), 7.98 (1H, dd, J = 
6.8 and 1.2 Hz, 4-H), 8.20 (1H, dd, J = 6.8 and 1.2 Hz, 6-H), 8.34 (1H, t, J = 2.0 Hz, 2-H) and 
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8.55 (1H, s, NH); δC/ppm (100 MHz; CDCl3) 17.8 (C-3'), 32.6 (CH2CO), 48.5 (CH2Cl), 113.7 (C-
2), 118.8 (C-4), 125.4 (C-6), 129.6 (C-5), 140.4 (C-1), 148.5 (C-3) and 174.6 (C=O).  
 
4-Chloro-N-[3-(hydroxymethyl)phenyl]butanamide 324g  
 
  
 
The procedure described for the synthesis of 4-chloro-N-(3-hydroxyphenyl)butanamide 
324a was employed, using 3-aminobenzylalcohol (1.02 g, 8.12 mmol), NaH (60 % dispersion 
in mineral oil; 0.52 g, 21 mmol) and 4-chlorobutanoyl chloride (0.68 mL, 8.1 mmol) in THF 
(15 mL), to yield 4-chloro-N-[3-(hydroxymethyl)phenyl]butanamide 324g as a light yellow 
solid (1.35 g, 73 %), m.p 80-82 °C; (Found: M+, 227.07341 C11H14ClNO2 requires: M
+, 
227.07131); ʋ/cm-1 1678 (C=O); δH/ppm (400 MHz; CDCl3) 2.16 (2H, m, 3'-CH2), 2.52 (2H, t, J 
= 7.6 Hz, CH2CO), 3.62 (2H, t, J = 6.4 Hz, CH2Cl), 4.62 (2H, s, 7-CH2), 7.02 (1H, d, J = 7.2 Hz, 4-
H), 7.27 (1H, t, J = 8.0 Hz, 5-H), 7.46 (1H, d, J = 8.4 Hz, 6-H), 7.56 (1H, s, 2-H), 7.62 (1H, s, OH) 
and 10.3 (1H, s, NH); δC/ppm (100 MHz; CDCl3) 26.8 (C-3'), 33.6 (CH2CO), 43.5 (CH2Cl), 62.7 
(CH2OH), 117.3 (C-2), 117.6 (C-6), 121.7 (C-4), 128.4 (C-5), 138.3 (C-1), 143.3 (C-3) and  164.5 
(C=O). 
 
3.3.3.1. Synthesis of diethyl propylphosphonates using Michaelis-Arbuzov 
methodology   
 
Diethyl [N-(3-hydroxyphenyl)carbamoyl]propylphosphonate 325a 
 
 
 
 
Triethyl phosphite (0.81 mL,  4.6 mmol) was added through a septum to 4-chloro-N-(3-
hydroxyphenyl)butanamide 324a (0.50 g, 2.3 mmol) under nitrogen in an oven-dried round-
bottomed flask equipped with a reflux condenser, and the resulting mixture was refluxed for 
ca. 9 h during which time the reaction was monitored by TLC. The cooled mixture was then 
stirred with hexane (20 mL) for ca. 30 minutes followed by decantation of the hexane layer 
N
H
O
Cl
OH
1
2
3
4
5
6
1'
2'
3'
7
4'
N
H
O
P
OH
O
O
O
1
2
3
4
5
6
1'
2'
3'
4'
  Experimental  
 
Page | 221  
to remove the excess triethyl phosphite; this was repeated three times. The crude product 
was purified by flash chromatography [on silica gel; elution with hexane-EtOAc (4:1)], and 
subsequent evaporation of the solvent in vacuo afforded diethyl [N(3-
hydroxyphenyl)carbamoyl)]propylphosphonate 325a as yellow oil (0.31 g, 65 %); (Found: M+, 
315.12483 C14H22NO5P requires: M
+, 315.12356); ʋ/cm-1 3308 (OH), 1678 (C=O), 1224 (P=O) 
and 1012 (P−OEt); δH/ppm (400 MHz; CDCl3) 1.31 (6H, t, J = 7.2 Hz, 2 × CH3), 2.16 (4H, m, 3'-
CH2 and CH2P), 2.68 (2H, m, CH2CO), 4.09 (4H, m, 2 × OCH2), 6.60 (1H, d, J = 8.0 Hz, 4-H), 
6.91 (1H, d, J = 7.6 Hz, 6-H), 7.10 (1H, t, J = 8.0 Hz, 5-H), 7.36 (1H, s, 2-H), 8.44 (1H, s, OH) 
and 8.92 (1H, s, NH); δC (100 MHz; CDCl3)  16.3 (d, JP–C = 6.0 Hz, 2 × CH3), 18.3 (d, JP–C = 15.2 
Hz, C-3'), 26.8 (d, JP–C = 136.2 Hz, CH2P), 36.5 (d, JP–C = 3.2 Hz, CH2CO), 62.3 (d, JP–C = 6.5 Hz, 2 
× OCH2), 107.5 (C-2), 111.3 (C-4), 112.3 (C-6), 129.1 (C-5), 138.9 (C-1), 157.7 (C-3) and 166.3 
(C=O). 
 
Diethyl [N-(3-methoxyphenyl)carbamoyl]propylphosphonate 325b   
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-
hydroxyphenyl)carbamoyl]propylphosphonate 325a was employed, using 4-chloro-N-(3-
methoxyphenyl)butanamide 324b (0.50 g, 2.2 mmol) and triethyl phosphite (0.76 mL, 4.3 
mmol). The crude product was purified by flash chromatography [on silica gel; elution with 
hexane-EtOAc (4:1)], and subsequent evaporation of the solvent in vacuo afforded diethyl 
[N-(3-methoxyphenyl)carbamoyl]propylphosphonate 325b as a clear oil (0.32 g, 66 %); 
(Found: M+, 329.14251 C15H24NO5P requires: M
+, 329.13921). ʋ/cm-1 1678 (C=O), 1251 (P=O) 
and 1039 (P−OEt); δH/ppm (400 MHz; CDCl3) 1.32 (6H, t, J = 6.8 Hz, 2 × CH3), 2.17 (2H, m, 
CH2P),  2.70 (2H, m, 3'-CH2), 3.08 (2H, t, J = 4.8 Hz, CH2CO), 3.77 (3H, s, OCH3), 4.10 (4H, m, 2 
× OCH2), 6.62 (1H, d, J = 6.4 Hz, 4-H), 7.06 (1H, d, J = 8.0 Hz, 6-H), 7.16 (1H, t, J = 8.4 Hz, 5-H), 
7.35 (1H, s, 2-H) and 9.00 (1H, s, NH); δC (100 MHz; CDCl3)  16.3 (d, JP–C = 6.5 Hz, 2 × CH3), 
18.1 (d, JP–C = 15.6 Hz, C-3'), 26.7 (d, JP–C = 142.1 Hz, CH2P), 36.3 (d, JP–C = 3.1 Hz, CH2CO), 55.3 
(OCH3), 62.4 (d, JP–C = 6.6 Hz, 2 × OCH2), 105.3 (C-2), 109.5 (C-4), 112.1 (C-6), 129.8 (C-5), 
139.8 (C-1), 159.7 (C-3) and 169.4 (C=O).  
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Diethyl [N-(3-bromophenyl)carbamoyl]propylphosphonate 325c   
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-
hydroxyphenyl)carbamoyl]propylphosphonate 325a was employed, using 4-chloro-N-(3-
bromophenyl)butanamide 324c (0.50 g, 1.8 mmol) and triethyl phosphite (0.62 mL, 3.6 
mmol). The crude product was purified by flash chromatography [on silica gel; elution with 
hexane-EtOAc (3:1)], and subsequent evaporation of the solvent in vacuo afforded diethyl 
[N-(3-bromophenyl)carbamoyl]propylphosphonate 325c as a brown oil (0.30 g, 63 %); 
(Found: M+, 377.04215 C14H21BrNO4P requires: M
+, 377.03916. ʋ/cm-1 1681 (C=O), 1232 
(P=O) and 1019 (P−OEt); δH/ppm (400 MHz; CDCl3) 1.32 (6H, t, J = 6.8 Hz, 2 × CH3), 1.80 (2H, 
m, CH2P),  2.17 (2H, m, 3'-CH2), 2.71 (2H, t, J = 7.6 Hz, CH2CO), 4.11 (4H, m, 2 × OCH2), 6.79 
(1H, t, J = 7.6 Hz, 5-H), 7.23 (2H, m, 4-H and 6-H), 7.48 (1H, t, J = 7.6 Hz, 5-H), 7.61 (1H, s, 2-
H) and 8.88 (1H, s, NH); δC (100 MHz; CDCl3) 16.4 (d, JP–C = 6.1 Hz, 2 × CH3), 18.2 (d, JP–C = 15.1 
Hz, C-3'), 27.2 (d, JP–C  = 142.2 Hz, CH2P), 36.7 (d, JP–C = 3.2 Hz, CH2CO), 62.4 (d, JP–C = 6.0 Hz, 2 
× OCH2), 118.1 (C-6), 122.6 (C-3), 123.1 (C-2), 126.7 (C-4), 130.0 (C-5), 139.8 (C-1) and 168.8 
(C=O).   
 
Diethyl [N-(3-fluorophenyl)carbamoyl]propylphosphonate 325d  
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-
hydroxyphenyl)carbamoyl]propylphosphonate 325a was employed, using 4-chloro-N-(3-
fluorophenyl)butanamide 324d (0.50 g, 2.3 mmol) and triethyl phosphite (0.80 mL, 4.6 
mmol). The crude product was purified by flash chromatography [on silica gel; elution with 
hexane-EtOAc (3:1)], and subsequent evaporation of the solvent in vacuo afforded diethyl 
[N-(3-fluorophenyl)carbamoyl]propylphosphonate 325d as a clear oil (0.25 g, 54 %); (Found: 
M+, 317.12162 C14H21FNO4P requires: M
+, 317.11922); ʋ/cm-1 1684 (C=O), 1233 (P=O) and 
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1021 (P−OEt); δH/ppm (400 MHz; CDCl3) 1.29 (6H, t, J = 7.2 Hz, 2 × CH3), 1.79 (2H, m, CH2P), 
2.18 (2H, m, 3'-CH2), 2.71 (2H, t, J = 6.8 Hz, CH2CO), 4.10 (4H, m, 2 × OCH2), 6.79 (1H, dd, J = 
6.4, 2.4 and 1.6 Hz, 4-H), 7.17 (1H, dd, J = 6.4 and 2.0 Hz, 6-H), 7.23 (1H, td, J = 6.4, 2.8 and 
1.6 Hz, 5-H) 7.52 (1H, dt, J = 2.4 and 1.6 Hz, 2-H) and 8.21 (1H, s, NH); δC (100 MHz; CDCl3) 
16.3 (d, JP–C = 6.1 Hz, 2 × CH3), 17.9 (d, JP–C = 15.6 Hz, C-3'), 26.8 (d, JP–C  = 143.9 Hz, CH2P), 
36.5 (d, JP–C = 3.2 Hz, CH2CO), 62.4 (d, JP–C = 6.6 Hz, 2 × OCH2), 107.6 (d, JF–C = 26.2 Hz, C-2), 
111.3 (d, JF–C = 21.2 Hz, C-4),  115.4 (d, JF–C = 2.8 Hz, C-6), 130.1 (d, JF–C = 9.0 Hz, C-5), 138.9 
(d, JF–C = 10.8 Hz, C-1), 162.7 (d, JF−C = 242.7 Hz, C-3) and 164.5 (C=O).  
 
Diethyl [N-(3-cyanophenyl)carbamoyl]propylphosphonate 325e  
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-hydroxyphenyl)carbamoyl]propyl 
phosphonate 325a was employed, using 4-chloro-N-(3-cyanophenyl)butanamide 324e (0.50 
g, 2.3 mmol) and triethyl phosphite (0.77 mL, 4.5 mmol). The crude product was purified by 
flash chromatography [on silica gel; elution with hexane-EtOAc (3:1)], and subsequent 
evaporation of the solvent in vacuo afforded diethyl [N-(3-cyanophenyl) 
carbamoyl]propylphosphonate 325e as a clear oil (0.28 g, 61 %). (Found: M+, 324.12408 
C15H21N2O4P requires: M
+, 324.12389); ʋ/cm-1 2218 (C≡N), 1652 (C=O), 1219 (P=O) and 1046 
(P−OEt); δH/ppm (400 MHz; CDCl3) 1.33 (6H, t, J = 7.2 Hz, 2 × CH3), 1.81 (2H, m, CH2P), 2.18 
(2H, m, 3'-CH2), 2.73 (2H, t, J = 7.2 Hz, CH2CO), 4.12 (4H, m, 2 × OCH2), 7.35 (2H, m, 4-H and 
6-H), 7.83 (1H, t, J = 8.4 Hz, 5-H), 7.95 (1H, t, J = 1.6 Hz, 2-H), and 9.83 (1H, s, NH); δC (100 
MHz; CDCl3) 16.4 (d, JP–C = 6.1 Hz, 2 × CH3), 18.2 (d, JP–C = 15.6 Hz, C-3'), 26.8 (d, JP–C  = 144.0 
Hz, CH2P), 36.8 (d, JP–C = 3.4 Hz, CH2CO), 62.4 (d, JP–C = 6.6 Hz, 2 × OCH2), 112.8 (C-3), 118.6 
(C≡N), 122.5 (C-2) 124.1 (C-5), 127.3 (C-6), 129.8 (C-4), 139.4 (C-1) and 172.2 (C=O).  
 
Diethyl [N-(3-nitrophenyl)carbamoyl]propylphosphonate 325f  
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The procedure described for the synthesis of diethyl [N-(3-hydroxyphenyl)carbamoyl]propyl 
phosphonate 325a was employed, using 4-chloro-N-(3-nitrophenyl)butanamide 324f (0.50 g, 
2.1 mmol) and triethyl phosphite (0.72 mL, 4.1 mmol). The crude product was purified by 
flash chromatography [on silica gel; elution with hexane-EtOAc (3:1)], and subsequent 
evaporation of the solvent in vacuo afforded diethyl[N-(3-nitrophenyl)carbamoyl]propyl 
phosphonate 325f as a yellow oil (0.35 g, 74 %); (Found: M+, 344.11837 C14H21N2O6P 
requires: M+, 344.11372); ʋ/cm-1 1683 (C=O), 1218 (P=O) and 1028 (P−OEt); δH/ppm (400 
MHz; CDCl3) 1.34 (6H, t, J = 7.2 Hz, 2 × CH3), 1.80 (2H, m, CH2P), 2.19 (2H, m, 3'-CH2), 2.75 
(2H, t, J = 7.6 Hz, CH2CO), 4.16 (4H, m, 2 × OCH2), 7.46 (1H, t, J = 8.4 Hz, 5-H), 7.91 (1H, dd, J 
= 8.0 and 1.6 Hz, 4-H), 8.15 (1H, dd, J = 8.4 and 1.6 Hz, 6-H), 8.39 (1H, t, J = 2.0 Hz, 2-H) and 
9.24 (1H, s, NH); δC (100 MHz; CDCl3) 16.8 (d, JP–C = 5.9 Hz, 2 × CH3), 18.2 (d, JP–C = 15.6 Hz, C-
3'), 33.7 (d, JP–C  = 131.4 Hz, CH2P), 48.9 (d, JP–C = 2.8 Hz, CH2CO), 62.0 (d, JP–C = 6.5 Hz, 2 × 
OCH2), 114.2 (C-2), 119.2 (C-4), 125.8 (C-6), 130.1 (C-5), 140.9 (C-1), 148.9 (C-3) and 175.1 
(C=O).  
 
Diethyl {N-[3-(hydroxymethyl)phenyl]carbamoyl}propylphosphonate 325g  
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-
hydroxyphenyl)carbamoyl]propylphosphonate 325a was employed, using 4-chloro-N-[3-
(hydroxymethyl)phenyl]butanamide 324g (0.50 g, 2.2 mmol) and triethyl phosphite (0.75 
mL, 4.4 mmol). The crude product was purified by flash chromatography [on silica gel; 
elution with hexane-EtOAc (4:1)], and subsequent evaporation of the solvent in vacuo 
afforded diethyl {N-[3-(hydroxymethyl)phenyl]carbamoyl}propylphosphonate 325g as a clear 
oil (0.31 g, 66 %); (Found: M+, 329.14287 C15H24NO5P requires: M
+, 329.13921); ʋ/cm-1 3173 
(OH), 1676 (C=O), 1236 (P=O) and 1048 (P−OEt); δH/ppm (400 MHz; CDCl3) 1.32 (6H, t, J = 
6.8 Hz, 2 × CH3), 1.79 (2H, m, CH2P), 2.17 (2H, m, 3'-CH2), 2.77 (2H, t, J = 6.8 Hz, CH2CO), 4.12 
(4H, m, 2 × OCH2), 4.48 (2H, s, CH2OH), 5.08 (1H, s, OH), 7.10 (1H, d, J = 7.6 Hz, 4-H), 7.27 
(1H, t, J = 8.0 Hz, 5-H), 7.45 (1H, d, J = 8.0 Hz, 6-H), 7.53 (1H, s, 2-H) and 8.61 (1H, s, NH); δC 
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(100 MHz; CDCl3) 16.3 (d, JP–C = 6.1 Hz, 2 × CH3), 18.2 (d, JP–C = 15.2 Hz, C-3'), 26.8 (d, JP–C  = 
138.9 Hz, CH2P), 36.8 (d, JP–C = 3.1 Hz, CH2CO), 62.2 (d, JP–C = 6.5 Hz, OCH2), 63.4 (CH2OH), 
118.1 (C-2), 118.9 (C-6), 122.8 (C-4), 129.4 (C-5), 138.9 (C-1), 139.8 (C-3) and 172.3 (C=O).  
 
3.3.3.2. Synthesis of propylphosphonic acids derivatives using TMSBr  
 
[N-(3-Hydroxyphenyl)carbamoyl]propylphosphonic acid 333a    
 
 
 
 
Trimethylsilyl bromide (0.21 mL, 1.6 mmol) was added to diethyl [N-(3-hydroxyphenyl)-
carbamoyl]propylphosphonate 325a (0.25 g, 0.79 mmol) in CH3CN (3 mL) and the mixture 
was heated in the microwave apparatus set to deliver 100 W of power, with a reaction 
temperature of 60 oC and reaction time of 10 min. After completion, the mixture was cooled 
to room temperature, treated with a 95:5 MeOH-H2O mixture and stirred for 30 min. The 
solvent was removed in vacuo and the residue chromatographed [preparative layer 
chromatography; elution with hexane-EtOAc-MeOH (1:1.5:1)] to yield [N-(3-
hydroxyphenyl)carbamoyl]propylphosphonic acid 333a as a yellow oil (0.10 g, 63 %); (Found: 
C, 46.47; H, 5.60; N, 5.47 %. C10H14NO5P requires C, 46.34; H, 5.44; N, 5.40 %); ʋ/cm
-1 3073 
(OH), 1681 (C=O) and 1228 (P=O); δH/ppm (400 MHz; DMSO-d6) 2.17 (4H, m, 3'-CH2 and 
CH2P), 2.70 (2H, m, CH2CO), 3.27 (2H, s, OH), 6.62 (1H, d, J = 8.0 Hz, 4-H), 6.87 (1H, d, J = 7.6 
Hz, 6-H), 7.12 (1H, t, J = 8.0 Hz, 5-H), 7.35 (1H, s, 2-H) and 8.34 (1H, s, NH); δC/ppm (100 
MHz; DMSO-d6) 18.0 (d, JP–C = 15.6 Hz, C-3'), 27.2 (d, JP–C = 141.7 Hz, CH2P), 36.2 (d, JP–C = 3.3 
Hz, CH2CO), 108.2 (C-2), 111.8 (C-4), 112.5 (C-6), 130.2 (C-5), 139.8 (C-1), 158.4 (C-3) and 
165.7 (C=O). 
 
[N-(3-Methoxyphenyl)carbamoyl]propylphosphonic acid 333b    
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The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]propyl 
phosphonic acid 333a was employed, using diethyl [N-(3-methoxyphenyl)carbamoyl]propyl 
phosphonate 325b (0.25 g, 0.76 mmol) in CH3CN (3 mL) and trimethylsilyl bromide (0.20 mL, 
1.5 mmol). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [N-(3-
methoxyphenyl)carbamoyl]propylphosphonic acid 333b as a yellow oil (0.11 g, 61 %); 
(Found: C, 48.51; H, 6.01; N, 5.20 %. C10H16NO5P requires C, 48.36; H, 5.90; N, 5.13 %); ʋ/cm
-
1, 1678 (C=O) and 1232 (P=O); δH/ppm (400 MHz; DMSO-d6) 1.93 (2H, m, CH2P), 2.17 (2H, m, 
3'-CH2), 2.81 (2H, t, J = 7.2 Hz, CH2CO), 3.78 (3H, s, OCH3), 5.71 (2H, s, 2 x OH), 6.62 (1H, d, J 
= 6.8 Hz, 4-H), 7.10 (1H, d, J = 8.0 Hz, 6-H), 7.17 (1H, t, J = 8.4 Hz, 5-H), 7.31 (1H, s, 2-H) and 
8.72 (1H, s, NH); δC/ppm (100 MHz; DMSO-d6) 18.3 (d, JP–C = 15.6 Hz, C-3'), 29.2 (d, JP–C = 
142.8 Hz, CH2P), 36.8 (d, JP–C = 3.2 Hz, CH2CO), 55.1 (OCH3), 104.8 (C-2), 110.2 (C-4), 112.4 (C-
6), 129.5 (C-5), 139.7 (C-1), 159.2 (C-3) and 172.3 (C=O).   
 
[N-(3-Bromophenyl)carbamoyl]propylphosphonic acid 333c    
 
 
 
 
The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]propyl 
phosphonic acid 333a was employed, using diethyl [N-(3-bromophenyl)carbamoyl]propyl 
phosphonate 325c (0.25 g, 0.66 mmol) in CH3CN (3 mL) and trimethylsilyl bromide (0.18 mL, 
1.3 mmol). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [N-
(3-bromophenyl)carbamoyl]propylphosphonic acid 333c as a light brown oil (0.098 g, 55 %); 
(Found: C, 37.35; H, 4.13; N, 4.30 %. C10H13BrNO4P requires C, 37.29; H, 4.07; N, 4.35 %); 
ʋ/cm-1 3127 (OH), 1685 (C=O) and 1224 (P=O); δH/ppm (400 MHz; DMSO-d6) 1.78 (2H, m, 
CH2P), 2.17 (2H, m, 3'-CH2), 2.68 (2H, t, J = 7.2 Hz, CH2CO), 5.99 (2H, s, 2 x OH), 6.80 (1H, t, J 
= 7.6 Hz, 5-H), 7.24 (1H, d, J = 6.4 Hz, 4-H), 7.45 (1H, d, J = 6.8 Hz, 6-H), 7.71 (1H, s, 2-H) and 
9.41 (1H, s, NH); δC/ppm (400 MHz; DMSO-d6) 17.8 (d, JP–C = 15.4 Hz, C-3'), 26.7 (d, JP–C  = 
144.0 Hz, CH2P), 36.4 (d, JP–C = 3.4 Hz, CH2CO), 115.8 (C-6), 118.4 (C-3), 122.2 (C-2), 127.6 (C-
4), 129.8 (C-5), 137.8 (C-1) and 167.9 (C=O).   
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[N-(3-Fluorophenyl)carbamoyl]propylphosphonic acid 333d    
 
 
 
 
The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]propyl 
phosphonic acid 333a was employed, using diethyl [N-(3-fluorophenyl)carbamoyl]propyl 
phosphonate 325d (0.25 g, 0.79 mmol) in CH3CN (3 mL) and trimethylsilyl bromide (0.21 mL, 
1.6 mmol). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [N-
(3-fluorophenyl)carbamoyl]propylphosphonic acid 333d as a clear oil (0.10 g, 57 %); (Found: 
C, 46.19; H, 5.09; N, 5.41 %. C10H13FNO4P requires C, 45.99; H, 5.02; N, 5.36 %); ʋ/cm
-1, 1656 
(C=O) and 1215 (P=O); δH/ppm (400 MHz; DMSO-d6) 1.78 (2H, m, CH2P), 2.17 (2H, m, 3'-
CH2), 2.70 (2H, t, J = 6.4 Hz, CH2CO), 4.82 (2H, s, 2 x OH), 6.77 (1H, ddd, J = 6.8, 2.0 and 1.6 
Hz, 4-H), 7.17 (1H, dd, J = 6.4 and 2.4 Hz, 6-H), 7.25 (1H, td, J = 6.4, 2.8 and 1.6 Hz, 5-H) 7.50 
(1H, dt, J = 6.8, 2.4 and 1.6 Hz, 2-H) and 8.87 (1H, s, NH); δC/ppm (100 MHz; DMSO-d6) 18.3 
(d, JP–C = 15.2 Hz, C-3'), 27.0 (d, JP–C  = 144.0 Hz, CH2P), 36.6 (d, JP–C = 3.1 Hz, CH2CO), 107.6 (d, 
JF–C = 26.2 Hz, C-2), 112.4 (d, JF–C = 21.2 Hz, C-4), 115.7 (d, JF–C = 2.7 Hz, C-6), 129.8 (d, JF–C = 
9.1 Hz, C-5), 139.5 (d, JF–C = 11.0 Hz, C-1), 164.2 (d, JF−C = 243.2 Hz, C-3) and 164.8 (C=O).  
 
  [N-(3-Cyanophenyl)carbamoyl]propylphosphonic acid 333e  
 
 
 
 
The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]propyl 
phosphonic acid 333a was employed, using diethyl [N-(3-cyanophenyl)carbamoyl]propyl 
phosphonate 325e (0.25 g, 0.77 mmol) in CH3CN (3 mL) and trimethylsilyl bromide (0.21 mL, 
1.5 mmol). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [N-
(3-cyanophenyl)carbamoyl]propylphosphonic acid 333e as a clear oil (0.11 g, 61 %); (Found: 
C, 49.37; H, 4.93; N, 10.39 %. C11H13N2O4P requires C, 49.26; H, 4.86; N, 10.44 %); (0.10 g, 59 
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%); ʋ/cm-1 3310 (OH), 2227 (C≡N), 1667 (C=O) and 1226 (P=O); δH/ppm (400 MHz; DMSO-d6) 
1.78 (2H, m, CH2P), 2.15 (2H, m, 3'-CH2), 2.75 (2H, t, J = 7.6 Hz, CH2CO), 5.87 (2H, s, 2 x OH), 
7.33 (2H, m, 4-H and 6-H), 7.80 (1H, t, J = 8.0 Hz, 5-H), 7.98 (1H, t, J = 1.6 Hz, 2-H), and 8.97 
(1H, s, NH); δC/ppm (400 MHz; DMSO-d6) 17.8 (d, JP–C = 15.6 Hz, C-3'), 27.1 (d, JP–C  = 142.7 
Hz, CH2P), 36.3 (d, JP–C = 3.2 Hz, CH2CO), 112.5 (C-3), 118.5 (C≡N), 123.2 (C-2) 124.6 (C-5), 
127.8 (C-6), 129.5 (C-4), 139.1 (C-1) and 173.5 (C=O).  
  
 [N-(3-Nitrophenyl)carbamoyl]propylphosphonic acid 333f    
 
 
 
 
The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]propyl 
phosphonic acid 333a was employed, using diethyl [N-(3-nitrophenyl)carbamoyl]propyl 
phosphonate 325f (0.25 g, 0.73 mmol) in CH3CN (3 mL) and trimethylsilyl bromide (0.13 mL, 
1.5 mmol). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:0.5)] to yield [N-
(3-nitrophenyl)carbamoyl]propylphosphonic acid 333f as a yellow oil (0.12 g, 66 %); (Found: 
C, 41.55; H, 4.63; N, 9.64 %. C10H13N2O6P requires C, 41.68; H, 4.55; N, 9.72 %); ʋ/cm
-1 3229 
(OH), 1664 (C=O) and 1239 (P=O); δH/ppm (400 MHz; DMSO-d6) 1.75 (2H, m, CH2P), 2.18 
(2H, m, 3'-CH2), 2.78 (2H, t, J = 7.6 Hz, CH2CO), 4.76 (2H, s, 2 x OH), 7.48 (1H, t, J = 8.0 Hz, 5-
H), 7.87 (1H, dd, J = 8.0 and 1.6 Hz, 4-H), 8.17 (1H, dd, J = 8.4 and 1.6 Hz, 6-H), 8.41 (1H, t, J = 
2.0 Hz, 2-H) and 9.34 (1H, s, NH); δC/ppm (400 MHz; DMSO-d6) 18.0 (d, JP–C = 15.4 Hz, C-3'), 
33.8 (d, JP–C  = 135.7 Hz, CH2P), 48.3 (d, JP–C = 3.2 Hz, CH2CO), 114.8 (C-2), 118.7 (C-4), 126.3 
(C-6), 129.7 (C-5), 141.2 (C-1), 148.3 (C-3) and 173.5 (C=O).  
 
 N-[3-(Hydroxymethyl)phenylcarbamoyl]propylphosphonic acid 333g   
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The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]propyl 
phosphonic acid 333a was employed, using diethyl {N-[3-(hydroxymethyl) 
phenyl]carbamoyl}propylphosphonate 325g (0.25 g, 0.79 mmol) in CH3CN (3 mL) and 
trimethylsilyl bromide (0.21 mL, 1.6 mmol). The solvent was removed in vacuo and the 
residue chromatographed [preparative layer chromatography; elution with hexane-EtOAc-
MeOH (1:1:1.5)] to yield N-[3-(hydroxymethyl)phenylcarbamoyl]propylphosphonic acid 333g 
as a clear oil ( 0.11 g, 60 %); (Found: C, 46.52; H, 5.61; N, 5.27 %. C11H16NO5P requires C, 
46.34; H, 5.44; N, 5.40 %); ʋ/cm-1 3267 (OH), 1687 (C=O) and 1232 (P=O); δH/ppm (400 MHz; 
DMSO-d6) 1.77 (2H, m, CH2P), 2.16 (2H, m, 3'-CH2), 2.77 (2H, t, J = 7.2 Hz, CH2CO), 3.68 (2H, 
s, 2 x OH), 4.46 (2H, s, CH2OH), 5.77 (1H, s, OH), 7.12 (1H, d, J = 7.6 Hz, 4-H), 7.25 (1H, t, J = 
8.0 Hz, 5-H), 7.48 (1H, d, J = 8.0 Hz, 6-H), 7.63 (1H, s, 2-H) and 8.78 (1H, s, NH); δC/ppm (400 
MHz; DMSO-d6) 19.9 (d, JP–C = 15.6 Hz, C-3'), 25.2 (d, JP–C  = 143.5 Hz, CH2P), 37.0 (d, JP–C = 3.3 
Hz, CH2CO), 67.7 (CH2OH), 118.2 (C-2), 120.6 (C-6), 122.3 (C-4), 129.1 (C-5), 138.5 (C-1), 
141.2 (C-3) and 171.2 (C=O). 
3.3.3.3. Synthesis of sodium hydrogen propylphosphonate derivatives 
 
Sodium hydrogen [N-(3-hydroxyphenyl)carbamoyl]propylphosphonate 334a 
 
 
  
 
[N-(3-Hydroxyphenyl)carbamoyl]propylphosphonic acid 333a (0.15 g, 0.58 mmol) was 
treated with a solution of NaOH (1.1 mol) in EtOH (0.55 mL) and the mixture was stirred for 
30 min. The solvent was removed in vacuo and the residue chromatographed [reverse-
phase column chromatography; elution with H2O-MeOH (1:1)] to yield sodium hydrogen [N-
(3-hydroxyphenyl)carbamoyl]propylphosphonate 334a as a pale yellow semi-solid (0.098 g, 
94 %); ʋ/cm-1 3317 (OH), 1682 (C=O) and 1215 (P=O); δH/ppm (400 MHz; D2O) 1.90 (2H, m, 
CH2P), 2.16 (2H, m, 3'-CH2), 2.73 (2H, m, CH2CO), 6.62 (1H, d, J = 7.9 Hz, 4-H), 6.85 (1H, d, J = 
7.6 Hz, 6-H), 7.11 (1H, t, J = 8.0 Hz, 5-H) and 7.33 (1H, s, 2-H); δC/ppm(100 MHz; D2O) 17.7 
(d, JP–C = 15.4 Hz, C-3'), 27.0 (d, JP–C = 143.7 Hz, CH2P), 37.3 (d, JP–C = 3.4 Hz, CH2CO), 108.5 (C-
2), 112.1 (C-4), 112.4 (C-6), 129.8 (C-5), 138.2 (C-1), 158.1 (C-3) and 166.3 (C=O). 
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Sodium hydrogen [N-(3-methoxyphenyl)carbamoyl]propylphosphonate 334b  
   
      
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]propylphosphonate 334a was employed, using [N-(3-
methoxyphenyl)carbamoyl]propylphosphonic acid 333b (0.15 g, 0.55 mmol) and a solution 
of NaOH (1.1 mol) in EtOH (0.52 mL). The solvent was removed in vacuo and the residue 
chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen [N-(3-methoxyphenyl)carbamoyl]propylphosphonate 334b as a light 
brown semi-solid (0.096 g, 92 %); ʋ/cm-1 3148 (OH), 1680 (C=O) and 1219 (P=O); δH/ppm 
(400 MHz; D2O) 1.87 (2H, m, CH2P), 2.16 (2H, m, 3'-CH2), 2.78 (2H, t, J = 7.2 Hz, CH2CO), 3.78 
(3H, s, OCH3), 6.60 (1H, d, J = 6.8 Hz, 4-H), 7.13 (1H, d, J = 8.0 Hz, 6-H), 7.20 (1H, t, J = 8.4 Hz, 
5-H) and 7.29 (1H, s, 2-H); δC/ppm (100 MHz; D2O) 18.0 (d, JP–C = 15.2 Hz, C-3'), 30.3 (d, JP–C = 
142.5 Hz, CH2P), 36.4 (d, JP–C = 2.8 Hz, CH2CO), 55.4 (OCH3), 105.2 (C-2), 109.7 (C-4), 112.7 (C-
6), 129.8 (C-5), 140.0 (C-1), 159.1 (C-3) and 172.6 (C=O).   
 
Sodium hydrogen [N-(3-bromophenyl)carbamoyl]propylphosphonate 334c 
 
  
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]propylphosphonate 334a was employed, using [N-(3-
bromophenyl)carbamoyl]propylphosphonic acid 333c (0.15 g, 0.47 mmol) and a solution of 
NaOH (1.1 mol) in EtOH (0.44 mL). The solvent was removed in vacuo and the residue 
chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen [N-(3-bromophenyl)carbamoyl]propylphosphonate 334c as a red-
brown semi-solid (0.097 g,  89 %); ʋ/cm-1 3209 (OH), 1648 (C=O) and 1221 (P=O); δH/ppm 
(400 MHz; D2O) 1.80 (2H, m, CH2P), 2.16 (2H, m, 3'-CH2), 2.71 (2H, t, J = 7.2 Hz, CH2CO), 6.79 
(1H, t, J = 7.6 Hz, 5-H), 7.24 (1H, t, J = 7.6 Hz, 4-H), 7.42 (1H, dd, J = 6.8 and 2.0 Hz, 6-H) and 
7.80 (1H, t, J = 2.0 Hz, 2-H); δC/ppm (100 MHz; D2O) 17.9 (d, JP–C = 15.6 Hz, C-3'), 26.3 (d, JP–C  
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= 143.8 Hz, CH2P), 37.0 (d, JP–C = 3.2 Hz, CH2CO), 115.5 (C-6), 118.6 (C-3), 122.8 (C-2), 127.6 
(C-4), 129.7 (C-5), 138.2 (C-1) and 165.7 (C=O).    
 
Sodium hydrogen [N-(3-fluorophenyl)carbamoyl]propylphosphonate 334d 
 
 
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]propylphosphonate 334a was employed, using [N-(3-
fluorophenyl)carbamoyl]propylphosphonic acid 333d (0.15 g, 0.57 mmol) and a solution of 
NaOH (1.1 mol) in EtOH (0.55 mL). The solvent was removed in vacuo and the residue 
chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen [N-(3-fluorophenyl)carbamoyl]propylphosphonate 334d as a cream 
semi-solid (0.11 g, 96 %); ʋ/cm-1 1684 (C=O) and 1231 (P=O); δH/ppm (400 MHz; D2O) 1.80 
(2H, m, CH2P), 2.15 (2H, m, 3'-CH2), 2.71 (2H, t, J = 6.4 Hz, CH2CO), 6.78 (1H, ddd, J = 6.8, 2.4 
and 1.6 Hz, 4-H), 7.16 (1H, dd, J = 6.4 and 1.6 Hz, 6-H), 7.24 (1H, td, J = 6.4, 2.8 and 1.6 Hz, 5-
H) and 7.50 (1H, dt, J = 6.8, 2.4 and 1.6 Hz, 2-H); δC/ppm (100 MHz; D2O) 17.8 (d, JP–C = 15.6 
Hz, C-3'), 26.5 (d, JP–C  = 142.0 Hz, CH2P), 36.4 (d, JP–C = 3.2 Hz, CH2CO), 107.7 (d, JF–C = 26.3 Hz, 
C-2), 112.6 (d, JF–C = 21.2 Hz, C-4),  116.2 (d, JF–C = 2.7 Hz, C-6), 129.5 (d, JF–C = 8.8 Hz, C-5), 
139.5 (d, JF–C = 11.2 Hz, C-1), 164.0 (d, JF−C = 243.1 Hz, C-3) and 168.7 (C=O).  
 
 Sodium hydrogen [N-(3-cyanophenyl)carbamoyl]propylphosphonate 334e 
 
 
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]propylphosphonate 334a was employed, using [N-(3-
cyanophenyl)carbamoyl]propylphosphonic acid 333e (0.15 g, 0.56 mmol) and a  solution of 
NaOH (1.1 mol) in EtOH (0.53 mL). The solvent was removed in vacuo and the residue 
chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen [N-(3-cyanophenyl)carbamoyl]propylphosphonate 334e as a pale 
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yellow semi-solid (0.12 g, 96 %); ʋ/cm-1 2231 (C≡N), 1678 (C=O) and 1219 (P=O); δH/ppm 
(400 MHz; D2O) 1.77 (2H, m, CH2P), 2.17 (2H, m, 3'-CH2), 2.72 (2H, t, J = 7.2 Hz, CH2CO), 7.35 
(2H, m, 4-H and 6-H), 7.79 (1H, t, J = 8.0 Hz, 5-H) and 8.01 (1H, t, J = 1.6 Hz, 2-H); δC/ppm 
(100 MHz; D2O) 18.1 (d, JP–C = 15.3 Hz, C-3'), 26.8 (d, JP–C  = 143.2 Hz, CH2P), 36.7 (d, JP–C = 3.3 
Hz, CH2CO), 112.4 (C-3), 118.2 (C≡N), 122.8 (C-2) 124.5 (C-5), 127.8 (C-6), 129.8 (C-4), 138.7 
(C-1) and 173.7 (C=O).   
 
Sodium hydrogen [N-(3-nitrophenyl)carbamoyl]propylphosphonate 334f 
 
 
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]propylphosphonate 334a was employed, using [N-(3-
nitrophenyl)carbamoyl]propylphosphonic acid 333f (0.15 g, 0.52 mmol) and a solution of 
NaOH (1.1 mol) in EtOH (0.49 mL). The solvent was removed in vacuo and the residue 
chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen [N-(3-nitrophenyl)carbamoyl]propylphosphonate 334f as a yellow 
semi-solid (0.12 g, 96 %); ʋ/cm-1 3150 (OH), 1684 (C=O) and 1230 (P=O); δH/ppm (400 MHz; 
D2O) 1.78 (2H, m, CH2P), 2.16 (2H, m, 3'-CH2), 2.77 (2H, t, J = 7.6 Hz, CH2CO), 7.51 (1H, t, J = 
8.0 Hz, 5-H), 7.88 (1H, dd, J = 8.0 and 1.6 Hz, 4-H), 8.20 (1H, dd, J = 8.4 and 1.6 Hz, 6-H) and 
8.38 (1H, t, J = 2.0 Hz, 2-H); δC/ppm (100 MHz; D2O) 18.4 (d, JP–C = 15.6 Hz, C-3'), 32.9 (d, JP–C  
= 140.8 Hz, CH2P), 46.7 (d, JP–C = 3.1 Hz, CH2CO), 114.5 (C-2), 119.2 (C-4), 126.8 (C-6), 129.7 
(C-5), 140.8 (C-1), 148.5 (C-3) and 170.1 (C=O).  
 
Sodium hydrogen {N-[3-(hydroxymethyl)phenyl]carbamoyl}propylphosphonate 334g   
 
 
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]propylphosphonate 334a was employed, using [N-(3-
(hydroxymethyl)phenylcarbamoyl]propylphosphonic acid 333g (0.15 g, 0.55 mmol) and a 
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solution of NaOH (1.1 mol) in EtOH (0.52 mL). The solvent was removed in vacuo and the 
residue chromatographed [reverse-phase column chromatography; elution with H2O-MeOH 
(1:1)] to yield sodium hydrogen {N-[3-(hydroxymethyl)phenyl]carbamoyl}propylphosphonate 
334g as a pale yellow semi-solid (0.092 g, 85 %); ʋ/cm-1 1675 (C=O) and 1231 (P=O); δH/ppm 
(400 MHz; D2O) 1.80 (2H, m, CH2P), 2.18 (2H, m, 3'-CH2), 2.77 (2H, t, J = 7.2 Hz, CH2CO), 4.47 
(2H, s, CH2OH), 7.10 (1H, d, J = 7.6 Hz, 4-H), 7.23 (1H, t, J = 8.0 Hz, 5-H), 7.46 (1H, d, J = 8.0 
Hz, 6-H) and 7.56 (1H, s, 2-H); δC/ppm (100 MHz; D2O) 18.0 (d, JP–C = 15.5 Hz, C-3'), 26.7 (d, 
JP–C  = 143.8 Hz, CH2P), 36.5 (d, JP–C = 3.4 Hz, CH2CO), 64.2 (CH2OH), 118.2 (C-2), 118.8 (C-6), 
122.6 (C-4), 129.8 (C-5), 138.2 (C-1), 139.8 (C-3) and 166.5 (C=O).  
 
3.3.4. Reaction of 3-substituted anilines with 5-chloropentanoyl chloride  
 
5-Chloro-N-(3-hydroxyphenyl)pentanamide 326a   
 
 
 
 
To a stirred solution of 3-aminophenol  (1.50 g, 14.0 mmol) in THF (30 mL) under nitrogen 
was added NaH (60 % dispersion in mineral oil; 0.60 g, 24 mmol) in small portions to permit 
controlled evolution of hydrogen. 5-Chloropentanoyl chloride (1.67 mL, 14.0 mmol) was 
then added through a septum and the resulting solution was stirred for ca. 6 h. The solvent 
was evaporated in vacuo and the residue dissolved in EtOAc (2 x 50 mL). The organic 
solution was washed sequentially with satd. aq. NaHCO3 (2 × 100 mL), water (2 x 100 mL) 
and brine (2 × 100 mL). The aqueous washings were extracted with EtOAc and the combined 
organic solutions were dried (anhydr. MgSO4). Evaporation of the solvent in vacuo afforded 
5-chloro-N-(3-hydroxyphenyl)pentanamide 326a as a brown gum (2.42 g, 76 %); (Found: M+, 
227.07866 C11H14ClNO2 requires: M
+, 227.07131); ʋmax (solid deposit/cm
-1) 1672 (C=O); 
δH/ppm (400 MHz; CDCl3) 1.88 (4H, m, 3-CH2 and 4-CH2), 2.41 (2H, t, J = 6.8 Hz, CH2CO), 3.57 
(2H, t, J = 6.0 Hz, CH2Cl), 6.80 (1H, d, J = 7.2 Hz, 4'-H), 7.18 (1H, d, J = 8.0 Hz, 6'-H), 7.25 (1H, 
t, J = 8.0 Hz, 5'-H), 7.28 (1H, s, OH), 7.42 (1H, s, 2'-H) and 7.46 (1H, s, NH); δC/ppm (100 MHz; 
CDCl3) 22.2 (C-4), 31.8 (C-3), 33.5 (CH2CO), 44.3 (CH2Cl), 113.3 (C-2'), 116.9 (C-4'), 117.1 (C-
6'), 129.5 (C-5'), 139.0 (C-1'), 151.0 (C-3') and 171.7 (C=O).  
NH
O
OH
Cl
1
2
3
4
51'
2'
3'
4'
5'
6'
  Experimental  
 
Page | 234  
5-Chloro-N-(3-methoxyphenyl)pentanamide 326b 246   
 
 
 
 
The procedure described for the synthesis of 5-chloro-N-(3-hydroxyphenyl)pentanamide 
326a was employed, using 3-methoxyaniline (0.91 mL, 8.1 mmol), NaH (60 % dispersion in 
mineral oil; 0.36 g, 15 mmol) and 5-chloropentanoyl chloride (0.97 mL, 8.1 mmol) in THF (15 
mL), to yield 5-chloro-N-(3-methoxyphenyl)pentanamide 326b as a yellow gum (1.41 g, 72 
%); ʋmax (solid deposit/cm
-1) 1682 (C=O); δH/ppm (400 MHz; CDCl3) 1.78 (4H, m, 3-CH2 and 4-
CH2), 2.29 (2H, t, J = 6.8 Hz, CH2CO), 3.50 (2H, t, J = 6.0 Hz, CH2Cl), 3.74 (3H, s, OCH3), 6.60 
(1H, dd, J = 6.4 and 1.6 Hz, 4'-H), 6.95 (1H, d, J = 7.6 Hz, 6'-H), 7.14 (1H, t, J = 8.0 Hz, 5'-H), 
7.29 (1H, t, J = 2.0 Hz, 2'-H) and 8.12 (1H, s, NH); δC/ppm (100 MHz; CDCl3) 22.8 (C-4), 31.8 
(C-3), 36.7 (CH2CO), 44.5 (CH2Cl), 55.3 (OCH3), 105.6 (C-2'), 110.2 (C-6'), 111.8 (C-4'), 129.7 
(C-5'), 130.0 (C-1'), 160.2 (C-3') and 170.5 (C=O).   
 
N-(3-Bromophenyl) 5-chloropentanamide 326c 247 
 
 
 
 
The procedure described for the synthesis of 4-chloro-N-(3-hydroxyphenyl)pentanamide 
326a was employed, using 3-bromoaniline (0.63 mL, 5.80 mmol), NaH (60 % dispersion in 
mineral oil; 0.26 g, 10.8 mmol) and 5-chloropentanoyl chloride (0.69 mL, 5.80 mmol) in THF 
(15 mL), to yield N-(3-bromophenyl) 5-chloropentanamide 326c as a brown gum (1.10 g, 65 
%); ʋmax (solid deposit/cm
-1) 1676 (C=O); δH/ppm (400 MHz; CDCl3) 1.80 (4H, m, 3-CH2 and 4-
CH2), 2.32 (2H, t, J = 6.8 Hz, CH2CO), 3.51 (2H, t, J = 6.8 Hz, CH2Cl), 7.11 (1H, t, J = 8.0 Hz, 5-
H), 7.17 (1H, d, J = 8.0 Hz, 4-H), 7.37 (1H, d, J = 8.0 Hz, 6-H), 7.74 (1H, s, 2-H) and 8.18 (1H, s, 
NH); δC/ppm (100 MHz; CDCl3) 22.2 (C-4'), 31.8 (C-3'), 33.5 (CH2CO), 44.3 (CH2Cl), 113.8 (C-
6), 117.4 (C-3), 117.7 (C-2), 128.3 (C-4), 130.4 (C-5), 139.4 (C-1) and 172.2 (C=O).   
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5-Chloro-N-(3-fluorophenyl)pentanamide 326d 247 
 
 
 
 
The procedure described for the synthesis of 5-chloro-N-(3-hydroxyphenyl)pentanamide 
326a was employed, using 3-fluoroaniline (1.05 mL, 5.80 mmol), NaH (60 % dispersion in 
mineral oil; 0.26 g, 11 mmol) and 5-chloropentanoyl chloride (0.69 mL, 5.8 mmol) in THF (15 
mL), to yield 5-chloro-N-(3-fluorophenyl)pentanamide 326d as a light brown gum (0.96 g, 72 
%); ʋmax (solid deposit/cm
-1) 1669 (C=O); δH/ppm (400 MHz; CDCl3) 1.93 (4H, m, 3'-CH2 and 
4'-CH2), 2.55 (2H, t, J = 6.8 Hz, CH2CO), 3.63 (2H, t, J = 6.8 Hz, CH2Cl), 6.93 (1H, ddd, J =  6.4, 
2.4 and 0.8 Hz, 4-H), 6.99 (1H, dt, J = 6.4 and 1.6 Hz, 5-H), 7.03 (1H, dd, J = 6.8 and 0.8 Hz, 6-
H), 7.31 (1H, td, J = 6.4, 2.0 and 1.2 Hz, 2-H) and 8.23 (1H, s, NH); δC/ppm (100 MHz; CDCl3) 
22.8 (C-4'), 32.5 (C-3'), 36.2 (CH2CO), 44.2 (CH2Cl), 107.8 (d, JF–C = 26.2 Hz, C-2), 111.1 (d, JF–C 
= 21.4 Hz, C-4), 114.6 (d, JF–C = 3.8 Hz, C-6), 129.8 (d, JF–C = 10.2 Hz, C-5), 139.7 (d, JF–C = 11.3 
Hz, C-1), 163.6 (d, JF–C = 241.8 Hz, C-3) and 173.2 (C=O).    
 
5-Chloro-N-(3-cyanophenyl)pentanamide 326e  
 
 
 
 
The procedure described for the synthesis of 5-chloro-N-(3-hydroxyphenyl)pentanamide 
326a was employed, using 3-aminobenzonitrile (1.20 g, 10.1 mmol), NaH (60 % dispersion in 
mineral oil; 0.54 g, 23 mmol) and 5-chloropentanoyl chloride (1.20 mL, 10.1 mmol) in THF 
(15 mL), to yield 5-chloro-N-(3-cyanophenyl)pentanamide 326e as a yellow viscous oil (2.00 
g, 84 %); (Found: M+, 236.07431 C12H13ClN2O requires: M
+, 236.07164); ʋmax (thin film/cm
-1) 
2223 (C≡N), 1689 (C=O); δH/ppm (400 MHz; CDCl3) 1.88 (4H, m, 3'-CH2 and 4'-CH2), 2.43 (2H, 
t, J = 6.8 Hz, CH2CO), 3.57 (2H, t, J = 6.2 Hz, CH2Cl), 7.39 (2H, m, 4-H and 6-H), 7.54 (1H, s, 
NH), 7.72 (1H, t, J = 7.2 Hz, 5-H) and 7.93 (1H, s, 2-H); δC/ppm (100 MHz; CDCl3) 22.6 (C-4'), 
31.8 (C-3'), 36.5 (CH2CO), 44.5 (CH2Cl), 112.9 (C-3), 118.5 (C=N), 122.8 (C-2), 123.8 (C-5), 
127.6 (C-6), 129.9 (C-4), 138.7 (C-1) and 171.0 (C=O).  
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5-Chloro-N-(3-nitrophenyl)pentanamide 326f  
 
 
 
 
The procedure described for the synthesis of 5-chloro-N-(3-hydroxyphenyl)pentanamide 
326a was employed, using 3-nitroaniline (1.01 g, 7.27 mmol), NaH (60 % dispersion in 
mineral oil; 0.33 g, 13 mmol) and 5-chloropentanoyl chloride (0.87 mL, 7.3 mmol) in THF (15 
mL), to yield 5-chloro-N-(3-nitrophenyl)pentanamide 326f as a dark yellow viscous oil (1.60 
g, 86 %); (Found: M+, 256.06328 C11H13ClN2O3 requires: M
+, 256.06147); ʋmax (solid 
deposit/cm-1) 1685 (C=O); δH/ppm (400 MHz; CDCl3) 1.85 (4H, m, 3'-CH2 and 4'-CH2), 2.46 
(2H, t, J = 6.8 Hz, CH2CO), 3.53 (2H, t, J = 6.4 Hz, CH2Cl), 7.43 (1H, t, J = 8.4 Hz, 5-H), 7.90 (2H, 
m, 4-H and 6-H), 8.34 (1H, s, NH) and 8.40 (1H, t, J = 2.0 Hz, 2-H); δC/ppm (100 MHz; CDCl3) 
22.5 (C-4'), 31.6 (C-3'), 36.4 (CH2CO), 44.4 (CH2Cl), 113.3 (C-2), 118.7 (C-4), 125.7 (C-6), 129.9 
(C-5), 139.8 (C-1), 148.6 (C-3) and 173.3 (C=O).  
 
5-Chloro-N-[3-(hydroxymethyl)phenyl]pentanamide 326g  
 
 
 
 
The procedure described for the synthesis of 5-chloro-N-(3-hydroxyphenyl)pentanamide 
326a was employed, using 3-aminobenzylalcohol (1.02 g, 8.12 mmol), NaH (60 % dispersion 
in mineral oil; 0.52 g, 21 mmol) and 5-chloropentanoyl chloride (0.97 mL, 8.1 mmol) in THF 
(15 mL), to yield 5-chloro-N-[3-(hydroxymethyl)phenyl]pentanamide 326g as a brown gum 
(1.51 g, 77 %); (Found: M+, 241.09015 C12H16ClNO2 requires: M
+, 241.08696); ʋmax (solid 
deposit/cm-1) 1684 (C=O); δH/ppm (400 MHz; CDCl3) 2.12 (4H, m, 3'-CH2 and 4'-CH2), 2.49 
(2H, t, J = 6.8 Hz, CH2CO), 3.59 (2H, t, J = 6.4 Hz, CH2Cl), 4.58 (2H, s, 7-CH2), 7.02 (1H, d, J = 
7.6 Hz, 4-H), 7.11 (1H, d, J = 7.6 Hz, 6-H), 7.23 (1H, t, J = 7.6 Hz, 5-H), 7.59 (1H, s, 2-H), 7.76 
(1H, s, OH) and 8.00 (1H, s, NH); δC/ppm (100 MHz; CDCl3) 22.7 (C-4'), 32.1 (C-3'), 36.8 
(CH2CO), 44.6 (CH2Cl), 63.1 (CH2OH), 117.1 (C-2), 117.8 (C-6), 122.3 (C-4), 128.6 (C-5), 138.6 
(C-1), 142.9 (C-3) and  168.9 (C=O).  
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3.3.4.1. Synthesis of diethyl butylphosphonates via Michaelis-Arbuzov methodology   
 
Diethyl [N-(3-hydroxyphenyl)carbamoyl]butylphosphonate 327a 
 
 
 
 
Triethyl phosphite (0.76 mL,  4.4 mmol) was added through a septum to 5-chloro-N-(3-
hydroxyphenyl)pentanamide 326a (0.50 g, 2.2 mmol) under nitrogen in an oven-dried 
round-bottomed flask equipped with a reflux condenser, and the resulting mixture was 
refluxed for ca. 9 h during which time the reaction was monitored by TLC. The cooled 
mixture was then stirred with hexane (20 mL) for ca. 30 minutes followed by decantation of 
the hexane layer to remove the excess triethyl phosphite; this was repeated three times. 
The crude product was purified by flash chromatography [on silica gel; elution with hexane-
EtOAc (4:1)], and subsequent evaporation of the solvent in vacuo afforded diethyl [N(3-
hydroxyphenyl)carbamoyl)]butylphosphonate 327a as clear oil (0.22 g, 55 %); (Found: M+, 
329.14287 C15H24NO5P requires: M
+, 329.13921); ʋ/cm-1 3128 (OH), 1672 (C=O), 1219 (P=O) 
and 1018 (P−OEt); δH/ppm (400 MHz; CDCl3) 1.19 (2H, m, 4'-CH2), 1.30 (6H, t, J = 7.2 Hz, 2 × 
CH3), 1.77 (2H, m, CH2P), 1.98 (2H, m, 3'-CH2), 2.38 (2H, t, J = 6.4 Hz, CH2CO), 4.12 (4H, m, 2 × 
OCH2), 6.63 (1H, d, J = 7.2 Hz, 4-H), 6.87 (1H, d, J = 7.6 Hz, 6-H), 7.12 (1H, t, J = 7.6 Hz, 5-H), 
7.40 (1H, s, 2-H), 7.64 (1H, s, OH) and 8.46 (1H, s, NH); δC (100 MHz; CDCl3)  16.3 (d, JP–C = 6.0 
Hz, 2 × CH3), 21.9 (d, JP–C = 15.2 Hz, C-4'), 23.6 (d, JP–C = 141.2 Hz, CH2P), 26.6 (d, JP–C = 4.8 Hz, 
C-3'), 36.5 (d, JP–C = 3.2 Hz, CH2CO), 62.1 (d, JP–C = 6.5 Hz, 2 × OCH2), 107.7 (C-2), 111.8 (C-4), 
112.6 (C-6), 129.1 (C-5), 138.7 (C-1), 158.2 (C-3) and 164.8 (C=O). 
 
Diethyl [N-(3-methoxyphenyl)carbamoyl]butylphosphonate 327b   
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-hydroxyphenyl)carbamoyl]- 
butylphosphonate 327a was employed, using 5-chloro-N-(3-methoxyphenyl)pentanamide 
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326b (0.50 g, 2.1 mmol) and triethyl phosphite (0.72 mL, 4.1 mmol). The crude product was 
purified by flash chromatography [on silica gel; elution with hexane-EtOAc (3:1)], and 
subsequent evaporation of the solvent in vacuo afforded diethyl [N-(3-
methoxyphenyl)carbamoyl]butylphosphonate 327b as a brown oil (0.32 g, 66 %); (Found: 
M+, 343.15836 C16H26NO5P requires: M
+, 343.15486); ʋ/cm-1 1681 (C=O), 1237 (P=O) and 
1038 (P−OEt); δH/ppm (400 MHz; CDCl3) 1.28 (2H, m, 4'-CH2), 1.31 (6H, t, J = 6.8 Hz, 2 × CH3), 
2.06 (4H, m, 3'-CH2 and CH2P), 2.39 (2H, t, J = 6.4 Hz, CH2CO), 3.80 (3H, OCH3), 4.13 (4H, m, 2 
× OCH2), 6.65 (1H, d, J = 8.4 Hz, 4-H), 6.93 (1H, d, J = 7.2 Hz, 6-H), 7.10 (1H, s, 2-H), 7.20 (1H, 
t, J = 8.0 Hz, 5-H) and 7.30 (1H, s, NH); δC (100 MHz; CDCl3)  16.2 (d, JP–C = 6.6 Hz, 2 × CH3), 
22.2 (d, JP–C = 15.2 Hz, C-4'), 23.4 (d, JP–C = 141.2 Hz, CH2P), 26.7 (d, JP–C = 4.7 Hz, C-3'), 36.5 
(d, JP–C = 4.2 Hz, CH2CO), 55.2 (OCH3), 62.4 (d, JP–C = 6.5 Hz, 2 × OCH2), 105.5 (C-2), 109.5 (C-
4), 112.4 (C-6), 129.9 (C-5), 139.5 (C-1), 160.2 (C-3) and 167.3 (C=O). 
  
Diethyl [N-(3-bromophenyl)carbamoylbutylphosphonate 327c   
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-hydroxyphenyl)carbamoyl] 
butylphosphonate 327a was employed, using 5-chloro-N-(3-bromophenyl)pentanamide 
326c (0.50 g, 1.7 mmol) and triethyl phosphite (0.58 mL, 3.4 mmol). The crude product was 
purified by flash chromatography [on silica gel; elution with hexane-EtOAc (3:1)], and 
subsequent evaporation of the solvent in vacuo afforded diethyl [N-(3-
bromophenyl)carbamoyl]butylphosphonate 327c as a brown oil (0.30 g, 63 %); (Found: M+, 
391.05517 C15H23BrNO4P requires: M
+, 391.05481; ʋ/cm-1 1685 (C=O), 1221 (P=O) and 1029 
(P−OEt); δH/ppm (400 MHz; CDCl3) 1.17 (2H, m, 4'-CH2), 1.27 (6H, t, J = 6.8 Hz, 2 × CH3), 1.79 
(2H, m, CH2P), 1.99 (2H, m, 3'-CH2), 2.37 (2H, t, J = 6.4 Hz, CH2CO), 4.12 (4H, m, 2 × OCH2), 
6.78 (1H, t, J = 7.6 Hz, 5-H), 7.25 (1H, d, J = 7.6 Hz, 4-H), 7.31 (1H, d, J = 7.2 Hz, 6-H), 7.48 
(1H, s, 2-H) and 8.36 (1H, s, NH); δC (100 MHz; CDCl3) 16.3 (d, JP–C = 6.6 Hz, 2 × CH3), 22.1 (d, 
JP–C = 15.6 Hz, C-4'), 23.3 (d, JP–C = 141.4 Hz, CH2P), 26.4 (d, JP–C = 4.8 Hz, C-3'), 36.4 (d, JP–C = 
3.8 Hz, CH2CO), 62.8 (d, JP–C = 6.5 Hz, 2 × OCH2), 115.6 (C-6), 118.3 (C-3), 122.6 (C-2), 126.4 
(C-4), 129.7 (C-5), 139.7 (C-1) and 168.1 (C=O).   
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Diethyl [N-(3-fluorophenyl)carbamoyl]butylphosphonate 327d  
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-
hydroxyphenyl)carbamoyl]butylphosphonate 327a was employed, using 5-chloro-N-(3-
fluorophenyl)pentanamide 326d (0.50 g, 2.2 mmol) and triethyl phosphite (0.75 mL, 4.4 
mmol). The crude product was purified by flash chromatography [on silica gel; elution with 
hexane-EtOAc (3:1)], and subsequent evaporation of the solvent in vacuo afforded diethyl 
[N-(3-fluorophenyl)carbamoyl]butylphosphonate 327d as a clear oil (0.25 g, 54 %); (Found: 
M+, 331.13529 C15H23FNO4P requires: M
+, 331.13487); ʋ/cm-1 1653 (C=O), 1231 (P=O) and 
1023 (P−OEt); δH/ppm (400 MHz; CDCl3) 1.22 (2H, m, 4'-CH2), 1.31 (6H, t, J = 7.2 Hz, 2 × CH3), 
1.91 (2H, m, CH2P), 2.10 (2H, m, 3'-CH2), 2.38 (2H, t, J = 6.4 Hz, CH2CO), 4.12 (4H, m, 2 × 
OCH2), 6.81 (1H, ddd, J = 6.4, 2.4 and 1.6 Hz, 4-H), 7.17 (1H, d, J = 6.4 Hz, 6-H), 7.25 (1H, td, J 
= 6.8, 2.8 and 1.2 Hz, 5-H) 7.43 (1H, dt, J = 6.4 and 2.4 Hz, 2-H) and 7.98 (1H, s, NH); δC (100 
MHz; CDCl3) 16.4 (d, JP–C = 6.6 Hz, 2 × CH3), 22.0 (d, JP–C = 15.6 Hz, C-4'), 23.6 (d, JP–C = 140.8 
Hz, CH2P), 26.4 (d, JP–C = 4.5 Hz, C-3'), 36.4 (d, JP–C = 4.2 Hz, CH2CO), 63.1 (d, JP–C = 6.7 Hz, 2 × 
OCH2), 108.2 (d, JF–C = 25.7 Hz, C-2), 111.4 (d, JF–C = 20.8 Hz, C-4),  115.6 (d, JF–C = 3.1 Hz, C-6), 
129.9 (d, JF–C = 8.7 Hz, C-5), 138.7 (d, JF–C = 11.3 Hz, C-1), 163.2 (d, JF−C = 241.2 Hz, C-3) and 
168.3 (C=O).  
 
Diethyl [N-(3-cyanophenyl)carbamoyl]butylphosphonate 327e  
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-hydroxyphenyl)carbamoyl]butyl- 
phosphonate 327a was employed, using 5-chloro-N-(3-cyanophenyl)pentanamide 326e 
(0.50 g, 2.1 mmol) and triethyl phosphite (0.72 mL, 4.2 mmol). The crude product was 
purified by flash chromatography [on silica gel; elution with hexane-EtOAc (3:1)], and 
subsequent evaporation of the solvent in vacuo afforded diethyl [N-(3-
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cyanophenyl)carbamoyl]butylphosphonate 327e as a clear oil (0.28 g, 61 %); (Found: M+, 
338.14137 C156H23N2O4P requires: M
+, 338.13954); ʋ/cm-1 2238 (C≡N), 1667 (C=O), 1218 
(P=O) and 1046 (P−OEt); δH/ppm (400 MHz; CDCl3) 1.19 (2H, m, 4'-CH2), 1.34 (6H, t, J = 7.2 
Hz, 2 × CH3), 1.70 (2H, m, CH2P), 1.92 (2H, m, 3'-CH2), 2.43 (2H, t, J = 6.8 Hz, CH2CO), 4.14 
(4H, m, 2 × OCH2), 7.38 (2H, t, J = 7.2 Hz, 5-H), 7.64 (1H, d, J = 5.8 Hz, 4-H), 7.72 (1H, d, J = 7.6 
Hz, 6-H) 7.93 (1H, s, 2-H) and 9.79 (1H, s, NH); δC (100 MHz; CDCl3) 16.3 (d, JP–C = 6.5 Hz, 2 × 
CH3), 22.4 (d, JP–C = 15.6 Hz, C-4'), 23.5 (d, JP–C = 142.0 Hz, CH2P), 26.3 (d, JP–C = 4.8 Hz, C-3'), 
37.1 (d, JP–C = 3.9 Hz, CH2CO), 62.6 (d, JP–C = 6.7 Hz, 2 × OCH2), 112.6 (C-3), 118.8 (C≡N), 122.6 
(C-2), 124.6 (C-5), 127.2 (C-6), 129.8 (C-4), 139.8 (C-1) and 173.5 (C=O).  
 
Diethyl [N-(3-nitrophenyl)carbamoyl]butylphosphonate 327f  
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-hydroxyphenyl)carbamoyl]butyl 
phosphonate 326a was employed, using 5-chloro-N-(3-nitrophenyl)pentanamide 326f (0.50 
g, 2.0 mmol) and triethyl phosphite (0.68 mL, 3.9 mmol). The crude product was purified by 
flash chromatography [on silica gel; elution with hexane-EtOAc (3:1)], and subsequent 
evaporation of the solvent in vacuo afforded diethyl [N-(3-nitrophenyl)carbamoyl]butyl 
phosphonate 327f as a yellow oil (0.35 g, 74 %); (Found: M+, 358.13018 C15H23N2O6P 
requires: M+, 358.12937); ʋ/cm-1 1683 (C=O), 1218 (P=O) and 1028 (P−OEt); δH/ppm (400 
MHz; CDCl3) 1.16 (2H, m, 4'-CH2), 1.30 (6H, t, J = 7.6 Hz, 2 × CH3), 1.79 (4H, m, 3'-CH2 and 
CH2P), 2.46 (2H, t, J = 6.8 Hz, CH2CO), 4.07 (4H, m, 2 × OCH2), 7.47 (1H, s, 2-H), 7.49 (1H, t, J = 
8.4 Hz, 5-H), 7.96 (2H, m, 4-H and 6-H) and 8.36 (1H, s, NH); δC (100 MHz; CDCl3) 16.5 (d, JP–C 
= 6.4 Hz, 2 × CH3), 22.1 (d, JP–C = 15.6 Hz, C-4'), 23.4 (d, JP–C = 141.2 Hz, CH2P), 26.6 (d, JP–C = 
4.8 Hz, C-3'), 36.4 (d, JP–C = 4.5 Hz, CH2CO), 62.4 (d, JP–C = 6.5 Hz, 2 × OCH2), 113.8 (C-2), 119.1 
(C-4), 124.9 (C-6), 129.8 (C-5), 140.7 (C-1), 149.1 (C-3) and 173.4 (C=O).  
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Diethyl {N-[3-(hydroxymethyl)phenyl]carbamoyl}butylphosphonate 327g  
 
 
 
 
 
The procedure described for the synthesis of diethyl [N-(3-hydroxyphenyl)carbamoyl]- 
butylphosphonate 327a was employed, using 5-chloro-N-[3-(hydroxymethyl)phenyl]- 
pentanamide 326g (0.50 g, 2.1 mmol) and triethyl phosphite (0.72 mL, 4.1 mmol). The crude 
product was purified by flash chromatography [on silica gel; elution with hexane-EtOAc 
(4:1)], and subsequent evaporation of the solvent in vacuo afforded diethyl {N-[3-
(hydroxymethyl)phenyl]carbamoyl}butylphosphonate 327g as a clear oil (0.31 g, 66 %); 
(Found: M+, 343.15504 C16H26NO5P requires: M
+, 343.15486); ʋ/cm-1 3173 (OH), 1676 (C=O), 
1236 (P=O) and 1048 (P−OEt); δH/ppm (400 MHz; CDCl3) 1.20 (2H, m, 4'-CH2), 1.31 (6H, t, J = 
7.6 Hz, 2 × CH3), 1.85 (4H, m, 3'-CH2 and CH2P), 2.43 (2H, t, J = 6.8 Hz, CH2CO), 4.11 (4H, m, 2 
× OCH2), 4.53 (2H, s, CH2OH), 5.62 (1H, s, OH), 7.12 (1H, d, J = 7.2 Hz, 4-H), 7.23 (1H, t, J = 8.0 
Hz, 5-H), 7.43 (1H, d, J = 8.0 Hz, 6-H), 7.50 (1H, s, 2-H) and 8.13 (1H, s, NH); δC (100 MHz; 
CDCl3) 16.3 (d, JP–C = 6.5 Hz, 2 × CH3), 21.8 (d, JP–C = 15.3 Hz, C-4'), 23.8 (d, JP–C = 143.8 Hz, 
CH2P), 26.3 (d, JP–C = 4.8 Hz, C-3'), 36.4 (d, JP–C = 3.8 Hz, CH2CO), 62.8 (d, JP–C = 6.5 Hz, 2 × 
OCH2), 64.7 (CH2OH), 118.2 (C-2), 118.7 (C-6), 123.2 (C-4), 129.8 (C-5), 138.7 (C-1), 140.7 (C-
3) and 173.5 (C=O).   
 
3.3.4.2. Synthesis of butylphosphonic acids derivatives using TMSBr  
 
[N-(3-Hydroxyphenyl)carbamoyl]butylphosphonic acid 335a    
 
 
 
 
Trimethylsilyl bromide (0.20 mL, 1.6 mmol) was added to diethyl [N-(3-hydroxyphenyl) 
carbamoyl]butylphosphonate 327a (0.25 g, 0.75 mmol) in CH3CN (3 mL) and the mixture was 
heated in the microwave apparatus set to deliver 100 W of power, with a reaction 
temperature of 60 oC and reaction time of 10 min. After completion, the mixture was cooled 
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to room temperature, treated with a 95:5 MeOH-H2O mixture and stirred for 30 min. The 
solvent was removed in vacuo and the residue chromatographed [preparative layer 
chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [N-(3-
hydroxyphenyl)carbamoyl]butylphosphonic acid 335a as a yellow oil (0.11 g, 67 %); (Found: 
C, 48.51; H, 5.82; N, 5.08 %. C11H16NO5P requires C, 48.36; H, 5.90; N, 5.13 %); ʋ/cm
-1 3376 
(OH), 1687 (C=O) and 1235 (P=O); δH/ppm (400 MHz; CDCl3) 1.25 (2H, m, 4'-CH2), 2.06 (4H, 
m, CH2P), 2.39 (2H, t, J = 6.4 Hz, CH2CO), 6.05 (2H, s, 2 x OH), 6.65 (1H, d, J = 7.2 Hz, 4-H), 
6.93 (1H, d, J = 7.6 Hz, 6-H), 7.10 (1H, s, OH), 7.18 (1H, t, J = 7.6 Hz, 5-H), 7.30 (1H, s, 2-H) 
and 8.28 (1H, s, NH); δC/ppm (100 MHz; CDCl3) 21.3 (d, JP–C = 15.2 Hz, C-4'), 23.6 (d, JP–C = 
143.5 Hz, CH2P), 26.4 (d, JP–C = 4.8 Hz, C-3'), 36.2 (d, JP–C = 3.3 Hz, CH2CO), 107.9 (C-2), 112.3 
(C-4), 112.8 (C-6), 128.7 (C-5), 138.7 (C-1), 158.3 (C-3) and 164.1 (C=O). 
 
[N-(3-Methoxyphenyl)carbamoylbutylphosphonic acid 335b    
 
 
 
 
The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]butyl 
phosphonic acid 335a was employed, using diethyl [N-(3-methoxyphenyl)carbamoyl]butyl 
phosphonate 327b (0.25 g, 0.73 mmol) in CH3CN (3 mL) and trimethylsilyl bromide (0.19 mL, 
1.5 mmol). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [N-
(3-methoxyphenyl)carbamoyl]butylphosphonic acid 335b as a yellow oil (0.097 g, 60 %); 
(Found: C, 50.27; H, 6.38; N, 4.82 %. C12H18NO5P requires C, 50.18; H, 6.32; N, 4.88 %); ʋ/cm
-
1 3152 (OH), 1679 (C=O) and 1231 (P=O); δH/ppm (400 MHz; CDCl3) 1.29 (2H, m, 4'-CH2), 2.03 
(4H, m, 3'-CH2 and CH2P), 2.42 (2H, t, J = 6.4 Hz, CH2CO), 3.79 (3H, OCH3), 4.89 (2H, s, 2 × 
OH), 6.60 (1H, d, J = 8.4 Hz, 4-H), 7.01 (1H, d, J = 7.2 Hz, 6-H), 7.12 (1H, s, 2-H), 7.23 (1H, t, J = 
8.0 Hz, 5-H) and 7.83 (1H, s, NH); δC/ppm (100 MHz; CDCl3) 21.9 (d, JP–C = 15.6 Hz, C-4'), 23.6 
(d, JP–C = 141.2 Hz, CH2P), 26.2 (d, JP–C = 4.3 Hz, C-3'), 36.3 (d, JP–C = 4.5 Hz, CH2CO), 55.3 
(OCH3), 106.2 (C-2), 109.4 (C-4), 112.7 (C-6), 129.8 (C-5), 139.8 (C-1), 159.9 (C-3) and 169.2 
(C=O).   
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[N-(3-Bromophenyl)carbamoyl]butylphosphonic acid 335c    
 
 
 
 
The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]butyl 
phosphonic acid 335a was employed, using diethyl [N-(3-bromophenyl)carbamoyl]butyl 
phosphonate 325c (0.25 g, 0.63 mmol) in CH3CN (3 mL) and trimethylsilyl bromide (0.17 mL, 
1.3 mmol). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [N-
(3-bromophenyl)carbamoyl]butylphosphonic acid 335c as a brown oil (0.099 g, 60 %); 
(Found: C, 39.54; H, 4.59; N, 4.25 %. C11H15BrNO4P requires C, 39.31; H, 4.50; N, 4.17 %); 
ʋ/cm-1 3163 (OH), 1680 (C=O) and 1219 (P=O); δH/ppm (400 MHz;CDCl3) 1.25 (2H, m, 4'-
CH2), 1.77 (2H, m, CH2P), 2.00 (2H, m, 3'-CH2), 2.38 (2H, t, J = 6.4 Hz, CH2CO), 5.77 (2H, x, 2 × 
OH), 6.80 (1H, dd, J = 5.2 and 2.0 Hz, 4-H), 7.05 (1H, t, J = 2.0 Hz, 2-H), 7.09 (1H, dd, J = 5.6 
and 0.8 Hz, 6-H), 7.23 (1H, t, J = 8.0 Hz, 5-H) and 7.48 (1H, s, NH); δC/ppm (400 MHz; CDCl3) 
21.7 (d, JP–C = 15.6 Hz, C-4'), 23.5 (d, JP–C = 144.5 Hz, CH2P), 26.7 (d, JP–C = 5.2 Hz, C-3'), 36.1 
(d, JP–C = 4.1 Hz, CH2CO), 115.8 (C-6), 118.2 (C-3), 122.5 (C-2), 126.8 (C-4), 129.8 (C-5), 138.9 
(C-1) and 170.4 (C=O).   
 
[N-(3-Fluorophenyl)carbamoyl]butylphosphonic acid 335d    
 
 
 
 
The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]butyl 
phosphonic acid 335a was employed, using diethyl [N-(3-fluorophenyl)carbamoyl]butyl 
phosphonate 327d (0.25 g, 0.73 mmol) in CH3CN (3 mL) and trimethylsilyl bromide (0.20 mL, 
1.5 mmol). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [N-
(3-fluorophenyl)carbamoyl]butylphosphonic acid 335d as a yellow oil (0.10 g, 63 %); (Found: 
C, 48.12; H, 5.60; N, 6.87 %. C11H15FNO4P requires C, 48.01; H, 5.49; N, 6.90 %); ʋ/cm
-1 3019 
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(OH), 1664 (C=O) and 1216 (P=O); δH/ppm (400 MHz; CDCl3) 1.23 (2H, m, 4'-CH2), 1.90 (2H, 
m, CH2P), 2.03 (2H, m, 3'-CH2), 2.43 (2H, t, J = 6.4 Hz, CH2CO), 3.65 (2H, s, 2 × OH), 6.83 (1H, 
ddd, J = 6.4, 2.4 and 1.6 Hz, 4-H), 6.90 (1H, dd, J = 6.4 and 0.8 Hz, 6-H), 6.92 (1H, td, J = 6.8, 
2.4 and 1.2 Hz, 5-H) 7.54 (1H, dt, J = 6.4 and 2.4 Hz, 2-H) and 9.01 (1H, s, NH); δC/ppm (100 
MHz; CDCl3) 20.7 (d, JP–C = 15.6 Hz, C-4'), 22.9 (d, JP–C = 142.0 Hz, CH2P), 26.8 (d, JP–C = 4.4 Hz, 
C-3'), 36.4 (d, JP–C = 3.9 Hz, CH2CO), 108.5 (d, JF–C = 26.3 Hz, C-2), 111.1 (d, JF–C = 21.2 Hz, C-4),  
115.7 (d, JF–C = 3.3 Hz, C-6), 129.8 (d, JF–C = 8.8 Hz, C-5), 138.7 (d, JF–C = 10.8 Hz, C-1), 164.3 (d, 
JF−C = 243.2 Hz, C-3) and 167.6 (C=O).  
  
 [N-(3-Cyanophenyl)carbamoyl]butylphosphonic acid 335e  
 
 
 
 
The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]butyl 
phosphonic acid 335a was employed, using diethyl [N-(3-cyanophenyl)carbamoyl]butyl 
phosphonate 327e (0.25 g, 0.74 mmol) in CH3CN (3 mL) and trimethylsilyl bromide (0.20 mL, 
1.5 mmol). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [N-
(3-cyanophenyl)carbamoyl]butylphosphonic acid 335e as a clear oil (0.096 g, 59 %); (Found: 
C, 51.21; H, 5.45; N, 9.98 %. C12H15N2O4P requires C, 51.07; H, 5.36; N, 9.93 %); (0.10 g, 59 
%); ʋ/cm-1 3235 (OH), 2234 (C≡N), 1684 (C=O) and 1232 (P=O); δH/ppm (400 MHz; CDCl3) 
1.24 (2H, m, 4'-CH2), 1.73 (2H, m, CH2P), 1.89 (2H, m, 3'-CH2), 2.41 (2H, t, J = 6.8 Hz, CH2CO), 
7.18 (2H, s, 2 x OH), 7.35 (2H, t, J = 7.2 Hz, 5-H), 7.50 (1H, d, J = 6.2 Hz, 4-H), 7.69 (1H, d, J = 
7.6 Hz, 6-H), 7.89 (1H, s, 2-H) and 9.78 (1H, s, NH); δC/ppm (400 MHz; CDCl3) 21.8 (d, JP–C = 
15.6 Hz, C-4'), 23.5 (d, JP–C = 143.5 Hz, CH2P), 26.9 (d, JP–C = 4.8 Hz, C-3'), 36.6 (d, JP–C = 3.8 Hz, 
CH2CO), 112.5 (C-3), 118.4 (C≡N), 122.6 (C-2), 124.2 (C-5), 127.4 (C-6), 129.7 (C-4), 139.2 (C-
1) and 169.4 (C=O).  
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 [N-(3-Nitrophenyl)carbamoyl]butylphosphonic acid 335f    
 
 
 
 
The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]butyl 
phosphonic acid 335a was employed, using diethyl [N-(3-nitrophenyl)carbamoyl]butyl 
phosphonate 327f (0.25 g, 0.70 mmol) in CH3CN (3 mL) and trimethylsilyl bromide (0.18 mL, 
1.4 mmol). The solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [N-
(3-nitrophenyl)carbamoyl]butylphosphonic acid 335f as a yellow oil (0.12 g, 69 %); (Found: C, 
43.79; H, 5.09; N, 9.35 %. C11H15N2O6P requires C, 43.72; H, 5.00; N, 9.27 %); ʋ/cm
-1 3267 
(OH), 1659 (C=O) and 1235 (P=O); δH/ppm (400 MHz; CDCl3) 1.20 (2H, m, 4'-CH2), 1.81 (4H, 
m, 3'-CH2 and CH2P), 2.44 (2H, t, J = 6.8 Hz, CH2CO), 5.89 (2H, s, 2 × OH), 7.48 (1H, s, 2-H), 
7.52 (1H, t, J = 8.4 Hz, 5-H), 7.95 (2H, m, 4-H and 6-H) and 8.89 (1H, s, NH); δC/ppm (400 
MHz; CDCl3) 21.8 (d, JP–C = 15.8 Hz, C-4'), 24.1 (d, JP–C = 143.5 Hz, CH2P), 26.7 (d, JP–C = 4.2 Hz, 
C-3'), 36.9 (d, JP–C = 4.6 Hz, CH2CO), 114.2 (C-2), 118.8 (C-4), 124.5 (C-6), 129.6 (C-5), 139.8 
(C-1), 148.4 (C-3) and 169.7 (C=O).   
 
4-{[3-(Hydroxymethyl)phenyl]carbamoyl}butylphosphonic acid 335g   
 
 
 
 
The procedure described for the synthesis of [N-(3-hydroxyphenyl)carbamoyl]butyl 
phosphonic acid 335a was employed, using diethyl {N-[3-(hydroxymethyl) 
phenyl]carbamoyl}butylphosphonate 327g (0.25 g, 0.76 mmol) in CH3CN (3 mL) and 
trimethylsilyl bromide (0.20 mL, 1.5 mmol). The solvent was removed in vacuo and the 
residue chromatographed [preparative layer chromatography; elution with hexane-EtOAc-
MeOH (1:1:1.5)] to yield {N-[3-(hydroxymethyl)phenyl]carbamoyl}butylphosphonic acid 335g 
as a yellow oil ( 0.094 g, 57 %); (Found: C, 50.24; H, 6.39; N, 4.95 %. C12H18NO5P requires C, 
50.18; H, 6.32; N, 4.88 %); ʋ/cm-1 3276 (OH), 1682 (C=O) and 1234 (P=O); δH/ppm (400 MHz; 
NH
O
P
OH
O
OH
NO2
1
2
3
4
5
6
1'
2'
3'
4'
5'
NH
O
P
OH
O
OH
OH
1
2
3
4
5
6
1'
2'
3'
7
4'
5'
  Experimental  
 
Page | 246  
CDCl3) 1.24 (2H, m, 4'-CH2), 1.87 (4H, m, 3'-CH2 and CH2P), 2.39 (2H, t, J = 6.8 Hz, CH2CO), 
3.22 (2H, s, 2 x OH), 5.08 (2H, s, CH2OH), 7.11 (1H, d, J = 7.2 Hz, 4-H), 7.19 (1H, s, 2-H), 7.23 
(1H, t, J = 8.0 Hz, 5-H), 7.60 (1H, d, J = 8.0 Hz, 6-H), 7.75 (1H, s, OH) and 8.15 (1H, s, NH); 
δC/ppm (400 MHz; CDCl3) 21.8 (d, JP–C = 15.6 Hz, C-4'), 23.6 (d, JP–C = 142.0 Hz, CH2P), 26.7 (d, 
JP–C = 4.8 Hz, C-3'), 35.8 (d, JP–C = 3.8 Hz, CH2CO), 64.3 (CH2OH), 118.1 (C-2), 118.8 (C-6), 123.6 
(C-4), 129.8 (C-5), 138.9 (C-1), 141.3 (C-3) and 169.8 (C=O).   
 
3.3.4.3. Synthesis of sodium hydrogen butylphosphonate derivatives 
 
Sodium hydrogen [N-(3-hydroxyphenyl)carbamoyl]butylphosphonate 336a 
 
 
  
 
[N-(3-Hydroxyphenyl)carbamoyl]butylphosphonic acid 335a (0.15 g, 0.55 mmol) was treated 
with a solution of NaOH (1.1 mol) in EtOH (0.52 mL) and the mixture was stirred for 30 min. 
The solvent was removed in vacuo and the residue chromatographed [reverse-phase 
column chromatography; elution with H2O-MeOH (1:1)] to yield sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]butylphosphonate 336a as a grey semi-solid (0.094 g, 91 %);  
(Found: C, 44.85; H, 5.23; N, 4.79 %. C11H15NNaO5P requires C, 44.75; H, 5.12; N, 4.74 %); 
ʋ/cm-1 3265 (OH), 1653 (C=O) and 1219 (P=O); δH/ppm (400 MHz; D2O) 1.21 (2H, m, 4'-CH2), 
1.79 (2H, m, CH2P), 2.03 (2H, m, 3'-CH2), 2.41 (2H, t, J = 6.4 Hz, CH2CO), 6.63 (1H, d, J = 7.2 
Hz, 4-H), 6.95 (1H, d, J = 7.6 Hz, 6-H), 7.12 (1H, t, J = 7.6 Hz, 5-H) and 7.40 (1H, s, 2-H); 
δC/ppm(100 MHz; D2O) 22.5 (d, JP–C = 15.6 Hz, C-4'), 23.6 (d, JP–C = 143.5 Hz, CH2P), 26.7 (d, 
JP–C = 4.8 Hz, C-3'), 35.9 (d, JP–C = 3.4 Hz, CH2CO), 108.0 (C-2), 112.1 (C-4), 112.8 (C-6), 128.2 
(C-5), 138.3 (C-1), 158.5 (C-3) and 168.1 (C=O). 
  
Sodium hydrogen [N-(3-methoxyphenyl)carbamoyl]butylphosphonate 336b  
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The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]butylphosphonate 336a was employed, using [N-(3-
methoxyphenyl)carbamoyl]butylphosphonic acid 335b (0.15 g, 0.52 mmol) and a solution of 
NaOH (1.1 mol) in EtOH (0.49 mL). The solvent was removed in vacuo and the residue 
chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen [N-(3-methoxyphenyl)carbamoyl]butylphosphonate 336b as a yellow 
semi-solid (0.098 g, 94 %); (Found: C, 46.73; H, 5.62; N, 4.57 %. C12H17NNaO5P requires C, 
46.61; H, 5.54; N, 4.53 %); ʋ/cm-1 3317 (OH), 1678 (C=O) and 1232 (P=O); δH/ppm (400 MHz; 
D2O) 1.25 (2H, m, 4'-CH2), 1.98 (4H, m, 3'-CH2 and CH2P), 2.44 (2H, t, J = 6.4 Hz, CH2CO), 3.78 
(3H, OCH3), 6.61 (1H, d, J = 8.0 Hz, 4-H), 7.02 (1H, d, J = 7.2 Hz, 6-H), 7.11 (1H, s, 2-H) and 
7.23 (1H, t, J = 7.6 Hz, 5-H); δC/ppm (100 MHz; D2O) 22.8 (d, JP–C = 15.6 Hz, C-4'), 24.1 (d, JP–C 
= 141.8 Hz, CH2P), 26.7 (d, JP–C = 4.4 Hz, C-3'), 36.3 (d, JP–C = 4.3 Hz, CH2CO), 54.7 (OCH3), 
106.5 (C-2), 110.2 (C-4), 112.5 (C-6), 129.9 (C-5), 140.0 (C-1), 159.7 (C-3) and 167.3 (C=O).   
 
Sodium hydrogen [N-(3-bromophenyl)carbamoyl]butylphosphonate 336c 
 
  
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]butylphosphonate 336a was employed, using [N-(3-
bromophenyl)carbamoyl]butylphosphonic acid 335c (0.15 g, 0.44 mmol) and a solution of 
NaOH (1.1 mol) in EtOH (0.41 mL). The solvent was removed in vacuo and the residue 
chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen [N-(3-bromophenyl)carbamoyl]butylphosphonate 336c as a pale 
yellow semi-solid (0.098 g,  94 %); (Found: C, 37.01; H, 4.17; N, 3.88 %. C11H14BrNNaO4P 
requires C, 36.89; H, 3.94; N, 3.91 %); ʋ/cm-1 3271 (OH), 1666 (C=O) and 1230 (P=O); 
δH/ppm (400 MHz; D2O) 1.27 (2H, m, 4'-CH2), 1.80 (2H, m, CH2P), 1.98 (2H, m, 3'-CH2), 2.41 
(2H, t, J = 6.2 Hz, CH2CO), 6.78 (1H, t, J = 7.6 Hz, 5-H), 7.21 (1H, d, J = 7.6 Hz, 4-H), 7.29 (1H, 
d, J = 7.2 Hz, 6-H) and 7.43 (1H, s, 2-H); δC/ppm (100 MHz; D2O) 22.3 (d, JP–C = 15.4 Hz, C-4'), 
24.2 (d, JP–C = 144.1 Hz, CH2P), 26.5 (d, JP–C = 5.6 Hz, C-3'), 36.6 (d, JP–C = 4.2 Hz, CH2CO), 115.5 
(C-6), 118.3 (C-3), 123.4 (C-2), 126.5 (C-4), 129.7 (C-5), 138.8 (C-1) and 167.4 (C=O).  
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Sodium hydrogen [N-(3-fluorophenyl)carbamoyl]butylphosphonate 336d 
 
 
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]butylphosphonate 336a was employed, using [N-(3-
fluorophenyl)carbamoyl]butylphosphonic acid 335d (0.15 g, 0.54 mmol) and a solution of 
NaOH (1.1 mol) in EtOH (0.52 mL). The solvent was removed in vacuo and the residue 
chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen [N-(3-fluorophenyl)carbamoyl]butylphosphonate 336d as a grey 
semi-solid (0.010 g, 96 %); (Found: C, 44.53; H, 4.70; N, 4.80 %. C11H14FNNaO4P requires C, 
44.45; H, 4.75; N, 4.71 %); ʋ/cm-1 3416 (OH), 1683 (C=O) and 1239 (P=O); δH/ppm (400 MHz; 
D2O) 1.28 (2H, m, 4'-CH2), 1.92 (2H, m, CH2P), 1.99 (2H, m, 3'-CH2), 2.36 (2H, t, J = 6.4 Hz, 
CH2CO), 6.80 (1H, ddd, J = 6.8, 2.4 and 1.6 Hz, 4-H), 7.20 (1H, dd, J = 6.2 and 0.8 Hz, 6-H), 
7.26 (1H, td, J = 6.8, 2.4 and 1.6 Hz, 5-H) and 7.40 (1H, dt, J = 6.4 and 2.4 Hz, 2-H); δC/ppm 
(100 MHz; D2O) 22.2 (d, JP–C = 15.6 Hz, C-4'), 23.1 (d, JP–C = 142.0 Hz, CH2P), 26.5 (d, JP–C = 3.8 
Hz, C-3'), 36.8 (d, JP–C = 3.2 Hz, CH2CO), 108.3 (d, JF–C = 26.2 Hz, C-2), 111.5 (d, JF–C = 20.8 Hz, 
C-4),  115.4 (d, JF–C = 3.8 Hz, C-6), 129.7 (d, JF–C = 10.2 Hz, C-5), 138.9 (d, JF–C = 11.2 Hz, C-1), 
163.6 (d, JF−C = 241.7 Hz, C-3) and 172.1 (C=O).  
 
 Sodium hydrogen [N-(3-cyanophenyl)carbamoyl]butylphosphonate 336e 
 
 
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]butylphosphonate 336a was employed, using [N-(3-
cyanophenyl)carbamoyl]butylphosphonic acid 335e (0.15 g, 0.53 mmol) and a solution of 
NaOH (1.1 mol) in EtOH (0.50 mL). The solvent was removed in vacuo and the residue 
chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen [N-(3-cyanophenyl)carbamoyl]butylphosphonate 336e as a yellow 
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semi-solid (0.10 g, 94 %); (Found: C, 47.27; H, 4.73; N, 9.25 %. C12H14N2NaO4P requires C, 
47.38; H, 4.64; N, 9.21 %); (0.10 g, 59 %); ʋ/cm-1 3849 (OH), 2225 (C≡N), 1678 (C=O) and 
1219 (P=O); δH/ppm (400 MHz; D2O) 1.23 (2H, m, 4'-CH2), 1.77 (2H, m, CH2P), 1.90 (2H, m, 
3'-CH2), 2.43 (2H, t, J = 6.8 Hz, CH2CO), 7.37 (2H, t, J = 7.6 Hz, 5-H), 7.63 (1H, d, J = 6.8 Hz, 4-
H), 7.69 (1H, d, J = 7.6 Hz, 6-H) and 7.87 (1H, s, 2-H); δC/ppm (100 MHz; D2O) 22.3 (d, JP–C = 
15.8 Hz, C-4'), 22.6 (d, JP–C = 143.6 Hz, CH2P), 26.6 (d, JP–C = 4.8 Hz, C-3'), 36.4 (d, JP–C = 3.7 Hz, 
CH2CO), 112.6 (C-3), 118.2 (C≡N), 122.6 (C-2), 124.8 (C-5), 127.5 (C-6), 129.6 (C-4), 138.8 (C-
1) and 173.5 (C=O).   
  
Sodium hydrogen [N-(3-nitrophenyl)carbamoyl]butylphosphonate 336f 
 
 
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]butylphosphonate 336a was employed, using [N-(3-
nitrophenyl)carbamoyl]butylphosphonic acid 335f (0.15 g, 0.49 mmol) and a solution of 
NaOH (1.1 mol) in EtOH (0.46 mL). The solvent was removed in vacuo and the residue 
chromatographed [reverse-phase column chromatography; elution with H2O-MeOH (1:1)] to 
yield sodium hydrogen [N-(3-nitrophenyl)carbamoyl]butylphosphonate 336f as a yellow 
semi-solid (0.099 g, 92 %); (Found: C, 40.89; H, 4.47; N, 8.57 %. C11H14N2NaO6P requires C, 
40.75; H, 4.35; N, 8.64 %); ʋ/cm-1 3423 (OH), 1678 (C=O) and 1227 (P=O); δH/ppm (400 MHz; 
D2O) 1.21 (2H, m, 4'-CH2), 1.80 (4H, m, 3'-CH2 and CH2P), 2.32 (2H, t, J = 6.8 Hz, CH2CO), 7.43 
(1H, s, 2-H), 7.55 (1H, t, J = 8.0 Hz, 5-H) and 7.86 (2H, m, 4-H and 6-H); δC/ppm (100 MHz; 
D2O) 23.4 (d, JP–C = 15.6 Hz, C-4'), 24.2 (d, JP–C = 142.9 Hz, CH2P), 25.8 (d, JP–C = 4.2 Hz, C-3'), 
36.4 (d, JP–C = 3.2 Hz, CH2CO), 114.7 (C-2), 118.3 (C-4), 123.7 (C-6), 128.6 (C-5), 139.7 (C-1), 
149.3 (C-3) and 168.6 (C=O).    
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Sodium hydrogen {N-[3-(hydroxymethyl)phenyl]carbamoyl}butylphosphonate 336g   
 
 
 
 
The procedure described for the synthesis of sodium hydrogen [N-(3-
hydroxyphenyl)carbamoyl]butylphosphonate 336a was employed, using {N-[(3-
(hydroxymethyl)phenyl]carbamoyl}butylphosphonic acid 335g (0.15 g, 0.52 mmol) and a 
solution of NaOH (1.1 mol) in EtOH (0.49 mL). The solvent was removed in vacuo and the 
residue chromatographed [reverse-phase column chromatography; elution with H2O-MeOH 
(1:1)] to yield sodium hydrogen {N-[3-(hydroxymethyl)phenyl]carbamoyl}butylphosphonate 
336g as a white semi-solid (0.011 g, 96 %); (Found: C, 46.71; H, 5.58; N, 4.50 %. 
C12H17NNaO5P requires C, 46.61; H, 5.54; N, 4.53 %); ʋ/cm
-1 3384 (OH), 1682 (C=O) and 1234 
(P=O); δH/ppm (400 MHz; D2O) 1.27 (2H, m, 4'-CH2), 1.84 (4H, m, 3'-CH2 and CH2P), 2.35 (2H, 
t, J = 6.8 Hz, CH2CO), 4.62 (2H, s, CH2OH), 7.17 (1H, d, J = 7.2 Hz, 4-H), 7.22 (1H, t, J = 8.0 Hz, 
5-H), 7.38 (1H, d, J = 8.0 Hz, 6-H) and 7.42 (1H, s, 2-H); δC/ppm (100 MHz; D2O) 22.0 (d, JP–C = 
15.6 Hz, C-4'), 23.7 (d, JP–C = 143.7 Hz, CH2P), 26.3 (d, JP–C = 4.5 Hz, C-3'), 36.1 (d, JP–C = 3.6 Hz, 
CH2CO), 63.7 (CH2OH), 118.0 (C-2), 118.8 (C-6), 124.3 (C-4), 129.9 (C-5), 139.4 (C-1), 140.9 
(C-3) and 167.8 (C=O).     
 
3.4. Furan-containing phosphoric acid derivatives 
 
3-[(Trityloxy)methyl]furan 339 176   
 
                  
 
   
 
A solution of triphenylmethyl chloride 342 (6.00 g, 20.5 mmol), 3-furanmethanol 338 (2.00 
g, 20.4 mmol), triethylamine (4.46 mL, 20.4 mmol) and DMAP (0.61 g, 5.0 mmol) in THF (30 
mL) was stirred under N2 at 80 
oC for 15 hours. The solvent was evaporated in vacuo and the 
residue dissolved in EtOAc (100 mL). The organic phase was washed sequentially with water 
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(2 x 50 mL) and brine (2 x 50 mL). The aqueous washings were extracted with EtOAc and the 
organic layers were combined and dried (anhydr. MgSO4). The solvent was evaporated in 
vacuo to afford 3-[(trityloxy)methyl]furan 339 as a yellow gum (4.98 g, 72 %); δH/ppm (400 
MHz; CDCl3) 4.06 (2H, s, OCH2), 6.43 (1H, s, 2-H), 7.27 – 7.54 (17H, m, 4-H, 5-H and trityl 
group); δC/ppm (100 MHz; CDCl3) 58.4 (OCH2), 86.9 (C-2'), 109.9 (C-4), 123.1 (C-3), 127.0 (C-
6'), 127.8 (C-4' and C-8'), 128.6 (C-5' and C-7'), 139.7 (C-3'), 143.0 (C-2) and 144.0 (C-5).   
 
3-[(Trityloxy)methyl]furan-2-carbaldehyde 340a and 4-[(trityloxy)methyl]furan-2-carb-
aldehyde 340b 176    
 
 
 
 
 
 
 
Method 1 
To a stirred solution of 3-[(trityloxy)methyl]furan 339 (2.00 g, 5.88 mmol) in THF (20 mL) 
under N2 at ca. -30 
oC, butyllithium (6.0 mL, 12 mml) was slowly added dropwise via a 
septum, ensuring that the temperature did not exceed -30 oC. The resulting mixture was 
stirred for 4 hours; DMF (1.38 mL) was then added and the mixture stirred for a further 2 
hours. The reaction mixture was allowed to warm to room temperature and stirred for an 
additional 2 hours before being quenched with water (15 mL) and extracted with diethyl 
ether (2 x 50 mL). The organic extracts were washed sequentially with 10 % aq. NaHCO3 (2 x 
50 mL), brine (2 x 50 mL) and dried (anhydr. MgSO4). The solvent was removed in vacuo to 
obtain the crude product as a yellow solid. The crude product was purified [normal-phase 
HPLC; elution with hexane-EtOAc (4:1)] to yield two products.          
  
i. 3-[(Trityloxy)methyl]furan-2-carbaldehyde 340a as a white solid (4 mg, 6 %); δH/ppm 
(400 MHz; CDCl3) 4.14 (2H, s, OCH2), 7.31 – 7.69 (17H, m, 4-H, 5-H and trityl group) and 
9.68 (1H, s, CHO); δC/ppm (100 MHz; CDCl3) 58.1 (OCH2), 87.6 (C-2'), 113.1 (C-4), 127.3 
(C-6'), 128.0 (C-4' and C-8'), 128.6 (C-5' and C-7'), 135.4 (C-3), 143.5 (C-3'), 147.2 (C-5), 
147.8 (C-2) and 178.5 (C=O).      
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ii. 4-[(Trityloxy)methyl]furan-2-carbaldehyde 340b as a pale yellow solid (12 mg, 12 %); 
δH/ppm (400 MHz; CDCl3) 4.45 (2H, s, OCH2), 6.75 (1H, s, 5-H), 7.26 – 7.49 (15H, m, 
trityl group), 7.61 (1H, s, 3-H) and 9.73 (1H, s, CHO); δC/ppm (100 MHz; CDCl3) 57.8 
(OCH2), 87.3 (C-2’), 120.5 (C-3), 126.4 (C-4), 127.2 (C-6’) 128 (C-4’ and C-8’), 128.5 (C-
5’ and C-7’), 143.6 (C-3’), 145.2 (C-5), 153.1 (C-2) and 178.0 (C=O). 
 
Method 2  
The Vilsmeier reagent was prepared by adding phosphorus oxychloride (1.86 mL, 26.0 
mmol) dropwise to DMF (20 mL) under nitrogen over a period of 30 min, maintaining the 
temperature below 5 oC. The mixture was stirred for 30 min, after which 3-
[(trityloxy)methyl]furan 339 (2.00 g, 5.88 mmol) in DMF (5 mL) was added. The reaction 
mixture was stirred for 3 hours at room temperature and then heated at 80 oC for 1 hour. 
After cooling, the mixture was poured into ice-water (200 mL) and the pH adjusted to pH 10 
with 0.1 M aq. NaOH. The solution was extracted with diethyl ether (4 x 50 mL), and the 
organic extracts were combined, washed with water and brine and the dried (anhydr. 
MgSO4). The solvent was removed in vacuo to afford the crude product, which was 
recrystallised from MeOH to yield 4-[(trityloxy)methyl]furan-2-carbaldehyde 340b as a pale 
yellow crystals (1.39 g, 64 %).  
 
2-Acetyl-4-[(trityloxy)methyl]furan 340c and 2-acetyl-3-[(trityloxy)methyl]furan 369      
  
 
 
 
 
 
 
Method 1 
Acetic anhydride (0.27 mL, 2.9 mmol) was added dropwise to a solution of SnCl4 (0.12 mL, 
0.49 mmol) in DCM (10 mL) under N2 at 0 
oC and the mixture was stirred for 15 min. 3-
[(Trityloxy)methyl]furan 339 (1.00 g, 2.94 mmol) in DCM (10 mL) was added and the 
reaction mixture was stirred at 0 oC for 1 hour. The reaction mixture was then warmed to 40 
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oC and stirred for 4 hours. After completion, the mixture was treated with saturated aq. 
NaHCO3 (50 mL) and extracted with diethyl ether (2 x 50 mL). The organic extracts were 
combined, dried (anhydr. MgSO4) and filtered. The solvent was removed under reduced 
pressure and the residue was purified [normal-phase HPLC; elution with hexane-EtOAc (3:1)] 
to yield two products.      
     
i. 2-Acetyl-4-[(trityloxy)methyl]furan 340c as a yellow oil (47 mg, 64 %); (Found: C, 
81.58; H, 5.76 %. C26H22O3 requires C, 81.65; H, 5.80 %); ʋ/cm
-1 1675 (C=O); δH/ppm 
(400 MHz; CDCl3) 2.57 (3H, s, CH3CO), 4.42 (2H, s, OCH2) and 7.14 – 7.34 (17H, m, 3-
H, 5-H and trityl group); δC/ppm (100 MHz; CDCl3) 24.2 (CH3), 57.3 (OCH2), 87.6 (C-
2'), 120.4 (C-3), 126.4 (C-4), 127.4 (C-6') 127.9 (C-4' and C-8'), 128.4 (C-5' and C-7'), 
143.5 (C-3'), 145.3 (C-5), 153.5 (C-2) and 181.3 (C=O). 
 
ii. 2-Acetyl-3-[(trityloxy)methyl]furan 369 as a yellow oil (2 mg, 2.4 %); (Found: C, 81.60; 
H, 5.82 %. C26H22O3 requires C, 81.65; H, 5.80 %); ʋ/cm
-1 1682 (C=O); δH/ppm (400 
MHz; CDCl3) 2.59 (3H, s, CH3CO), 4.45 (2H, s, OCH2) and 7.12 – 7.28 (17H, m, 4-H, 5-H 
and trityl group); δC/ppm (100 MHz; CDCl3) 24.8 (CH3), 56.8 (OCH2), 87.3 (C-2'), 112.8 
(C-4), 126.7 (C-6'), 128.1 (C-4' and C-8'), 128.8 (C-5' and C-7'), 134.6 (C-3), 143.6 (C-
3'), 147.3 (C-2), 148.2 (C-5) and 181.8 (C=O). 
 
Method 2 
Acetic anhydride (0.14 mL, 1.5 mmol) was added dropwise to a solution of 3-
[(trityloxy)methyl]furan 339 (0.50 g, 1.5 mmol) and ZnCl2 (0.10 g, 0.75 mmol) in DCM (10 mL) 
under N2 at 0 
oC and the mixture was stirred for 1 hour. The reaction mixture was then 
warmed to 40 oC and stirred for 8 hours. After completion, the mixture was treated with 
saturated aq. NaHCO3 (20 mL) and extracted with diethyl ether (2 x 25 mL). The organic 
extracts were combined, dried (anhydr. MgSO4) and filtered. The solvent was removed 
under reduced pressure and the residue was purified [normal-phase HPLC; elution with 
hexane-EtOAc (3:1)] to yield 2-acetyl-4-[(trityloxy)methyl]furan 340c as a yellow oil (28 mg, 
37 %) and 2-acetyl-3-[(trityloxy)methyl]furan 369 as a yellow oil (0.88 mg, 1.1 %).     
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2-(3,3-Dimethylbutanoyl)-4-[(trityloxy)methyl]furan 340d and 2-(3,3-dimethylbutanoyl)-3-
[(trityloxy)methyl]furan 370  
  
        
       
 
 
 
 
The procedure described for the synthesis of 2-acetyl-4-[(trityloxy)methyl]furan 340c was 
employed, using 3-[(trityloxy)methyl]furan 339 (1.01 g, 2.94 mmol), tert-butylacetyl chloride 
(0.42 mL, 2.9 mmol) and SnCl4 (0.12 mL, 0.49 mmol). The solvent was removed under 
reduced pressure and the residue was purified [normal-phase HPLC; elution with hexane-
EtOAc (4:1)] to yield two products.    
 
i. 2-(3,3-Dimethylbutanoyl)-4-[(trityloxy)methyl]furan 340d as a yellow oil (32 mg, 56 
%); (Found: C, 82.30; H, 6.78 %. C30H30O3 requires C, 82.16; H, 6.89 %); ʋ/cm
-1 1685 
(C=O); δH/ppm (400 MHz; CDCl3) 1.19 (9H, s, 3 x CH3), 2.58 (2H, s, CH2CO), 4.47 (2H, 
s, OCH2) and 7.19 – 7.31 (17H, m, 3-H, 5-H and trityl group); δC/ppm (100 MHz; 
CDCl3) 29.1 (3 x CH3), 30.2 (C-3''), 47.4 (C-2''), 57.9 (OCH2), 87.4 (C-2'), 120.6 (C-3), 
126.4 (C-4), 127.3 (C-6') 128.0 (C-4' and C-8'), 128.6 (C-5' and C-7'), 143.7 (C-3'), 
145.3 (C-5), 153.2 (C-2) and 187.0 (C=O).  
 
ii. 2-(3,3-Dimethylbutanoyl)-3-[(trityloxy)methyl]furan 370 as a yellow oil ( 1.6 mg, 2.9 
%); (Found: C, 82.35; H, 6.83 %. C30H30O3 requires C, 82.16; H, 6.89 %); ʋ/cm
-1 1691 
(C=O); δH/ppm (400 MHz; CDCl3) 1.21 (9H, s, 3 x CH3), 2.56 (2H, s, CH2CO), 4.52 (2H, 
s, OCH2) and 7.14 – 7.21 (17H, m, 4-H, 5-H and trityl group); δC/ppm (100 MHz; 
CDCl3) 29.5 (3 x CH3), 31.3 (C-3''), 46.8 (C-2''), 58.2 (OCH2), 87.3 (C-2'), 113.2 (C-4), 
126.6 (C-6'), 127.8 (C-4' and C-8'), 128.9 (C-5' and C-7'), 132.8 (C-3), 143.8 (C-3'), 
145.7 (C-5), 146.4 (C-2) and 186.4 (C=O).  
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4-(Hydroxymethyl)furan-2-carbaldehyde 347b 248    
 
          
 
A suspension of 4-[(trityloxy)methyl]furan-2-carbaldehyde 340b (0.25 g, 0.70 mmol) in 
HCOOH-THF-H2O (1:1:0.1;  5 mL) was heated at 50 
oC for 2 hours. The solvent was removed 
in vacuo, [co-evaporated with hexane (2 x 10 mL)] to yield 4-(hydroxymethyl)furan-2-
carbaldehyde 347b as a clear oil (0.20 g, 82 %), (Lit.248); ʋ/cm-1 3347 (OH) and 1672 (C=O); 
δH/ppm (400 MHz; CDCl3) 2.00 (1H, s, OH), 4.57 (2H, s, OCH2), 6.46 (1H, s, 5-H), 7.42 (1H, s, 
3-H) and 9.64 (1H, s, CHO); δC/ppm (100 MHz; CDCl3) 58.2 (CH2OH), 119.7 (C-3), 126.2 (C-4), 
145.5 (C-5), 152.8 (C-2) and 182.5 (C=O).  
 
2-Acetyl-1-[4-(Hydroxymethyl)furan 347c 249  
 
 
 
The procedure described for the synthesis of 4-(hydroxymethyl)furan-2-carbaldehyde 347b 
was employed, using 2-acetyl-4-[(trityloxy)methyl]furan 340c (0.25 g, 0.65 mmol) in HCOOH-
THF-H2O (1:1:0.1;  5 mL). The solvent was removed in vacuo, co-evaporated with hexane (2 x 
10 mL) to yield 2-acetyl-1-[4-(Hydroxymethyl)furan 347c as a colourless oil (0.21 g, 84 %); 
ʋ/cm-1 3284 (OH) and 1687 (C=O); δH/ppm (400 MHz; CDCl3) 2.56 (3H, s, CH3CO), 3.20 (1H, s, 
OH), 4.52 (2H, s, OCH2), 6.43 (1H, s, 5-H) and 7.36 (1H, s, 3-H); δC/ppm (100 MHz; CDCl3) 24.6 
(CH3), 57.7 (OCH2), 120.3 (C-3), 125.8 (C-4), 145.3 (C-5), 153.4 (C-2) and 178.9 (C=O). 
 
2-(3,3-Dimethylbutanoyl)-1-[4-(hydroxymethyl)]furan 347d  
   
       
 
 
The procedure described for the synthesis of 4-(hydroxymethyl)furan-2-carbaldehyde 347b 
was employed, using 2-(3,3-dimethylbutanoyl)-4-[(trityloxy)methyl]furan 340d (0.25 g, 0.60 
mmol) in HCOOH-THF-H2O (1:1:0.1; 5 mL). The solvent was removed in vacuo, [co-
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evaporated] with hexane (2 x 10 mL) to yield 2-(3,3-dimethylbutanoyl)-1-[4-(hydroxyl-
methyl)]furan 347d as a colourless oil (0.20 g, 81 %); δH/ppm (400 MHz; CDCl3) 1.19 (9H, s, 3 
x CH3), 2.12 (1H, s, OH), 2.54 (2H, s, CH2CO), 4.52 (2H, s, OCH2), 6.41 (1H, s, 5-H) and 7.39 
(1H, s, 3-H); δC/ppm (100 MHz; CDCl3) 28.6 (3 x CH3), 32.6 (C-3'), 36.7 (C-2'), 58.6 (CH2OH), 
120.2 (C-3), 123.8 (C-4), 145.3 (C-5), 153.2 (C-2) and 184.7 (C=O). 
 
 Diethyl (2-formylfuran-4-yl)methyl phosphate 348b 
 
 
 
 
Diethyl chlorophosphate (0.52 g, 3.0 mmol) was added slowly to a stirred solution of 4-
(hydroxymethyl)furan-2-carbaldehyde 347b (0.20 g, 1.5 mmol) in pyridine (10 mL) at 0 oC. 
The reaction mixture was allowed to reach room temperature and the stirred for 24 hours. 
The solvent was removed in vacuo and the residue was dissolved in DCM (25 mL). The 
organic phase was washed with satd. aq. NaHCO3 (2 x 50 mL), water (2 x 50 mL) and brine (2 
x 50 mL), and dried (anhydr. MgSO4). The solvent was evaporated in vacuo and the residue 
chromatographed [preparative layer chromatography; elution with hexane-EtOAc (4:1)] to 
yield diethyl (2-formylfuran-4-yl)methyl phosphate 348b as a clear oil (0.14 g, 71 %); (Found: 
C, 45.90; H, 5.84 %. C10H15O6P requires C, 45.81; H, 5.77 %); ʋ/cm
-1 1677 (C=O) and 1227 
(P=O); δH/ppm (400 MHz; CDCl3) 1.29 (6H, m, 2 x CH3), 4.10 (4H, m, 2 x CH2CH3), 4.87 (2H, d, 
J = 2.2 Hz, OCH2), 6.45 (1H, s, 5-H), 7.39 (1H, s, 3-H) and 10.12 (1H, s, CHO); δC/ppm (100 
MHz; CDCl3) 16.3 (d, JF–C = 6.1 Hz, 2 x CH3), 60.8 (d, JP–C =  6.4 Hz, OCH2), 61.4 (d, JP–C = 6.6 Hz, 
2 x CH2CH3), 120.3 (C-3), 125.6 (C-4), 145.3 (C-5), 153.2 (C-2) and 181.7 (C=O).  
 
(2-Acetylfuran-4-yl)methyl diethyl phosphate 348c   
 
 
 
 
The procedure described for the synthesis of (2-formylfuran-4-yl)methyl diethyl phosphate 
348b was employed, using 2-acetyl-1-[4-(Hydroxymethyl)furan 347c (0.20 g, 1.4 mmol) and  
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diethyl chlorophosphate (0.47 g, 2.8 mmol) in pyridine (10 mL). The solvent was evaporated 
in vacuo and the residue chromatographed [preparative layer chromatography; elution with 
hexane-EtOAc (4:1)] to yield (2-acetylfuran-4-yl)methyl diethyl phosphate 348c as a yellow 
oil (0.15 g, 74 %); (Found: C, 48.01; H, 6.15 %. C11H17O6P requires C, 47.83; H, 6.20 %); ʋ/cm
-1 
1680 (C=O) and 1223 (P=O); δH/ppm (400 MHz; CDCl3) 1.30 (6H, t, J = 6.8 Hz, 2 x CH2CH3), 
2.54 (3H, s, CH3CO), 4.07 (4H, m, 2 x CH2CH3), 5.05 (2H, d, J = 1.6 Hz, OCH2), 7.11 (1H, s, 5-H) 
and 7.13 (2H, s, 3-H); δC/ppm (100 MHz; CDCl3) 16.3 (d, JP–C = 6.0 Hz, 2 x CH3), 24.6 (CH3CO), 
61.5 (d, JP–C = 6.5 Hz, OCH2 and 2 x CH2CH3), 120.8 (C-3), 122.9 (C-4), 145.7 (C-5), 150.1 (C-2) 
and 182.6 (C=O).  
 
Diethyl [2-(3,3-dimethylbutanoyl)furan-4-yl]methyl phosphate 348d  
 
 
  
 
 
The procedure described for the synthesis of diethyl (2-formylfuran-4-yl)methyl phosphate 
348b was employed, using 2-(3,3-dimethylbutanoyl)-1-[4-(hydroxymethyl)]furan 347d (0.20 
g, 1.0 mmol) and  diethyl chlorophosphate (0.39 g, 2.0 mmol) in pyridine (10 mL). The 
solvent was evaporated in vacuo and the residue chromatographed [preparative layer 
chromatography; elution with hexane-EtOAc (4:1)] to yield diethyl [2-(3,3-
dimethylbutanoyl)furan-4-yl]methyl phosphate 348d as a yellow oil (0.14 g, 71 %); (Found: C, 
54.30; H, 7.60 %. C15H25O6P requires C, 54.21; H, 7.58 %); ʋ/cm
-1 1681 (C=O) and 1232 (P=O); 
δH/ppm (400 MHz; CDCl3) 1.21 (9H, s, 3 x CH3), 1.31 (6H, t, J = 6.8 Hz, 2 x CH2CH3), 2.56 (2H, 
s, CH2CO), 4.08 (4H, m, 2 x CH2CH3), 5.09 (2H, d, J = 1.6 Hz, OCH2), 6.47 (1H, s, 5-H) and 7.12 
(1H, s, 3-H); δC/ppm (100 MHz; CDCl3) 16.3 (d, JP–C = 6.1 Hz, 2 x CH2CH3), 29.2 (3 x CH3), 32.3 
(C-3'), 36.8 (C-2'), 62.3 (d, JP–C = 6.5 Hz, OCH2 and 2 x CH2CH3), 120.5 (C-3), 124.2 (C-4), 145.7 
(C-5), 153.4 (C-2) and 185.3 (C=O).   
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(2-Formylfuran-4-yl)methyl dihydrogen phosphate 341b  
 
 
 
 
A solution of 4-[(trityloxy)methyl]furan-2-carbaldehyde 340b (0.30 g, 0.84 mmol) and 
H3PO4:THF (1:1 v/v; 2.0 mL) was stirred at room temperature for ca. 2 days. The solvent was 
removed under reduced pressure and the residue dissolved in EtOAc (25 mL). The organic 
phase was washed with 10 % aq. NaHCO3 (2 × 50 mL), and the aqueous layers were 
collected and acidified (pH 2.0) with 0.1M-HCl. The aqueous phase was extracted with 
EtOAc (3 x 25 mL) and the combined organic solutions were dried (anhydr. MgSO4). The 
solvent was evaporated in vacuo and the residue chromatographed [preparative layer 
chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield (2-formylfuran-4-
yl)methyl dihydrogen phosphate 341b as a yellow oil (0.12 g, 65 %); (Found: C, 35.01; H, 3.49 
%. C6H7O6P requires C, 34.97; H, 3.42 %); ʋ/cm
-1 1673 (C=O) and 1234 (P=O); δH/ppm (400 
MHz; D2O) 5.11 (2H, d, J = 1.6 Hz, OCH2), 7.10 (1H, s, 5-H), 7.40 (1H, s, 3-H) and 9.74 (1H, s, 
CHO); δC/ppm (100 MHz; D2O) 61.9 (d, JP–C = 6.4 Hz, 2 × OCH2), 120.9 (C-3), 123.0 (C-4), 
145.8 (C-5), 150.2 (C-2) and 180.0 (C=O).   
 
(2-Acetylfuran-4-yl)methyl dihydrogen phosphate 341 c  
 
 
 
 
The procedure described for the synthesis of (2-Formylfuran-4-yl)methyl dihydrogen 
phosphate 341b was employed, using 2-acetyl-4-[(trityloxy)methyl]furan 340c (0.2 g, 0.52 
mmol) and H3PO4:THF (1:1 v/v, 1.0 mL). The solvent was evaporated in vacuo and the 
residue chromatographed [preparative layer chromatography; elution with hexane-EtOAc-
MeOH (1:1:1)] to yield (2-acetylfuran-4-yl)methyl dihydrogen phosphate 341c as a colourless 
oil (0.12 g, 61 %); (Found: C, 38.27; H, 4.09 %. C7H9O6P requires C, 38.20; H, 4.12 %); ʋ/cm
-1 
1687 (C=O) and 1241 (P=O); δH/ppm (400 MHz; D2O) 2.61 (3H, s, CH3CO), 5.07 (2H, d, J = 2.3 
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Hz, OCH2), 7.12 (1H, s, 5-H) and 7.35 (1H, s, 3-H); δC/ppm (100 MHz; D2O) 24.3 (CH3), 62.3 (d, 
JP–C = 6.5 Hz, OCH2), 120.7 (C-3), 122.9 (C-4), 145.5 (C-5), 153.2 (C-2) and 182.3 (C=O).  
  
[2-(3,3-Dimethylbutanoyl)furan-4-yl]methyl dihydrogen phosphate 341d           
    
 
 
 
The procedure described for the synthesis of (2-Formylfuran-4-yl)methyl dihydrogen 
phosphate 341b was employed, using 2-(3,3-dimethylbutanoyl)-4-[(trityloxy)methyl]furan 
340d (0.20 g, 0.46 mmol) and H3PO4:THF (1:1 v/v, 1.0 mL). The solvent was evaporated in 
vacuo and the residue chromatographed [preparative layer chromatography; elution with 
hexane-EtOAc-MeOH (1:1:0.5)] to yield [2-(3,3-dimethylbutanoyl)furan-4-yl]methyl 
dihydrogen phosphate 341d as a colourless oil (0.10 g, 58 %); (Found: C, 47.91; H, 6.11 %. 
C11H17O6P requires C, 47.83; H, 6.20 %); ʋ/cm
-1 3307 (OH), 1687 (C=O) and 1231 (P=O); 
δH/ppm (400 MHz; D2O) 1.21 (9H, s, 3 x CH3), 2.55 (2H, s, CH2CO), 5.02 (2H, d, J = 2.4 Hz, 
OCH2), 7.15 (1H, s, 5-H) and 7.39 (1H, s, 3-H); δC/ppm (100 MHz; D2O) 29.3 (3 x CH3), 32.2 (C-
3'), 36.8 (C-2'), 62.2 (d, JP–C = 6.5 Hz, OCH2), 120.4 (C-3), 123.7 (C-4), 145.5 (C-5), 152.8 (C-2) 
and 185.6 (C=O).  
 
Diethyl {2-[(hydroxyimino)methyl]furan-4-yl}methyl phosphate 349b 
  
 
 
 
Diethyl (2-formylfuran-4-yl)methyl phosphate 348b (0.11 g, 0.46 mmol), hydroxylamine 
hydrochloride (0.10 g, 1.5 mmol) and sodium acetate (0.020 g, 0.24 mmol) were dissolved in 
EtOH (8 mL) and the mixture was refluxed at 80 oC for 1 hour. After completion of the 
reaction, the solvent was removed under reduced pressure and the residue was dissolved in 
diethyl ether (20 mL). The organic layer was washed sequentially with water (20 mL) and 
brine (20 mL), and dried (anhydr. Na2SO4). The solvent was removed in vacuo and the 
residue chromatographed [preparative layer chromatography; elution with hexane-EtOAc 
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(4:1)] to yield diethyl {2-[(hydroxyimino)methyl]furan-4-yl}methyl phosphate 349b as a 
colourless oil (97 mg, 87 %); (Found: C, 43.47; H, 5.69; N, 5.11 %. C10H16NO6P requires C, 
43.33; H, 5.82; N, 5.05 %); ʋ/cm-1 3271 (OH), 1651 (C=N) and 1218 (P=O); δH/ppm (400 MHz; 
CDCl3) 1.28 (6H, m, 2 x CH3), 4.08 (4H, m, 2 x CH2CH3), 5.05 (2H, d, J = 2.0 Hz, OCH2), 6.44 
(1H, s, 5-H), 7.41 (1H, s, 3-H), 8.17 (1H, s, OH) and 9.89 (1H, s, aldehydic proton); δC/ppm 
(100 MHz; CDCl3) 16.2 (d, JP–C = 6.5 Hz, 2 x CH3), 59.8 (d, JP–C =  6.4 Hz, OCH2), 61.3 (d, JF–C = 
6.5 Hz, 2 x CH2CH3), 110.7 (C-3), 125.7 (C-4), 145.1 (C-5), 149. 6 (C=N) and 153.7 (C-2). 
 
Diethyl {2-[1-(hydroxyimino)ethyl]furan-4-yl}methyl phosphate 349c  
 
 
 
 
 
The procedure described for the synthesis of diethyl {2-[(hydroxyimino)methyl]furan-4-
yl}methyl phosphate 349b was employed, using (2-acetylfuran-4-yl)methyl diethyl 
phosphate 348c (0.10 g, 0.40 mmol), hydroxylamine hydrochloride (0.10 g, 1.5 mmol) and 
sodium acetate (0.020, 0.24 mmol) in EtOH (8 mL). The solvent was removed in vacuo and 
the residue chromatographed [preparative layer chromatography; elution with hexane-
EtOAc (4:1)] to yield diethyl {2-[1-(hydroxyimino)ethyl]furan-4-yl}methyl phosphate 349c as a 
colourless oil (91 mg, 91 %); (Found: C, 45.27; H, 6.14; N, 4.88 %. C11H18NO6P requires C, 
45.36; H, 6.23; N, 4.81 %); ʋ/cm-1 3243 (OH), 1672 (C=N) and 1225 (P=O); δH/ppm (400 MHz; 
CDCl3) 1.31 (6H, t, J = 7.2 Hz, 2 x CH3), 2.53 (3H, s, CH3C=N), 4.09 (4H, m, 2 x CH2CH3), 5.02 
(2H, d, J = 2.0 Hz, OCH2), 5.87 (1H, s, OH), 6.48 (1H, s, 5-H) and 7.11 (1H, s, 3-H); δC/ppm (100 
MHz; CDCl3) 13.0 (CH3C=N) 16.3 (d, JP–C = 6.0 Hz, 2 x CH3), 61.7 (d, JP–C = 6.4 Hz, OCH2 and 2 x 
CH2CH3), 109.8 (C-3), 127.2 (C-4), 143.7 (C-5), 148.5 (C=N) and 151.3 (C-2).  
 
Diethyl {2-[1-(hydroxyimino)-3,3-dimethylbutyl]furan-4-yl}methyl phosphate 349d 
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The procedure described for the synthesis of diethyl {2-[(hydroxyimino)methyl]furan-4-
yl}methyl phosphate 349b was employed, using diethyl [2-(3,3-dimethylbutanoyl)furan-4-
yl]methyl phosphate 348d (0.10 g, 0.75 mmol), hydroxylamine hydrochloride (0.10 g, 1.5 
mmol) and sodium acetate (0.020, 0.24 mmol) in EtOH (8 mL). The solvent was removed in 
vacuo and the residue chromatographed [preparative layer chromatography; elution with 
hexane-EtOAc (4:1)] to yield diethyl {2-[1-(hydroxyimino)-3,3-dimethylbutyl]furan-4-
yl}methyl phosphate 349d as a colourless oil (92 mg, 92 %); (Found: C, 51.79; H, 7.49; N, 3.97 
%. C15H26NO6P requires C, 51.87; H, 7.54; N, 4.03 %); ʋ/cm
-1 3281 (OH) 1663 (C=N) and 1218 
(P=O); δH/ppm (400 MHz; CDCl3) 1.15 (9H, s, 3 x CH3), 1.26 (6H, t, J = 6.8 Hz, 2 x CH2CH3), 
2.55 (2H, CH2C=N), 4.03 (4H, m, 2 x CH2CH3), 4.98 (2H, d, J = 1.6 Hz, OCH2), 5.67 (1H, s, OH), 
6.50 (1H, s, 5-H) and 7.12 (1H, s, 3-H); δC/ppm (100 MHz; CDCl3) 16.2 (d, JP–C = 6.0 Hz, 2 x 
CH2CH3), 28.6 (3 x CH3), 32.4 (C-3'), 36.6 (C-2'), 62.0 (OCH2), 62.1 (d, JP–C = 6.7 Hz, 2 x 
CH2CH3), 110.3 (C-3), 127.6 (C-4), 143.3 (C-5), 149.8 (C=N) and 153.4 (C-2).  
 
{2-[(Hydroxyimino)methyl]furan-4-yl}methyl dihydrogen phosphate 337b 
  
    
 
 
(2-Formylfuran-4-yl)methyl dihydrogen phosphate 341b (0.10 g, 0.48 mmol), hydroxylamine 
hydrochloride (0.10 g, 1.5 mmol) and sodium acetate (0.020 g, 0.24 mmol) were dissolved in 
EtOH (8 mL) and the mixture was refluxed at 80 oC for 1 hour. After completion of the 
reaction, the solvent was removed under reduced pressure and the residue was dissolved in 
diethyl ether (20 mL). The organic solution was washed sequentially with water (20 mL) and 
brine (20 mL), and dried (anhydr. Na2SO4). The solvent was removed in vacuo and the 
residue chromatographed [preparative layer chromatography; elution with hexane-EtOAc-
MeOH (1:1:1)] to yield {2-[(hydroxyimino)methyl]furan-4-yl}methyl dihydrogen phosphate 
337b as a colourless oil (88 mg, 88 %); (Found: C, 32.71; H, 3.72; N, 6.30 %. C6H8NO6P 
requires C, 32.59; H, 3.65; N, 6.33 %); ʋ/cm-1 3245 (OH), 1657 (CH=N) and 1232 (P=O); 
δH/ppm (400 MHz; DMSO-d6) 3.57 (2H, s, 2 x OH), 5.11 (2H, d, J = 2.0 Hz, OCH2), 5.89 (1H, s, 
CH=N), 7.10 (1H, s, 5-H), 7.37 (1H, s, 3-H) and 9.41 (1H, s, NOH); δC/ppm (100 MHz; DMSO-
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d6) 62.2 (d, JP–C = 5.9 Hz, OCH2), 110.1 (C-3), 127.0 (C-4), 143.2 (C-5), 150.7 (C=NOH) and 
151.8 (C-2).  
 
{2-[1-(Hydroxyimino)ethyl]furan-4-yl}methyl dihydrogen phosphate 337c  
 
 
 
 
The procedure described for the synthesis of {2-[(hydroxyimino)methyl]furan-4-yl}methyl 
dihydrogen phosphate 337b was employed, using (2-acetylfuran-4-yl)methyl dihydrogen 
phosphate 341c (0.10 g, 0.44 mmol), hydroxylamine hydrochloride (0.10 g, 1.5 mmol) and 
sodium acetate (0.020, 0.24 mmol) in EtOH (8 mL). The solvent was removed in vacuo and 
the residue chromatographed [preparative layer chromatography; elution with hexane-
EtOAc-MeOH (1:1:1)] to yield {2-[1-(Hydroxyimino)ethyl]furan-4-yl}methyl dihydrogen 
phosphate 337c as a colourless oil (91 mg, 91 %); (Found: C, 35.84; H, 4.31; N, 5.32 %. 
C7H10NO6P requires C, 35.76; H, 4.29; N, 5.29 %); ʋ/cm
-1 3253 (OH), 1648 (HC=N) and 1228 
(P=O); δH/ppm (400 MHz; DMSO-d6) 2.37 (3H, s, CH3), 3.90 (2H, s, 2 x OH), 5.11 (2H, d, J = 2.0 
Hz, OCH2), 7.12 (1H, s, 5-H), 7.32 (1H, s, 3-H) and 8.93 (1H, s, NOH); δC/ppm (100 MHz; 
DMSO-d6) 13.2 (CH3), 62.5 (d, JP–C = 6.3 Hz, OCH2), 110.2 (C-3), 127.1 (C-4), 143.7 (C-5), 150.8 
(C=NOH) and 153.3 (C-2).   
 
{2-[1-(Hydroxyimino)-3,3-dimethylbutyl]furan-4-yl}methyl dihydrogen phosphate 337d 
 
 
 
 
The procedure described for the synthesis of 2-[(hydroxyimino)methyl]furan-4-yl}methyl 
dihydrogen phosphate 337b was employed, using [2-(3,3-dimethylbutanoyl)furan-4-
yl]methyl dihydrogen phosphate 341d (0.10 g, 0.36 mmol), hydroxylamine hydrochloride 
(0.10 g, 1.5 mmol) and sodium acetate (0.020, 0.24 mmol) in EtOH (8 mL). The solvent was 
removed in vacuo and the residue chromatographed [preparative layer chromatography; 
elution with hexane-EtOAc-MeOH (1:1:1)] to yield {2-[1-(hydroxyimino)-3,3-
O
N
CH3
O
P
OH
OH
O
OH 1
2
3
4
5
1'
O
N
O
P
OH
OH
O
CH3
CH3
CH3
OH 1
2
3
4
5
1'
2'
3'
  Experimental  
 
Page | 263  
dimethylbutyl]furan-4-yl}methyl dihydrogen phosphate 337d as a colourless oil (87 mg, 87 
%); (Found: C, 45.29; H, 6.31; N, 4.79 %. C11H8NO6P requires C, 45.36; H, 6.23; N, 4.81 %); 
ʋ/cm-1 3260 (OH), 1678 (HC=N) and 1229 (P=O); δH/ppm (400 MHz; DMSO-d6) 1.12 (9H, s, 3 
x CH3), 1.83 (2H, s, CH2C=N), 2.31 (2H, s, 2 x OH), 5.09 (2H, d, J = 1.6 Hz, OCH2), 7.17 (1H, s, 5-
H), 7.32 (1H, s, 3-H) and 10.41 (1H, s, NOH); δC/ppm (100 MHz; DMSO-d6) 29.0 (3 x CH3), 
32.6 (C-3'), 36.3 (C-2'), 62.3 (d, JP–C = 6.6 Hz, OCH2), 110.8 (C-3), 127.5 (C-4), 142.7 (C-5), 
150.3 (C=NOH) and 152.2 (C-2).    
 
3.5. N-Benzyl substituted phosphoramidic acid derivatives  
 
Diethyl N-(2,2-diethoxyethyl)phosphoramidate 353 199  
 
 
 
 
A solution of diethyl N-(trimethylsilyl)phosphoramidate 358 (5.00 g, 22.0 mmol) in dry 
benzene (30 mL) was added slowly over a period of 30 min to a stirred suspension of sodium 
hydride (60 % dispersion in mineral oil; 1.07 g, 26.8 mmol) in dry benzene (10 mL) under N2. 
Bromoacetaldehyde diethyl acetal (3.3 mL, 22 mmol) and tetrabutylammonium bromide 
(0.71 g, 2.2 mmol) were then added and the resulting mixture was refluxed at 80 oC for 4 
hours. EtOH (18 mL) was then added dropwise and the mixture was refluxed at 80 oC for a 
further 1 hour. After cooling, EtOAc (100 mL) was added and the mixture was washed with 
water (3 x 20 mL). The aqueous layers were combined and extracted with EtOAc (3 x 10 mL). 
The combined organic phases were dried (anhydr. MgSO4), filtered and the solvent was 
evaporated in vacuo at 30-40 oC to afford diethyl N-(2,2-diethoxyethyl)phosphoramidate 
353 as a yellow oil (4.69 g, 87 %); δH/ppm (400 MHz; CDCl3) 1.16 (6H, t, J = 7.2 Hz, 2 x 2'-
CH3), 1.25 (6H, t, J = 7.2 Hz, 2 x 2''-CH3), 3.94 (1H, s, NH), 3.29 (2H, d, J = 5.2 Hz, CH2N), 3.51 
and 3.62 (4H, m, 2 x 1'-OCH2), 4.00 (4H, m, 2 x 1''-OCH2) and 4.59 (1H, t, J = 5.4 Hz, 2-CH); 
δC/ppm (100 MHz; CDCl3) 15.3 (2 x 2'-CH3), 16.1 (d, JP–C = 6.5 Hz, 2 x 2''-CH3), 31.9 (CH2N), 
61.8 (d, JP–C = 5.8 Hz, 2 x 1''-OCH2), 62.0 (2 x 1'-OCH2) and 101.1 (C-2).   
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Diethyl N-benzyl-N-(2,2-diethoxyethyl)phosphoramidate 354a 
  
 
              
 
 
 
To a stirred solution of diethyl N-(2,2-diethoxyethyl)phosphoramidate 353 (1.00 g, 3.71 
mmol) in dry THF (20 mL) under N2 was added NaH (60 % dispersion in mineral oil; 0.20 g, 
7.4 mmol) in small portions to permit controlled evolution of hydrogen. Benzyl bromide 
(0.44 mL, 3.7 mmol) in dry THF (5 mL) was then added and the resulting solution was stirred 
for at room temperature for ca. 24 hours.  The solvent was evaporated in vacuo and the 
residue extracted with EtOAc (2 x 25 mL). The organic phase was washed sequentially with 
satd. aq. NaHCO3 (2 × 50 mL), water (2 x 50 mL) and brine (2 × 50 mL). The aqueous 
washings were extracted with EtOAc (2 x 25 mL) and the combined organic layers were 
dried (anhydr. MgSO4). The solvent was removed in vacuo and the residue 
chromatographed [on silica gel; elution with hexane-EtOAc (4:1)] to yield diethyl N-benzyl-N-
(2,2-diethoxyethyl)phosphoramidate 354a as a yellow oil (0.60 g, 71 %); (Found: C, 56.93; H, 
8.49; N, 3.84 %. C17H30NO5P requires C, 56.81; H, 8.41; N, 3.90 %); ʋ/cm
-1 1232 (P=O); 
δH/ppm (400 MHz; CDCl3) 1.18 (6H, t, J = 6.8 Hz, 2 x 2'-CH3), 1.27 (6H, t, J = 7.2 Hz, 2 x 2''-
CH3), 3.32 (2H, d, J = 5.6 Hz, CH2N), 3.51 and 3.64 (4H, m, 2 x 1'-OCH2), 3.85 (2H, s, 3-CH2), 
4.03 (4H, m, 2 x 1''-OCH2), 4.61 (1H, t, J = 5.2 Hz, 2-CH) and 7.29 – 7.37 (5H, m, Ar-H); 
δC/ppm (100 MHz; CDCl3) 15.1 (2 x 2'-CH3), 16.1 (d, JP–C = 7.2 Hz, 2 x 2''-CH3), 31.8 (CH2N), 
52.7 (3-CH2), 62.4 (d, JP–C = 5.5 Hz, 2 x 1''-OCH2), 62.7 (2 x 1'-OCH2), 101.4 (C-2), 127.3 (C-4'''), 
128.3 (C-2''' and C-6'''), 128.6 (C-3''' and C-5''') and 137.4 (C-1''').  
Diethyl N-(2,2-diethoxyethyl)-N-[4-(hydroxymethyl)benzyl]phosphoramidate 354b   
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The procedure described for the synthesis of diethyl N-benzyl-N-(2,2-diethoxyethyl)- 
phosphoramidate 354a was employed, using NaH (60 % dispersion in mineral oil; 0.20 g, 7.4 
mmol), diethyl N-(2,2-diethoxyethyl)phosphoramidate 353 (1.00 g, 3.7 mmol) in dry THF (20 
mL) and 4-(chloromethyl)benzyl alcohol (0.58 g, 3.7 mmol) in dry THF (5 mL).  After work-up, 
the solvent was removed in vacuo and the residue chromatographed [on silica gel; elution 
with hexane-EtOAc (4:1)] to yield diethyl N-(2,2-diethoxyethyl)-N-[4-(hydroxymethyl)benzyl]-
phosphoramidate 354b as a colourless oil (0.63 g, 77 %); (Found: C, 55.60; H, 8.24; N, 3.63 
%. C18H32NO6P requires C, 55.52; H, 8.28; N, 3.60 %); ʋ/cm
-1 3360 (OH) and 1232 (P=O); 
δH/ppm (400 MHz; CDCl3) 1.16 (6H, t, J = 7.2 Hz, 2 x 2'-CH3), 1.28 (6H, t, J = 6.8 Hz, 2 x 2''-
CH3), 2.13 (1H, s, OH), 3.27 (2H, d, J = 5.2 Hz, CH2N), 3.48 and 3.61 (4H, m, 2 x 1'-OCH2), 3.82 
(2H, s, 3-CH2), 4.05 (4H, m, 2 x 1''-OCH2), 4.47 (1H, t, J = 5.2 Hz, 2-CH), 4.82 (2H, s, CH2OH) 
and 7.02 – 7.10 (4H, m, Ar-H); δC/ppm (100 MHz; CDCl3) 15.2 (2 x 2'-CH3), 16.2 (d, JP–C = 7.2 
Hz, 2 x 2''-CH3), 33.6 (CH2N), 53.5 (3-CH2), 62.1 (d, JP–C = 6.6 Hz, 2 x 1''-OCH2), 62.5 (2 x 1'-
OCH2), 64.2 (CH2OH), 101.5 (C-2), 127.4 (C-2''' and C-6'''), 128.7 (C-3''' and C-5'''), 136.1 (C-
1''') and 139.7 (C-4''').    
Diethyl N-(3-aminobenzyl)-N-(2,2-diethoxyethyl)phosphoramidate 354c 
 
   
 
 
 
The procedure described for the synthesis of diethyl N-benzyl-N-(2,2-diethoxyethyl) 
phosphoramidate 354a was employed, using NaH (60 % dispersion in mineral oil; 0.20 g, 7.4 
mmol), diethyl N-(2,2-diethyoxyethyl)phosphoramidate 353 (1.00 g, 3.71 mmol) in dry THF 
(20 mL) and 3-aminobenzyl bromide (0.69 g, 3.7 mmol) in dry THF (5 mL).  After work-up, 
the solvent was removed in vacuo and the residue chromatographed [on silica gel; elution 
with hexane-EtOAc (4:1)] to yield diethyl N-(3-aminobenzyl)-N-(2,2-diethoxyethyl)-
(phosphoramidate 354c as a colourless oil (0.58 g, 67 %); (Found: C, 54.67; H, 8.45; N, 7.44 
%. C17H31N2O5P requires C, 54.53; H, 8.35; N, 7.48 %); ʋ/cm
-1 3348 (NH2) and 1241 (P=O); 
δH/ppm (400 MHz; CDCl3) 1.18 (6H, t, J = 7.2 Hz, 2 x 2'-CH3), 1.30 (6H, t, J = 6.8 Hz, 2 x 2''-
CH3), 2.87 (2H, d, J = 5.6 Hz, CH2N), 3.47 and 3.62 (4H, m, 2 x 1'-OCH2), 3.83 (2H, s, 3-CH2), 
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3.91 (2H, s, NH2), 4.07 (4H, m, 2 x 1''-OCH2), 4.48 (1H, t, J = 5.2 Hz, 2-CH) and 6.31 – 6.87 (4H, 
m, Ar-H); δC/ppm (100 MHz; CDCl3) 14.9 (2 x 2'-CH3), 15.9 (d, JP–C = 7.0 Hz, 2 x 2''-CH3), 31.6 
(CH2N), 53.3 (3-CH2), 62.1 (d, JP–C = 5.4 Hz, 2 x 1''-OCH2), 62.2 (2 x 1'-OCH2), 101.2 (C-2), 114.1 
(C-4'''), 114.8 (C-2'''), 118.6 (C-6'''), 129.5 (C-5'''), 138.2 (C-1''') and 147.3 (C-3'''). 
Diethyl N-(2,2-diethoxyethyl)-N-(3-mercaptobenzyl)phosphoramidate 354d 
 
 
 
 
 
 
The procedure described for the synthesis of diethyl N-benzyl-N-(2,2-diethoxyethyl) 
phosphoramidate 354a was employed, using NaH (60 % dispersion in mineral oil; 0.20 g, 7.4 
mmol), diethyl N-(2,2-diethoxyethyl)phosphoramidate 353 (1.00 g, 3.71 mmol) in dry THF 
(20 mL) and 3-sulfanylbenzyl bromide (0.75 g, 3.7 mmol) in dry THF (5 mL).  After work-up, 
the solvent was removed in vacuo and the residue chromatographed [on silica gel; elution 
with hexane-EtOAc (4:1)] to yield diethyl N-(2,2-diethoxyethyl)-N-(3-mercaptobenzyl)-
phosphoramidate 354d as a colourless oil (0.61 g, 69 %); (Found: C, 52.23; H, 7.67; N, 3.53 
%. C17H30NO5PS requires C, 52.16; H, 7.72; N, 3.58 %); ʋ/cm
-1 2547 (SH) and 1224 (P=O); 
δH/ppm (400 MHz; CDCl3) 1.20 (6H, t, J = 7.2 Hz, 2 x 2'-CH3), 1.29 (6H, t, J = 6.8 Hz, 2 x 2''-
CH3), 2.96 (1H, s, SH), 3.34 (2H, d, J = 5.2 Hz, CH2N), 3.53 and 3.66 (4H, m, 2 x 1'-OCH2), 3.84 
(2H, s, 3-CH2), 4.05 (4H, m, 2 x 1''-OCH2), 4.63 (1H, t, J = 5.6 Hz, 2-CH) and 6.89 – 7.01 (4H, m, 
Ar-H); δC/ppm (100 MHz; CDCl3) 15.5 (2 x 2'-CH3), 16.5 (d, JP–C = 7.1 Hz, 2 x 2''-CH3), 32.2 
(CH2N), 62.7 (d, JP–C = 7.0 Hz, 2 x 1''-OCH2), 62.8 (2 x 1'-OCH2),, 69.0 (3-CH2), 101.8 (C-2), 
124.8 (C-6'''), 126.0 (C-2'''), 127.4 (C-4'''), 129.0 (C-5'''), 130.8 (C-3''') and 136.7 (C-1''').        
Diethyl N-benzyl-N-(2-oxoethyl)phosphoramidate 355a  
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Diethyl N-benzyl-N-(2,2-diethoxyethyl)phosphoramidate 354a (0.50 g, 1.4 mmol) and 2M-
HCl (4 mL) was stirred at room temperature for ca. 24 hours. After completion, the reaction 
mixture was added to CHCl3 (20 mL) and the organic phase was washed with water (3 x 20 
mL). The aqueous washings were combined and extracted with CHCl3 (30 mL). The organic 
extract was washed sequentially with satd. aq. NaHCO3 (3 x 20 mL) and brine (3 x 20 mL) and 
then dried (anhydr. MgSO4). The solvent was evaporated in vacuo and the residue 
chromatographed [on silica gel; elution with hexane-EtOAc (4:1)] to yield diethyl N-benzyl-N-
(2-oxoethyl)phosphoramidate 355a as a yellow oil (0.44 g, 88 %); (Found: C, 54.79; H, 7.01; 
N, 4.88 %. C13H20NO4P requires C, 54.73; H, 7.07; N, 4.91 %); ʋ/cm
-1 1698 (C=O) and 1228 
(P=O); δH/ppm (400 MHz; CDCl3) 1.33 (6H, t, J = 6.8 Hz, 2 x 2'-CH3), 3.74 (2H, d, J = 6.0 Hz, 
CH2CO), 3.83 (2H, s, CH2Ph), 4.12 (4H, m, 2 x 1'-OCH2), 7.31 – 7.37 (5H, m, Ar-H) and 9.82 
(1H, s, CHO); δC/ppm (100 MHz; CDCl3) 16.2 (d, JP–C = 5.9 Hz, 2 x 2'-CH3), 51.9 (d, JP–C = 6.0 Hz, 
CH2CO), 62.4 (d, JP–C = 6.5 Hz, 2 x 1'-OCH2), 67.6 (CH2Ph), 127.6 (C-4''), 128.0 (C-2'' and C-6''), 
128.1 (C-3'' and C-5''), 137.7 (C-1'') and 175.2 (C=O).  
Diethyl N-[4-(hydroxymethyl)benzyl]-N-(2-oxoethyl)phosphoramidate 355b 
 
 
 
 
 
 
 
The procedure described for the synthesis of diethyl N-benzyl-N-(2-
oxoethyl)phosphoramidate 355a was employed, using diethyl N-(2,2-diethoxyethyl)-N-[4-
(hydroxymethyl)benzyl]phosphoramidate 354b (0.50 g, 1.3 mmol) and 2M-HCl (4 mL). After 
work-up, the solvent was removed in vacuo and the residue chromatographed [on silica gel; 
elution with hexane-EtOAc (4:1)] to yield diethyl N-[4-(hydroxymethyl)benzyl]-N-(2-
oxoethyl)phosphoramidate 355b as a yellow oil (0.44 g, 88 %); (Found: C, 53.51; H, 7.12; N, 
4.40 %. C14H22NO5P requires C, 53.33; H, 7.03; N, 4.44 %); ʋ/cm
-1 3261 (OH), 1738 (C=O) and 
1219 (P=O); δH/ppm (400 MHz; CDCl3) 1.36 (6H, t, J = 7.2 Hz, 2 x 2'-CH3), 2.03 (1H, s, OH), 
3.72 (2H, d, J = 5.2 Hz, CH2CO), 3.82 (2H, s, CH2Ph), 4.18 (4H, m, 2 x 1'-OCH2), 4.82 (2H, s, 
CH2OH), 7.09 – 7.17 (4H, m, Ar-H) and 9.81 (1H, s, CHO); δC/ppm (100 MHz; CDCl3) 16.3 (d, 
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JP–C = 5.8 Hz, 2 x 2''-CH3), 48.9 (d, JP–C = 5.9 Hz, CH2CO), 63.0 (d, JP–C = 6.3 Hz, 2 x 1'-OCH2), 
64.9 (CH2OH), 67.2 (CH2Ph), 127.1 (C-2'' and C-6''), 128.2 (C-3'' and C-5''), 135.8 (C-1''), 139.8 
(C-4'') and 172.8 (C=O).  
Diethyl N-(3-aminobenzyl)-N-(2-oxoethyl)phosphoramidate 355c 
 
 
 
   
   
 
The procedure described for the synthesis of diethyl N-benzyl-N-(2-
oxoethyl)phosphoramidate 355a was employed, using diethyl N-(3-aminobenzyl)-N-(2,2-
diethoxyethyl)phosphoramidate 354c (0.50 g, 1.3 mmol) and 2M-HCl (4 mL). After work-up, 
the solvent was removed in vacuo and the residue chromatographed [on silica gel; elution 
with hexane-EtOAc (4:1)] to yield diethyl N-(3-aminobenzyl)-N-(2-oxoethyl)phosphoramidate 
355c as a yellow oil (0.46 g, 92 %); (Found: C, 52.11; H, 7.10; N, 9.29 %. C13H21N2O4P requires 
C, 52.00; H, 7.05; N, 9.33 %); ʋ/cm-1 3371 (NH2), 1715 (C=O) and 1230 (P=O); δH/ppm (400 
MHz; CDCl3) 1.35 (6H, t, J = 6.8 Hz, 2 x 2'-CH3), 3.24 (2H, s, NH2), 3.71 (2H, d, J = 5.2 Hz, 
CH2CO), 3.83 (2H, s, CH2Ph), 4.17 (4H, m, 2 x 1'-OCH2), 7.00 – 7.47 (4H, m, Ar-H) and 9.81 
(1H, s, CHO); δC/ppm (100 MHz; CDCl3) 16.3 (d, JP–C = 6.0 Hz, 2 x 2'-CH3), 52.8 (d, JP–C = 4.9 Hz, 
CH2CO), 61.7 (d, JP–C = 6.4 Hz, 2 x 1'-OCH2), 68.3 (CH2Ph), 114.0 (C-4''), 114.9 (C-2''), 118.3 (C-
6''), 129.8 (C-5''), 137.7 (C-1''), 147.8 (C-3'') and 174.8 (C=O).  
 
Diethyl N-(3-mercaptobenzyl)-N-(2-oxoethyl)phosphoramidate 355d 
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The procedure described for the synthesis of diethyl N-benzyl-N-(2-oxoethyl)-
phosphoramidate 355a was employed, using diethyl N-(3-mercaptobenzyl)-N-(2-
oxoethyl)phosphoramidate 354d (0.50 g, 1.3 mmol) and 2M-HCl (4 mL). After work-up, the 
solvent was removed in vacuo and the residue chromatographed [on silica gel; elution with 
hexane-EtOAc (4:1)] to yield diethyl N-(3-mercaptobenzyl)-N-(2-oxoethyl)phosphoramidate 
355d as a yellow oil (0.45 g, 90 %); Found: C, 49.28; H, 6.43; N, 4.47 %. C13H20NO4PS requires 
C, 49.20; H, 6.35; N, 4.41 %); ʋ/cm-1 2567 (SH), 1692 (C=O) and 1215 (P=O); δH/ppm (400 
MHz; CDCl3) 1.36 (6H, t, J = 7.2 Hz, 2 x 2'-CH3), 2.77 (1H, s, SH), 3.53 (2H, d, J = 6.0 Hz, 
CH2CO), 3.79 (2H, s, CH2Ph), 4.12 (4H, m, 2 x 1'-OCH2), 6.86 – 7.40 (4H, m, Ar-H) and 9.87 
(1H, s, CHO); δC/ppm (100 MHz; CDCl3) 16.4 (d, JP–C = 6.0 Hz, 2 x 2'-CH3), 52.7 (d, JP–C = 4.7 Hz, 
CH2CO), 61.4 (d, JP–C = 6.4 Hz, 2 x 1'-OCH2), 68.6 (CH2Ph), 124.6 (C-6''), 126.2 (C-2''), 127.8 (C-
4''), 128.3 (C-5''), 130.4 (C-3''), 137.7 (C-1'') and 173.8 (C=O).  
Diethyl N-benzyl-N-[2-(benzyloxyamino)ethyl]phosphoramidate 356a   
   
   
 
 
 
 
 
To a stirred solution of diethyl N-benzyl-N-(2-oxoethyl)phosphoramidate 355a (0.40 g, 1.4 
mmol) in MeOH (5 mL) was added a solution of O-benzylhydroxylamine (0.21 g, 1.8 mmol) in 
MeOH (8 mL). The reaction mixture was heated at 40 oC for 3 hours, cooled to room 
temperature and diluted with MeOH (50 mL). After the addition of sodium 
cyanoborohydride (0.27 g, 4.1 mmol), conc. HCl (1.6 mL) was added dropwise over a period 
of 30 min and the mixture was stirred for 1 hour. Sodium cyanoborohydride (0.10 g, 1.4 
mmol) was again added and the mixture was stirred for 1 hour. The solvent was removed 
under reduced pressure, the residue dissolved in MeOH (30 mL) and then treated with ice-
water (50 mL). The pH of the resulting mixture was adjusted to pH 10 with an aq. KOH 
solution and extracted with DCM (3 x 20 mL). The combined organic layers were washed 
with 10 % NaHCO3 (50 mL) and brine (50 mL) and then dried (anhydr. MgSO4). The solvent 
was evaporated in vacuo and the residual oil was purified by flash chromatography [on silica 
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gel; elution with hexane-EtOAc (3:1)] to yield diethyl N-benzyl-N-[2-(benzyloxyamino)ethyl]-
phosphoramidate 356a as a yellow oil (0.26 g, 65 %); (Found: C, 61.30; H, 7.49; N, 7.21 %. 
C20H29N2O4P requires C, 61.21; H, 7.45; N, 7.14 %); ʋ/cm
-1 3267 (NH) and 1242 (P=O); 
δH/ppm (400 MHz; CDCl3) 1.32 (6H, t, J = 7.2 Hz, 2 x 2'-CH3), 2.89 (4H, m, 1-CH2 and 2-CH2), 
3.82 (2H, s, 4-CH2Ph), 4.10 (4H, m, 2 x 1''-OCH2), 4.74 (2H, s, 3-CH2Ph), 5.23 (1H, s, NH) and 
7.29 – 7.37 (10H, m, Ar-H); δC/ppm (100 MHz; CDCl3) 16.5 (d, JP–C = 6.0 Hz, 2 x 2'-CH3), 36.7 
(d, JP–C = 4.5 Hz, 1-CH2), 52.1 (d, JP–C = 16.7 Hz, 2-CH2), 61.5 (d, JP–C = 6.4 Hz, 2 x 1'-OCH2), 67.3 
(4-CH2Ph), 68.3 (3-CH2Ph), 127.6 (C-4''), 127.9 (C-8), 128.3 (C-2'' and C-6''), 128.4 (C-6 and C-
10), 128.5 (C-3'' and C-5''), 128.7 (C-7 and C-9), 137.8 (C-1'') and 138.3 (C-5).   
Diethyl N-[2-(benzyloxyamino)ethyl]-N-[4-(hydroxymethyl)benzyl]phosphoramidate     
356b  
     
     
 
 
 
 
 
The procedure described for the synthesis of diethyl N-benzyl-N-[2-(benzyloxyamino)ethyl]-
phosphoramidate 356a was employed, using diethyl N-[4-(hydroxymethyl) benzyl]-N-(2-
oxoethyl)phosphoramidate 355b (0.42 g, 1.3 mmol), O-benzylhydroxylamine (0.20 g, 1.6 
mmol) in MeOH (10 mL), sodium cyanoborohydride (0.24 g, 3.8 mmol), conc. HCl (1.6 mL) 
and further sodium cyanoborohydride (0.080 g, 1.2 mmol). After work-up, the solvent was 
evaporated in vacuo and the remaining oil was purified by flash chromatography [on silica 
gel; elution with hexane-EtOAc (3:1)] to yield diethyl N-[2-(benzyloxyamino)ethyl]-N-[4-
(hydroxymethyl)benzyl]phosphoramidate 356b as a yellow oil (0.26 g, 63 %); (Found: C, 
59.86; H, 7.47; N, 6.69 %. C21H31N2O5P requires C, 59.70; H, 7.40; N, 6.63 %); ʋ/cm
-1 3326 
(OH), 3248 (NH) and 1223 (P=O); δH/ppm (400 MHz; CDCl3) 1.29 (6H, t, J = 7.2 Hz, 2 x 2'-CH3), 
2.87 (4H, m, 1-CH2 and 2-CH2), 3.80 (2H, s, 4-CH2Ph), 4.07 (4H, m, 2 x 1''-OCH2), 4.77 (2H, s, 
3-CH2Ph), 4.86 (2H, s, CH2OH), 7.33 – 7.42 (9H, m, Ar-H), 7.97 (1H, s, OH) and 8.11 (1H, s, 
NH); δC/ppm (100 MHz; CDCl3) 16.3 (d, JP–C = 6.0 Hz, 2 x 2'-CH3), 36.4 (d, JP–C = 4.8 Hz, 1-CH2), 
52.0 (d, JP–C = 16.4 Hz, 2-CH2), 61.3 (d, JP–C = 6.5 Hz, 2 x 1'-OCH2), 64.7 (CH2OH), 67.2 (4-
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CH2Ph), 69.2 (3-CH2Ph), 127.7 (C-2'' and C-6''), 127.8 (C-6 and C-10), 128.2 (C-8), 128.3 (C-3'' 
and C-5''), 128.3 (C-7 and C-9), 137.4 (C-1''), 137.8 (C-5) and 138.3 (C-4'').   
Diethyl N-(3-aminobenzyl)-N-[2-(benzyloxyamino)ethyl]phosphoramidate 356c   
      
 
 
 
 
 
 
The procedure described for the synthesis of diethyl N-benzyl-N-[2-(benzyloxyamino)ethyl]-
phosphoramidate 356a was employed, using diethyl N-(3-aminobenzyl)-N-(2-
oxoethyl)phosphoramidate 355c (0.44 g, 1.5 mmol), O-benzylhydroxylamine (0.22 g, 1.8 
mmol) in MeOH (10 mL), sodium cyanoborohydride (0.28 g, 4.4 mmol), conc. HCl (1.6 mL) 
and further sodium cyanoborohydride (0.090 g, 1.3 mmol). After work-up, the solvent was 
evaporated in vacuo and the remaining oil was purified by flash chromatography [on silica 
gel; elution with hexane-EtOAc (3:1)] to yield diethyl N-(3-aminobenzyl)-N-[2-
(benzyloxyamino)ethyl]phosphoramidate 356c as a yellow oil (0.30 g, 68 %); (Found: C, 
59.08; H, 7.37; N, 10.33 %. C20H30N3O4P requires C, 58.96; H, 7.42; N, 10.31 %); ʋ/cm
-1 3329 
(NH2), 3260 (NH) and 1232 (P=O); δH/ppm (400 MHz; CDCl3) 1.22 (6H, t, J = 6.0 Hz, 2 x 2'-
CH3), 2.95 (4H, m, 1-CH2 and 2-CH2), 3.59 (2H, s, 4-CH2Ph), 4.03 (4H, m, 2 x 1'-OCH2), 4.62 
(2H, s, 3-CH2Ph), 5.55 (2H, s, NH2), 6.59 – 6.87 (4H, m, Ar-H), 7.28-7.37 (5H, m, Ar-H) and 
8.40 (1H, s, NH); δC/ppm (100 MHz; CDCl3) 16.4 (d, JP–C = 6.0 Hz, 2 x 2'-CH3), 36.5 (d, JP–C = 4.8 
Hz, 1-CH2), 52.0 (d, JP–C = 16.7 Hz, 2-CH2), 61.5 (d, JP–C = 6.5 Hz, 2 x 1'-OCH2), 67.4 (4-CH2Ph), 
69.9 (3-CH2Ph), 113.9 (C-4''), 114.9 (C-2''), 118.3 (C-6''), 126.9 (C-6 and C-10), 127.8 (C-8), 
128.3 (C-7 and C-9), 129.3 (C-5''), 136.7 (C-1''), 137.7 (C-5) and 148.3 (C-3'').   
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Diethyl N-[2-(benzyloxyamino)ethyl]-N-(3-mercaptobenzyl)phosphoramidate 356d 
 
 
 
 
 
 
The procedure described for the synthesis of diethyl N-benzyl-N-[2-(benzyloxyamino)ethyl]-
phosphoramidate 356a was employed, using diethyl N-(3-mercaptobenzyl)-N-(2-
oxoethyl)phosphoramidate 355d (0.44 g, 1.4 mmol), O-benzylhydroxylamine (0.14 g, 1.1 
mmol) in MeOH (10 mL), sodium cyanoborohydride (0.27 g, 4.3 mmol), conc. HCl (1.6 mL) 
and further sodium cyanoborohydride (0.090 g, 1.3 mmol). After work-up, the solvent was 
evaporated in vacuo and the remaining oil was purified by flash chromatography [on silica 
gel; elution with hexane-EtOAc (3:1)] to yield diethyl N-[2-(benzyloxyamino)ethyl]-N-(3-
mercaptobenzyl)phosphoramidate 356d as a yellow oil (0.29 g, 66 %); Found: C, 56.71; H, 
6.95; N, 6.65 %. C20H29N2O4PS requires C, 56.59; H, 6.89; N, 6.60 %); ʋ/cm
-1 3271 (NH), 2567 
(SH) and 1219 (P=O); δH/ppm (400 MHz; CDCl3) 1.28 (6H, t, J = 7.2 Hz, 2 x 2'-CH3), 2.61 (4H, 
m, 1-CH2 and 2-CH2), 3.38 (1H, s, SH), 3.61 (2H, s, 4-CH2Ph), 4.04 (4H, m, 2 x 1'-OCH2), 4.81 
(2H, s, 3-CH2Ph), 6.75 - 7.18 (4H, m, Ar-H), 7.31 - 7.35 (5H, m, Ar-H) and 8.18 (1H, s, NH); 
δC/ppm (100 MHz; CDCl3) 16.4 (d, JP–C = 6.0 Hz, 2 x 2'-CH3), 36.8 (d, JP–C = 4.8 Hz, 1-CH2), 52.1 
(d, JP–C = 16.7 Hz, 2-CH2), 61.5 (d, JP–C = 6.5 Hz, 2 x 1'-OCH2), 66.7 (4-CH2Ph), 71.2 (3-CH2Ph), 
124.6 (C-6''), 125.9 (C-2''), 127.6 (C-4''), 127.9 (C-6 and C-10), 128.0 (C-8), 128.3 (C-5''), 128.4 
(C-7 and C-9), 130.6 (C-3'') and 137.8 (C-1'') and 138.0 (C-5).    
Diethyl N-benzyl-2-[N-benzyloxy)acetamido]ethylphosphoramidate 357a   
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Acetyl chloride (0.12 mL, 1.3 mmol) was added dropwise to a stirred solution of diethyl N-
benzyl-N-[2-(benzyloxyamino)ethyl]-phosphoramidate 356a (0.25 g, 0.64 mmol) and 
triethylamine (0.13 mL, 0.96 mmol) in DCM (10 mL) under N2 at 0 
oC. The mixture was 
stirred at 0 oC for 1 hour, allowed to warm to room temperature and then stirred for ca. 24 
hours. The solvent was removed under reduced pressure and the residual oil dissolved in 
diethyl ether (20 mL). The ethereal solution was washed sequentially with aq. K2CO3 
solution, 0.5M-HCl and water. The organic solution was dried over anhydr. MgSO4, the 
solvent removed in vacuo and the residue purified by flash chromatography [on silica gel; 
elution with hexane-EtOAc (7:3)] to yield diethyl N-benzyl-2-[N-benzyloxy)acetamido]-
ethylphosphoramidate 357a as a yellow oil (0.23 g, 83 %); (Found: C, 60.88; H, 7.23; N, 6.52 
%. C22H31N2O5P requires C, 60.82; H, 7.19; N, 6.45 %); ʋ/cm
-1 1683 (C=O) and 1246 (P=O); 
δH/ppm (400 MHz; CDCl3) 1.29 (6H, t, J = 7.2 Hz, 2 x 2'-CH3), 2.00 (3H, s, CH3CO), 2.71 (2H, m, 
1-CH2N), 3.01 (2H, t, J = 6.4 Hz, 2-CH2N), 3.67 (2H, s, 4-CH2Ph), 4.08 (4H, m, 2 x 1''-OCH2), 
4.77 (2H, s, 3-CH2Ph) and 7.27 - 7.39 (10H, m, Ar-H); δC/ppm (100 MHz; CDCl3) 16.4 (d, JP–C = 
5.9 Hz, 2 x 2'-CH3), 23.7 (CH3CO), 35.4 (d, JP–C = 5.4 Hz, 1-CH2), 52.6 (d, JP–C = 16.8 Hz, 2-CH2), 
62.5 (d, JP–C = 6.7 Hz, 2 x 1'-OCH2), 66.8 (4-CH2Ph), 68.7 (3-CH2Ph), 124.8 (C-4''), 124.9 (C-8), 
127.5 (C-2'' and C-6''), 127.8 (C-6 and C-10), 128.5 (C-3'' and C-5''), 128.7 (C-7 and C-9), 138.3 
(C-1'), 138.4 (C-5) and 171.6 (C=O).   
Diethyl 2-[(N-benzyloxy)acetamido]-N-[4-(hydroxymethyl)benzyl]ethylphosphoramidate 
357b 
     
     
 
 
 
 
 
 
The procedure described for the synthesis of diethyl N-benzyl-2-[N-benzyloxy)acetamido]-
ethylphosphoramidate 357a was employed, using diethyl N-[2-(benzyloxyamino)ethyl]-N-[4-
(hydroxymethyl)benzyl]phosphoramidate 356b (0.25 g, 0.59 mmol), acetyl chloride (0.12 
mL, 1.3 mmol) and triethylamine (0.12 mL, 0.89 mmol) in DCM (10 mL). The solvent was 
evaporated in vacuo and the residue was purified by flash chromatography [on silica gel; 
elution with hexane-EtOAc (7:3)] to yield diethyl 2-[(N-benzyloxy)acetamido]-N-[4-
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(hydroxymethyl)benzyl]ethylphosphoramidate 357b as a yellow oil (0.23 g, 85 %); (Found: C, 
59.57; H, 7.23; N, 6.10 %. C23H33N2O6P requires C, 59.47; H, 7.16; N, 6.03 %); ʋ/cm
-1 3243 
(OH), 1687 (C=O) and 1223 (P=O); δH/ppm (400 MHz; CDCl3) 1.32 (6H, t, J = 7.2 Hz, 2 x 2'-
CH3), 2.04 (3H, s, CH3CO), 2.32 (2H, m, 1-CH2N), 2.76 (2H, t, J = 6.0 Hz, 2-CH2N), 3.71 (2H, s, 
4-CH2Ph), 4.11 (4H, m, 2 x 1''-OCH2), 4.79 (2H, s, 3-CH2Ph), 4.84 (2H, s, CH2OH), 7.22 - 7.43 
(9H, m, Ar-H) and 8.22 (1H, s, OH); δC/ppm (100 MHz; CDCl3) 16.4 (d, JP–C = 5.9 Hz, 2 x 2'-
CH3), 23.0 (CH3CO), 36.8 (d, JP–C = 4.1 Hz, 1-CH2), 52.8 (d, JP–C = 16.6 Hz, 2-CH2), 62.3 (d, JP–C = 
6.6 Hz, 2 x 1'-OCH2), 65.9 (CH2OH), 66.6 (4-CH2Ph), 68.7 (3-CH2Ph), 126.3 (C-2'' and C-6''), 
126.4 (C-6 and C-10), 126.8 (C-8), 127.0 (C-3'' and C-5''), 127.7 (C-7 and C-9), 137.2 (C-1''), 
137.4 (C-5), 140.2 (C-4'') and 171.1 (C=O).  
Diethyl N-(3-aminobenzyl)-2-[(N-benzyloxy)acetamido]ethylphosphoramidate 357c   
      
 
 
 
 
 
 
The procedure described for the synthesis of diethyl N-benzyl-2-[N-benzyloxy)acetamido]-
ethylphosphoramidate 357a was employed, using diethyl N-[2-(benzyloxyamino)ethyl]-N-(3-
mercaptobenzyl)phosphoramidate 356c (0.28 g, 0.68 mmol), acetyl chloride (0.13 mL, 1.4 
mmol) and triethylamine (0.14 mL, 1.0 mmol) in DCM (10 mL). The solvent was evaporated 
in vacuo and the residue was purified by flash chromatography [on silica gel; elution with 
hexane-EtOAc (7:3)] to yield diethyl N-(3-aminobenzyl)-2-[(N-benzyloxy)acetamido]-
ethylphosphoramidate 357c as a yellow oil (0.22 g, 80 %); (Found: C, 58.86; H, 7.29; N, 9.41 
%. C22H33N3O5P requires C, 58.79; H, 7.18; N, 9.35 %); ʋ/cm
-1 3387 (NH2), 1692 (C=O) and 
1220 (P=O); δH/ppm (400 MHz; CDCl3) 1.30 (6H, t, J = 7.2 Hz, 2 x 2'-CH3), 2.02 (3H, s, CH3CO), 
2.81 (2H, m, 1-CH2N), 3.23 (2H, t, J = 4.4 Hz, 2-CH2N), 3.79 (2H, s, 4-CH2Ph), 4.08 (4H, m, 2 x 
1'-OCH2), 4.52 (2H, s, NH2), 4.81 (2H, s, 3-CH2Ph), 6.63 - 6.78 (4H, m, Ar-H) and 7.16 - 7.19 
(5H, m Ar-H); δC/ppm (100 MHz; CDCl3) 16.4 (d, JP–C = 6.6 Hz, 2 x 2'-CH3), 23.8 (CH3CO), 36.7 
(d, JP–C = 4.7 Hz, 1-CH2), 52.1 (d, JP–C = 16.7 Hz, 2-CH2), 61.4 (d, JP–C = 6.5 Hz, 2 x 1'-OCH2), 68.4 
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(4-CH2Ph), 69.8 (3-CH2Ph), 114.1 (C-4''), 114.8 (C-2''), 118.6 (C-6''), 126.5 (C-6 and C-10), 
127.8 (C-8), 128.3 (C-7 and C-9), 129.8 (C-5''), 137.3 (C-1''), 137.7 (C-5), 147.9 (C-3'') and 
170.8 (C=O).  
Diethyl 2-[(N-benzyloxy)acetamido]-N-(3-mercaptobenzyl)ethylphosphoramidate 357d 
 
 
 
 
 
 
The procedure described for the synthesis of diethyl N-benzyl-2-[N-benzyloxy)acetamido]-
ethylphosphoramidate 357a was employed, using diethyl N-[2-(benzyloxyamino)ethyl]-N-(3-
mercaptobenzyl)phosphoramidate 356d (0.27 g, 0.64 mmol), acetyl chloride (0.12 mL, 1.3 
mmol) and triethylamine (0.12 mL, 0.88 mmol) in DCM (10 mL). The solvent was evaporated 
in vacuo and the residue was purified by flash chromatography [on silica gel; elution with 
hexane-EtOAc (7:3)] to yield diethyl 2-[(N-benzyloxy)acetamido]-N-(3-mercaptobenzyl)-
ethylphosphoramidate 357d as a yellow oil (0.23 g, 81 %); Found: C, 56.77; H, 6.79; N, 5.92 
%. C22H31N2O5PS requires C, 56.64; H, 6.70; N, 6.00 %); ʋ/cm
-1 2554 (SH), 1698 (C=O) and 
1217 (P=O); δH/ppm (400 MHz; CDCl3) 1.36 (6H, t, J = 7.2 Hz, 2 x 2'-CH3), 2.20 (3H, s, CH3CO), 
2.79 (2H, m, 1-CH2N), 3.25 (2H, t, J = 5.6 Hz, 2-CH2N), 3.83 (2H, s, 4-CH2Ph), 4.19 (4H, m, 2 x 
1'-OCH2), 4.71 (2H, s, 3-CH2Ph), 6.21 (1H, s, SH), 6.63 - 7.29 (4H, m, Ar-H) and 7.42 - 7.50 (5H, 
m, Ar-H); δC/ppm (100 MHz; CDCl3) 16.4 (d, JP–C = 5.9 Hz, 2 x 2'-CH3), 24.2 (CH3CO), 36.7 (d, 
JP–C = 4.8 Hz, 1-CH2), 52.9 (d, JP–C = 16.8 Hz, 2-CH2), 61.6 (d, JP–C = 6.5 Hz, 2 x 1'-OCH2), 68.1 (4-
CH2Ph), 70.8 (3-CH2Ph), 124.7 (C-6''), 126.0 (C-2''), 126.2 (C-4''), 126.8 (C-6 and C-10), 128.7 
(C-8), 129.1 (C-5''), 129.4 (C-7 and C-9), 130.3 (C-3''), 138.5 (C-1''), 138.8 (C-5) and 167.3 
(C=O).    
Diethyl N-(trimethylsilyl)phosphoramidate 358 199 
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Hexamethyldisilazane (2.46 mL, 12 mmol) was added to a stirred solution of diethyl 
phosphoramidate 352 (3.00 g, 19.8 mmol) in dry benzene (10 mL) under N2 and the mixture 
was refluxed at 80 oC for 3 hours. The solvent and excess hexamethyldisilazane were 
removed in vacuo at 60 oC for 1 hour to afford diethyl N-(trimethylsilyl)phosphoramidate as 
a brown oil, which crystallised on cooling to afford hygroscopic off-white crystals (4.69 g, 87 
%); δH/ppm (400 MHz; CDCl3) 0.19 (9H, s, 3 x CH3Si), 1.30 (6H, t, J = 7.2 Hz, 2 x CH3), 2.25 (1H, 
s, NH) and 4.04 (4H, m, 2 x OCH2); δC/ppm (100 MHz; CDCl3) 0.6 (d, JP–C = 2.4 Hz, 3 x CH3Si), 
16.2 (d, JP–C = 7.3 Hz, 2 x CH3) and 61.9 (d, JP–C = 5.3 Hz, 2 x OCH2).     
3-Aminobenzyl bromide 360c 251  
 
 
 
 
Phosphorous tribromide (0.62 mL, 6.5 mmol) was added dropwise to a stirred solution of 3-
aminobenzyl alcohol (0.80 g, 6.5 mmol) in DCM (10 mL) under N2 at 0 
oC and the resulting 
mixture was stirred for 1 hour. The mixture was allowed to warm to room temperature and 
stirred further for ca. 24 hours. After the addition of satd. aq. NaHCO3 (30 mL), the organic 
layer was separated and the aqueous layer was extracted with diethyl ether (3 x 20 mL). The 
organic layers were combined, dried over anhydrous MgSO4 and filtered. The solvent was 
evaporated in vacuo and the residue was purified by flash chromatography [on silica gel; 
elution with hexane-EtOAc (4:1)] to yield 3-aminobenzyl bromide 360c as a clear oil (0.92 g, 
76 %); δH/ppm (400 MHz; CDCl3) 2.95 (1H, s, NH2), 4.62 (2H, s, CH2Br), 7.43 - 7.67 (4H, m, Ar-
H); δC/ppm (100 MHz; CDCl3) 36.6 (CH2Br), 115.5 (C-2), 116.4 (C-4), 119.9 (C-6), 129.0 (C-5), 
138.0 (C-1) and 147.5 (C-3).  
3-Mercaptobenzyl bromide 360d  
 
 
 
 
A solution of sodium nitrite (0.32 g, 4.6 mmol) in water (2 mL) was slowly added to a 
mixture of 3-aminobenzyl bromide 360c (0.50 g, 2.7 mmol) in water (4 mL) and conc. HCl (1 
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mL) at -5 oC - 0 oC. The mixture was stirred for 1 hour, ensuring that the temperature did not 
exceed 0 oC. A solution of sodium sulphide (1.20 g, 4.97 mmol) and sulphur (0.16 g, 5.0 
mmol) in water (15 mL) was then added dropwise during 1 hour to the cold solution of the 
diazonium salt and the resulting mixture was stirred at 0 oC for 1 hour. The mixture was 
allowed to warm to room temperature and then stirred further for 1 hour. After completion, 
the mixture was acidified (pH 2.5) with 2M-HCl and extracted with EtOAc (3 x 15 mL). The 
organic extracts were washed sequentially with 20 % aq. Na2CO3 (2 x 20 mL), water (2 x 20 
mL) and brine (2 x 20 mL), and then dried (anhydr. MgSO4). The solvent was removed in 
vacuo to give the disulphide 362, which was used in the next step without further 
purification. In another flask, sodium borohydride (0.12 g, 3.2 mmol) in THF (3 mL) was 
added to a solution of disulphide 362 (0.25 g, 0.80 mmol) in THF (3 mL) under N2 at 0 
oC. 
After the addition, the mixture was allowed to warm to room temperature and stirred 
further for 1 hour. The reaction was quenched with water (6 mL), acidified (pH 2.5) with 2M-
HCl and extracted with EtOAc (3 x 10 mL). The organic extracts were combined, washed 
sequentially with 20 % aq. Na2CO3 (3 x 10 mL) and brine (3 x 10 mL), and then dried (anhydr. 
MgSO4). The solvent was removed in vacuo and the residue purified by flash 
chromatography [on silica gel; elution with hexane-EtOAc (4:1)] to yield 3-mercaptobenzyl 
bromide 360d as a clear oil (0.92 g, 76 %); δH/ppm (400 MHz; CDCl3) 3.35 (1H, s, SH), 4.65 
(2H, s, CH2Br), and 7.44 - 7.66 (4H, m, Ar-H); δC/ppm (100 MHz; CDCl3) 36.4 (CH2Br), 125.8 
(C-2), 126.4 C-6), 128.3 (C-5), 130.0 (C-4), 130.2 (C-3) and 137.6 (C-1).    
Diethyl N-benzyl-2-(N-hydroxyacetamido)ethylphosphoramidate 363a   
   
   
 
 
 
 
 
A solution of diethyl N-benzyl-2-[N-benzyloxy)acetamido]-ethylphosphoramidate 357a (0.20 
g, 0.46 mmol) in dry MeOH (2 mL) was added to a solution of Pd/C (10 %, 0.35 g) in dry 
MeOH (10 mL) under an H2-atmosphere and the mixture was stirred at room temperature 
for 18 hours. The reaction mixture was then filtered through a celite pad, the filtrate was 
1''    
2''
3''      
4''
5''  
6''  
1
2
1'
2'
3
P
NO
O
O
CH3
CH3
N CH3
OH
O
  Experimental  
 
Page | 278  
evaporated in vacuo and the residue purified by flash chromatography [on silica gel; elution 
with hexane-EtOAc (3:1)] to yield diethyl N-benzyl-2-(N-hydroxyacetamido)ethyl-
phosphoramidate 363a as a clear oil (0.13 g, 83 %); (Found: C, 52.40; H, 7.38; N, 8.19 %. 
C15H25N2O5P requires C, 52.32; H, 7.32; N, 8.14 %); ʋ/cm
-1 3221 (OH), 1688 (C=O) and 1238 
(P=O); δH/ppm (400 MHz; CDCl3) 1.28 (6H, t, J = 7.2 Hz, 2 x 2'-CH3), 1.83 (1H, s, NOH), 2.08 
(3H, s, CH3CO), 2.89 (2H, m, 1-CH2N), 3.21 (2H, t, J = 6.0 Hz, 2-CH2N), 3.79 (2H, s, 3-CH2Ph), 
4.17 (4H, m, 2 x 1''-OCH2) and 7.32 - 7.45 (5H, m, Ar-H); δC/ppm (100 MHz; CDCl3) 16.1 (d, JP–
C = 7.2 Hz, 2 x 2'-CH3), 20.8 (CH3CO), 35.8 (d, JP–C = 5.0 Hz, 1-CH2), 53.6 (d, JP–C = 16.5 Hz, 2-
CH2), 62.3 (d, JP–C = 5.6 Hz, 2 x 1'-OCH2), 67.5 (3-CH2Ph), 127.3 (C-4''), 128.3 (C-2'' and C-6''), 
128.6 (C-3'' and C-5''), 137.4 (C-1') and 167.5 (C=O).  
Diethyl 2-(N-hydroxyacetamido)-N-[4-(hydroxymethyl)benzyl]ethylphosphoramidate 363b     
     
 
 
 
 
 
 
The procedure described for the synthesis of diethyl N-benzyl-2-(N-hydroxyacetamido)ethyl-
phosphoramidate 363a was employed, using diethyl 2-[(N-benzyloxy)acetamido]-N-[4-
(hydroxymethyl)benzyl]ethylphosphoramidate 357b (0.20 g, 0.43 mmol) in MeOH (2 mL) 
and Pd/C (10 %, 0.33 g) in MeOH (10 mL). The solvent was evaporated in vacuo and the 
residue was purified by flash chromatography [on silica gel; elution with hexane-EtOAc (3:1)] 
to yield diethyl 2-(N-hydroxyacetamido)-N-[4-(hydroxymethyl)benzyl]ethylphosphoramidate 
363b as a yellow oil (0.14 g, 84 %); (Found: C, 51.39; H, 7.22; N, 7.53 %. C16H27N2O6P requires 
C, 51.33; H, 7.27; N, 7.48 %); ʋ/cm-1 3313 (OH), 1695 (C=O) and 1218 (P=O); δH/ppm (400 
MHz; CDCl3) 1.32 (6H, t, J = 7.2 Hz, 2 x 2'-CH3), 1.91 (1H, s, NOH), 2.12 (3H, s, CH3CO), 2.80 
(2H, m, 1-CH2N), 3.38 (2H, t, J = 6.4 Hz, 2-CH2N), 3.85 (2H, s, 3-CH2Ph), 4.12 (4H, m, 2 x 1''-
OCH2), 5.10 (2H, s, CH2OH), 7.25 - 7.30 (4H, m, Ar-H) and 8.02 (1H, s, CH2OH); δC/ppm (100 
MHz; CDCl3) 16.3 (d, JP–C = 6.1 Hz, 2 x 2'-CH3), 23.4 (CH3CO), 37.4 (d, JP–C = 5.2 Hz, 1-CH2), 52.5 
(d, JP–C = 16.5 Hz, 2-CH2), 63.6 (d, JP–C = 5.8 Hz, 2 x 1'-OCH2), 66.4 (CH2OH), 68.8 (3-CH2Ph), 
123.4 (C-2'' and C-6''), 123.7 (C-3'' and C-5''), 136.6 (C-1''), 138.3 (C-4'') and 170.1 (C=O).     
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Diethyl N-(3-aminobenzyl)-2-(N-hydroxyacetamido]ethylphosphoramidate 363c   
 
      
 
 
 
The procedure described for the synthesis of diethyl N-benzyl-2-(N-hydroxyacetamido)ethyl-
phosphoramidate 363a was employed, using diethyl N-(3-aminobenzyl)-2-[(N-
benzyloxy)acetamido]-ethylphosphoramidate 357c (0.20 g, 0.44 mmol) in MeOH (2 mL) and 
Pd/C (10 %, 0.33 g) in MeOH (10 mL). The solvent was evaporated in vacuo and the residue 
was purified by flash chromatography [on silica gel; elution with hexane-EtOAc (3:1)] to yield 
diethyl N-(3-aminobenzyl)-2-(N-hydroxyacetamido]ethylphosphoramidate 363c as a yellow 
oil (0.12 g, 79 %); (Found: C, 50.22; H, 7.35; N, 11.67 %. C15H26N3O5P requires C, 50.13; H, 
7.29; N, 11.69 %); ʋ/cm-1 3387 (OH), 3327 (NH2), 1705 (C=O) and 1224 (P=O); δH/ppm (400 
MHz; CDCl3) 1.29 (6H, t, J = 6.8 Hz, 2 x 2'-CH3), 2.14 (3H, s, CH3CO), 2.69 (2H, m, 1-CH2N), 
3.26 (2H, t, J = 6.8 Hz, 2-CH2N), 3.81 (2H, s, 3-CH2Ph), 4.09 (4H, m, 2 x 1'-OCH2), 4.78 (2H, s, 
NH2), 5.68 (1H, s, OH) and 6.59 - 7.16 (4H, m, Ar-H); δC/ppm (100 MHz; CDCl3) 16.3 (d, JP–C = 
6.2 Hz, 2 x 2'-CH3), 21.5 (CH3CO), 36.4 (d, JP–C = 4.7 Hz, 1-CH2), 53.2 (d, JP–C = 16.4 Hz, 2-CH2), 
62.2 (d, JP–C = 6.5 Hz, 2 x 1'-OCH2), 68.3 (3-CH2Ph), 114.0 (C-4''), 114.7 (C-2''), 118.6 (C-6''), 
129.6 (C-5''), 136.7 (C-1''), 148.2 (C-3'') and 166.6 (C=O).   
Diethyl 2-(N-hydroxyacetamido)-N-(3-mercaptobenzyl)ethylphosphoramidate 363d 
 
 
 
 
 
 
The procedure described for the synthesis of diethyl N-benzyl-2-(N-hydroxyacetamido)ethyl-
phosphoramidate 363a was employed, using diethyl 2-[(N-benzyloxy)acetamido]-N-(3-
mercaptobenzyl)-ethylphosphoramidate 357d (0.20 g, 0.43 mmol) in MeOH (2 mL) and Pd/C 
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(10 %, 0.33 g) in MeOH (10 mL). The solvent was evaporated in vacuo and the residue was 
purified by flash chromatography [on silica gel; elution with hexane-EtOAc (3:1)] to yield 
diethyl 2-(N-hydroxyacetamido)-N-(3-mercaptobenzyl)ethylphosphoramidate 363d as a 
yellow oil (0.14 g, 88 %); Found: C, 47.93; H, 6.73; N, 7.46 %. C15H25N2O5PS requires C, 47.86; 
H, 6.69; N, 7.44 %); ʋ/cm-1 3219 (OH), 2534 (SH), 1693 (C=O) and 1225 (P=O); δH/ppm (400 
MHz; CDCl3) 1.30 (6H, t, J = 6.8 Hz, 2 x 2'-CH3), 1.87 (1H, s, OH), 2.12 (3H, s, CH3CO), 2.71 (2H, 
m, 1-CH2N), 3.08 (1H, s, SH), 3.29 (2H, t, J = 6.8 Hz, 2-CH2N), 3.83 (2H, s, 3-CH2Ph), 4.09 (4H, 
m, 2 x 1'-OCH2) and 6.61 - 7.18 (4H, m, Ar-H); δC/ppm (100 MHz; CDCl3) 16.4 (d, JP–C = 6.0 Hz, 
2 x 2'-CH3), 22.4 (CH3CO), 36.4 (d, JP–C = 4.8 Hz, 1-CH2), 48.7 (d, JP–C = 16.5 Hz, 2-CH2), 61.5 (d, 
JP–C = 6.5 Hz, 2 x 1'-OCH2), 66.6 (3-CH2Ph), 124.2 (C-6''), 125.0 (C-2''), 127.8 (C-4''), 128.3 (C-
5''), 129.6 (C-3''), 137.2 (C-1'') and 163.0 (C=O).  
N-Benzyl-2-(N-hydroxyacetamido)ethylphosphoramidic acid 351a 
 
 
 
 
 
 
Trimethylsilyl bromide (0.15 mL, 1.0 mmol) was added dropwise to diethyl N-benzyl-2-(N-
hydroxyacetamido)ethylphosphoramidate 363a (0.12 g, 0.34 mmol) in DCM (5 mL) under N2 
at 0 oC and the mixture was stirred for 1 hour. The mixture was allowed to warm to room 
temperature, water was added (1 mL) and the resulting mixture was stirred overnight. After 
completion, the solvent was removed in vacuo and the residue chromatographed 
[preparative layer chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield N-
benzyl-2-(N-hydroxyacetamido)ethylphosphoramidic acid 351a as a colourless oil (85 mg, 87 
%); (Found: C, 45.76; H, 6.01; N, 9.79 %. C11H17N2O5P requires C, 45.84; H, 5.94; N, 9.72 %); 
ʋ/cm-1 3245 (OH), 1653 (C=O) and 1228 (P=O); δH/ppm (400 MHz; DMSO-d6) 2.09 (3H, s, 
CH3CO), 2.79 (2H, m, 1-CH2N), 3.34 (2H, t, J = 6.4 Hz, 2-CH2N), 3.83 (2H, s, 3-CH2), 5.25 (1H, s, 
NOH), 7.29 - 7.37 (5H, m, Ar-H) and 8.15 (2H, s, 2 x OH); δC/ppm (100 MHz; DMSO-d6) 20.7 
(CH3), 42.6 (d, JP–C = 4.7 Hz, 1-CH2N), 52.3 (d, JP–C = 16.9 Hz, 2-CH2N), 67.2 (3-CH2), 126.4 (C-
4'), 128.6 (C-2' and C-6'), 129.4 (C-3' and C-5'), 139.4 (C-1') and 171.5 (C=O).   
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2-(N-Hydroxyacetamido)-N-[4-(hydroxymethyl)benzyl]ethylphosphoramidic acid 351b 
 
     
      
 
 
The procedure described for the synthesis of N-benzyl-2-(N-hydroxyacetamido) 
ethylphosphoramidic acid 351a was employed, using diethyl 2-(N-hydroxyacetamido)-N-[4-
(hydroxymethyl)benzyl]ethylphosphoramidate 363b (0.12 g, 0.31 mmol) and TMSBr (0.12 
mL, 0.93 mmol) in DCM (5 mL). The solvent was removed in vacuo and the residue 
chromatographed [preparative layer chromatography; elution with hexane-EtOAc-MeOH 
(1:1:0.5)] to yield 2-(N-Hydroxyacetamido)-N-[4-(hydroxymethyl)benzyl]ethylphosphoramidic 
acid 351b as a colourless oil (87 mg, 89 %); (Found: C, 45.35; H, 6.09; N, 8.73 %. C12H19N2O6P 
requires C, 45.29; H, 6.02; N, 8.80 %); ʋ/cm-1 3329 (OH), 1667 (C=O) and 1220 (P=O); 
δH/ppm (400 MHz; DMSO-d6) 1.76 (1H, s, CH2OH), 2.07 (3H, s, CH3CO), 2.75 (2H, m, 1-CH2N), 
3.27 (2H, t, J = 6.0 Hz, 2-CH2N), 3.82 (2H, s, 3-CH2), 4.78 (2H, s, CH2OH), 6.67 (1H, s, NOH), 
7.09 - 7.24 (4H, m, Ar-H) and 8.92 (2H, s, 2 x OH); δC/ppm (100 MHz; DMSO-d6) 20.3 (CH3), 
37.5 (d, JP–C = 5.1 Hz, 1-CH2N), 51.8 (d, JP–C = 16.6 Hz, 2-CH2N), 65.7 (CH2OH), 68.4 (3-CH2), 
126.2 (C-3' and C-5'), 128.3 (C-2' and C-6'), 136.5 (C-1'), 139.2 (C-4') and 166.3 (C=O).   
N-(3-Aminobenzyl)-2-(N-hydroxyacetamido)ethylphosphoramidic acid 351c 
 
 
  
       
 
 
The procedure described for the synthesis of diethyl N-benzyl-2-(N-
hydroxyacetamido)ethylphosphoramidate 351a was employed, using diethyl N-(3-
aminobenzyl)-2-(N-hydroxyacetamido)ethylphosphoramidate 363c (0.10 g, 0.27 mmol) and 
TMSBr (0.10 mL, 0.81 mmol) in DCM (5 mL). The solvent was removed in vacuo and the 
residue chromatographed [preparative layer chromatography; elution with hexane-EtOAc-
MeOH (1:1:0.5)] to yield N-(3-aminobenzyl)-2-(N-hydroxyacetamido)ethylphosphoramidic 
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acid 351c as a colourless oil (71 mg, 87 %); (Found: C, 43.70; H, 5.91; N, 13.82 %. 
C11H18N3O5P requires C, 43.57; H, 5.98; N, 13.86 %); ʋ/cm
-1 3361 (OH), 3298 (NH2), 1684 
(C=O) and 1230 (P=O); δH/ppm (400 MHz; DMSO-d6) 2.08 (3H, s, CH3CO), 2.81 (2H, m, 1-
CH2N), 3.28 (2H, t, J = 6.0 Hz, 2-CH2N), 3.60 (2H, s, 3-CH2), 4.66 (1H, s, NOH), 5.48 (2H, s, 
NH2), 7.00 (2H, s, 2 x OH) and 7.10 - 7.29 (4H, m, Ar-H); δC/ppm (100 MHz; DMSO-d6) 19.8 
(CH3), 36.7 (d, JP–C = 4.9 Hz, 1-CH2N), 53.0 (d, JP–C = 16.5 Hz, 2-CH2N), 68.1 (3-CH2), 113.9 (C-
4'), 114.7 (C-2'), 117.8 (C-6'), 128.4 (C-5'), 138.3 (C-1'), 146.5 (C-3') and 166.8 (C=0).   
2-(N-Hydroxyacetamido)-N-(3-mercaptobenzyl)ethylphosphoramidic acid 351d 
 
 
 
 
 
The procedure described for the synthesis of diethyl N-benzyl-2-(N-
hydroxyacetamido)ethylphosphoramidate 351a was employed, using diethyl 2-(N-
hydroxyacetamido)-N-(3-mercaptobenzyl)ethylphosphoramidate 363d (0.12 g, 0.31 mmol) 
and TMSBr (0.13 mL, 92 mmol) in DCM (5 mL). The solvent was removed in vacuo and the 
residue chromatographed [preparative layer chromatography; elution with hexane-EtOAc-
MeOH (1:1:1)] to yield 2-(N-hydroxyacetamido)-N-(3-mercaptobenzyl)ethylphosphoramidic 
acid 351d as a colourless oil (83 mg, 84 %); (Found: C, 41.34; H, 5.41; N, 8.68 %. 
C11H17N2O5PS requires C, 41.25; H, 5.35; N, 8.75 %); ʋ/cm
-1 3326 (OH), 2575 (SH), 1687 (C=O) 
and 1228 (P=O); δH/ppm (400 MHz; D2O) 2.09 (3H, s, CH3CO), 2.68 (2H, m, 1-CH2N), 2.80 (1H, 
s, SH), 3.33 (2H, t, J = 6.0 Hz, 2-CH2N), 3.84 (2H, s, 3-CH2) and 6.85 – 7.37 (4H, m, Ar-H); 
δC/ppm (100 MHz; D2O) 22.4 (CH3), 40.6 (d, JP–C = 4.8 Hz, 1-CH2N), 52.7 (d, JP–C = 16.5 Hz, 2-
CH2N), 68.2 (3-CH2), 119.2 (C-6'), 123.1 (C-2'), 126.6 (C-4'), 129.4 (C-5'), 130.2 (C-3'), 138.5 
(C-1') and 162.1 (C=0).  
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3.6. Synthesis of fosmidomycin and FR900098 
 Diethyl (3-oxopropyl)phosphonate 365 118,119  
 
 
 
 
A solution of diethyl (3,3-diethoxypropyl)phosphonate 364 (2.00 g, 7.45 mmol) in 2M-HCl 
solution (8 mL) was stirred at room temperature for ca. 24 hours. The reaction mixture was 
then extracted with CHCl3 (3 x 25 mL) and the organic layers were combined, and washed 
with water (2 x 25 mL). The aqueous washings were combined and extracted with CHCl3 (2 x 
50 mL). The combined organic extracts were washed sequentially with satd. aq. NaHCO3 (2 x 
50 mL) and brine (2 x 50 mL), and then dried (anhydr. MgSO4). The solvent was evaporated 
in vacuo and the residue chromatographed [on silica gel; elution with hexane-EtOAc (3:1)] 
to yield diethyl (3-oxopropyl)phosphonate 365 as a yellow oil (1.08 g, 75 %); δH/ppm (400 
MHz; CDCl3) 1.24 (6H, t, J = 6.8 Hz, 2 x 2'-CH3), 1.96 (2H, m, CH2P), 2.71 (2H, m, CH2CO), 4.03 
(4H, q, J = 4.4 Hz, 2 x OCH2) and 9.72 (1H, s, CHO); δC/ppm (100 MHz; CDCl3) 16.2 (d, JP–C = 
6.3 Hz, 2 x 2'-CH3), 20.7 (d, JP–C = 143.9 Hz, CH2P), 27.1 (d, JP–C = 3.8 Hz, CH2CO), 62.1 (d, JP–C = 
6.7 Hz, 2 x 1'-OCH2) and 174.5 (d, JP–C = 18.8 Hz, C=O).    
Diethyl {3-[(benzyloxy)amino]propyl}phosphonate 366 118,119 
 
 
 
 
 
To a stirred solution of diethyl (3-oxopropyl)phosphonate 365 (0.80 g, 4.1 mmol) in MeOH (5 
mL) was added a solution of O-benzylhydroxylamine (0.68 g, 4.9 mmol) in MeOH (15 mL). 
The reaction mixture was heated at 40 oC for 3 hours, cooled to room temperature and 
diluted with MeOH (80 mL). After the addition of sodium cyanoborohydride (0.80 g, 12.4 
mmol), conc. HCl (4.5 mL) was added dropwise over a period of 30 min and the mixture was 
stirred for 1 hour. Sodium cyanoborohydride (0.27 g, 4.1 mmol) was again added and the 
mixture was stirred for another 1 hour. The solvent was removed under reduced pressure, 
1
2
1'
2'
P
O
O
O
CH3
CH3
O
H
1'
1
2
3
1''
2''
P
O
O
O
CH3
CH3
NH
O
2'
3'
4'
5'
6'
7'
  Experimental  
 
Page | 284  
the residue dissolved in MeOH (50 mL) and then treated with ice-water (50 mL). The 
resulting mixture was adjusted to pH 10 with aq. KOH-solution and extracted with DCM (2 x 
100 mL). The combined organic layers were washed with 10 % NaHCO3 (100 mL) and brine 
(100 mL), and then dried (anhydr. MgSO4). The solvent was evaporated in vacuo and the 
remaining oil was purified by flash chromatography [on silica gel; elution with hexane-EtOAc 
(3:1)] to yield diethyl {3-[(benzyloxy)amino]propyl}phosphonate 366 as a yellow oil (0.52 g, 
65 %); δH/ppm (400 MHz; CDCl3) 1.29 (6H, t, J = 6.4 Hz, 2 x 2''-CH3), 1.82 (4H, m, 1-CH2 and 2-
CH2), 2.93 (2H, t, J = 6.0 Hz, CH2N), 4.08 (4H, m, 2 x 1''-OCH2), 4.67 (2H, s, CH2Ph), 5.58 (1H, s, 
NH) and 7.31 – 7.33 (5H, m, Ar-H); δC/ppm (100 MHz; CDCl3) 16.4 (d, JP–C = 6.0 Hz, 2 x 2''-
CH3), 20.4 (d, JP–C = 4.9 Hz, C-2), 23.1 (d, JP–C = 141.2 Hz, CH2P), 52.0 (d, JP–C = 16.7 Hz, CH2N), 
61.5 (d, JP–C = 6.5 Hz, 2 x 1''-OCH2), 76.3 (CH2Ph), 127.8 (C-5'), 128.2 (C-3' and C-7'), 128.3 (C-
4' and C-6') and 137.7 (C-2').  
Diethyl [3-(N-benzyloxy-N-formylamino)propyl]phosphonate 367a 118,119 
 
 
 
 
 
Formic acid (0.12 mL, 3.3 mmol) was added to a mixture of diethyl {3-
[(benzyloxy)amino]propyl} phosphonate 366 (0.25 g, 0.85 mmol) and sodium formate (0.02 
g, 0.33 mmol) in THF (10 mL) under N2 and the resulting mixture was refluxed at 80 
oC for 2 
hours. The solvent was removed in vacuo and the residue dissolved in EtOAc (25 mL). The 
organic phase was washed with water (2 x 25 mL). The aqueous washings were combined 
and extracted with EtOAc (2 x 10 mL). The combined organic extracts were washed 
sequentially with satd. aq. NaHCO3 (2 x 50 mL) and brine (2 x 50 mL), and then dried 
(anhydr. MgSO4). The solvent was evaporated in vacuo and the residue chromatographed 
[on silica gel; elution with hexane-EtOAc (3:1)] to yield diethyl [3-(N-benzyloxy-N-
formylamino)propyl]phosphonate 367a as a yellow oil (0.16 g, 66 %); δH/ppm (400 MHz; 
CDCl3) 1.32 (6H, t, J = 6.8 Hz, 2 x 2''-CH3), 1.77 (4H, m, 1-CH2 and 2-CH2), 3.72 (2H, t, J = 6.4 
Hz, CH2N), 4.09 (4H, m, 2 x 1''-OCH2), 4.84 (2H, s, CH2Ph), 7.40 (5H, s, Ar-H) and 8.13 (1H, s, 
CHO); δC/ppm (100 MHz; CDCl3) 16.3 (d, JP–C = 6.0 Hz, 2 x 2''-CH3), 20.6 (d, JP–C = 4.9 Hz, C-2), 
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23.5 (d, JP–C = 141.2 Hz, CH2P), 51.7 (d, JP–C  = 16.8 Hz, CH2N), 61.3 (d, JP–C = 6.5 Hz, 2 x 1''-
OCH2), 76.7 (CH2Ph), 127.7 (C-5'), 128.0 (C-3' and C-7'), 128.3 (C-4' and C-6'), 137.8 (C-2') and 
165.8 (C=O).  
Diethyl [3-(N-acetyl-N-benzyloxylamino)propyl]phosphonate 367b 118,119 
   
           
 
 
 
 
Acetyl chloride (0.08 mL, 0.96 mmol) was added dropwise to a stirred solution of diethyl {3-
[(benzyloxy)amino]propyl} phosphonate 366 (0.25 g, 0.83 mmol) and triethylamine (0.13 
mL, 0.99 mmol) in DCM (10 mL) under N2 at 0 
oC. The mixture was stirred at 0 oC for 1 hour, 
allowed to warm to room temperature and then stirred further for ca. 24 hours. The solvent 
was removed under reduced pressure and the residual oil dissolved in diethyl ether (20 mL). 
The solution was washed sequentially with aq. K2CO3 solution, 0.5M-HCl and water, and 
then dried over anhydrous MgSO4. The solvent was removed in vacuo and the residue 
purified by flash chromatography [on silica gel; elution with hexane-EtOAc (3:1)] to yield 
diethyl [3-(N-acetyl-N-benzyloxylamino)propyl]phosphonate 367b as a yellow oil (0.18 g, 73 
%); δH/ppm (400 MHz; CDCl3) 1.33 (6H, t, J = 6.8 Hz, 2 x 2''-CH3), 1.82 (4H, m, 1-CH2 and 2-
CH2), 2.06 (3H, s, CH3CO), 3.69 (2H, t, J = 6.4 Hz, CH2N), 4.11 (4H, m, 2 x 1''-OCH2), 4.85 (2H, 
s, CH2Ph) and 7.37 (5H, s, Ar-H); δC/ppm (100 MHz; CDCl3) 16.9 (d, JP–C = 6.0 Hz, 2 x 2''-CH3), 
19.7 (CH3CO), 20.8 (d, JP–C = 4.9 Hz, C-2), 23.6 (d, JP–C = 141.2 Hz, CH2P), 52.4 (d, JP–C = 16.4 Hz, 
CH2N), 62.0 (d, JP–C = 6.5 Hz, 2 x 1''-OCH2), 76.4 (CH2Ph), 128.4 (C-5'), 128.3 (C-3' and C-7'), 
128.9 (C-4' and C-6'), 138.0 (C-2') and 163.0 (C=O).  
Diethyl [3-(N-hydroxyformamido)propyl]phosphonate 368a 251,252  
 
 
  
  
A solution of diethyl {3-[(benzyloxy)(formyl)amino]propyl}phosphonate 367a (0.15 g, 0.46 
mmol) in dry MeOH (5 mL) was added to a solution of Pd/C (10 %, 0.35 g) in dry MeOH (10 
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mL) under H2 and the mixture was stirred at room temperature for 18 hours. The reaction 
mixture was then filtered through a celite pad, the filtrate was evaporated in vacuo and the 
residue purified by flash chromatography [on silica gel; elution with hexane-EtOAc (4:1)] to 
yield diethyl [3-(N-hydroxyformamido)propyl]phosphonate 368a as a clear oil (0.11 g, 77 %); 
δH/ppm (400 MHz; CDCl3) 1.29 (6H, t, J = 6.8 Hz, 2 x 2''-CH3), 1.80 (4H, m, 1-CH2 and 2-CH2), 
3.75 (2H, t, J = 6.4 Hz, CH2N), 4.13 (4H, m, 2 x 1''-OCH2), 5.03 (1H, s, OH) and 9.71 (1H, s, 
CHO); δC/ppm (100 MHz; CDCl3) 16.3 (d, JP–C = 6.0 Hz, 2 x 2''-CH3), 20.8 (d, JP–C = 4.8 Hz, C-2), 
23.2 (d, JP–C = 141.2 Hz, CH2P), 51.9 (d, JP–C  = 16.7 Hz, CH2N), 61.5 (d, JP–C = 6.5 Hz, 2 x 1''-
OCH2) and 158.2 (C=O).   
Diethyl [3-(N-hydroxyacetamido)propyl]phosphonate 368b 251,252  
 
      
 
 
 
The procedure described for the synthesis of diethyl [3-(N-hydroxyformamido)propyl]-
phosphonate 368a was employed, using diethyl [3-(N-acetyl-N-benzyloxylamino)propyl]-
phosphonate 367b (0.15 g, 0.44 mmol) in MeOH (5 mL) and Pd/C (10 %, 0.34 g) in MeOH (10 
mL). The solvent was evaporated in vacuo and the residue was purified by flash 
chromatography [on silica gel; elution with hexane-EtOAc (3:1)] to yield diethyl [3-(N-
hydroxyacetamido)propyl]phosphonate 368b as a yellow oil (0.12 g, 81 %); δH/ppm (400 
MHz; CDCl3) 1.33 (6H, t, J = 6.8 Hz, 2 x 2''-CH3), 1.80 (4H, m, 1-CH2 and 2-CH2), 2.08 (3H, s, 
CH3CO), 3.71 (2H, t, J = 6.8 Hz, CH2N), 4.12 (4H, m, 2 x 1''-OCH2) and 5.87 (1H, s, OH); δC/ppm 
(100 MHz; CDCl3) 16.4 (d, JP–C = 6.0 Hz, 2 x 2''-CH3), 20.2 (CH3CO), 20.7 (d, JP–C = 4.8 Hz, C-2), 
23.5 (d, JP–C = 143.9 Hz, CH2P), 52.6 (d, JP–C = 16.4 Hz, CH2N), 62.2 (d, JP–C = 6.5 Hz, 2 x 1''-
OCH2) and 163.7 (C=O).    
[3-(N-Hydroxyformamido)propyl]phosphonic acid 236 (Fosmidomycin) 251,252  
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Trimethylsilyl bromide (0.17 mL, 1.3 mmol) was added dropwise to diethyl {3-
[formyl(hydroxyl)amino]propyl}phosphonate 368a (0.10 g, 0.42 mmol) in DCM (3 mL) under 
N2 at 0 
oC and the mixture was stirred for 1 hour. The mixture was allowed to warm to room 
temperature, water was added (1 mL) and the resulting mixture was stirred overnight. The 
solvent was removed in vacuo and the residue chromatographed [preparative layer 
chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [3-(N-
hydroxyformamido)propyl]phosphonic acid 236 as a colourless oil (66 mg, 67 %); δH/ppm 
(400 MHz; D2O) 1.83 (4H, m, 1-CH2 and 2-CH2), 3.73 (2H, t, J = 6.4 Hz, CH2N) and  9.68 (1H, s, 
CHO); δC/ppm (100 MHz; D2O) 21.0 (d, JP–C = 4.8 Hz, C-2), 23.6 (d, JP–C = 141.2 Hz, CH2P), 51.5 
(d, JP–C  = 16.7 Hz, CH2N) and 155.7 (C=O).     
[3-(N-Hydroxyacetamido)propyl]phosphonic acid 237 201,252  
 
 
 
The procedure described for the synthesis of [3-(N-hydroxyformamido)propyl]phosphonic 
acid 236 was employed, using  diethyl [3-(N-hydroxyacetamido)propyl]phosphonate 368b 
(0.10 g, 0.39 mmol) and trimethylsilyl bromide (0.16 mL, 1.2 mmol) in DCM (3 mL). The 
solvent was removed in vacuo and the residue chromatographed [preparative layer 
chromatography; elution with hexane-EtOAc-MeOH (1:1:1)] to yield [3-(N-
Hydroxyacetamido)propyl]phosphonic acid 237 as a colourless oil (61 mg, 64 %); δH/ppm 
(400 MHz; D2O) 1.82 (4H, m, 1-CH2 and 2-CH2), 2.10 (3H, s, CH3CO) and 3.69 (2H, t, J = 6.8 Hz, 
CH2N); δC/ppm (100 MHz; D2O) 20.0 (CH3CO), 20.6 (d, JP–C = 4.8 Hz, C-2), 23.2 (d, JP–C = 143.9 
Hz, CH2P), 52.1 (d, JP–C = 16.4 Hz, CH2N) and 162.8 (C=O).    
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3.7. Saturation Transfer Difference (STD) NMR binding studies  
The EcDXR enzyme was expressed and purified, for the author, using standard 
protocols115,142 by Miss Taryn Bodill in the Rhodes Centre for Chemico- and Biomedicinal 
Research.211 An STD experiment was run on the different sets of ligands as follows: EcDXR, 
stored in sodium phosphate buffer (pH 7.0), was freeze-dried and re-suspended in D2O to 
make a final concentration of 20 μM. Each set of ligands was dissolved in the protein 
solution to give a final ligand concentration of 800 μM and thus a protein: ligand molar ratio 
of 1:40. The STD experiment was carried out using parameters optimized in a previous study 
in our group.129 The saturating on-resonance and off-resonance pulses were set at 
frequencies of 0.73 ppm and 20 ppm, respectively, while cycling between the on- and off-
resonance phases was used to reduce the effects of changes in temperature or magnetic 
field homogeneity. A 3-9-19 water suppression pulse was applied at 4.7 ppm and 6000 scans 
were acquired. The on- and off-resonance spectra were subtracted from each other and 
processed using Bruker Topspin software.   
3.8. NADPH-dependent DXR inhibition assay  
The bio-assay was carried out, for the author, using a reaction mixture containing 100 mM 
Tris–HCl (pH 7.5), 1 mM MnCl2, 0.3 mM DOXP and 0.3 mM NADPH, made up to a final 
volume of 100 μl with assay buffer. Equal volumes of EcDXR and ligand were incubated at 37 
oC for 5 min and the reaction was initiated by adding 100 μL of the enzyme-ligand mixture to 
the rest of the assay components to make a total of 200 μL, with a final EcDXR 
concentration of 5 μg.mL-1. The decrease in absorbance at 340 nm as a result of the 
reduction of NADPH (εNADPH = 6.3 x 103 L.mol
-1.cm-1) was monitored at 37 oC for 10 min, 
using a PowerWave™ microtitre plate reader. The specific activity of the enzyme in the 
absence of a ligand was considered to be 100% (i.e. 0% inhibition) and the % relative 
inhibition of each ligand was determined in triplicate.  
 
 
 
  Experimental  
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3.9. Modelling and simulated docking studies  
The Accelrys Cerius2 module213 was used to construct the selected compounds in silico as 
their mono-deprotonated species. Using Gaussian 03,214 the structure for each compound 
was energy-minimised at the density functional theory (DFT) B3LYP level with the 6-31G(d) 
base set, using (IEFPCM) solvent correction (water). Docking studies of the energy-
minimised ligands were carried out using Autodock version 4.0,215 using the 
crystallographically-determined enzyme structure, EcDXR 2EGH,103 which was downloaded 
from the Protein Data Bank (PDB; E.C. 1.1.1.267). Using Autodock 4.0, Gasteiger charges 
were added and the non-polar hydrogens were merged for the respective ligands and the 
protein model.  The active-site residues Ser185, Ser221, Asn226, Lys227 and Glu230 were 
assigned as flexible. The AutoGrid 4.0 algorithm was employed to represent the active site 
with a grid box of dimensions 60 x 60 x 60 units (grid-point spacing of 0.375 Å) along the x-, 
y- and z-directions, and atom maps were calculated for all possible active-site residue-ligand 
interactions. In silico dockings were conducted using the Lamarckian algorithm with a 
population size of 150, allowing for a maximum of 27 000 generations and 2.5 x 106 energy 
evaluations. For each ligand docking experiment, ten possible docked-conformers were 
generated. The lowest docked-conformer for each of the ligands was selected and visualised 
using the Accelrys Discovery Studio Visualizer 2.0220 software package.        
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